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Abstract 
Background 
 
Between 1961-1971 vitamin D deficiency was recognized as a public health issue in the 
UK, because of the lack of effective sunlight and the population mix [1, 2].  In recent 
years, health care professionals have cited evidence suggesting a re-emergence of the 
vitamin D deficiency linked to a number of health consequences as a concern [3-6]. 
Evidence from observational studies has linked low vitamin D status with impairment in 
glucose homeostasis and immune dysfunction [7-9].  However, interventional studies, 
particularly those focused on paediatric populations, have been limited and inconsistent. 
There is a need for detailed studies, to clarify the therapeutic benefits of vitamin D in these 
important clinical areas.  
 
Objective  
 
The aims of this PhD thesis were two-fold.  Firstly, to perform preliminary work assessing 
the association between vitamin D deficiency and bone status, glucose homeostasis and 
immune function, and to explore any changes in these parameters following short term 
vitamin D3 replacement therapy.  Secondly, to assess the effectiveness of an electronic 
surveillance system (ScotPSU) as a tool to determine the current incidence of hospital-
based presentation of childhood vitamin D deficiency in Scotland. 
 
Methods  
 
Active surveillance was performed for a period of two years as a part of an electronic web-
based surveillance programme performed by the Scottish Paediatric Surveillance Unit 
(ScotPSU).  The validity of the system was assessed by identifying cases with profound 
vitamin D deficiency (in Glasgow and Edinburgh) from the regional laboratory. All 
clinical details were checked against those identified using the surveillance system. 
Thirty-seven children aged 3 months to 10 years, who had been diagnosed with vitamin D 
deficiency, were recruited for the bone, glucose and immunity studies over a period of 24 
months. Twenty-five samples were analysed for the glucose and bone studies; of these, 18 
samples were further analysed for immune study.  Treatment consisted of six weeks taking 
5000 IU units cholecalciferol orally once a day.  At baseline and after completion of 
treatment, 25 hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH), alkaline 
phosphatase (ALP), collagen type 1 cross-linked C-telopeptide (CTX), osteocalcin (OCN), 
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calcium, phosphate, insulin, glucose, homeostasis model assessment index, estimated 
insulin resistance (HOMA IR), glycated hemoglobin (HbA1c), sex hormone binding 
globulin (SHBG), lipids profiles, T helper 1 (Th1) cytokines (interleukin-2 ( IL-2), tumor 
necrosis factors-alpha (TNF-α), interferon-gamma (INF-γ)), T helper 2 (Th2) cytokines 
(interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6)), T helper 17 (Th17) 
cytokine (interleukin-17 (IL-17)), Regulatory T (Treg) cytokine (interleukin-10 (IL-10)) 
and chemokines/cytokines, linked with Th1/Th2 subset balance and/or differentiation 
(interleukin-8 (IL-8), interleukin-12 (IL-12), eosinophil chemotactic protein ( EOTAXIN), 
macrophage inflammatory proteins-1beta (MIP-1β), interferon-gamma-induced protein-10 
(IP-10), regulated on activation, normal T cell expressed and secreted (RANTES), 
monocyte chemoattractant protein-1(MCP-1)) were measured.  Leukoocyte subset analysis 
was performed for T cells, B cells and T regulatory cells and a luminex assay was used to 
measure the cytokiens.  
 
Results 
 
Between September 2009 and August 2011, 163 cases of vitamin D deficiency were 
brought to the attention of the ScotPSU, and the majority of cases (n = 82) were reported in 
Glasgow.  The cross-validation checking in Glasgow and Edinburgh over a one-year 
period revealed only 3 (11%) cases of clearly symptomatic vitamin D deficiency, which 
had been missed by the ScotPSU survey in Glasgow.  While 16 (67%) symptomatic cases 
had failed to be reported through the ScotPSU survey in Edinburgh.  
 
For the 23 children who are included in bone and glucose studies, 22 (96%) children had 
basal serum 25(OH)D in the deficiency range (< 50 nmol/l) and one (4%) child had serum 
25(OH)D in the insufficiency range (51-75 nmol/l). Following vitamin D3 treatment, 2 
(9%) children had final serum 25(OH)D lower than 50 nmol/l, 6 (26%) children had final 
serum 25(OH)D between >50-75 nmol/l, 12 (52%) children reached a final serum 
25(OH)D >75-150 nmol/l and finally 3 (13%) exceeded the normal reference range with a 
final 25(OH)D >150 nmol/l.  Markers for remodelling ALP and PTH had significantly 
decreased (p = 0.001 and <0.0001 for ALP and PTH respectively).  
 
In 17 patients for whom insulin and HOMA IR data were available and enrolled in glucose 
study, significant improvements in insulin resistance (p = 0.04) with a trend toward a 
reduction in serum insulin (p = 0.05) was observed.  Of those 14 children who had their 
cytokines profile data analysed and enrolled in the immunity study, insulin and HOMA IR 
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data were missed in one child.  A significant increase in the main Th2 secreted cytokine 
IL-4 (p = 0.001) and a tendency for significant increases in other Th2 secreted cytokines 
IL-5 (p = 0.05) and IL-6 (p = 0.05) was observed following vitamin D3 supplementation. 
 
Conclusion 
 
An electronic surveillance system can provide data for studying the epidemiology of 
vitamin D deficiency.  However, it may underestimate the number of positive cases. 
Improving vitamin D status in vitamin D deficient otherwise healthy children significantly 
improved their vitamin D deficient status, and was associated with an improvement in bone 
profile, improvements in insulin resistance and an alteration in main Th2 secreting 
cytokines.   
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Chapter 1 
 Introduction 
 
 
1.1 Vitamin D: Background 
  History of vitamin D  
 
Vitamin D, which is also known as the ‘sunshine vitamin’ is a family of fat-soluble 
molecules.  Vitamin D is not actually a true vitamin as the molecules are not obtained 
exclusively from the diet.  Most of the plants and animals that are exposed to sunlight have 
an ability to produce vitamin D.  
 
Studies of rickets and related bone disorders throughout history have led to the discovery 
of vitamin D.  Soranus, a Roman physician in the 1st and 2nd century AD is often credited 
as one of the early describers of some rickets deformities (the backbone bending and legs 
twisting at the thigh).  Soranus attributed these changes to inappropriate maternal hygiene 
and lifestyle [10].  Around the middle of 17th century, the first clear scientific descriptions 
of rickets were provided by Dr Whistler and Professor Glisson, in 1645 and 1650, 
respectively.  Whistler described the rickets skeleton as poorly mineralized and deformed 
while Professor Glisson provided a detailed published description [11].  During that period, 
rickets was endemic in England. Known as ‘the English disease’, it was explained by the 
population’s urbanization [12].  However, the mystery of nutritional vitamin D deficiency 
and its relationship with rickets was solved by Sir Edward Mellanby in 1920 through an 
experimental demonstration and dietary manipulation of captive dogs. Sir Mellanby was 
able to cure nutritional rickets with regular doses of cod liver oil or egg yolk, although he 
incorrectly concluded that the causative factor was a newly-diagnosed fat-soluble vitamin 
A [13].  
 
In 1921, Dr Elmer McCollum, by the process of aerating and heating of cod liver oil was 
able to distinguish between vitamin A, can be inactivated, and vitamin D, retains its 
antirachitic activity [14].  A year later, Hess et al.(1922) were able to cure rickets in rats by 
exposing them to sunlight without dietary modification.  This group was also able to 
demonstrate the ability of artificial radiation and sunlight to induce the skin synthesis of 
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vitamin D and prevent the disease [15].  Clinical use of fish liver oil, and later exposure to 
sunlight or mercury arc lamp to treat children with rickets started shortly after that [16].  
Vitamin D refers to two biological precursors: vitamin D2 (ergocalciferol) and vitamin D3 
(cholecalciferol), collectively known as Calciferol.  The chemical structure of vitamin D2 
or ergocalciferol was first discovered in the 1930s by a British group led by Askew.  They 
showed that vitamin D2 is produced by ultraviolet irradiation of mixtures of plant sterols 
[17].  This discovery was followed by identification of 7-dehydrocholesterol by Windaus 
et al.(1935) [18].  Esvelt et al.(1978) were able to identify and isolate vitamin D3 in rat 
skins via irradiation of 7-dehydrocholesterol [19] (see Figure 1-1). 
 
 
 
Figure 1-1: Photolysis of the skin’s 7- dehydrocholesterol (pro-vitamin D3) under the 
influence of UV-B light to vitamin D3, via its intermediate previtamin D3. 
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 Sources 
Vitamin D3 constitutes around 80-90% of the circulating metabolites that can be obtained 
exogenously from sunlight exposure, from diet, or from supplements.  Vitamin D2 can be 
obtained through supplements or diet [20].  Both vitamin D2 and vitamin D3 are suggested 
to have the same functional consequence, though vitamin D3 may be more potent than 
vitamin D2 in maintaining serum vitamin D status [21]. 
 
1.1.2.1 Sunlight 
The main natural source of vitamin D is derived from the photolysis of the skin’s 7- 
dehydrocholesterol (pro-vitamin D3) under the influence of UV-B light (see figure 1-1). 
Photosynthesized vitamin D3 is believed to stay longer in the circulation compared with 
the externally digested [22].  Ultraviolet radiation can provide approximately 20,000 IU of 
vitamin D which is equivalent to exposure to 1 minimal erythemal dose (MED), the dose 
of radiation that causes a slight pinkness to the skin 24 hours after exposure in a bathing 
suit.  Therefore, exposure of arms and legs to 0.5 MED is equivalent to ingesting ~ 3000 
IU vitamin D3 [23].  Dark skinned adults require 10-15 times longer sun exposure than a 
white adult in order to synthesize a similar amount of vitamin D [24]. 
 
1.1.2.2 Natural dietary sources 
Few foods in nature contain vitamin D3 and vitamin D2.  Oily fish including salmon, 
mackerel and herring or fish liver oil are considered as main dietary sources of vitamin D3. 
Cheese, beef liver and egg yolks contain small amount of vitamin D3.  Sun dried 
mushrooms, because of the UV-B irradiation of the yeast sterol ergosterol, are considered 
as main sources of vitamin D2 [23].  Table 1-1 provides some of the nutritional vitamin D 
content of selected dietary products.  
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Table 1-1: Nutritional vitamin D content of selected dietary products. 
Natural sources Vitamin D content 
Cod liver oil, 1 tablespoon ~ 400-1000 IU vitamin D3 
Salmon, fresh wild, 3.5 oz   ~ 600-1000 IU vitamin D3 
Salmon, fresh farmed, 3.5 oz   ~100- 250 IU vitamin D3, D2 
Salmon, canned, 3.5 oz   ~ 300- 600 IU vitamin D3 
Sardines, canned, 3.5 oz   ~ 300 IU vitamin D3 
Mackerel, canned, 3.5 oz   ~ 250 IU vitamin D3 
Tuna, canned, 3.5 oz   ~ 230 IU/ 3.6 oz of vitamin D3 
Shiitake mushrooms, fresh, 3.5 oz   ~ 100 IU/ 3.5 oz of vitamin D2 
Shiitake mushrooms, sun-dried, 3.5 oz   ~ 1600 IU/ 3.5 oz of vitamin D2 
Egg yolk, 1 ~ 20 IU/ yolk vitamin D3 or D2 
To convert from International Unit (IU) to micrograms, divide by 40.Taken from [23]. 
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1.1.2.3 Supplements 
Most people are able to obtain the required vitamin D through a healthy balanced diet 
accompanied with summer sun exposure.  However, the high-risk population such as 
pregnant women, under-five children and elderly people may need an extra supplement. 
Vitamin D supplementation remains the most effective way to boost vitamin D levels in 
vitamin D-deficient or high-risk individuals [25].  Both forms of vitamin D, ergocalciferol 
(vitamin D2) and cholecalciferol (vitamin D3) are available as supplements in the form of 
an isolated capsule (prepared with glycerol due to their solubility in fat) or as 
vitamin/multivitamin preparations, containing from 400 IU to 5000 IU vitamin D2/D3 
[23].   
 
Both vitamins D2 and D3 are considered as metabolically equal based on their ability to 
cure rickets.  However, vitamin D2 has been found to be less potent, with shorter duration 
of action compared with vitamin D3 [26].  Vitamin D is available commercially as a 
supplement in a range of licensed medicines and multivitamin preparations (including fish 
oil products and calcium supplements) for infants and children.  The bioavailability of 
these supplements depends on the type of vehicle providing the supplement and the 
individual’s body mass index, whether they have malabsorption or are on medications such 
as anticonvulsants, glucocorticoids, antifungals such as ketoconazole, and medications for 
AIDS [27, 28].  Table 1-2 lists the vitamin D content of selected multivitamin preparation 
for children available in the UK market. 
 
Table 1-2: Vitamin D content of selected children’s supplements available in the UK. 
Supplement 
Vitamin D content 
(IU)* 
Dalivit and Abidec: 0.3ml-0.6 ml 200- 400 
Healthy start** 300 
Well Baby, Well Kid, Well Teen 200- 340 
Haliborange Kids, Haliborange Teen 100-200 
When the product is labelled as vitamin D or calciferol, it usually contains vitamin D2; cholecalciferol 
or vitamin D3 indicates that the product contains vitamin D3.  
* To convert from International Units (IU) to micrograms, divide by 40. ** Product is only available 
through NHS channels. 
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1.1.2.4 Vitamin D fortified food 
The high calcium and phosphorus content of dairy products facilitates vitamin D 
absorption.  Therefore, milk and other dairy products can be considered the ideal target for 
vitamin D fortification.  However, fortified cows milk may not be suitable for people with 
milk allergies or lactose intolerance, or to prevent vitamin D deficiency among people with 
special dietary requirements [29].  Therefore, bread, orange juice and breakfast cereal may 
be suitable alternative options for fortification [30-32]. 
 
 In the 1920s, ergosterol (pro-vitamin D2) was found in yeast and fungi, added to milk and 
then irradiated by UVB to stimulate antirachitic activity.  By 1930s, an ergosterol analogue 
had become commercially available in the United States and was added directly to the milk 
without irradiation [33].  Currently, both the United States and Canada use the same 
dietary guidelines for optimal and safe levels of vitamin D intake, with fortification being 
optional in the US and mandatory for some nutrients in Canada.  For instance, cheese, 
enriched rice, ready-to-eat cereals, orange juice and macaroni products are fortified in the 
US but not in Canada.  Margarine is mandatorily fortified in Canada and optional in the 
US.  Infant milk and evaporated milk are mandatorily fortified in both the United States 
and Canada [34]. 
 
In the UK, the Welfare Food Scheme was originally introduced in 1940 as a universal 
measure to ensure an adequate diet during World War II.  Under that scheme, children 
were given cod liver oil and dried milk fortified with vitamin D [35].  However, since 1957 
vitamin D fortification has been strictly regulated and even forbidden for some dairy 
products, due to outbreaks in the 1950s of hypercalcaemia, which is occasionally fatal and 
is linked to vitamin D intoxication [36].  The scheme was progressively changed to focus 
on people with special circumstances such as low income families and job seekers. 
In 2002, the Department of Health proposed a Healthy Start Scheme for reforming the 
Welfare Food Scheme which came into practise in 2006.  The Healthy Start Scheme 
targeted low income families, job seekers, pregnant and lactating mothers and under-18s 
and aimed to provide free milk, fruit, vegetables and vitamins for women, and children 
under 5 [37].  Under UK legislation, vitamin D fortification of infant formula and 
margarine is mandatory.  Breakfast cereals, yoghurts, some processed milk and some 
powdered milk are optionally fortified by commercial manufacturers.  Addition of vitamins 
and minerals to fortify any kind of unprocessed nutrients, vegetables, meat, poultry and 
fish is unlawful [38].  It has been found that the dietary vitamin D intake of preschool 
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children in the UK is very low and there is a need to reconsider milk fortification as a 
strategy to boost their intake [39]. 
 
 Current intake recommendation for vitamin D 
The recognized level for a safe intake of vitamin D is known as the tolerable upper intake 
level (UL), i.e. the amount of vitamin D that can be taken chronically without adverse 
health consequences.  There is a number of guidelines which have been published over the 
last decade to evaluate, manage and prevent vitamin D deficiency [28, 40].  However, there 
is little consensus on the threshold which reflects biological vitamin D sufficiency at the 
end-organ level.  In addition, there is substantial uncertainty about the extra-skeletal 
benefits of vitamin D supplementation, especially in those who have a relatively mild 
vitamin D deficiency [28, 41].  In 2011, the Endocrine Society established a guideline for 
clinicians for prevention and treatment of vitamin D deficiency with special emphasis on 
high-risk individuals.  This guideline assumed minimal sun exposure and aimed to provide 
the essential requirement of vitamin D to maintain normal calcium homeostasis for all age 
groups [28].  Table 1-3 shows the Endocrine Society’s Recommended Dietary Allowance 
(RDA) of vitamin D. 
 
 
Table 1-3: Endocrine Society dietary reference intake for vitamin D for patients at risk. 
 
Recommended Dietary Allowance 
(Maintenance) 
Age 
*LL 
(IU/day) 
**UL 
(IU/day) 
Upper tolerable 
maintenance 
(IU/day) 
0-6 months 400 At least 1000 1000 
6-12 months 400 At least 1000 1500 
1-3 years 600 At least 1000 2500 
4-8 years 600 At least 1000 3000 
8-19 years 600 At least 1000 4000 
19- <70 years 600-800 At least 1500-2000 4000 
Pregnant & lactating 600 At least 1500-2000 4000 
*LL: Lower limit. **UL: Upper limit of safe intake. Minimum needs to be maintained at a 25(OH)D 
level of above 75 nmol/l (30 ng/ml). Upper tolerable maintenance should not be exceeded without 
medical supervision [42].  
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 Toxicity 
Toxicity is extremely rare and may happen due to excessive vitamin D intake via food or 
supplements [43, 44].  The precise vitamin D metabolites contributing to intoxication is 
still a matter of debate [45].  Several theories have tried to explain the mechanisms by 
which hypervitaminosis D can lead to vitamin D intoxication.  Most of the suggestions 
involve an increase in one of the vitamin D metabolites, 25(OH)D3, 24,25(OH)2D3, 
25,26(OH)2D3, or 25(OH)D3-26,23-lactone.  Another suggestion is either an increase or a 
reduction of free 1,25(OH)2D [45, 46].  During intoxication, increased levels of 25(OH)D 
will exceed the vitamin D binding protein (DBP) binding capacity and bind directly with 
VDR in target cells.  Alternatively, the elevated 25(OH)D concentrations can compete and 
displace 1,25(OH)2D from its transport protein, DBP causing a release of ‘free’ 
1,25(OH)2D which enters the target cells and stimulates gene expression.  Vitamin D 
signal transduction procedure becomes overwhelmed, and fails to effectively clear the 
excessive metabolites [45, 47]. 
 
The outcome of vitamin D intoxication is hypercalcaemia as a result of increasing 
intestinal calcium absorption and the stimulation of bone resorption [48].  Initially, it can 
be presented as loss of appetite, fatigue, weight loss, excessive thirst, excessive urination, 
dehydration, constipation, muscle weakness, irritability and confusion.  Prolonged vitamin 
D intoxication may lead to chronic toxicity that affects bones, tissues and other organs, 
which can result in calcification of soft tissue and bone resorption causing kidney and heart 
damage [45, 49].  Toxicity thresholds are a little less debated than sufficient or deficient 
levels [50].  The Institute of Medicine (IOM) suggested that 25(OH)D of lower than 125-
150 nmol/l and up to 250 nmol/l is safe for both children and adults. Serum concentration 
of more than 375 nmol/l is dangerous and may lead to hypercalcaemia.  It has been shown 
that adult 25(OH)D levels remain around 125-150 nmol/l after maximal sun exposure [45, 
51, 52]. 
 
Due to the relatively short biological half-life of 1,25(OH)2D (1 to 2 days) there is no 
specific treatment for vitamin D toxicity.  Stopping taking vitamin D supplements, and if 
necessary rehydrating using intravenous saline solution to enhance the glomerular filtration 
rate and calcium excretion should be sufficient.  In some cases, corticosteroids or 
bisphosphonates may be used to enhance renal calcium reabsorption and inhibit the 
production and activity of 1,25(OH)2D [49, 53]. 
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 Assessment of vitamin D status 
1.1.5.1 Dietary methods 
Dietary intake assessment is a part of the process of defining nutritional status and may 
reflect the likelihood of developing vitamin D deficiency or to predict outcomes in clinical 
studies.  Precise assessment of vitamin D intake is challenging to achieve and is very 
difficult to obtain due to the effect of multiple confounders.  For example, vitamin D intake 
estimated from food and dietary supplement can only be compared on group mean rather 
than individuals data.  Furthermore, the effect of sun exposure and lifestyle factors is very 
difficult to measure [54].  
 
The most frequently used method for dietary assessment is the Food Frequency 
Questionnaires (FFQ), pre-printed lists of foods which could be either long or short and 
can be self-administered or performed by a professional.  Other methods include 24-hour 
food recalls, three-day dietary records, observed food intake and weighted food 
inventories, in which subjects are taught to describe and measure all food prior to 
consumption and then to record any leftovers [55, 56].  For more detailed dietary 
information such as for assessment of vitamin D and calcium intake, using a FFQ designed 
to ask pointed questions specific to the nutrient and age group in a study could be an 
effective and cost-effective method to collect data [57].  Other methods such as weighted 
food inventories may be more accurate but require more time, trained staff and specific 
equipment, and are more expensive, time consuming and difficult to apply.  For larger 
studies other inexpensive and quicker methods such as 24-hour recall and the three-day 
food record may be preferable.  However, the last two methods may provide a better idea 
about the habitual intake rather than nutritional assessment as there may be an 
overestimation of the intake [58].   
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1.1.5.2 Biochemical measurement 
Measurement of the major circulating form of vitamin D, 25(OH)D is currently considered 
as the best parameter that reflects the circulatory vitamin D status from either cutaneous 
synthesis or nutritional consumption [59].  However, 25(OH)D is an indicator of the 
supply rather than the biological function.  Biologically the most active vitamin D 
metabolite, 1α,25(OH)D,  is unsuitable for measuring the vitamin D status for many 
reasons.  Firstly, in secondary hyperparathyroidism due to mild or moderate vitamin D 
deficiency, plasma 1α,25(OH)D is maintained at normal or slight elevated levels [60]. 
Secondly, plasma levels of 25(OH)D are nearly 100 times higher than for 1α,25(OH)2D, 
and thirdly, circulating 25(OH)D can be converted locally in almost all peripheral tissues 
to 1α,25(OH)2D in order to cover local needs [61-63].  
 
There are many commercially available 25(OH)D assays used to assess vitamin D status 
such as high-pressure liquid chromatography (HPLC)  mass spectrometry [64, 65], radio 
immunoassays, enzyme immunoassays, competitive protein binding assays, automated 
chemiluminescence protein binding assays, and chemiluminescence immunoassays (CLIA) 
[66].  Significant variability in results between assay methods and laboratories has been 
reported in the literature and the concern regarding performance and accuracy of 25(OH)D 
has risen resulting in the recommendation to adopt the same standards between laboratories 
to reduce the variability [67]. 
 
The International Vitamin D External Quality Assessment Scheme (DEQAS) was 
established in 1989 with the aim of ensuring the analytical reliability and performance of 
individual laboratories [68].  In this scheme, five samples of unprocessed human serum are 
distributed quarterly and the results analysed to give an All-Laboratory Trimmed Mean 
(ALTM) and standard deviation (SD).  The participating laboratories require that 80% or 
more of their results are within 30% of the ALTM in order to be awarded a certificate for 
meeting the performance targets [68].  However, using the ALTM as the standard has its 
own issues.  The ALTM has deviated from the gold standard, gas chromatography-mass 
spectrometry, due to the increasing number of methods used to measure 25(OH)D [69]. 
Additionally, the available results by DEQAS do not judge the absolute accuracy of the 
method but only the relative accuracy of laboratories using the same method [69]. 
Recently, the National Institute of Standards and Technology (NIST) has introduced a 
standard reference material in human serum (SRM 972) in order to improve accuracy and 
assay comparability [70]. 
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 Vitamin D metabolism 
At the initial stages, both vitamin D2 and D3 undergo different pathways of metabolism 
before joining pathways to become biologically available, or activated. Dietary vitamin D 
gets combined into chylomicrons, subsequent to ingestion.  Exposure to UV radiation 
(280-315 nm) converts 7-dehydrocholesterol in the skin into pre-vitamin D3, which is 
rapidly transformed to vitamin D3.  Vitamin D3 in turn binds to the DBP and is transported 
to the liver.  Both vitamin D molecules, externally ingested and photosynthesized, then 
travel via the lymphatic system and subsequently enter circulation [42].  Figure 1-2 shows 
that the vitamin D metabolic pathway including several steps of degradation and 
activation.  
 
Vitamin D from the skin and diet has no biological activity without a two-step 
hydroxylation process in the liver and kidneys.  The first step, in the liver, requires P450 
enzymes such as CYP2R1 and CYP27A1 (25-hydroxylases) [71, 72].  In this step a 
hydroxyl group is attached at the carbon-25 atom (C-25) to form the major circulating form 
of 25-hydroxyvitamin D, 25(OH)D. 25-hydroxyvitamin D is also considered to be the most 
abundant circulating form of vitamin D, even though it is biologically inactive.  25-
hydroxyvitamin D is also used to determine human vitamin D status.  The role of the liver 
in this stage of hydroxylation was first reported in 1966 by DeLuca et al. [73].  The second 
step, in the kidneys, requires the P450 enzyme, CYP27B1 (1α-25 hydroxylase), to form the 
main active metabolite 1,25-hydroxyvitamin D (1,25(OH)2D or calcitriol).  1α-25 
hydroxylase is considered the major rate-limiting step in 1,25(OH)2D synthesis.  The renal 
hydroxylation reaction is tightly regulated by plasma parathyroid hormone (PTH) and 
serum calcium and phosphate levels.  Fibroblast growth factor 23 (FGF-23), which is 
secreted mainly by osteocytes, can suppress the expression of calcium and phosphate co-
transporters and inhibit 1,25(OH)2D synthesis [74, 75].  Another significant enzyme in 
vitamin D metabolism is 24-hydroxylase (CYP24A1).  This enzyme has been identified in 
almost all cells and is highly unregulated by the kidneys.  The main defined role of 
CYP24A1 is to convert 1,25(OH)D to its inactive metabolites, including 1,24,25-(OH)3D 
and calcitroic acid and converting 25(OH)D to 24,25-(OH)3D [76]. 
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Figure 1-2: Photochemical synthesis of vitamin D and main target tissues. 
  
PTH: parathyroid hormone. FGF-23: fibroblast growth factor-23. GH: growth hormone. IGF-1: insulin-
like growth factor-1. GI: gastrointestinal.  
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 Mechanism of action of vitamin D 
Experimental evidence supports the hypothesis that 1,25(OH)2D can produce its effect at 
the target tissues by transmitting signals and regulating gene transcription that results in 
both genomic and non-genomic responses.  Genomic responses are involved in the 
formation of a ligand-receptor complex with vitamin D nuclear receptors (VDR).  Through 
non-genomic action, 1,25(OH)2D can generate a rapid cellular response, a mechanism 
which can be mediated at the plasma membrane involving a membranous localized vitamin 
D nuclear receptor (VDRmem) (see Figure 1-3).  
 
1.1.7.1 Genomic action 
The examination of the primary sequence of vitamin D receptor cDNAs showed that VDRs 
are members of the nuclear receptor superfamily (NHR) which consists of more than 350 
different receptors.  A common feature for all NHRs is that they act by regulating gene 
expression [77]. 
 
The genomic actions of the active form of 1,25(OH)2D is mediated through nuclear 
vitamin D receptors (VDRs).  The VDRs act as transcriptional factors which modulate 
gene expression in a ligand-dependent way.  Human VDR protein consists of three main 
regions: an N-terminal dual zinc finger domain that binds to DNA, a C-terminal domain 
that binds to 1,25(OH)2D, and an extensive unstructured region that links these two 
functional domains.  The process of transcriptional activation of the target genes is initiated 
by ligand binding of 1,25(OH)2D to the VDR.  This leads to conformational changes 
within the receptors that stimulate heterodimerization with retinoic X receptors (RXR) and 
high specificity and affinity binding to the vitamin D-responsive element (VDRE) in the 
DNA of the target gene [78].  In addition to VDR/RXR heterodimers, VDR can form 
homodimers that bind DNA and regulate target gene expression [79].  The classical role of 
1,25(OH)2D is the control of serum calcium and phosphorus levels through its 
transcriptional regulation of calbindin D38d, a specific calcium–binding protein in the 
intestine, and osteocalcin, osteopontin, and receptor activator of the nuclear factor κβ 
ligand (RANKL) in bone [80].  
 
The 1,25D-VDR complex plays an important role in the regulation of VDR, CYP27B1, 
and CYP24A1.  As will be discussed later in this chapter, both CYP27B mRNA and VDRs 
have been identified in many other tissues such as β cells of the pancreas, skeletal muscles 
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and immune cells.  They are suggested to play a critical role in many cellular functions 
such  insulin secretion, insulin sensitivity and modulation of immune responses. 
 
1.1.7.2 Non-genomic action  
The active form of vitamin D, 1,25(OH)2D, can bind to putative cell membrane receptors 
1,25(OH)2D (mVDR) and generates a non-genomic response [81].  This action is mediated 
through several signal transduction systems such as protein kinases and phospholipase C 
pathways and involving the rapid opening of voltage-gated Ca2+ and Cl- channels [81]. 
Evidence has suggested that through the non-genomic response, 1,25(OH)2D  may be able 
to modulate the genomic pathway via effects on the function of the VDR in the nucleus. 
 
 
 
Figure 1-3: Mechanism of action of vitamin D: Up-regulation of genomic and non-genomic 
signalling via 1,25(OH)2D.  
 
1,25(OH)2D interacts with the VDR in the nucleus to initiate the genomic response through regulation 
of gene transcription. It can also bind to the membranous VDR to generate the non-genomic 
responses. In the genomic pathway, association of the nuclear VDR with 1,25(OH)2D with the ligand 
will result in heterodimerization with RXR, leading to either suppression or stimulation of the 
transcription of genes subject to hormone regulation. Binding of 1,25(OH)2D to the plasma 
membrane pits-associated VDR results in the activation of second messenger systems to elicit short-
term non-genomic responses. Probable consequences include opening of voltage-gated chloride or 
calcium channels or initiation of second messengers. Some of these mechanisms may lead to 
changes in gene expression through effects on the function of the VDR in the nucleus.  
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1.2 Epidemiology of vitamin D deficiency 
 Definition of vitamin D deficiency 
Although there is no consensus on optimal levels of 25-hydroxyvitamin D, vitamin D 
deficiency has been defined by the Institute of Medicine (IOM) as a measured serum 
25(OH)D of <50 nmol/l (20 ng/ml) and vitamin D insufficiency when the serum 25(OH)D 
is 52-73 nmol/l (21-29 ng/ml) [42].  There is a number of guidelines which have been 
published over the last decade to evaluate, manage and prevent vitamin D deficiency [40, 
42].  Nevertheless, there is a little consensus on the threshold which reflects biological 
vitamin D sufficiency at the end-organ level.  In addition, there is a  substantial uncertainty 
about the extra-skeletal benefits of vitamin D supplementation especially in those who 
have relatively mild vitamin D deficiency [28, 40]. 
 
 Risk factors 
The risk factors of vitamin D deficiency can be categorized as environmental, personal and 
genetic risk factors. 
 
1.2.2.1 Environmental risk factors 
Although the relationship between vitamin D and sunlight is clearly identified, vitamin D 
deficiency still continues to exist even in those areas where there is plenty of sunshine.  For 
example, poor vitamin D status has been reported among children, young adults and 
elderly across Europe, Canada, USA and Africa [23].  The higher prevalence of 
hypovitaminosis D during the winter and autumn has been reported and attributed to a 
decrease in outdoor activities and an increase in wearing heavy winter clothing, thus 
decreasing the surface area exposed to sunlight [20, 82].  Additionally, the significant 
impact of seasonal and latitudinal changes on vitamin D status is mainly related to both the 
quantity and quality of solar radiation reaching the globe's surface.  The solar zenith angle, 
defined as the angle between the sun and the vertical (zenith sky), increases during winter 
time and the amount of solar ultraviolet radiation that reaches the global surface is 
markedly reduced which significantly affects vitamin D3 skin production [23]. 
16 
 
In addition to season, the duration of vitamin D production depends on many other 
environmental parameters such as time of day, total ozone, clouds, aerosols, surface 
reflectivity and altitude.  For instance, in winter, heavy cloudy conditions and the ozone 
layer can absorb or reduce the necessary UVB rays to induce the photosynthesis of vitamin 
D [83].  
 
1.2.2.2 Personal risk factors 
There are several factors which may contribute to an individual’s risk for vitamin D 
deficiency through their diet and sun exposure and including personal, social and cultural 
factors such as age, gender, obesity, ethnicity, use of sun screen, cultural background and 
working patterns.  Analysis of NHANES 2001–2004, showed that older, female, obese, 
non-white individuals who drank milk less frequent and had a sedentary lifestyle were 
more likely to be vitamin deficient with 25(OH)D levels of lower than 37.5 nmol/l [84]. 
 
The risk of vitamin D deficiency increases with age due to a reduced capacity to synthesize 
vitamin D.  For instance, a 70-year-old exposed to a similar quantity of sunlight as a person 
in their twenties will make only around 25% of the vitamin D3 that the 20-year-old can 
make [24].  There are many reasons for this, including the decrease in cutaneous 
production of vitamin D due to a decline in 7-dehydrocholesterol, impaired intestinal 
absorption, and impaired hydroxylation in the liver and kidney, in addition to a lack of 
sunlight exposure. 
 
There is an inverse relationship between obesity and vitamin D which has been suggested 
as one of the predisposing factors for the development of metabolic syndrome in obese 
people [85, 86].  Many mechanisms have been suggested which are related to the lipophilic 
nature of vitamin D which results in it being sequestered deeply in the body fat tissue, in 
addition to its interfering with several metabolic processes that affect glucose and insulin 
metabolism in obese individuals [86].  
 
People with dark skin synthesize markedly less vitamin D than those with a light or fair 
complexion.  This is due to the high skin content of melanin pigment which serves as a 
barrier that prevents UVB radiation from penetrating the skin, thereby decreasing the 
efficiency of photosynthesis of precholecalciferol [87].  People with dark skin require more 
time for sun exposure than people with light skin to make sufficient vitamin D [88]. 
However, the increase in serum 25(OH)D after vitamin D supplementation is similar for 
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both groups [89].  Sunscreen also can absorb UVB depending on the sunscreen’s sun 
protection factor [90]. 
 
Vitamin D deficiency is believed to be significantly affected by working patterns as certain 
professions require many more hours to be spent indoors and allow less time for sun 
exposure than those who work outdoors [91].  For example, osteomalacia has been 
reported in night nurses who are regularly employed on the night shift for many years [92] 
and higher vitamin D levels have been recorded in lifeguards compared with submarine 
sailors [93]. 
 
Vitamin D deficiency has been correlated with specific cultural behaviours such as full-
coverage clothes or  prolonged breast feeding.  Therefore, vitamin D deficiency is very 
common among black African, South Asian and Middle Eastern immigrants, and the trend 
is more significant in women than men [5, 94].  In many areas across North Africa and 
Asia, vitamin D deficiency has been reported as a major public health issue [95].  Breast-
fed babies whose mothers are vitamin D deficient and those who are breast-fed for a 
prolonged period are at a high risk for developing vitamin D deficiency.  The reason for 
this is the 25(OH)D passes very poorly and 1,25(OH)2D does not appear to pass at all into 
breast milk.  It has been estimated that breast milk can provide an average of 22 IU/l (from 
15 to 50 IU/l) in a vitamin D sufficient mother [96].  Therefore, exclusive breastfeeding 
without sun exposure would provide only 11 to 38 IU/day in babies who consume around 
750 ml milk per day and therefore breast milk cannot provide the amount needed to meet 
the recommended dietary vitamin D intake [97].  
 
1.2.2.3  Genetic risk factors 
Researchers suggest a strong genetic influence on vitamin D status.  Despite abundant sun 
exposure in some countries, vitamin D deficiency is still common even among healthy 
adults, regardless of gender or lifestyle [98, 99].  Genetic  predisposition has been 
considered as an additional risk factor.  A study conducted in the USA provided a possible 
explanation and showed that South Asian immigrants have a significant increase in 
25(OH)D-24-hydroxylase activity compared with Caucasians [94].  Their genetic 
predisposition may facilitate the occurrence of symptomatic vitamin D deficiency among 
Asian, Middle Eastern and African immigrants, particularly when there are other risk 
factors involved, including early childhood, adolescence, pregnancy and lactation. 
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Analysis of the Framingham Offspring Study showed that the variation in circulatory 
vitamin D levels may be attributed to genetic susceptibility (heritability estimate = 28.8%, 
p < 0.01) [100].  A UK twin study suggested that around 60-65% of hormones regulating 
calcium homeostasis, PTH and vitamin D are under strict genatic control [101].  Several 
polymorphisms in the VDR gene have been investigated, and reviewed, with several 
candidate genes being suggested to contribute to this genetic effect [102].  For example, 
high winter vitamin D status in BB homozygotes (BsmI-polymorphism of the VDR gene) 
compared with other genotypes, has been reported in a sample of 93 Finnish females [103] 
 
 Vitamin D deficiency in the United Kingdom 
In the UK, several epidemiological and regional monitoring studies have provided strong 
evidence that lower vitamin D status is highly prevalent and is becoming an alarming 
public health issue, particularly among ethnic minorities [104].  A large-scaled dataset 
which involved 7437 British Caucasians who were born in England, Scotland, or Wales 
during the same week in 1958 showed that circulatory 25(OH)D levels follow a yearly 
cycle pattern that is highly affected by season and geographical location.  The lowest 
recorded levels for circulatory 25(OH)D were <25, <40, and <75 nmol/l during late winter 
and spring in 15.5%, 46.6%, and 87.1% of study subjects respectively [82].  In Scotland, a 
recent survey conducted by the Food Standards Agency and the Scottish Government 
between 2010-2013 included around 1400 blood samples showed that the average vitamin 
D level of the Scottish population was 37.5nmol/l.  This provided further evidence for the 
high prevalence of hypovitaminosis D among the Scottish population of various 
background [105].  
 
During 2000, a West Midlands prospective one year survey of 119 consultant 
paediatricians  targeting under-5-year-old children identified 24 new cases of  profound 
vitamin D deficiency [106].  Between May 2001 and July 2002, another group studied 
children from ethnic minority backgrounds who were attended a child health clinic in 
Central Manchester for immunisation, identified two of 124 ethnic minority children with 
clinical rickets with a prevalence of 1.6% [6].  However, there was a question about the 
validity of these surveys and it is more likely that the actual number of cases was 
underestimated.  A further survey conducted in three hospitals in Birmingham between 
2001 and 2003 reported 65 new cases of profound vitamin D deficiency with 25(OH)D 
levels of< 25 nmol/l including 17 cases of hypocalcaemic seizures [107]. 
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The increase in the occurrence of vitamin D deficiency among the population in Scotland 
has been attributed mainly to its northerly location, insufficient dietary intake and 
population mix.  Scotland’s latitude position at 55° to 59° north explains the lack of 
sunlight for vitamin D synthesis.  In addition, an indoor lifestyle, obesity, high alcohol 
intake, and poor diet, which are common among the Scottish population, further adversely 
affect vitamin D status [3, 4].  Since the identification of rickets and osteomalacia among 
the Asian community in the Glasgow in 1962, evidence has shown that despite a gradual 
decline in the prevalence of vitamin D deficiency, the problem was not eliminated 
completely [1, 108].  As a result, the Glasgow Stop Rickets campaign was held from 1979-
1981 with the aim of introducing a free prophylactic supplementation (400 IU) for Asian 
school-age children in need.  Post-campaign assessment showed that the un-supplemented 
group had four times higher incidence of rickets compared with the regularly supplemented 
children.  However, there was also a lack of organization and effectiveness in this 
campaign [109, 110].  
 
The impact of geographic location, decreased sun exposure and low dietary calcium on 
vitamin D status become evident after the development of a multivariate logistic regression 
model analysing the risk factors [111, 112].  Dietary pattern and the degree of lacto-
vegetarianism (no meat, fish and egg intake) were significant independent risk factors for 
nutritional rickets and osteomalacia among Asian women [113].  Therefore, further 
attempts to provide more effective preventive measures were represented in the Healthy 
Start scheme which was launched in November 2006 to replace the Food Welfare scheme. 
Two years after the introduction of this new scheme, the number of cases of rickets 
presenting at the Royal Hospital for Sick Children (RHSC) remained unchanged at under 
30 per year [5].  It remains unclear whether this new scheme is effective at reducing the 
incidence of rickets.  
 
In Glasgow, a retrospective survey of suspected vitamin D deficiency cases which were 
identified through clinicians’ own records, clinical biochemistry and diagnostic imaging 
records and carried out between 2002 and 2008 at RHSC showed the incidence increasing 
over time to reach a peak in 2008 with 42 cases.  This report documented 160 cases with 
various clinical features providing an average annual incidence of 23 cases per year [5].  It 
is important to note that there are other cases of symptomatic vitamin D deficiency which 
were not treated in the metabolic bone clinic at RHSC as well as other suspected cases 
where the diagnosis was not completely clear which were not included in this survey. 
Therefore, the actual incidence has still not yet been determined and this survey provided 
20 
 
 
further evidence that the prevalence of vitamin D deficiency in the West of Scotland seems 
to be increasing.   
 
The National Diet and Nutrition Survey (NDNS) (2008/09 – 2011/12), jointly funded by 
Public Health England (PHE), an executive agency of the Department of Health, and the 
UK Food Standards Agency (FSA), was originally created in 1992 as a series of cross-
sectional age groups representing, pre-school children (aged 1.5- 4.5 years); young people 
(aged 4-18 years); adults (aged 19-64 years); and older adults (aged 65 years and over). 
The main aim of the NDNS was to collect information about dietary habits and nutritional 
status of adults and children in the UK.  Post April 2008, the NDNS has been a rolling 
programme (RP), designed to collect data from a representative sample of 1,000 people per 
year (500 children, 500 adults), aged 1.5 years and older, living in private households.  The 
dietary assessment and nutritional data in the survey was collected using face-to-face 
interviews, unweighted four-day diaries, and blood and urine samples [114].  
 
Data from years one to four of the NDNS  rolling programme (2008/09 – 2011/12) showed 
that the proportion of children with a serum 25(OH)D concentration lower than 25 nmol/l 
at the time of venepuncture, ranged from 7.5% for children aged 1.5-3 years, to  24.4% for 
girls aged 11-18 years.  When subdivided by season, the survey revealed that more than 
40 % of children aged 11-18 years had a serum 25 (OH)D concentration below 25 nmol/l 
in the winter months (January to March).  This was in contrast to the summer months (July 
to September), when the proportion ranged from 1.7% for children aged 4-10 years, to 
13.4% for children aged 11-18 years.  
 
The result from the NDNS has also shown that decreased dietary intake of vitamin D 
among UK population  was associated with an increased risk of vitamin D deficiency.  The 
data  revealed that the average vitamin D intake were 2.2 µg/day (88 IU) for boys aged 4-
18 years, 1.9µg/day (76 IU) for girls aged 4-18 years and 1.9 µg/day (76 IU) for children 
aged 1.5-3 years.  A slightly higher total dietary intake (food plus supplements) was seen 
among supplement users: 2.7 µg/day (108 IU) for boys aged 4-18 years, and 2.3 µg/day 
(92 IU) for girls aged 4-18 years and children aged 1.5-3 years. 
 
The Reference Nutrient Intake (RNI) can be defined as the amount of a nutrient that is 
sufficient to meet the needs of almost the entire population (97.5%).  In the UK, there are 
no RNIs set for those aged 4–64 years, and it is only expressed for populations aged 
between 1.5-3 and over 65 years (vitamin D ' RNIs for children aged 1.5-3 years is 7 
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µg/day (280 IU), and 10 µg/day (400 IU) for adults aged 65 years and over).  Using these 
values, data from the NDNS showed that the mean intake of vitamin D from food sources 
was 27% of the RNI for children aged 1.5-3 years, compared with 29%  for adults aged 65 
years and over.  With and the contribution of vitamin D-containing supplements, the mean 
vitamin D intake increased to 32% and 51% of RNI for children aged 1.5-3 years, and 
adults older than 65 years, respectively. 
 
With the exception of children aged 1.5-3 years, meat and meat products have been 
indicated as a major contributor to vitamin D intake for all age groups (23-35% of vitamin 
D intake).  For children aged 1.5-3 years, milk and milk products were the major 
contributors to vitamin D intake (providing 24% of the intake).  Vitamin D-fortified fat 
spreads provided 19-21% of vitamin D intake for all age groups. Cereals and cereal based 
products, including pasta, rice, pizza, buns, cakes, pastries, and fruit pies provided 17-20% 
of the vitamin D intake for children aged 4-18 years and 14% for children aged 1.3-3 years.  
Fish and fish dishes (mainly oily fish) contributed 22% of the vitamin D intake, compared 
to 8-9% in children [114]. 
 
In summary, rickets and osteomalacia are associated with morbidity in children and can be 
prevented.  Profound vitamin D deficiency, presenting mainly as rickets, is a real problem 
in Scotland and many other parts of the UK.  The occurrence of vitamin D deficiency is 
becoming increasingly common among the UK population.  The results from emerging 
data highlighted that the recommendations of the Department of Health for vitamin D 
supplementation may be ineffective or are just being ignored, due to changes in levels of 
awareness of referring clinicians. There is a need for more effective public health measures 
which particularly target the at-risk population or a surveillance system that monitors 
incidence uniformly across Scotland.
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 Screening for vitamin D deficiency 
The Endocrine Society and the U.S. Preventive Services Task Force (USPSTF) have 
suggested that there is not sufficient evidence to prove that vitamin D screening is 
beneficial in routine clinical practise.  Therefore, there is no need for implementation of a 
universal screening for serum vitamin D deficiency among the general population [28, 41, 
42, 115].  Regarding the at-risk population, such as people with dark skin, malabsorption, 
decreased sun exposure or pregnant women, both the Endocrine Society and the USPSTF 
indicated that there is a lack of evidence to support the direct advantage of screening for 
vitamin D deficiency in adults.  Additionally, there are no available studies evaluating the 
benefits and drawbacks of screening [115].  There is general agreement for using 
supplementation for the purpose of preventing skeletal consequences of vitamin D 
deficiency among high-risk adults.  The USPSTF recommends prescribing vitamin D 
supplementation to prevent other diseases such as cardiovascular or immune disorders, or 
for improving quality of life.  However, the Endocrine Society did not advocate this due to 
a lack of sufficient evidence [41, 42, 115].  
 
Screening for vitamin D deficiency is recommended for high-risk children presenting with 
non-specific symptoms such as poor growth and irritability, children with recurrent 
fractures or those with chronic diseases such as malabsorption [41, 42].  A suggested 
screening method for vitamin D deficiency rickets is serum alkaline phosphatase (ALP) 
[116].  If the ALP is found to be elevated, then follow-up measurements of serum 
25(OH)D, calcium, phosphorus, and PTH should be carried out, along with radiologic 
examination.  However, there are arguments against this screening tool as not all children 
with subclinical vitamin D deficiency rickets have raised ALP levels [117].  
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1.3 Skeletal effect of vitamin D deficiency  
The relationship between vitamin D and bone health has been well documented and 
involves the role of vitamin D in maintaining calcium and phosphorus homeostasis and 
supporting bone mineralization.  The conventional skeletal consequences of prolonged 
vitamin D deficiency are: rickets among infants, young children and adolescents [118], 
osteomalacia among adults [1, 119] and osteoporosis in older adults [120].  
 
 Structural anatomy of bone 
The function of the skeleton is not just as a supporter and a protector for the vital organs 
but also includes other essential roles such as blood cell production, participation in acid–
base balance, acting as a reservoir for minerals needed for normal calcium homeostasis and 
acting as a pool for growth factors and cytokines [121].  Bone is a functional unit of the 
skeleton, defined as a metabolically active, highly vascularised and mineralised connective 
tissue which undergoes regular remodelling or skeletal renewing process in order to 
produce mechanically stronger bone which is able to adapt to biomechanical changes 
[122].  Generally, bones can be classified according to their shape into: flat bones such as 
the skull, scapula and ribs; long bones such as the ulna, radius, humerus and femur; short 
bones such as carpal bones (wrist); sesamoid bones such as the patella; sutural bones 
including the irregularly shaped bone within the skull, and, finally, irregular bones such as 
vertebrae.   
 
The anatomical structure of long bones involves three parts.  The peripheral parts comprise 
both the epiphysis and metaphysis, which are separated by a developmental growth plate or 
an epiphyseal cartilage plate.  The mid shaft of long bones is called the diaphysis. The wall 
of the diaphysis is made of three layers.  The outer thinner layer is called the periosteum. 
Periosteum is a sheet of connective tissue covering the bone except at the site of 
articulation with another bone where the bone is instead covered by articular cartilage. The 
middle layer of the diaphysis is called cortical (compact) bone.  The inner layer is known 
as the medullary cavity or marrow cavity, which contains bone marrow and adipose tissue. 
The epiphysis consists of mainly spongy bone in addition to the thin layer of cortex (see 
Figure 1-4) [121].    
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Based on its gross appearance, two basic structural units of bone are distinguished; 
compact and spongy (cancellous) bones.  
 
Compact bone accounts for 80% of the total bone mass and contains few cells and blood 
vessels.  The main functional microscopic unit of the compact bone is the osteon or 
Haversian system. Each osteon comprises of a central canal (Haversian canal) surrounded 
by osteocytes and containing the blood supply to the osteon.  Another canal known as 
Volkmann’s canal runs perpendicular to the surface of the bone and penetrates deeper to 
the cortical bone and connects with those of the medullary cavity.  The Haversian canal 
runs parallel to the bone surface, surrounded by the concentric lamellae forming a target-
like pattern.  Between the lamellae, there are small spaces, or lacunae, filled with 
extracellular fluid containing osteocytes.  Finally, radiating through the lamellae are small 
microscopic canals known as canaliculi [121].  
 
The second structural unit of bone is the spongy (cancellous) bone which accounts for 20% 
of the human skeleton weight.  In long bone, spongy bone constitutes the interior of the 
epiphyses. The lamellae in the spongy bone are not organized in the osteon, but instead 
arranged in an irregular meshwork called the trabeculae.  The macroscopic spaces between 
the trabeculae contain the red bone marrow, which is responsible for blood cell 
manufacture.  In early childhood, most of the skeleton is composed of cancellous bone, and 
all the bone marrow is red bone marrow.  As children grow up, the cancellous bone is 
slowly converted into cortical bone in the long bones and the red bone marrow is slowly 
converted to yellow bone marrow [121]. 
 
The outer cover of the bone called periosteum.  This consists of an inner layer of 
osteoblasts which are in direct contact with the bone and being more prominent during 
fetal life and early childhood.  The outer layer of the periosteum is abundant with blood 
vessels which penetrate the bone [121]. 
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Figure 1-4: Anatomical structure of long bone. 
 
Long bones consist of a long shaft (diaphysis) and two peripheral sections, epiphysis and 
metaphysis. The outer surface of the bone is covered by periosteum except at the articulation 
surface, at the epiphysis (covered by articular cartilage).  
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 Bone matrix  
Bone architecture is composed of two elements: around 90% is bone matrix and 10% are 
cellular elements.  Bone matrix is further divided into organic (35%) and inorganic (65%). 
Around 90% of the organic component is a non-mineral collagen tissue (osteoid) and 10% 
is non-collagenous proteins.  Type I collagen is the most abundant component of the 
osteoid, which is released from fibroblasts and osteoblasts.  The rest of the organic matrix 
components are non-collagenous proteins include osteocalcin, osteopontin and osteonectin 
which are produced mostly by osteoblasts.  Osteocalcin and osteopontin production is a 
unique feature of the mineralized bone  and  their production are further stimulated  by 
1,25(OH)2D [123].   
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 Cellular elements of bones (Bone cells)   
The actively growing bone contains cells derived from two lineages; the osteoblast lineage 
(osteoblast and osteocytes) and the osteoclast lineage (osteoclast).  Each of the cellular 
elements of bone has a specific function.  For example, bone tissue is formed by 
osteoblasts, maintained by osteocytes and removed by osteoclasts (Table 1-4) [123]. 
Table 1-4: Main types of bone cells, their locations and functions. 
*DMP 1, Dentin matrix protein; FGF23, fibroblast growth factor-23; IGF-1, insulin-like growth factor-
1; RANKL, Receptor activator of nuclear factor kappa B ligand; M–CSF, macrophage colony 
stimulating factor; IFN-γ, interferon gamma; TFN-α, tumor necrosis factor alpha; IL-6, interleukin 6; 
MMP 9, matrix metalloproteinase. (summarised from [123], unless otherwise stated). 
Bone cells Origin & regulation Location Function 
Osteoblasts 
 
 
Mononuclear derived mainly from 
mesenchymal stem cells. 
 
Have receptors for PTH, IGF-1 and 
vitamin D. 
 
Osteoblast differentiation to osteocyte 
requires an activation of key 
transcription factor Runx2 which is 
counteracted by another factor called 
Osterix (Osx) [124]. 
 
 
Fate; osteocytes, lining cells and 
apoptosis. 
Bone 
surfaces. 
 
Particularly 
active at 
places of 
bone 
growth and 
repair. 
Bone formation 
 
Through synthesis of organic bone 
matrix (osteoid). 
 
Control bone matrix mineralization 
by secretion of type 1 collagen and 
other non-collagenous matrix 
proteins such as; osteocalcin 
osteopontin and  sialoprotein  
 
Have surface protein alkaline 
phosphatase which is released in 
the process of bone formation. 
Osteocytes 
 
 
Mature bone cells derived from 
osteoblasts; make up 90-95% of all 
bone cells in adults [125]. 
 
Contain vitamin D & PTH receptors. 
 
CD44 and DMP1 molecules are the 
main positive regulators. Sclerostin is a 
main negative regulator [126, 127]. 
 
Major source of FGF23 [128].   
 
Trapped 
within in 
bone 
matrix. 
Preserve mineral concentration 
of the matrix 
 
Can express osteocalcin, 
osteonectin & osteopontin, but show 
little alkaline phosphatase activity. 
 
Provide a structure support for bone 
via cytoplasmic connections with 
neighboring cells. 
 
 Stimulate bone resorption 
Osteoclasts 
 
 
Giant multinucleated bone lining cells. 
Originated from bone marrow derived 
monocyte. 
 
M–CSF & RANKL (secreted and 
expressed by osteoblasts) molecules 
are critical for osteoclastogenesis [129, 
130]. 
 
Contain receptors for calcitonin, PTH 
and vitamin D; up regulate M-CSF 
activity. 
 
Cytokines such as IL-6, TNF-α and IFN-
γ also increase the osteoclasts activity. 
 
Fate; apoptosis. 
Bone 
surface. 
 
  
Particularly 
active at 
places of 
bone 
growth and 
repair. 
Bone resorption 
 
Firstly, osteoclasts attach to the 
bone through integrin, making a 
sealing zone, into which is secreted 
hydrochloric acid & acidic protease 
such as cathepsin K & MMP9. 
 
Secondly, hydrochloric acid is 
produced by the actions of H+ 
ATPase within acidified vesicles. 
 
Thirdly, integrin attachment to the 
bone results in signals that target 
acidified vesicles leading to 
secretion of the acid and proteases 
and finally bone resorption and 
degradation of exposed organic 
matrix. 
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 Bone remodelling  
Bone remodelling is a continuous process of bone recycling and renewing which takes 
place throughout human life and involves two counteracting processes, bone formation and 
bone resorption.  The balancing collaboration between bone resorption cells and bone 
formation cells is known as a basic multicellular unit.  Osteoporosis or bone loss is a 
consequence of increased osteoclasts function and/or reduced osteoblasts activity.  In 
contrast, conditions such as osteopetrosis may occur due to osteoclastic failure to resorb 
bone leading to an increase in the bone mass [131, 132].  Bone remodelling is divided into 
five consecutive phases: resting, activation, resorption, reversal and formation (see Figure 
1-5).  Remodelling starts with an activation phase at the resting surface by stimulation of 
osteoclastogenesis (generation of new osteoclasts).  The resorption phase is initiated after 
osteoclasts are formed via acidification and destruction of bone matrix.  In the formation 
phase, the osteoblasts are recruited via several growth factors which are produced during 
the process of resorption.  Once an osteoblast stops secreting bone matrix, it has one of 
these potential fates: it may change into a quiescent cell on the bone surface, called a lining 
cell, it can undergo apoptosis, or it can become embedded in osteoid and differentiate into 
an osteocyte [133]. 
 
1.3.4.1 Role of vitamin D in bone remodelling   
In bone, the active form of vitamin D, 1,25(OH) is critical for mineralization either via its 
direct action on bone cells, or indirectly via its role in regulation of the intestinal and renal 
calcium absorption [134].  Experimental studies have shown that the major bone cells, 
osteoblasts, osteoclasts and osteocytes are able to express the VDR and CYP27B receptor, 
and can locally synthesize 1,25(OH)2D from 25(OH)D [135, 136].  Moreover, it has been 
shown that 1,25(OH)2D can act in concert with PTH leading to inhibition of the rate of 
bone resorption and increasing the rate of bone formation, thereby promoting osteoblast 
proliferation and maturation [135-137].  However, in case of low serum calcium levels, 
1,25(OH) and PTH can promote osteoclastogenesis and bone resorption. Furthermore, in 
the literature there are some inconsistencies regarding the effects of vitamin D on bone 
differentiation and mineralization.  For instance, transgenic mice that overexpressed the 
VDR mature cells of the osteoblastic bone-forming cells showed an increase in bone 
formation rate as demonstrated by an increase in the trabecular thickness and bone strength 
[137].  Another experiment on VDR knockout mice also showed a similar observation, 
including an increase in the trabecular bone volume and mineralization, in addition to the 
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number of osteoblasts [138].  Although both of the studies support the direct role of 
vitamin D on bone formation, the first indicated that vitamin D is an anabolic factor 
whereas the second study showed of vitamin D is not required for normal skeletal 
formation. 
 
The content of the extracellular matrix (ECM) is an essential determinant of 
mineralization.  Several proteins have been found to be regulated by 1,25(OH)2D and 
ECM mineral contents such as osteocalcin [139], osteopontin [140] and bone sialoprotein 
[141].  Another important element for mineralization is matrix vesicles which are secreted 
into the ECM from osteoblasts and contain a large quantity of  alkaline phosphatase (ALP) 
[142].  It has been shown that treatment of pre-osteoblastic cell lines with 1,25(OH)2D can 
increase the production of mature matrix vesicles prior to mineralization leading to earlier 
onset and higher rates of mineralization, with no change in gene expression of the 
extracellular matrix [143].  These studies have suggested that vitamin D plays an important 
role in providing the extracellular matrix with the environment necessary for 
mineralization rather than being a direct participant in the process of mineral deposition. 
 
Osteocytes have been suggested as a regulator of bone mineralization via secretion of local 
regulatory factors that control the activity of both osteoclasts and osteoblasts such as 
Dentin Matrix Protein (DMP1) [127].  In addition to being critical mediators of bone 
metabolism by its secretion to fibroblast growth factor (FGF23), the influence of 
osteocytes extends to other tissues and organs such as kidneys and muscles, where they can 
serve as endocrine cells.  Fibroblast Growth Factor  is a bone-derived hormone known as a 
key regulator of phosphate homeostasis.  Both osteocytes and osteoblasts have been 
suggested as the main source of circulatory FGF23, and locally produced vitamin D has 
been proposed as an important regulator of FGF23 production [144, 145].  Fibroblast 
Growth Factor can inhibit phosphate reabsorption from renal tubular and suppress 
CYB27B1 production, leading to a decrease in the circulating 1,25(OH)2D level in 
addition to stimulating CYB24 catabolism of 1,25(OH)2D.  Additionally, FGF23 has also 
been linked to several inherited and/or acquired hypophosphatemic disorders such as 
autosomal dominant hypophosphatemic rickets and tumour induced osteomalacia [146]. 
Both 1,25(OH)2D and PTH can act on immature osteoblasts and osteoblast lining via VDR 
and PTH receptor type 1(PTH1R) leading to up-regulation of the expression of the 
RANKL and decreases the expression of its antagonist, osteoprotegerin (OPG).  However, 
1,25(OH)2D appears to have a regulatory effect on bone remodelling via stimulating 
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mature osteoblasts to secrete more OPG and less RANKL, thus reducing the rate of bone 
resorption [147-149].   
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Figure 1-5: Schematic diagram summarizes the main steps of the bone remodelling process.  
 
Bone resorption can be triggered by stimulation of the lining cells through several signals which are 
either related to mechanical stress or related to the bone microenvironment such as insulin-like 
growth factors1 (IGF1), parathyroid hormone (PTH) or interleukin-6 (IL-6). These signals stimulate 
osteoclasts (OCLs) formation by inducing of RANK/RANKL expression, on pre-OCLs and 
osteoblasts (OBLs). Additionally, OBLs signals [+] can also promote the differentiation and 
maturation of the osteoclast precursors (Pre-OCLs) to activated osteoclasts (OCLs). Activated 
osteoclasts express the resorption pits. The resorption pits dissolve the inorganic matrix and 
lysosomal enzymes and digest the exposed type-1 collagen. This also leads to the release of specific 
degradation products such as fibroblast growth factors (FGFs) and transforming growth factors-β 
(TGF-β) which are accountable for recruitment of osteoblasts in the resorbed area. Once recruited, 
osteoblasts generate new bone matrix, initially not mineralized known as osteoid, and then they 
stimulate its mineralization, thus completing the bone remodelling process.  
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1.3.4.2 Markers of bone remodelling 
Biomarkers of bone metabolism are bone tissue proteins, or their derivatives or enzymes. 
These analytics are secreted from bone cells during various stages of bone remodelling and 
can be measured in blood or urine.  There are several combinations of formation and 
resorption markers that reflect the metabolic activity of osteoblasts or osteoclasts, 
respectively.  Measuring the rate of bone remodelling using bone remodelling markers has 
the advantages of being relatively cheap and non-invasive for sample collection compared 
with traditional methods such as bone biopsy [150].   
1.3.4.2.1   Markers of bone formation 
  
Bone formation markers are either by-products of active osteoblasts or collagen synthesis 
which are produced during the various stages of their development.  These biomarkers 
include alkaline phosphatase (ALP) and osteocalcin (OCN), which are produced by 
osteoblasts.  The N-terminal and C-terminal extension peptides of procollagen are released 
during collagen synthesis. 
 
1.3.4.2.1.1 Alkaline Phosphatase (ALP) 
 
Alkaline phosphatase is localized on the outer surface of the osteoblasts and released into 
circulation during the process of bone remodelling [150].  Although the exact function of 
this enzyme is still unclear, evidence suggested it has a role in osteoid formation and 
mineralisation [151].  Total serum alkaline phosphatase (TAP) consists of several isoforms 
which are able to express in several tissues such as intestine, liver, bone, kidney, and 
placenta.  Three of these genes are tissue-specific, and encode the intestinal, placental and 
germ-line enzymes.  The non-tissue-specific gene encodes bone, liver, and kidney ALP 
[152-154].  Therefore, measurement of serum ALP, as a marker of bone remodelling can 
lack sensitivity and specificity particularly in adults as a bone-specific isoenzyme 
constitutes only up to 50% of the total ALP.   
 
In children and adolescents the most dominant isoform is bone-specific isoenzyme which 
predominates due to active skeletal development (up to 90%).  Some studies have 
suggested the utility of serum ALP as a specific screening test to identify vitamin D 
deficiency in children.  However, others have indicated that ALP can be used only to 
assess the progress of vitamin D status and to further confirm the diagnosis.  The reason 
for this is that measurement of serum ALP may not detect the subclinical cases of vitamin 
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D deficiency or vitamin D deficiency in a carrier of hypophosphatasia.  Immunoassays 
are simple and rapid methods to measure the bone-specific isoform of ALP [155].  
 
1.3.4.2.1.2 Osteocalcin or bone gamma-carboxyglutamic acid (Gla)  
 
Osteocalcin is a protein which is synthesized and secreted by differentiated osteoblasts 
constituting around 20% of the non-collagenous part of the bone matrix [156].  Osteocalcin 
is mainly known as a marker of bone formation [157].  However, it has been shown that it 
could participate in the process of osteoblast-osteoclast interaction and bone resorption by 
facilitating the process of recruitment and differentiation of circulating monocytes and 
osteoclast precursors [156, 158].  Osteocalcin consists of two forms: fully-carboxylated 
osteocalcin and under- carboxylated osteocalcin.  The first form (carboxylated osteocalcin) 
is characterised by high calcium affinity and hydroxyapatite binding properties due to the 
presence of three γ-carboxy residues at positions 17, 21 and 24 in glutamic acid (Gla), 
which allow osteocalcin deposition on mineralized bone matrix.  On the other hand, the 
lower affinity of the under- carboxylated part of osteocalcin to hydroxyapatite to be 
responsible for its easy release into circulation [155, 159].  
 
Experimental studies provided evidence for the extra-skeletal role of osteocalcin.  For 
example, activation of under-carboxylated osteocalcin in the circulation has been shown to 
promote insulin synthesis and to improve insulin resistance in mice.  Additionally, the 
under-carboxylated osteocalcin stimulates β-cell proliferation and adiponectin in 
adipocytes [160].  In mice, daily injections of osteocalcin can improve glucose homeostasis 
and prevent the development of type 2 diabetes; however, human interventional studies 
still show inconclusive results [161, 162].  Both the carboxylated and the under-
carboxylated forms are measurable in the circulation in addition to the total osteocalcin 
that is usually used as a marker of bone formation.  Due to the presence of multiple 
isoforms and the fact that it easily undergoes degradation in circulation, the utility of serum 
osteocalcin as a marker of bone formation is very limited and there is high variability 
between the available assays in the detection of different fragments of osteocalcin [155].   
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1.3.4.2.1.3     Procollagen type-1 propetides ; C-terminal (PICP) and N-terminal (PINP) 
propeptides  
 
In bone, type 1 collagen is synthesized in osteoblasts from the precursor protein, 
procollagen. Mature type 1 collagen is a heterotrimer consisting of two identical a1 chains 
and one a2 chain. During collagen synthesis, specific proteases remove amino-terminal 
 (N-) and carboxy-terminal (C-) extensions of the precursor protein procollagen type 1. 
These extensions are referred to as the C- and N-terminal propeptides of procollagen type 
1.  Both forms can be identified in the circulation and their concentrations reflect mainly 
the rate of collagen type I synthesis in bone.  Several extra-skeletal tissues such as skin, 
blood vessels, fibrocartilage and tendons can synthesize procollagen type-1 propetides; 
however, they have a minimal contribution to the total serum pool [155]. 
1.3.4.2.2  Bone resorption markers 
 
Most bone resorption markers are the result of bone collagen degradation products, apart 
from tartrate-resistant acid phosphatase.  Most of the available bone resorption markers are 
measured in urine.  Bone resorption markers are classified into three groups. The first 
group is the degradation products of bone collagen, such as hydroxyproline, collagen 
cross-links and pyridinium crosslinks.  The second group includes cross-linked 
telopeptides of type I collagens (NTX, CTX, ICTP), non-collagenous protein of bone 
matrix (bone sialoprotein and osteopontin) and osteocalcin fragments in urine.  The third 
group is osteoclast enzymes [155]. 
 
1.3.4.2.2.1 Cross-linked telopeptides of type I collagens (CTX, NTX) 
 
During the process of osteoclastic bone resorption, the collagen in the bone matrix is 
degraded and both collagen ends cleaved and released into circulation as amino- (N-) and 
carboxy- (C-) terminal telopeptides.  Two degradation products have been identified at the 
C- terminal telopeptide: ICTP (cross-linked C-terminal telopeptide of type I collagen) and 
CTX (C-terminal cross-linked telopeptide of type I collagen).  Two types of proteinases 
have been suggested to participate in collagen cleavage and degradation. The first type is 
cysteine proteinases such as cathepsin K, which is responsible for NTX and CTX cleavage, 
and the matrix metalloproteinases (MMP) which release ICTP.  Several immunoassays 
have been developed to assess the N- and C- telopeptides in both serum and/or urine [155].  
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Table 1-5: Commonly used bone remodelling biomarkers. 
Bone formation Bone resorption 
By-products of collagen synthesis: 
Procollagen type I C-terminal propeptide 
Procollagen type I N-terminal propeptide 
 
 
Collagen degradation products: 
Hydroxyproline* 
Pyridinoline** 
Deoxypyridinoline*** 
 
Matrix protein: 
Osteocalcin 
Cross-linked telopeptides of type I collagen 
N-terminal cross-linked telopeptide 
C-terminal cross-linked telopeptide 
Osteoblast enzyme: 
Total alkaline phosphatase 
Bone alkaline phosphatase 
 
Osteoclast enzymes: 
Tartrate-resistant acid phosphatase4 
Cathepsin K 
 
*Measured in urine and specific for all fibrillar collagens and some collagen protein. Found in bone, 
cartilage, soft tissues and skin. ** Measured in urine and highly abundant in bone collage and 
cartilage. Found in bone tendon and cartilage. ***Abundant only in bone collagen and can be 
measured in urine. 4: produced by osteoclasts, erythrocytes and thrombocytes and found in bone 
and blood. Can be measured in serum and urine. Taken from [163].  
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 Vitamin D, PTH and calcium  
Vitamin D plays a central role in calcium and phosphorus metabolism, and helps to 
maintain sufficient levels of these minerals for both metabolic functions and bone 
mineralization.  Vitamin D can interfere with calcium function in several ways.  Vitamin D 
is essential for dietary calcium absorption, calcium movement across epithelium cell 
membranes, and calcium reabsorption from renal tubules, and calcium resorption from 
bone. 
 
1.3.5.1 Vitamin D and calcium absorption  
Vitamin D had multiple roles in maintaining serum calcium levels.  Vitamin D increases 
dietary calcium absorption from 10% – 15% in case of vitamin D deficiency to around 35-
40% with vitamin D sufficiency.  Additionally, vitamin D plays an essential role in 
calcium translocation through the cytosol of the intestinal epithelium [164].  
 
Calcium transport across cell membranes is through both an active transport process 
(transcellular) and a passive process (paracellular diffusion).  Active or transcellular 
calcium transport occurs only in the beginning of the gut and involves the uptake of 
calcium from the apical surface (brush border of the intestine or renal epithelium), transfer 
through the cytoplasm and then active excretion across the basolateral cell membrane 
[164].  The main component of this process involves calcium binding protein, calbindin, 
and two ions channels called transient receptor potential channels (TRP channels), TRPV6 
and TRPV5 [165]. 
 
 Accumulating evidence shows that VDREs are expressed in TRPV6 promoter regions and 
are suggested to exert a direct effect of vitamin D on calcium influx.  Additionally, both 
TRPV6 and TRPV5 have been identified in the epithelial cell membrane of the intestine 
and/or  kidney [166].  Calbindin was down-regulated in vitamin D knock-out mice 
compared with wild type [167].  The paracellular calcium transport takes place throughout 
the entire length of the intestine and mainly in the more distal regions.  This pathway is 
dependent mainly on the luminal electrochemical gradient and the integrity of the tight 
junction.  It has been shown that vitamin D can increase permeability to tight junction ions, 
and VDR knockout mice have decreased levels of claudin which is a major component of 
transmembranous tight junction [168].  
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1.3.5.2 Vitamin D and endocrine control of calcium homeostasis 
Calcium homeostasis, the process of regulation of calcium ions in the extracellular fluid, is 
a vital mechanism required for many basic body functions such as muscle contraction 
[169].  In this mechanism parathyroid hormone (PTH) works together with 1,25(OH)2D, 
and, to a lesser extent, calcitonin (CT) to maintain serum calcium levels (see Figure 1-6) 
[170] . 
 
Parathyroid hormone is a true hormone which consists of a polypeptide of 84 amino acid 
peptide hormone synthesized and released from chief cells of parathyroid glands in 
response to changes in serum calcium levels.  After secretion, PTH then travels through the 
blood stream to produce its effect at the target tissues or organs, primarily in bone, kidney 
and intestine [171].  The acute secretory response of the PTH is regulated tightly by 
extracellular calcium concentration and G protein-coupled calcium sensing receptors 
(CaSR) located on the surface of chief cells. Any minimal reduction in serum calcium 
concentration will be sensed by the CaSR and stimulate PTH secretion from parathyroid 
cells.  For example, the reduction in serum calcium levels stimulates secretion of PTH via 
decreased binding to the calcium sensing receptors (CaSR). 
 
 Calcitonin (CT), is 32 amino acid peptide hormone synthesized and released from 
parafollicular cells of the thyroid in response to high serum calcium level.  Calcitonin 
secretion stimulates renal calcium excretion and its actions and inhibits calcium resorption 
from the bone and calcium absorption from the kidney [170].  
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Figure 1-6: Calcium homeostasis. 
 
 Low dietary calcium stimulates parathyroid hormone (PTH) release which, in turn, directly stimulates 
bone resorption,  stimulates conversion of vitamin D in the kidney to its active form, 1,25(OH)2D. 
The active form of vitamin D also works to increase blood concentrations of calcium through 
facilitating calcium absorption in the small intestine, enhancing fluxes of calcium out of bone and 
tubular calcium reabsorption, in conjunction with PTH. Calcitonin suppresses the renal tubular 
reabsorption of calcium and inhibits calcium bone resorption.  
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 Rickets 
Rickets, which originates from the Greek word rhakhis, meaning spinal column, has been 
known since early human history [10, 12].  In the last century, several advances have been 
made in terms of vitamin D pathophysiology, factor affecting metabolism and mineral 
homeostasis.  
 
1.3.6.1 Definition of rickets  
Rickets is a disease of growing bone caused by lack of vitamin D, calcium, or phosphate 
and affects children during active growing, prior to fusion of the growth plate.  In this 
disease there is a deficiency or failure in endochondral calcification at the growth plates 
resulting in distortion of the growth plate and a decrease in longitudinal growth and bone 
deformities [172].  Several types of rickets have been identified as shown in Table 1-6 and 
the next section will discuss the most common type of rickets, which is vitamin D 
deficiency rickets.  
 
1.3.6.2 Aetiology of vitamin D deficiency rickets  
As mentioned earlier in this chapter, limited sun exposure, high latitudes, seasons, 
clothing, increased indoor activity during daylight hours, skin pigmentation, sunscreen and 
inadequate dietary vitamin D intake in older children and exclusively breast fed infants are 
the main predisposing factors of nutritional vitamin D deficiency [173-175].  In addition to 
the above natural factors, co-existence of chronic systemic illnesses and chronic 
medications such as anticonvulsant drugs and glucocorticoids have a significant impact on 
vitamin D metabolism leading to vitamin D deficiency.  Chronic liver disease and hepatic 
failure may reduce the circulatory levels of 25(OH)D due to impaired synthesis and/or 
decreased vitamin D absorption due to portal hypertension, leading to intestinal edema. 
Steatorrhea (fat malabsorption) and other malabsorption diseases such as celiac disease and 
cystic fibrosis lead to vitamin D excretion in the stool due to decreased vitamin D 
absorption.  Renal disease/failure may also affect the circulatoring vitamin D levels.  For 
example, decreased renal function secondary to chronic renal failure may affect the 1-α-
hydroxylase availability, and decreased glomerular filtration rate may limit the delivery of 
substrate to the 1-α-hydroxylase enzyme and limit the ability of the kidney to produce 
1,25(OH)2D.  Finally, medications such as Phenobarbitone may increase the risk of 
vitamin D deficiency due to direct effects of CYP27A1 and CYP2D25 expression on 
hepatocytes [23, 176, 177].  
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Table 1-6: Suggested classification of rickets. 
Non-hereditary vitamin D deficiency rickets 
Type Biochemical changes Main cause 
 
Nutritional rickets 
↓ 25(OH)D, normal or ↓ calcium 
and phosphate, normal or ↑ PTH 
and ALP 
Low vit D and/or calcium intake, 
lack of sun exposure, sun screen 
and dark skin 
Congenital rickets (congenital 
vitamin D deficiency) 
Maternal vit D deficiency during 
pregnancy 
Secondary vitamin D 
deficiency 
Hepatic diseases (↓25 
hydroxylase production) 
Malabsorption (End-organ 
resistance to vit D) 
Renal disease (↓ renal 1,25 
hydroxylase) 
Iatrogenic due to medication such 
as anti-convulsion drugs; 
↑degradation of /↓ synthesis of vit 
D 
Hereditary rickets 
Type Biochemical changes Main cause 
Vitamin D-dependent rickets  
(Autosomal recessive)[178] 
Vitamin D-dependent rickets, 
type I 
No change in serum 25(OH)D; 
↓↓circulating 1,25(OH)2D, 
↓calcium, ↑ PTH, ↑ALP 
Mutations in the gene codes for 
1α-hydroxylase in kidney 
Vitamin D-dependent rickets, 
type II 
(Vitamin D resistant rickets) 
No change in serum 25(OH)D; 
↑ circulating 1,25(OH)2D, normal 
or ↓calcium, ↓ phosphate, ↑PTH, ↑ 
ALP 
Mutations in the gene codes for 
VDR. No response to vitamin D 
treatment 
Familial (X-linked dominant) 
hypophosphataemic 
rickets[179] 
No change in serum 25(OH)D, 
PTH and calcium; 
↓ or normal circulating 
1,25(OH)2D, ↑ renal phosphate 
loss, ↓ circulating phosphate 
associated with FGF-23 
abnormalities, ↑ ALP 
Mutations in the gene codes for 
PHEX causing renal tubular 
defect in phosphate transport 
Autosomal Dominant 
hypophosphataemic rickets 
[180] 
Mutations in the gene codes for 
FGF-23 
Autosomal  recessive 
hypophosphataemic rickets 
[180] 
Mutations in the gene codes for 
DMP1 
Other (renal) rickets 
Type Biochemical changes Main cause 
Proximal (type 2)  renal tubular 
acidosis (Fanconi syndrome)  
[181] 
No change in serum PTH, 
↑ renal phosphate loss. Not 
associated with FGF-23 (a 
circulating hormone that causes 
renal phosphate wasting ) 
Secondary to dysfunction of 
the proximal renal tubules due 
to; 
 
Genetic disorders such as Wilson 
disease 
 
Acquired disorders due to drugs 
such as aminoglycosides 
Distal (type 1) renal tubular 
acidosis [182] 
Secondary to dysfunction of 
the distal renal tubules due to; 
 
Genetic due to mutation in Band 
3 protein 
 
Diseases such as SLE and sickle 
cell anaemia 
 
Drugs such as lithium carbonate 
*VDR: Vitamin D receptor. PHEX: Phosphate-regulating gene homologous to endopeptidases on the 
X chromosome. FGF23: Fibroblast growth factor 23. DMP1: Dentin Matrix Acidic Phosphoprotein 1. 
SLE: Systemic lupus erythematosus. 
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1.3.6.3 Growth plate and pathophysiology of rickets  
The main function of vitamin D is to promote calcium absorption through the small 
intestine.  In a vitamin D sufficient state, intestinal calcium absorption reaches as high as 
80% of the intake whereas in a state of vitamin D deficiency, calcium absorption from the 
gut is severely affected and reduced to become as low as 10-15% of dietary calcium intake 
[24].  This reduction in intestinal calcium absorption leads to hypocalcaemia which in turn 
stimulates production of PTH, leading to an increase in urinary phosphorus excretion.  In 
bone, there is an increase in the rate of phosphorus and calcium resorption in an effort to 
maintain serum calcium levels accompanied by defective mineralization of the growth 
plate [134, 183, 184].  However, the direct effect of vitamin D on the growth plate cannot 
be excluded as shown by the healing of rachitic chick plates following 24,25(OH)D3 
injection directly into rachitic chick growth plates [185].  
 
The growth plate, which is also known as the epiphyseal plate, refers to the growing area 
of immature bone tissue near the end of the long bones (metaphysis) in children and 
adolescents.  Longitudinal bone growth takes place at the growth plate by a process known 
as endochondral ossification in which the chondrocytes are produced and then 
progressively replaced by bone tissue.  Vitamin D receptors have been identified on growth 
plate chondrocytes suggesting a direct role for the vitamin D in chondrocyte metabolism 
[186].  
 
The anatomical structure of growth plate is composed of  matrix (non-cellular components) 
through which the cell columns organized.  The growth plate consists of four zones: 
 
The germinal zone (the resting or reserve zone): Consists of small and irregularly 
scattered cartilage cells.  These cells do not have an active function in bone growth.  They 
connect the growth plate to the bone of the epiphysis, serve as storage for nutrients and a 
place for supplies for the developing cartilage cells.  Injury to this layer results in 
interruption of growth [187].  
 
The proliferative and columnar zones: These layers are where the cell division and 
active growth of cartilage cells takes place.  Chondrocytes divide to replace those that die 
at the diaphyseal surface of the epiphyseal plate.  Before division, the chondrocytes have a 
flattened appearance.  Once they begin to divide, they arrange into columns [187].  
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The hypertrophic zone: Also known as the maturing zone.  No active growth takes place 
at this layer.  The cells begin to differentiate, and are involved in the process of maturation, 
where they display higher metabolic activity leading to apoptosis.  In rickets, the failure of 
calcification causes accumulation of cells in this layer and the width of this zone is 
increased, leading to mineralization defects (see Figure 1-7) [188]. 
 
The zone of provisional calcification: Death of cartilage cells, high production of ALP 
and calcification of the cartilage matrix occurs in this zone.  The calcified matrix then 
became a template for osteoblastic bone formation.  Invasion from metaphyseal blood 
vessels also takes place [187].  
 
 
 
 
Figure 1-7: The anatomy of the growth plate in normal and rickets conditions. 
 
 In rickets, the growth plate becomes more thickened due to growth plate cartilage accumulation. 
The chondrocytes of the growth plate become disorganized, losing their columnar orientation. In 
bone tissue below the growth plate (metaphysis), there will be mineralization defect, increased width, 
cortical thinning and bowing. 
 
43 
 
 
1.3.6.4 Clinical presentation 
Three main clinical symptoms can be seen in children presenting with vitamin D 
deficiency rickets: delayed growth, bone pain, and bone deformity, depending on the age 
of the child and the biomechanical situation at the time of presentation.  Clinical 
presentation of rickets in infants mainly reflects the consequence of hypocalcaemia in 
relation to the muscular skeletal system.  Rickets is manifested as part of three stages.  The 
first stage is characterized by initial temporary hypocalcaemia.  The child may present with 
irritability, excessive crying, apnoeic episodes, hypocalcaemia seizure, tetany, stridor, or 
even heart failure.  No bone abnormalities are obvious during this stage.  In the case of 
congenital rickets, the child will exhibit hypocalcaemia during the neonatal period, which 
is also reflected in the maternal vitamin D status.   In stage II, skeletal abnormalities 
become evident and deteriorate in stage III.  Older infants and younger children may 
present with delayed motor development, slow growth, abnormal gait, muscular weakness 
and bone pain [172, 176]. 
   
1.3.6.5 Clinical examination  
Generalized muscular weakness and craniotabes (soft skull bones) may be seen in young 
infants.  Thickening and enlargement of the skull may occur if  the rickets presented at a 
later age (manifested as frontal bossing due to delays in the closure of the anterior 
fontanelle).  Other skeletal deformities including bow legs, forward projection of the 
breastbone (pigeon chest or pectus carinatum), funnel chest (pectus excavatum) and 
rachitic rosary.  The weakened lower ribs may also be strained inferiorly toward the inside 
by the attachment of the diaphragm which is called Harrison’s sulcus.  At the ankle, 
palpation of the tibial malleolus may look like a double epiphysis which is called Marfan 
sign.  Spine deformities such as scoliosis or kyphosis occur in chronic cases of profound 
vitamin D deficiency.  The bone deformities such as Genu Varum (bow legs) can be seen 
clinically and radiologically and mostly in toddlers when they start walking whereas older 
children may have valgus or windswept deformities [172, 176]. 
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1.3.6.6 Osteomalacia 
In childhood  rickets, the primary defective organ is the growth plate with its chondrocytes 
and chondrocyte-derived extracellular matrix.  Osteomalacia developed following the 
closure of the growth plate and generally refers to bone disease due to vitamin D 
deficiency in adults which leads to accumulation of unmineralized or poorly mineralized 
bone matrix. 
 
The main clinical presentation of osteomalacia is bone pain and tenderness, and sometimes 
bone fracture. The main definitive diagnosis is made through laboratory investigation. The 
biochemical characteristics of osteomalacia are similar to those of rickets. Due to growth 
plates being closed in adults, the distinctive radiographic features of childhood rickets is 
absent [189, 190].   
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1.3.6.7 Radiographic findings in rickets and osteomalacia 
Clinically, assessment of changes in bone modelling can be carried out using several 
densitometry techniques such as the gold standard dual-energy x-ray absorptiometry 
(DXA).   More dynamic assessment can be provided by using biochemical markers of bone 
turnover in both circulation and urine [191, 192].  In young children, due to an active 
growing skeleton, the effect of vitamin D deficiency on the normal mineralization process 
can be easily recognized in X-rays.  This becomes further manifested at the growth plate, 
at the distal ulna and radiud, and at the metaphysis around the knee joint.   
 
Normally, the growth plate appears is a radiolucent gap between the epiphyseal/ 
metaphyseal interface in X-ray.  At the initial stages the epiphyseal part of the growth plate 
widens with some degree of irregularity.  As the disease progresses, the fraying and 
widening becomes more prominent and can be recognised by the formation of cortical 
spurs and stippling.  This will be more evident at the metaphyseal end of the femur, tibia, 
or radius.  Thin tubular bones such as the ulna and fibula show cupping at metaphysis.  
Due to this expansion in the width of the metaphysis, soft tissue swelling will be apparent 
around the ends of the long bones.  This can be seen more clearly at the anterior rib ends at 
the costochondral junctions and is known as ‘rachitic rosary’.   
 
In both rickets in children and osteomalacia in adults, the diaphysis of the long bones is 
weak (osteopenic) with cortical thinning.  Trabeculae of the long bone may have a coarse 
shape and in some cases may have a ground glass appearance.  In severe rickets and 
osteomalacia, there will be pathological fractures and looser zones.  Looser zones, which 
are also known as pseudofractures or Milkman's fractures are narrow radiolucent lines with 
irregular sclerotic margins and are not true fractures or stress fractures.  The lesions 
typically consist of poorly mineralized osteoid matrix and are specifically found in 
osteomalacia.  Adults with prolonged vitamin D deficiency may have reduced bone density 
leading to osteopenia and osteoporosis.  A dual-energy x-ray absorptiometry (DXA) scan 
should therefore be performed to assess bone density (see Figure 1-8, Figure 1-9 and 
Figure 1-10) [172, 176, 193]. 
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Figure 1-8: Radiological signs of rickets.  
 
Radiograph of finger in the infant showing decreased bone density, coarsening of trabecular pattern, 
and cortical erosion indicating hyperparathyroidism (taken with permission from [193]). 
 
 
 
 
 
 
 
 
Figure 1-9:  Radiological signs of rickets. 
 
 A: Chest radiograph in an infant showing expansion of the anterior rib ends (arrows), marked 
reduction in bone density, cortical tunnelling and fraying, and splaying of the proximal humeral growth 
plate (arrow heads). B: closer chest radiograph illustrates the expansion of the anterior rib ends 
(arrows), known as a “rachitic rosary” (taken with permission from [193]). 
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Figure 1-10: Radiological signs of rickets.   
 
Genu Varum, fraying and splaying of the metaphyses with fragmentation of the medial aspect of the 
lower femoral metaphysis (white arrowhead). Dense zone of provisional ossification (black arrows) 
indicates that this is intermittent rickets currently in a healing phase (taken with permission from 
[193]).   
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1.3.6.8 Laboratory findings 
The confirming diagnosis of vitamin D deficiency and insufficiency in both adults and 
children is completed by determining the level of serum 25(OH)D.  In addition, measuring 
plasma concentrations of calcium, phosphorus, PTH and ALP may further confirm the 
diagnosis and be assessed to identify the degree of  underlying pathology.  The classical 
laboratory finding, in vitamin D deficiency rickets is a reduction in serum calcium and 
phosphate.  Parathyroid hormone, ALP and urinary phosphorus levels is expected to be 
elevated.  However, in some individuals, a longer time may pass before the clinical and 
radiological signs appear.  During this period hypo, normo or hypercalcemia, high levels of 
PTH, normo or hypophosphatemia, high ALP, high, normal or low levels of 1,25(OH)2D 
may be identified [172, 176, 193]. 
 
1.3.6.9 Treatment of vitamin D deficiency  
The most widely used treatment for vitamin D deficiency consists of vitamin D2 
(ergocalciferol) or vitamin D3 (cholecalciferol).  However, evidence from clinical trials 
has shown that vitamin D3 is more effective in treating and maintaining serum 25(OH)D 
levels than vitamin D2 [26, 194].  In a parallel, single-blind trial involving 33 healthy 
adults randomized to take 50,000 IU/week for 12 weeks of either form of calciferols, 
Heaney et al. (2011) demonstrated that vitamin D3 is nearly 87% more potent than 
Vitamin D2 in raising and maintaining serum 25(OH)D concentrations [194].  However, 
there are several conflicts regarding this issue as other studies have reported that both 
vitamin D2 and vitamin D3 are effective in treating and maintaining serum 25(OH)D 
concentrations [195, 196].  In a six-week randomized controlled trial involving 40 infants 
and toddlers aged between eight and 24 months, Gordon et al. (2008) showed that short-
term doses of 2,000 IU vitamin D2 daily, 50,000 IU of vitamin D2 weekly, or 2,000 IU of 
vitamin D3 daily had an equal result in the treatment of vitamin D deficiency [196].    
 
Table 1-7 summarises the Endocrine Society’s recommendation for treatment of vitamin D 
deficiency.  Monitoring of the treatment progression is very important.  Obtaining serum 
calcium, phosphorus, 25(OH)D and ALP levels four weeks after beginning therapy is 
strongly recommended.  The first biochemical change, an increase in serum phosphate 
levels, may occur within one or two weeks.  High ALP levels before the treatment is an 
indication of a transient rise in the bone formation rate with an initial rise in 1,25(OH)2D 
levels.  Complete radiologic may take months, although changes started as early as one 
week.  Investigations should be repeated after three months [40, 42].   
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Table 1-7: Treatment of vitamin D defiency according to age groups. 
Age  
Therapeutic  
Maintenance  
Per day 
(Vitamin D2 or 
vitamin D3) 
Per week 
(Vitamin D2 or 
vitamin D3) 
0-12 months 2000 IU for six 
weeks 
50,000 IU for 6 
weeks  
400-1000 IU/day 
1-18 years 2000 IU for six 
weeks 
50,000 IU for 6 
weeks 
600- 1000 IU/day 
19-50 years 6000 IU for six 
weeks 
50,000 IU for 8 
weeks 
1500-2000 IU/day 
51- >70 years 6000 IU for six 
weeks 
50 000 IU for 8 
weeks 
1500-2000 IU/day 
Obese patients/on medication 
e.g. glucocorticoids & 
ketoconazole/ malabsorption   
6000-1000 IU for 
six weeks 
- 3000-6000 IU/day 
Information adapted and edited from [42].     
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1.4  Extra-skeletal effects of vitamin D deficiency  
Over the past decades, there has been a great deal of interest in vitamin D as a potential 
modulator of several non-skeletal systems and related diseases.  It has been suggested that 
vitamin D deficiency may influence the development of diabetes and autoimmune diseases 
[197, 198].  Although there is good evidence to show that there is an association between 
vitamin D deficiency and an abnormality of the above systems, there is little evidence to 
show that vitamin D supplementation leads to an improvement in function, especially in 
childhood. 
 
 Link between vitamin D and glucose homeostasis 
1.4.1.1 Glucose metabolism - an overview 
Glucose is one of the vital metabolic fuels required for cellular function, and the process of 
maintaining blood glucose at a steady state is known as glucose homeostasis. Maintaining 
euglycemia involves a complex network of mechanisms and requires coordination and 
communication between several organs under strict neuronal and hormonal control [199].  
Any defect in the glucose homeostasis pathway may result in insulin resistance and 
hyperglycaemia which are characteristic features of metabolic syndrome.  Metabolic 
syndrome can be defined as a cluster of cardiovascular risk factors that have been shown to 
predict the development of cardiovascular disease and type 2 diabetes, and include obesity, 
impaired insulin resistance, hyperglycaemia, hyperlipidemia and hypertension.  In children 
aged between 10-16 years the diagnostic criteria for this condition include: obesity (age 
and sex specific BMI –Z score ≥ 2.0), triglycerides ≥ 1.7 mmol/l, HDL < 1.03 mmol/l, 
fasting glucose ≥ 5.6 mmol/l and systolic blood pressure ≥ 130. However, metabolic 
syndrome cannot be diagnosed in children younger than 10 years, but further close follow-
up is needed if there is a family history of metabolic syndrome, type 2 diabetes mellitus or 
hypertension [200, 201]. 
 
The liver plays a critical role in maintaining steady glucose levels by switching between 
glucose uptake and storage through glycogenesis and glucose release through a process of 
glycogenolysis and gluconeogenesis.  Additionally, the pancreas is known as a key 
coordinator of glucose homeostasis by releasing hormones that target glucose production 
in the liver [202]. 
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There are two major ways in which insulin can affect glucose homeostasis during food 
intake.  Firstly, in skeletal muscle and adipose tissue, insulin enables glucose uptake 
through the cell membrane by stimulating mobilization of a transporter called GLUT 4 
from intracellular vesicles into the cellular surface [203].  In liver and pancreatic β cells, 
glucose uptake depends on transporters called GLUT1 and GLUT 2 but does not depend 
on insulin [204].  
 
Depending on the target tissue, insulin affects glucose metabolism.  For example, in 
skeletal muscle glucose will increase the rate of glycogen synthesis, while in adipose 
tissues insulin suppresses lipolysis and encourages lipogenesis.  Secondly, insulin is a 
potent inhibitor of hepatic glucose production.  Therefore, in the liver, the insulin promotes 
glycogen synthesis and lipogenesis and inhibits gluconeogenesis.  On the other hand, 
during starvation, insulin secretion is decreased and another pancreatic hormone, glucagon, 
is increased, leading to an increase in hepatic gluconeogenesis and glycogenolysis. 
Subsequently, glucose is released into the circulation and the blood sugar level is 
maintained.  Additionally, the rate of lipogenesis in the liver is reduced while lipolysis in 
adipose tissue increases (see Figure 1-11) [202].  
52 
 
 
 
 
Figure 1-11: Glucose homeostasis. 
 
During food intake, blood glucose concentration increases, stimulating insulin secretion from β cells 
of pancreas, and eventual glucose absorption by peripheral tissues. During fasting or between the 
meals, in order to maintain the normal concentration of blood sugar, the α-cells of the pancreas 
release another hormone called glucagon to encourage glycogenolysis and gluconeogenesis, 
leading to elevation of blood glucose. Blue arrows: stimulation and release. 
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1.4.1.2 Insulin synthesis, secretion and mechanism of action   
Beta cells (β cells) which constitute around 65-80% of the cells in the pancreatic islets 
(islets of Langerhans) are the site of insulin synthesis.  Insulin synthesis begins with the 
translation of its respective mRNA on the ribosome into inactive preproinsulin, followed 
by insertion into rough endoplasmic reticulum.  In rough endoplasmic reticulum, 
preproinsulin is cleaved into proinsulin which consists of three domains: an amino-
terminal B chain, a carboxy-terminal A chain and a linking peptide known as the C 
peptide.  Proinsulins are then further cleaved into insulin and free C-peptides before being 
transported to the Golgi apparatus where it is packaged into secretory granules located 
close to the cell membrane [205, 206].  Insulin is released from the secretory granules by 
fusion of the granules with the cell membrane and exocytosis of insulin and C-peptides 
[207]. 
 
Insulin secretion from filled vesicles in β cells follows a biphasic pattern.  The first phase, 
known as acute insulin release occurs in the first 5–10 minutes subsequent to glucose 
stimulation.  Insulin secretion from the ‘readily released’ pool which is situated near, or 
even docked to, the plasma membrane accounts for only about 5% of the total amount 
released after a meal.  After the acute insulin response, there is a second insulin secretion 
in which insulin is released more gradually, but is longer lasting as a result of the secretion 
from granules in the ‘reserve pool’.  Here, granules are translocated from the intracellular 
‘reserve pool’ into the ‘readily released’ pool at the cell membrane [207]. 
 
Insulin release leads to activation of insulin receptors in the target tissues followed by 
phosphorylation and recruitment of a variety of substrate adaptors such as insulin-receptor 
substrate (IRS) proteins.  Insulin receptor substrate (IRS) proteins are docking proteins that 
act as key mediators triggering a complex signalling network involving second messenger 
systems that regulate distinct biological effects such as alterations in glucose and lipid 
metabolism [208, 209] (see Figure 1-12). 
 
Energy is essential for maintaining life, and glucose metabolism is a primary source of 
energy.  As mentioned earlier, glucose enters the β cells via facilitated diffusion mediated 
by glucose transporters such as GLUT1 and GLUT2 [204].  In the first step of glucose 
metabolism, glucokinase on the mitochondria is responsible for the conversion of glucose 
into glucose-6-phosphate. Glucose-6-phosphate lies at the beginning of the two major 
metabolic pathways, the glycolytic pathway, which generates NADH, ATP, and pyruvate 
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(generating ATP through the Tricarboxylic acid cycle (TCA) and oxidative 
phosphorylation in the mitochondria) or the pentose phosphate pathway (PPP) [210]. 
Increasing the ATP/ADP ratio from the glycolytic pathway closes ATP- gated potassium 
channels, leading to cellular depolarization and opens voltage-gated calcium channels. 
Opening voltage-gated calcium channels then leads to a high calcium concentration inside 
the cell, triggering the first phase of insulin release through the translocation of storage 
vesicles toward the cell membrane and insulin exocytosis [208].  The pentose phosphate 
pathway is an antioxidant cellular defence pathway which plays a key role in the synthesis 
of nucleic acids for DNA and RNA, as well as the generation of NADPH for the synthesis 
of lipids and intracellular redox homeostasis maintenance (reduction-oxidation reaction) 
[211].  
 
Finally, it has been suggested that the liver is responsible for most circulatory insulin 
clearance, compared with peripheral tissue, and both insulin clearance and sensitivity have 
been shown to be closely correlated.  Therefore, decreased hepatic sensitivity may 
represent the initial stage of insulin resistance instead of increased peripheral resistance . 
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Figure 1-12: Simplified diagram shows insulin receptors and main signalling pathways. 
 
1: Binding of insulin to the insulin receptor causing them to dimerise, 2: Dimerised receptor undergoes trans-auto-phosphorylation (grey ovals), 3: Proteins linking to 
phosphate groups/signal 1; IRS proteins can lead to recruitment of Grb2 and SHC , initiating of RAS pathway and generating a signalling cascade that is involved in cell 
differentiation, survival and growth. 4: Proteins linking to phosphate groups/signal 2; Following phosphorylation, IRS proteins can also recruit P85 and P110 subunits of PI(3)K 
which in turn activates and localizes protein kinases such as PDK1 followed by activation of members of other kinases such as  aPKC and Akt and initiating a cascade of events 
playing a key role in modulation of glucose, glycogen, lipid and protein metabolism, 5: Activated Akt substrate P70s6k also stimulates GLUT 4 translocation to the cell 
membrane and enhances glucose uptake in peripheral tissues.  
IGF-I: insulin-like growth factor. IRS: insulin receptor substrate. SHC: Src Homology 2 domain containing. Grb2: growth factor receptor-bound protein 2. SOS: Ras guanine 
nucleotide exchange factor, Son of Sevenless. MAP kinases: Mitogen-activated protein kinases. PI(3)K: phosphoinositide 3-kinase. Akt/ PKB: protein kinase B pathway. FOXO1: 
Fork head box protein O1. GSK3: Glycogen synthase kinase 3. P70s6k: serine/threonine kinase.
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1.4.1.3  Insulin resistance 
Insulin resistance can be defined as the failure of proper response to insulin action. Generally, 
there will be a profound dysregulation in glucose homeostasis due to a reduction in glucose 
oxidation and glycogen synthesis leading to decrease energy production, while glucose 
production continues unsuppressed.  At the cellular level, there will be a decreased sensitivity 
to insulin action, with an increase in insulin release to compensate for the high glucose level. 
At the molecular level, there will be a reduction in the strength of insulin signalling via the 
IRS-1/PI(3)K pathway, resulting in diminished glucose uptake and insulin utilization in target 
tissues.  In this context, two mechanisms have been suggested.  The first mechanism is 
triggered by mitochondrial dysfunction, which causes phosphorylation of IRS-1 by other 
serine kinases, which in turn decreases the ability of IRS-1 to attract and activate PI(3)K . 
 The second mechanism is an upregulation of the P85 subunit of PI(3)K that affects PI(3)K 
signalling pathway activation.  However, it has been indicated that both increased expression 
of p85 and increased serine phosphorylation of IRS-1 are required in order for signs of insulin 
resistance to be displayed in a clinical setting [208, 212].  
 
When insulin resistance occurs in healthy individuals, the pancreatic β cells secrete more 
insulin in order to overcome the decreased effectiveness of insulin.  However, in genetically 
susceptible individuals, the β cells are eventually unable to overcome this increased load, 
leading to hyperglycemia as in type 2 diabetes.  Accordingly, insulin resistance has been 
suggested as an early sign and a significant player in the pathogenesis of this disorder [213]. 
 
A number of methods are commonly used in the clinical setting to assess insulin resistance 
and β cell dysfunction as described below. 
 
The hyperinsulinaemic-euglycaemic clamp is widely considered as the ‘gold standard’ method 
for assessing insulin sensitivity by measuring the rate of whole-body glucose disposal during 
steady state hyperinsulinaemia, while maintaining a steady blood glucose level by continuous 
infusion of glucose at 5-10 minute intervals [214].  This technique cannot assess β cell 
function and is often combined with the hyperglycaemic clamp to quantify the adequacy of β 
cell response (insulin secretion) to glucose infusion [215].  Although clamp technology has 
been applied to the study of insulin sensitivity and insulin secretion during childhood, it is 
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time-consuming (taking between 2-4 hours), invasive, and is technically difficult to perform 
on very young children [216].   
 
Because no intravenous access is needed, the oral glucose tolerance test (OGTT) has been 
suggested as a reliable minimal-risk procedure suitable for assessment of large populations. 
There are several discrepancies in this test in terms of the oral dose of glucose and sampling.  
A standard oral glucose load of 75g is often used in adults, following an overnight fast.  If the 
glucose is administered intravenously, the test is called an intravenous glucose tolerance test 
(IVGTT).  Although the OGTT does not require IV access, it does require several blood draws 
over the two- or three-hour period following oral glucose administration [206, 217]. 
 
The homeostasis model assessment (HOMA) for insulin resistance (HOMA IR) and the 
quantitative insulin-sensitivity check index (QUICKI) are simple methods to assess insulin 
sensitivity and β cell function [218].  Two versions of the HOMA method are currently 
available.  The original HOMA1 was developed in 1985 based on a simple formula using 
fasting serum insulin (FSI) (mIU/l) and fasting serum glucose (FSG) (mmol/l) measurements 
to assess insulin resistance with the formula: HOMA1 IR = (FSI×FSG)/22.5.  The updated 
computer model HOMA2 can be calculated using specific software and is employed to 
determine insulin sensitivity (HOMA2%S), and HOMA IR  from fasting glucose (mmol/l) and 
insulin (mIU/l), and β cell function from fasting glucose (mmol/l) and C-peptide 
concentrations (a marker of insulin secretion).  The quantitative insulin-sensitivity check index 
(QUICKI) is employed to measure fasting insulin and fasting glucose to assess insulin 
sensitivity.  
 
In children, the accuracy and precision of the basal fasting methods have been assessed and 
found to correlate reasonably well with clamp techniques [219, 220].  The fact that these tests 
require only a single venepuncture in the fasting state and do not call for concomitant 
intravenous access makes them particularly attractive for using in the paediatric population. 
Additionally, childhood assessment of basal fasting glucose homeostasis variables such as 
fasting glucose, fasting insulin and HOMA IR has been suggested as significant predictors of 
future adulthood pre-diabetes, type 2 diabetes and cardiometabolic risk factors [221].  
However, it is important to note that the interpretation of HOMA IR values is particularly 
challenging in children and adolescents due to the pre-existence of multiple HOMA IR 
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thresholds to describe IR.  Furthermore, HOMA measures are a reflection of the basal status 
which represent a single point, whereas OGTT and clamp measures represent a wider picture 
of the dynamic of β cells in response to rising and falling glucose concentrations, which may 
not be suitable for children at risk of developing impaired glucose homeostasis [222]. 
 
Sex hormone binding globulin (SHBG) is a glycoprotein known traditionally to binds, 
regulates, and affects the bioavailability of the sex steroids, testosterone and oestradiol.   
Evidence from observational studies links low serum testosterone level in men and prepubertal 
children with the tendency towards future development of central obesity, insulin resistance, 
metabolic syndrome, and diabetes [223, 224].  Evidence also links lower SHBG status with an 
increasing incidence of type 2 diabetes mellitus, independent of sex hormone levels .  One 
genetic study showed that three single nucleotide polymorphisms of the SHBG gene might 
have been related to an increased risk of developing type 2 diabetes mellitus; suggesting an 
association between SHBG and glucose homeostasis parameters prior to the onset of diabetes 
mellitus [225].  Accordingly, SHBG can be used as a biomarker to identify children at risk of 
developing  obesity-related chronic diseases such as diabetes mellitus. 
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1.4.1.4 Link between Vitamin D & glucose homeostasis – putative mechanisms 
Evidence from in vitro and in vivo studies has supported the role of vitamin D in glucose 
metabolism and β cell function.  Schneider et al.(1977) provided a direct in vitro indication for 
the involvement of vitamin D in glucose homeostasis by observing abnormal serum 
1,25(OH)2D levels in diabetic rats compared with healthy controls, and the restoration of 
1,25(OH)2D to a normal level after insulin treatment [226].  Coexisting hypovitaminosis D 
and abnormal glucose metabolism has also been reported in patients with type 2 diabetes 
mellitus (T2DM) compared with healthy controls [227].  A possible link with vitamin D was 
also raised when seasonal variation in plasma glucose and insulin was observed in normal 
individuals [228]. 
 
There have been several biological mechanisms suggested by which vitamin D may contribute 
to the development of T2DM, mainly through its direct/indirect contribution to the 
abnormality in β cell function and glucose metabolism, insulin resistance and systemic 
inflammation, which are the main characteristics of the pathophysiology of T2DM.  Table 1-8 
summarises some of the current plausible biological evidence for mechanisms by which 
vitamin D may contributes to the abnormality in glucose homeostasis and development of 
T2DM.  In accordance with these findings, a significant reduction in insulin secretion in VDR 
mutant mice has been observed [229] and the human insulin gene has been shown to be 
transcriptionally activated by 1,25(OH)2D [230].  
 
Vitamin D supplementation also appears to have a beneficial effect on glucose-dependent 
insulin secretion in the case of vitamin D deficiency [231].  Vitamin D may influence insulin 
secretion indirectly through its role in the regulation of calcium flux through the cell 
membrane and ensuring a sufficient cytoplasmic pool of Ca+2, combined with its role in the 
synthesis and regulation of calbindin (a vitamin D-dependent Ca-binding protein in pancreatic 
β cells) [232].  Treatment of hypocalcaemic wild type-mice with food rich in calcium results 
in a significant reduction in blood sugar.  However, this is not evident in mice that express a 
functionally inactive mutant VDR [229].
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Vitamin D may also protect β cells from fatal immune attacks, or programmed cell death, 
either directly or through its effect on various components of the innate and adaptive immune 
system at different levels (as discussed later).  It has been reported that 1,25(OH)2D may 
counteract apoptotic pathways and the inflammatory effect induced by cytokines through 
inactivation of NF-kappa-B anti apoptotic protein and suppression of  Fas receptor expression 
[233, 234]. 
 
Another possible mechanism explaining the involvement of vitamin D in abnormalities of 
glucose homeostasis and pathogenesis of T2DM is the role of hypovitaminosis D in enhancing 
insulin resistance at the target tissues [235, 236].  The presence of the VDR in extra-skeletal 
target sites, such as skeletal muscle and adipose tissues, together with the up-regulation of 
insulin receptors (INS-R) after 1,25(OH)2D treatment appears to support this hypothesis 
[237]. 
 
Elevated PTH has also been suggested as a direct modulator for both insulin sensitivity and 
secretion by affecting glucose uptake and inhibiting insulin transport signalling in the target 
tissues, primarily by increasing intracellular calcium concentration [238].  Chronic 
inflammation may increase insulin resistance and vitamin D may influence the inflammatory 
reaction through several mechanisms, including modulation of the release of inflammatory 
cytokines such as TNFα, regulation of the activity of NF-kappa-B, regulation of genes 
encoding pro-inflammatory cytokines and down-regulation of Toll-like receptors two (TLR2) 
and Toll-like receptors four (TLR4) expression [239-241].  Figure 1-13 illustrates the putative 
role of vitamin D on insulin synthesis, release from β cells, stimulation of insulin receptors by 
1,25-dihydroxyvitamin D3 and expression and responsiveness of target tissues to insulin 
stimulation. 
 
Finally, Experimental evidence suggests that vitamin D may play a role in the sex hormone 
co-regulation and low vitamin D status has been suggested as a risk factor for conditions 
linked to sex hormone levels, such as insulin resistance and adiposity [242, 243].   
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Table 1-8: Some evidence supporting the putative role of vitamin D in beta (β) cell function and 
insulin action in peripheral tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evidence from pancreatic β cells 
High local expression of VDR and the presence of VDR in insulin gene promoter [244, 245]. 
 
Impairment of glucose-mediated insulin secretion can be normalized with vitamin D supplementation 
in cases of vitamin D deficiency [231, 246].  *Conflicting evidence [232]. 
 
Vitamin D can induce glucose-mediated insulin release [247].  
 
Vitamin D deficiency may alter islet cells’ mitochondrial metabolism, mainly the oxidative events 
[248].  
Evidence from systemic circulation 
Counteract apoptotic pathways via suppression of the cytokine-induced Fas expression at mRNA 
and protein levels [234]. * Conflicting  evidence [197].  
 
Vitamin D can upregulate and maintain high levels of A20, an antiapoptotic protein which is known to 
block NF-κB activation [233].   
 
Reduce susceptibility of β cells to cytotoxic T lymphocytes and protect cells from auto-destruction 
[249]. 
Evidence from peripheral tissues 
Identification of VDR in skeletal muscle [250]. 
 
Vitamin D can enhance insulin receptor capacity and stimulate insulin response in the control of 
glucose transport, in vitro [237]. 
 
Vitamin D may indirectly participate in the process of extracellular calcium normalization and normal 
calcium influx through cell membranes, ensuring a sufficient intracellular calcium pool which is vital 
for insulin function in peripheral tissues such as skeletal muscle and adipose tissue [251-253] .  
 
High PTH accompanied by vitamin D deficiency may decrease glucose uptake by the liver, muscle 
and adipose cells [254]. 
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Figure 1-13: Vitamin D and its role in glucose homoeostasis and pancreatic beta-cell function. 
 
A. Beta cells (β cells): 1,25(OH)2 D can come directly from the circulation or is synthesised within pancreatic beta 
cells. I. 1,25(OH)2 D causes upregulation of the insulin gene via VDR binding which leads to more insulin synthesis. 
II. Vitamin D also improves insulin secretion and glucose tolerance through indirect regulation of intracellular calcium 
through increasing the ATP/ADP ratio resulting in closure of the plasma membrane ATP-gated channels and 
depolarisation of the cell leading to exocytosis of insulin-containing secretory granules. III. Modulation of cytokine 
secretion and apoptotic pathways occurs through interaction with VDRE in cytokine genes, inactivation of NF-κB 
and suppression of the Fas receptor. IV. Upregulation of calbindin may also protect against cytokine-induced 
apoptosis by increasing intracellular free calcium.  B. Target tissues: I. Vitamin D stimulates the expression of 
insulin receptors and signalling transduction, resulting in translocation of GLUT4 to the membrane and glucose 
transport in peripheral tissues. II. Vitamin D causes activation of peroxisome proliferator-activated receptor (PPAR-
δ), a transcription factor implicated in the regulation of fatty acid metabolism. 
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1.4.1.5 Link between vitamin D & glucose homeostasis – evidence from 
observational studies 
In a cross-sectional study, Orwoll et al.(1994) reported no relationship between serum 
25(OH)D, fasting or post-challenge glucose and insulin secretion [255].  However, the indirect 
method for measuring insulin level and unadjusted results for confounders may have had an 
impact on the study outcome.  A positive association between 25(OH)D and insulin secretion 
has been reported in both glucose intolerant East London women of South Asian origin [256] 
and healthy Caucasian elderly men [257].  These studies were performed using an oral glucose 
tolerance test and have been further supported by other studies which used a hyperglycaemic 
clamp technique [258, 259].  Indeed, most of the available cross-sectional studies, including a 
large dataset from the National Health and Nutrition Examination Survey (NHANES), support 
an inverse relationship between serum 25(OH)D and glycaemia and insulin resistance.  
However, the results from this survey were applied only to particular ethnic groups, non-
Hispanic whites and Mexican–Americans but not non-Hispanic blacks [260].  
 
Prospective studies assessing the association between 25(OH)D and diabetes risks are very 
limited.  A negative association between basal serum concentration of 25(OH)D and future 
hyperglycaemia and insulin resistance has been found in one longitudinal study conducted 
over a 10 year period [261].  A recent systematic review and meta-analysis showed that each 
10 nmol/l increase in 25(OH)D level was associated with a 4% decrease in risk of type 2 
diabetes.   In addition, the relative risk of type 2 diabetes was 0.62 (95% CI 0.54-0.70) when 
compared with the highest to the lowest category of 25(OH)D levels [262]. 
 
A number of observational studies have explored the association between vitamin D status and 
markers of glucose homeostasis in both normal weight and obese adolescents.  An association 
between vitamin D deficiency and insulin resistance has been reported in overweight and 
obese adolescents.  Most of these studies have shown the impact of pubertal status, vitamin D 
status, influence of PTH status, and the presence of non-alcoholic fatty liver disease (NAFLD) 
on their study results.  Three studies have failed to find any association between vitamin D and 
insulin resistance in obese children [85, 263, 264].  Other studies report an inverse association 
between hypovitaminosis D and measures of insulin resistance and glycaemia in obese 
children [265-267].  Table 1-9 summarises some recent studies that have investigated the 
association of 25(OH)D with glucose homeostasis in children. 
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In summary, observational studies investigating an association between vitamin D status (as 
indicated by 25(OH)D levels) and glycaemia, diabetic risk and β cell function have been 
performed in multiple cohorts.  Despite the overall view in favour of a negative impact of 
hypovitaminosis D on glucose homeostasis and β cell function, the available literature 
demonstrates inconsistent results. There are still also inconsistencies regarding the sufficient 
dose required to improve vitamin D status.  There are several possible explanations for this 
variation, including differences in study design, subject characteristics, study population, 
confounders and techniques used to assess glucose homeostasis and β cell function. 
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Table 1-9: Summary of studies reporting an association between 25(OH)D and glucose homeostasis in fasted state (boys and girls). 
Ref 
Age 
(Years) 
BMI N Method 25(OH)D  (nmol/l) 
Association 
with glucose 
homeostasis 
Adjusted for 
variable 
Comment 
Reinehr et al 
[263]  
 
12.1 ± 2.4 
 
27.7 ± 3.8 
 
133 
 
Glucose, insulin 50 No BMI Longitudinal study (1 year) 
Smotkin et al 
[85] 
 
12.9 ± 5.5 
 
32.3 ± 6.4 
 
217 
 
Glucose, insulin 
 
55.2% < 50, 
44.8% ≥ 50 
No None Retrospective study 
Delvin et al 
[268]   
9, 13, 16 
 
20.1 ± 4.2 (Boys), 
20.4 ± 4.5 (Girls) 
1745 Glucose, insulin 
 
45.9 ± 13 (Boys),   
45.9 ± 12.2(Girls) 
Yes 
 
Age, sex, BMI, 
smoking, income, 
activity 
- 
Ford et al 
[269] 
 
12 - 17 
(Range) 
- 
1941 
 
Glucose, insulin, 
HbA1c 
59 Yes 
 
Age, sex, BMI, 
ethnicity, activity 
vitamin intake, 
HDL 
Association with insulin 
resistance in selected sub-
groups. 
Kelly et al 
[270]  
11 ± 4 
2.1 (-1.2,4.1) 
(Median (min, max)) 
85 
 
Glucose, insulin, 
HbAIc 
 
59 ± 32 Yes 
 
Age, sex, season, 
ethnicity, BMI,  
puberty 
 
No correlation between 
HOMA and race, sex, 
season after adjustment 
for puberty and BMI-Z. 
Olson et al 
[271]  
6 - 16  
(Range) 
99.2 (Percentile for age) 411 
Glucose, insulin, 
OGTT, HbA1c 
49 ± 17.8 Yes Age, BMI 
 
Correlation exists only 
after adjustment. No 
correlation with HbA1c. 
Roth et al 
[266] 
11.9 ± 2.7 
 
SDS-BMI; 
20% (Non obese) 80% 
(Obese) 
156 
 
Glucose, insulin, 
HbA1c 
39.4 ± 6.6 Yes Age, sex, BMI 
 
No impact of adiposity on 
study result. 
Poomthavron 
et al [264] 
11.2 ± 2.6 28.6 ± 4.8 150 
 
OGTT( Obese), 
Glucose (Non 
obese), insulin 
70.4 No None 
Subjected to selection bias 
as recruited from obesity 
clinic. 
Nsiah-Kumi et 
al [267] 
10.8 ± 0.3 
77. ± 1.7 (Percentile for 
age & sex ) 
198 
Glucose, insulin, 
2hr blood glucose 
42.4 (16.9, 99.8) 
Median/range 
Yes BMI - 
*OGTT: Oral glucose tolerance test. QUICKI: Quantitative insulin sensitivity check index. HbA1c: Glycosylated haemoglobin. BMI: Body mass index (kg/m2). 
BMI-SDS: Body mass index – standred deviation score. Data are shown as mean (SD), unless otherwise specified.
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1.4.1.6 Link between Vitamin D & glucose homeostasis – evidence from 
interventional studies  
A possible association between vitamin D and insulin secretion was raised in some 
interventional studies over three decades ago [256, 272, 273].  However, other studies did not 
find any effect of vitamin D supplementation [274-276].  Grimnes et al. 2011 administered 
20,000 IU vitamin D3 orally twice a week for six months to a healthy Caucasian cohort who 
had vitamin D levels lower than 40.3 ± 12.8 nmol/l, but could not find any effect on insulin 
sensitivity or secretion [277].  This was consistent with another study which showed that the 
injection of two doses of 100,000 IU vitamin D3 did not lower fasting glucose or insulin 
sensitivity in a Caucasian cohort [278].  However, these results could not be applied to other 
ethnic populations as shown by a randomised, controlled trial which involved South Asian 
participants and demonstrated a significant effect of the administration of 4000 IU vitamin D3 
for six months; fasting glucose decreased and insulin sensitivity increased in vitamin D-
deficient and insulin-resistant South Asian women [279].  
 
Mitri et al. (2011) designed the short-term Calcium and Vitamin D for Diabetes Mellitus 
(CaDDM) 2 x 2 factorial, double-masked, placebo-controlled trial, which looked at the effect 
of vitamin D and calcium supplementation alone or in combination on pancreat ic β cell 
function, insulin sensitivity and glucose tolerance in 92 mainly Caucasian, obese and glucose 
tolerant adults.  Study participants were divided into four groups to receive either 2000 IU 
Cholecalciferol or 400 mg Calcium carbonate, or matching placebo once a day for 16 weeks. 
The deposition index, which was used as an indication for pancreatic β cell function was 
measured.  The results from this study showed a significant increase in the deposition index in 
the vitamin D supplement group and improvement in pancreatic β cell function by 15-30% 
with a tendency to decrease the rise in the measure of glycemia [280]. 
 
A more recent randomized, double-blind, placebo-controlled trial conducted by Krul-Poel et 
al. (2015) examined the effect of vitamin D3 supplementation (50 000 IU/month) on HbA1c, 
fasting glucose, fasting insulin and insulin resistance in a cohort of patients with type 2 
diabetes mellitus (n = 275).  After six months of vitamin D3 supplementation, serum 25(OH)D  
concentration was significantly improved in the vitamin D group compared to the placebo,       
p < 0.01 (from 60.6 ± 23.3 to 101.4 ± 27.6 nmol/l and 59.1 ± 23.2 to 59.8 ± 23.2 nmol/l  in the 
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vitamin D and placebo group, respectively).  However, there was no observed effect of 
vitamin D supplementation on markers of glycemic control [281]. 
 
Based on the available data, little is known about the association between insulin 
sensitivity/resistance, glucose intolerance and vitamin D deficiency in the paediatric 
population.  A recent double-blind, placebo-controlled trial of obese vitamin D-deficient 
adolescents aged 9-19 years failed to find any significant effect of six months supplementation 
of 4000 IU vitamin D on BMI, inflammatory markers, fasting glucose and insulin [282].  In a 
further two 12-week trials, administration of either 4000 IU/day or of 300,000 IU/week of 
Cholecalciferol demonstrated favourable effects on glucose homeostasis and/or metabolic 
syndrome outcomes on obese adolescents [283].  Although larger doses had been used in the 
weekly vitamin D trial, it seems that daily supplementation was more efficient in raising 
serum 25(OH)D concentrations (increase of ~47 nmol/l in the former versus 35 nmol/l in the 
latter).  A further non-randomized trial did not find any significant effects of 8 weeks of 
50,000 IU/week supplementation on glucose homeostasis of obese adolescents [9]. 
 
In conclusion, results from interventional studies show some degree of inconsistency with a 
heterogeneity of techniques, study designs, subject characteristics and therapeutic regimen.  
Most of the available studies used indirect methods to measure the effect of vitamin D on 
insulin sensitivity/resistance.  Basal vitamin D levels were not available for most of the studies 
and there was no universal threshold to define vitamin D deficiency, insufficiency or 
sufficiency.  There is a need for more interventional studies, involving larger sample sizes, 
focusing on both normal weight and obese children with careful selection of the dose, 
treatment regimen, and achievement of target 25(OH)D concentrations.  
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 Link between vitamin D and immune function 
1.4.2.1 Immune response - an overview  
The principle roles of the immune system are providing protection and recognition and 
responding with subsequent destruction of foreign and harmful events such as diseases and 
infections.  This is done by maintaining self-tolerance (discriminate self from non-self-
molecules), and developing immunologic memory against non-self-molecules.  The ability of 
the immune system to recognize self and respond to non-self-harmful events is known as 
immune response, which has been divided into innate and adaptive immune responses. The 
adaptive immune response is further divided into humoral and cell-mediated adaptive immune 
responses [284].   
1.4.2.1.1 Innate immune responses  
 
The main function of the innate immune response is to provide a first line of protection during 
the time between pathogen exposure and early adaptive response.  The significance of the 
innate immune responses can be appreciated by considering its initiation time, which may 
takes a few minutes, compared with the development of a specific adaptive immunity which 
may takes days to weeks [284].  
 
The first component of the innate immune system consists of a combination of physical and 
chemical barriers.  Physical barriers are not generally considered a proper part of the immune 
system; when an infection overwhelms the physical barriers the role of the immune system 
starts [285].  The second level of the innate immune system is the production of antimicrobial 
peptides (AMPs) such as α defensins (HNP1-4 and HD-5, 6), β defensins (Hbd-1 to 4) and 
cathelicidin (hCAP18) [285].  Activation of the innate immune response is mediated partly by 
a family of receptors called pattern-recognition receptors (PRRs) which sense and recognize 
the conserved pathogen-associated molecular patterns (PAMPs), such as microbes' cell-wall 
components and viral nucleic acids [286].  The recognition of microbes by PRRs direct the 
immune response accordingly through subsequent recruitment of innate and adaptive immune 
cells [287].  In mammals, toll-like receptors (TLRs) have been recognized as a family of PRRs 
and suggested to induce the innate inflammatory reaction causing a release of various 
inflammatory mediators and AMPs [288, 289].  The third and most specific level of innate 
immune system is phagocytosis, promotion of healing and initiation of inflammatory 
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responses though phagocytic leukocytes, dendritic cells and natural killer (NK) cells.  T helper 
type 2 (Th2) inflammatory responses is a specific type of innate immune response against 
helminths invading at cutaneous or mucosal sites and characterized by recruitment and 
activation of mast cells, basophils and eosinophils, and the production of Th2 cytokines such 
as interleukin-4 (IL-4), IL-5 and IL-13 by naive T cells before stimulation of the adaptive 
immune response (discussed in the next section) [290].   
1.4.2.1.2 Adaptive immune responses 
 
Unlike the innate immune responses, the adaptive responses are more specific and stimulated 
when a particular pathogen is ingested by immature dendritic cells in the infection site. There 
are two broad classes of adaptive immune responses - humoral (antibody response), and cell-
mediated immune responses.  Lymphocyte populations are key components for the adaptive 
immune responses, including thymus-derived lymphocytes (T-lymphocytes), CD8+ 
(cytotoxic) and CD4+ (helper) T cells, bone-marrow-derived (B-lymphocytes) and NK cells 
[284].  
 
The humoral immune response refers to the generation of antibodies by the B cell population 
known as plasmablasts (immature plasma cells) and plasma cells, leading to the destruction of 
invading microbes, providing both short and long term protection to pathogenic challenge 
[291].  Binding of antibodies to microbes inactivates them by blocking their ability to bind to 
corresponding receptors on targets cells, and marks them for phagocytic cells of the innate 
immune system to ingest them. This type of immune response may be stimulated directly by 
microbes or through collaboration with T cells which recognize antigens presented through 
MHC (major histocompatibility complex) class II molecules on the B-cell surface or through 
interaction between CD40 ligands (CD40L) on the T cell and CD40 on the B cell.   T helper 2 
(Th2) cells which secrete cytokines IL-4 have been suggested to play a key role in B cell 
differentiation and IGg/IgE response [292, 293]. 
 
Cell-mediated immunity involves the activation of macrophages and NK cells, the production 
of antigen-specific cytotoxic T-lymphocytes, and the release of various cytokines in response 
to an antigen.  Three major effector T cell classes have been identified which play essential 
roles in adaptive immune response: CD8 +T cells, cytotoxic T cells (antigens presented to its 
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surface by MHC class I molecules) and CD4+ T cells (differentiated further into several 
effectors as discussed below).  
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1.4.2.1.3   CD4-positive T cells (CD4+ T cells) 
 
Following their development in the thymus, naive T cells are conveyed through systemic 
circulation to peripheral lymphoid organs and remain in circulation between blood and 
lymphoid organs until they encounter their antigens.  Following antigen stimulation, the role 
of naive T cells in adaptive immune response begins by proliferation and differentiation into 
cells capable of contributing to the removal of the antigen known as effector T cells or CD4+ 
T cells.  
 
Accumulating evidence has suggested that CD4+ T cells are key players in the immune system 
response to harmful events.  Firstly, CD4+ T cells have been shown to assist B cells switch 
class to produce antibodies [274].  Secondly, activation of macrophages promotes microbial 
killing [275].  Thirdly, they stimulate and maintain responses of CD8+ T cells [276]. 
Furthermore, CD4+ T cells have been postulated to play a role in the process of recruitment of 
inflammatory cells such as eosinophils at sites of infection and inflammation [277].  Finally, 
through their ability to differentiate and to produce a wide range of cytokines and chemokines, 
CD4+ T cells can be considered  as a key coordinator of the immune response [278].  
  
During the process of adaptive immune response, the naive CD4+ T cell encounters an antigen 
presented to its surface by MHC proteins that protrude from the surface of APCs.  The MCH 
binds to peptide fragments (epitopes) derived from pathogens and presents them on the cell 
surface for recognition by T-cells.  After the antigen presentation, the naive CD4+ T cells then 
start to proliferate and differentiate into several T cell effectors/CD4+ Th cell subtypes 
including T helper 1 (Th1), T helper 2 (Th2), T helper 17 (Th17) and induced regulatory T 
(iTreg) cells [294, 295] (see Figure 1-14). 
 
 One of the most crucial factors determining the naive CD4+ Th cell differentiation/ 
polarization process is the effector cytokine environment produced by APCs  [294, 296].  For 
instance, activation of naive CD4+ T cells in the presence of IL-12 or IL-4 produced by 
dendritic cells (DCs) lead to production of Th1 or Th2 phenotypes.  Transcription factors such 
as T-bet (T-box) and signal transducers and activators of transcription (Stat 4) are required for 
Th1 cell differentiation, and transcription factors such as GATA-binding protein 3 (GATA3) 
and signal transducers and activators of transcription (STAT 6) are required for Th2 cell 
differentiation (see Figure 1-14). 
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Transcription factors play a crucial role in CD4 Th cell differentiation/polarization and 
cytokine production by providing a key link between cytokine receptors and cytokine-induced 
gene transcription [294].  For example, the STAT 4 signalling pathway can be activated by IL-
12, inducing IFN-γ transcription and initiating Th1 differentiation, while the presence of IL-4 
activates the Stat6 signalling pathway, resulting in IL-4 transcription and Th2 differentiation 
[297].  T-box transcription factor (T-bet), a master regulator for Th1 differentiation, is able to 
activate a panel of genes to promote Th1 phenotype differentiation of a particular phenotype, 
and is a powerful suppresser of Th2 differentiation [298].  Transcription factor GATA-binding 
protein 3 (GATA3) known as a master regulator needed for Th2 differentiation [299, 300].  
 
The two main classical types of effector CD4+ T helper cells, Th1 and Th2 have been 
characterised based on their distinct cytokine secretion patterns  Type 1 helper T (Th1) 
response, the production of  interleukin (IL)-2, gamma-interferon (IFN-γ) and tumour necrosis 
factor-α (TNF-α), whereas Th2 expresses IL-4, IL-5, IL-6 and IL-13.  The diversity in 
cytokine patterns lead to different functions of these two types of effector T cell subset [294, 
301].  Ideally, humans should produce well-balanced Th1/Th2 cell responses, and any 
dysregulation of the effector cells’ balance may cause a disruption in immune responses to 
infections (immunodeficiency) or excessive and incorrect immune responses to harmless 
environmental antigens (atopy) or self-antigens (autoimmunity).  Th1 cells are mainly 
involved in the development of cellular immune responses (stimulating phagocytosis, 
activating antigen-specific cytotoxic T-lymphocytes and cytokine release).  Th2 cells are 
generally related to humoral immune response (an antibody-mediated system) [302].  
 
The status of Th1/Th2 differentiation determines the type of immune response and how the 
body reacts to foreign antigens, and both Treg and Th17 can play a role in maintaining either 
Th1 or Th2 balance or both, which has been implicated in the pathogenesis of immune system-
related disorders [303-305].  For example, over-stimulation of the Th1 master gene, T-bet, 
shifts the differentiation into the Th1 phenotype, exacerbating colitis in experimental animals, 
whereas suppression of T-bet encourages differentiation to Th2 and Th17 lineages, resulting in 
decreased Th1 immunity and spontaneous asthma [306, 307].  Most of the CD4+ helper cells 
undergo apoptosis on resolution of infection, with a few remaining as CD4+ memory cells. 
Th17 cells were first characterized in 2005 as independent Th1 and Th2 cell linages [308].  
The main Th17-secreted cytokines are IL-17A, IL-21 and IL-22 and differentiation of naive 
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CD4+ Th cells into Th17 has been suggested to be reliant on TGF-β, IL-6, or IL-21 [309].  
Retinoic acid -related orphan receptor gamma t (RORγ t) has been suggested as a specific 
transcription factor stimulating Th17 cell differentiation although it also depends on other 
transcription factors such as STAT 3 [310, 311].  
 
It has been shown that Th17 can be stimulated in several immune cells found in mucosal sites. 
For example, at mucosal epithelial sites, IL-17 induces granulocyte colony-stimulating factor 
(G-CSF) and CXC chemokine (CXCL-8 and CXCL-2) production, leading to neutrophil 
activation that contributes to microorganism clearance at mucosal sites [312-314].  Moreover, 
both IL-22 and IL-17 stimulate antimicrobial peptides such as β-defensin production and 
epithelial repair functions important for the control of extracellular fungal pathogens [315].  
On the other hand, improper Th17 stimulation and/or balance has been linked with the 
development of several inflammatory and autoimmune diseases, such as multiple sclerosis, 
systemic lupus erythematosus, inflammatory bowel disease and asthma  [305, 316-319]. 
 
Regulatory T cells (Tregs) have been suggested as significant players in maintaining immune 
system homeostasis, prevention of autoimmunity and protection against infectious and allergic 
diseases [320, 321].  Evidence have shown that Tregs can be categorized into two main 
subtypes, natural CD4+ CD25+ FoxP3+ Treg cells (nTregs) and inducible/adaptive Treg cells 
(iTregs), which may further acquire CD25+ FoxP3+ expression [322].  Natural Treg cells 
(nTregs) have been suggested as a key player in several physiological and pathological 
conditions, such as pregnancy, autoimmunity and cancers [323-325].  Natural Treg cells 
(nTregs) differentiate in the thymus and migrate to peripheral tissues where they constitute, 
along with iTregs, approximately 5-10% of the total peripheral CD4+ T cells.The second type 
of Tregs are known as inducible Treg cells (iTregs) and include T regulatory 1 cells 
(CD4+CD25- FoxP3- Tr1), which secrete IL-10 , and T regulatory 3 cells (CD4+CD25+ 
FoxP3- Tr3), which secrete TGF-β, and may be converted to FoxP3+ Tregs following 
stimulation by TGF-β, in addition to various subsets of CD8+ Treg cells [326-328]. 
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Adaptive/inducible CD4+ Treg cells (iTregs), may generate from naive T cells and acquire 
CD25+FoxP3+ expression outside the thymus under the influence of TGF-β, and therefore 
suppress activation and expansion of naive T cells and their effector cells, Th1, Th2 and Th17. 
In addition to several pathological inducers for iTreg, such as autoimmune diseases and 
cancer, evidence has also shown that CD4+ iTregs may play a critical role in maintaining 
normal gut homeostasis [329-331].  
 
Transcription factor expression fork head box P3 (FoxP3) and the maintenance of the Treg 
cell-specific DNA hypomethylation pattern have been identified as key features of the Treg 
cell lineage which are necessary for maintaining Treg stability and required for their 
development.  Additionally, Tregs are able to express the high-affinity IL-2 receptor (IL-2R), 
also known as CD25, constitutively regardless of their functional status, and CD25 has been 
suggested as an essential element required for Treg survival and maintenance [323, 332, 333].  
Studies have shown that both nTregs and iTregs (CD4+ FoxP3+) share one substantial feature:  
they regulate and suppress naive CD4+ T cells and their effector cells in order to maintain the 
immune tolerance to self-antigens, and to prevent excessive responses to foreign antigens.  It 
has been suggested that Tregs may be able to suppress naive CD4+ T cells and their effector 
cell functions and activities through contact-dependent and independent mechanisms.  The 
first mechanism is via expression of negative regulatory receptors such as CTLA4, or 
destruction of associated dendritic cells (DCs) through secretion of perforin and granzyme B.  
The contact independent mechanisms involved are secretion of immunosuppressive cytokines 
IL-10 and TGF-β and consumption of IL-2 [322, 325, 330].  On the other hand, the main 
differences between nTregs and iTregs may be related to their origin and cell fate and 
functional stability of the master regulator transcriptional factor FoxP3.  For example, some 
studies have shown that nTreg cells are able to maintain stable FoxP3 expression regardless of 
extracellular conditions, Foxp3-stimulating signals, or cell proliferation.  In contrast, FoxP3+ 
iTreg cells induced in vitro by TGF-β  and/or retinoic acids are less stable in the expression of 
functional FoxP3 and CD4 as reviewed by Ohkura et al. 2013 [334]. 
 
Evidence has suggested that the migratory capacity (homing) of Treg cells to other tissue sites 
such as sites of infections or inflammations are controlled by a variety of adhesion molecules 
and chemokine receptors expressed by FoxP3+ Treg cells [335].  For example, it has been 
shown that FoxP3+ Treg cells are able to express chemokine receptors (CCR) 4, 5, 6, 7 and 8 
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at a relatively higher level than effector T cells. CCR7 is expressed by the vast majority of 
FoxP3+ Treg cells, which enables these cells to migrate towards chemokines CCL19 and 
CCL21.  Furthermore, it has been demonstrated that IL-10-producing nTreg cells can be 
recruited into the site of infection when they express CCR5, and inhibit the development of 
effector T cells and the production of IFN-γ, thereby promoting the survival of pathogens for 
long periods [336-338]. 
 
Due to some limitation of using CD25 as a specific surface markers for Tregs related to its co-
expression by activated effector T cells, FoxP3 has been identified as a better marker for 
CD4+Tregs.  However, there is some functional heterogeneity between different 
CD4+FoxP3+Tregs populations and several studies has been conducted to look at any cell 
surface antigens that distinguish Tregs from naive T cells or differentiate between different 
Treg populations [339, 340].    
 
Experimental studies on the synovial fluid of patients with juvenile arthritis showed that 
activated CD4+CD25+ Treg cells could be recognized by the expression of cell surface 
marker CD127 [341].  Other studies have tried to further characterise surface markers of 
FoxP3+ Tregs using antigens reviewed by Chen and Oppenheim 2011 [340], and several 
studies has been conducted to look at any cell surface antigens that distinctively distinguish 
Tregs from naive T cells or differentiate between different Treg populations [339].  Despite 
extensive research, however, permeabilisation of cells, which is necessary for intracellular 
antigen detection when the antibody is required for intracellular access, is still required to 
identify Tregs population by their Foxp3 expression.  To date, there is still no consensus about 
whether any particular markers can be used for identification of Tregs without permeabilising 
the cells to stain for FoxP3 [342].  
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Figure 1-14: Naive CD4+ T cell differentiation (adapted and modified from[343]).  
 
When naive CD4+ T cells are stimulated by antigen-presenting cells (APCs), they may proliferate and 
differentiate into one of several effectors of CD4+ Th cells, including T helper 1 (Th1), T helper 2 (Th2), 
T helper 17 (Th17) and regulatory T (iTreg) cells, as defined by their pattern of cytokine production and 
function. Several transcription factors have been suggested to coordinate this process (Blue boxes; the 
master regulators are underlined). Cytokines listed over the blue arrows represent major signalling 
cytokines which stimulate CD4+ T subset differentiations. Cytokines in green circles represent main Th 
subset-secreting cytokines. T-bet: T-box expressed in T cells. GATA-3: GATA-binding protein 3. STATs 
3, 4, 5 and 6: signal transducers and activators of transcription 3, 4, 5 and 6). RORγt: Retinoic acid -
related orphan receptor gamma.  
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Table 1-10: Selected CD4 T helper cell-associated cytokines and their main role in immune system. 
Cytokines Main producing cell Target cells Functions 
Th1 secreting cytokines 
IL-2 [344] 
  
Mainly from CD4+ Th cells. 
Others include: CD8+ T, 
dendritic & mast cells 
Activated T cells Skew naive CD4+T cells towards Th1 
& Treg. 
 ↑ CD8+ T cytotoxic activity. 
B cells ↑ Proliferation & antibody production. 
NK cells ↑ Proliferation & cytolytic activity. 
TNF-α  
[345-347]  
Th1cells, macrophages, mast 
& NK cells 
Macrophages ↑ Cytokine expression. 
Cancer cells Cell death. 
INF-γ  
 [346, 348, 
349] 
Th1& NK cells 
Immune system 
Modulate immune response 
Antiviral effects. 
APCs 
↑ MHC expression & pathogen 
elimination. 
Activated B cells Ig class switch to IgG2a. 
Th2 cells Skew T cell proliferation towards Th1. 
Th2 secreting cytokines 
IL-4 
 [301, 350, 
351] 
Th2 cells, Naive T cells, APC, 
mast cells, eosinophils & 
basophils 
 
       T cells 
Skew naive CD4+ T cells towards 
Th2 & inhibiting Th1 differentiation. 
Regulating cell growth and apoptosis. 
Macrophages MHC Class II expression. 
Activated B cells IgG1 and IgE synthesis 
IL-5  
[301, 352] 
Th2 cells 
Activated B cells & 
eosinophils 
Proliferation differentiation 
 
IL-6  
[353] 
Various, including monocytes, 
macrophages, endothelial 
cells, fibroblasts 
Activated B cells Differentiation into plasma cells 
Plasma cells Antibody production. 
T cells 
Skew CD4+ T towards Th2 & Th17  
Inhibiting Treg differentiation 
Anti-apoptosis. 
Main Treg and Th17 secreting cytokines 
IL-10  
[354, 355] 
Various, including Treg, Th2 
and APCs cells 
Monocytes & 
macrophages 
Inhibits MHC class II expression, 
limiting pro-inflammatory cytokine (IL-
6, IL-12, IL-18, and TNF-α) & 
chemokine (MCP1, RANTES, IL-8 
and IP-10) production. 
Naive T cells Differentiation into Treg. 
IL-17 
 [356, 357] 
Various, including Th17 
T cells, macrophages and 
NK cells 
APCs & neutrophils Recruitment. 
T cells ↑T cell proliferation. 
B cells ↑antibody production. 
Other cytokines 
RANTES 
 [358, 359] 
Various, including endothelial 
cells, fibroblasts, T cells & 
macrophages 
Eosinophils, 
basophils & 
monocytes 
Chemotaxis. 
NK & 
Naive cells 
 
Chemotaxis, proliferation & activation. 
INF γ & IL2 production by T cells 
(skew naive T CD4 towards Th1). 
MCP-1 
[360] 
Various, including endothelial 
cells, epithelial cells, 
monocytes & macrophages. 
Monocytes, 
basophils, NK cells, 
memory &T cells 
Chemotaxis., ↑ IL-4 production and 
differentiation towards Th2. 
MIP-1β [358] Lymphocytes Monocytes &T cells Chemotaxis. 
IP-10 
 [361] 
Secretion stimulated by INF-γ 
from various cells such as 
monocytes, endothelial cells, 
neutrophils & eosinophils 
Monocytes, 
macrophages, 
dendritic cells, NK 
& T cells 
Chemotaxis.  
Growth & proliferation. 
Angiogenesis at site of infection. 
EOTAXIN 
[359, 362-365] 
Various, including eosinophils, 
epithelial cells & B cells 
Eosinophils & 
basophils 
Th2 cells 
Chemotaxis & degranulation. 
↑ IL-4 & IL-5 production from Th2. 
IL-8 [366, 367] 
Macrophages & endothelial 
cells 
Neutrophils Chemotaxis & degranulation. 
Th1 TNF α production. 
IL-12 [354, 
368] 
Macrophages & B cells 
NK cells Activation. 
Th1 INF γ production. 
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1.4.2.2 Link between Vitamin D & immune system – putative mechanisms 
The immuno-regulatory role of vitamin D was suggested several decades ago when initial 
observations pointed to the effect of sunshine on increased resistance to infections in 
experimental animals [267].  The effect of seasons and/or latitude on vitamin D status has also 
been discussed extensively [20].  The role of vitamin D and/or ultraviolet radiation in curing 
some health-related illnesses and infections has also been reported [369].  Indeed, significant 
progress has been made in this area after the identification of the expression of vitamin D 
receptors (VDR) and of 1α-hydroxylase in most cells of the immune system including 
monocytes/macrophages, dendritic cells, and stimulated T & B lymphocytes, which indicated 
the potential for local synthesis of vitamin D by these cells [370-372].  This local production 
of vitamin D, in addition to the expression of VDR, also suggests that intracrine actions of 
vitamin D may modulate immune function and help fight external challenges [373, 374]. 
Recent advances have shown that active vitamin D metabolites are involved in the regulation 
and expression of several genes implicated in innate and adaptive immune defence 
mechanisms [375, 376].  The evidence for vitamin D as a modulator of immune responses is 
reviewed below. 
1.4.2.2.1 Physical barrier and innate immunity  
 
Expression of VDR and 1 α-hydroxylase by epithelial cells in the respiratory passages, skin, 
gut and urogenital system suggests that vitamin D may be involved in the preservation of 
barrier integrity and maintaining intracellular functions [377, 378].  Its role in maintaining 
barrier functions is also supported by the observation that vitamin D upregulates genes which 
encode junctional proteins between epithelial cells, such as tight junctions (e.g. Occludin), gap 
junctions (e.g. connexion 43) and adherens junctions (e.g. E-cadherin) [379-381].  However, 
more research is needed to fully understand the role of vitamin D in this area. 
 
Toll-like receptors (TLRs) have been identified in several cell types of the immune system, 
such as monocytes, macrophages and dendritic cells.  Stimulation of TLRs has been found to 
upregulate CYP27B1 and production of 1,25(OH)2D [382].  Several studies have reported a 
role for vitamin D in the production of antimicrobial peptides (AMPs).  Vitamin D has been 
suggested to stimulate human AMPs expression such as cathelicidin at different epithelial 
tissue sites such as bronchial [383], urogenital [384], skin [385] and myeloid cells [386], 
mainly by the ability of vitamin D to sense the pathogen-associated molecular patterns 
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(PAMPs) by means of TLRs [387].  Aside from their direct antimicrobial role, AMPs such as 
cathelicidin and defensins have also been reported to perform many other immune-mediating 
processes, including induction of chemotaxis, mast cell degranulation, stimulation of cytokine 
and chemokine production, cell differentiation, vascular permeability, mediators of 
inflammation, wound healing and the process of antigen presentation [388-391]. 
 
Finally, vitamin D has been suggested to play a vital role at the third level of defence, the 
specific immune response, mainly through its effect on the recruitment of phagocytic cells, 
promotion of healing and initiation of inflammatory responses [392, 393] as discussed below. 
1.4.2.2.2 Antigen presentation and adaptive immunity  
 
Macrophages and dendritic cells (DCs) express vitamin D receptors (VDR) and are able to 
present antigens to the immune cells, such as T cells [284].  Dendritic cells (DCs) are key 
immune system elements that processes and present antigens to T cells, and modified effector 
T cell responses. There are two different DC subtypes: myeloid DCs, which mainly act on the 
naive T cells [394] , and plasmacytoid DCs which have a more tolergenic phenotype  (prevent 
autoimmunity) [395].  
 
Vitamin D has been suggested to produce different effects on both DCs subsets to enable more 
tolergenic responses, rather than immunogenic response and thereby promote the development 
of regulatory T cells [396, 397].  While leaving plasmacytoid DCs unaffected, 1,25(OH)2D 
can block DCs myeloid maturation, causing a reduction in fully active MHC class ІІ, CD1a 
(marker molecule for mature DCs, CD83  (marker molecule for mature DCs) and  DCs co-
stimulatory molecules (CD40, CD80 and CD86) [398].  
 
Additionally, it has been reported that 1,25(OH)2D is able to inhibit IL-12 production by both 
activated macrophages and mature DCs  and to stimulate IL-10 production, resulting in 
induction of CD4+FoxP3+ Tregs and upregulation of DC-characterized molecules such as 
CD152. These  vitamin effects lead to inhibition of alloreactive T cell stimulation and 
decrease T sensitivity to alloantigens (transplant rejection) [398, 399]. 
 
Hewison et al. (2004) have shown that both macrophages and DCs are able to express 
mounting levels of 1α-hydroxylase as they differentiate towards a mature, antigen-presenting 
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phenotype. In dendritic cells, the outcome of this is that both vitamin D and its metabolite 
(25(OH)D3) are able to suppress the differentiation and function of these cells. Concomitantly, 
when the APCs become mature their ability to produce the active form of vitamin D is 
increased but they expresses less VDRs. The active form of vitamin D which is produced by 
APCs has been suggested to act in paracrine fashion on the neighbouring immature APCs to 
trigger more antigen presentation and the ability of mature APCs to decrease the expression of 
VDR prevents over-stimulation [400].  
 
Early researchers have demonstrated that T cells express VDR and appear to be a direct target 
of vitamin D [401].  This was followed by several studies which showed  that vitamin D is 
able to modulate naive T cells phenotypes and functions, affecting their differentiation into 
effector cell subsets and ability to produce more regulatory T cell (Treg) phenotypes [402, 
403]. 
 
It has been suggested that vitamin D may be able to inhibit the production of several Th1 
related cytokines such as TNF-α and INF-γ, whilst promoting production of Th2 cytokines 
such as IL-4 and IL-5 [404, 405]. However, other studies could not confirm these findings 
[406]. T helper 17 cells (Th17) are a recently discovered subset of Th cells, which are thought 
to be important in the pathogenesis of autoimmune diseases such as multiple sclerosis and 
rheumatoid arthritis. Experimental studies showed that vitamin D loss may lead to an 
increased Th17 population and vitamin D treatment  causing a down-regulation of Th17-
secreted cytokines such as IL-17 and IL-21 [406, 407].  
 
Vitamin D was also shown to increase IL-10 production by Treg and induce Treg activity 
leading to induction of DCs and suppress T cell activation.  Therefore, vitamin D deficiency 
may promote autoimmune diseases through both direct and indirect roles in regulating 
Th1/Th17 balance and in improving Treg function in addition to skewing cytokine production 
towards a Th2 phenotype.  Figure 1-15 shows the suggested effect of vitamin D on naive T 
cell differentiation and their effectors cells. 
 
Finally, a number of reports indicate that vitamin D can inhibit the generation of memory B 
cells from naive B cells, inhibit B cell proliferation, induce apoptosis and suppress 
immunoglobulin secretion and maintain the development and function of natural killer cells 
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[408-410].  Figure 1-16 summaries the potential role of vitamin D in the different components 
of the immune system.  
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Figure 1-16: Summary of the potential action of systemic and/or locally synthesized vitamin D on 
different components of the immune system.  
 
AMPs: Antimicrobial peptides. TLR: Toll-like receptors. NK cells: Natural killer cells. VDR: Vitamin D 
receptors. CYP27B1 (cytochrome p450- one-alpha-hydroxylase): Cytochrome p450 enzyme that catalyses 
the conversion of 25-hydroxyvitamin D3 (25(OH)D) to 1-alpha,25-dihydroxyvitamin D3 (1,25(OH)2D). MHC 
class ІІ: Major histocompatibility complex class II molecules. IL-12: Interleukin- 12. Th cells: T helper cells. 
Treg: Regulatory T cell. IgG: immunoglobulin G. IgM: immunoglobulin M. 
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1.4.2.2.3 Link between vitamin D & immune function – evidence from observational 
studies  
 
Clinical associations between the prevalence of immune related illness and vitamin D 
deficiency have been reported widely in the literature.  Results from most observational 
studies report an inverse relationship between vitamin D status and the risk of acute 
respiratory tract infection, tuberculosis and pneumonia in both paediatric and adult populations 
[409, 411-413].  In addition, there is a strong association between vitamin D and the 
prevalence of gastrointestinal [397], urinary tract [384] and ocular infections [414].  The 
impact of vitamin D on several dermatological conditions such as wound healing, psoriasis, 
atopic dermatitis and acne has also been reported [415-418].  Finally, several autoimmune 
diseases such as inflammatory bowel diseases, multiple sclerosis (MS), systemic lupus 
erythematosus, type 1 diabetes mellitus and rheumatoid arthritis have been reviewed. Again 
significant associations between a low vitamin D and the prevalence of autoimmune disorders 
were reported [419-421]. 
1.4.2.2.4 Link between Vitamin D & immune function – evidence from interventional 
studies  
 
As described earlier, the immunomodulatory effects of vitamin D have been well documented 
in vitro. It is therefore of potential importance to explore the effect of vitamin D 
supplementation as promising immunomodulatory therapy for infectious diseases associated 
with chronic inflammation and other immune system related disorders.  However, despite the 
strong observational and theoretical links between vitamin D and immune system disorders, 
interventional studies looking at the therapeutic effect of vitamin D supplementation show 
conflicting results.  In a randomized double-blind study, 4000 IU of vitamin D3 daily for one 
year in patients with immune disorders and frequent attacks of acute respiratory tract infection 
showed a 23% decrease in the number of attacks and 60% reduction of antibiotic use  
[422].  However, in another trial using healthy adults, administration of vitamin D did not 
affect the severity or prevalence of acute respiratory tract infection [423, 424].  In one study, a 
high dose vitamin D3 supplementation was reported to accelerate clinical and radiological 
improvement in pulmonary tuberculosis patients [425].  However, others reported no effect 
[426].  A recent systematic review of randomized, placebo-double-blind trials assessing the 
benefit of vitamin D administration in patients with multiple sclerosis was unable to reach a 
verdict with no significant effect seen in four out of five available trials [427].  Although there 
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are limited studies looking at the effect of vitamin D intervention in children, several 
publications have shown a beneficial effect of vitamin D supplementation on reducing acute 
respiratory tract infections [428, 429].  
 
A randomized controlled trial looking at the effect of 100,000 IU of vitamin D3 
supplementation in South Asian children with pneumonia showed a reduced number of repeat 
attacks in the vitamin D group (58%; relative risk 0.78; 95% CI 0.64, 0.94; p = 0.01) [8]. 
However, supplementation with the same dose once every three months for a period of 18 
months did not reduce the prevalence of pneumonia in high-risk South Asian infants [430]. 
Table 1-11 summarises some recent clinical studies which have been conducted in children.  
 
Accumulating experimental and animal evidence have indicated the involvement of CD4+ T 
cells in the pathogenesis of autoimmune diseases and immune system related disorders such as 
MS and HIV, and the immunomodulatory role of vitamin D on different effector CD4+ T 
subset balance [431].  Therefore, a number of studies were conducted to further explore these 
effects and look at the beneficial effects of vitamin D intervention in different CD4+ T cell 
subsets or related cytokines/chemokines in healthy and in diseased conditions in human 
subjects.  In one interventional study including participants with MS, six months of daily 1000 
IU vitamin D3 and 800 mg calcium supplementation significantly increased TGF-β1 levels. 
However, the results for IFN-γ, IL-2 and TNF-α were variable and inconclusive.  The 
increased TGF-β1 following vitamin D supplementation provides some evidence that vitamin 
D could potentially improve the symptoms of MS patients.  Further significant effects of 
vitamin D intervention as an anti-inflammatory agent were observed in another trial conducted 
in patients with congestive heart failure who received 1000 IU vitamin D3 and 500 mg 
calcium for nine months.  This trial showed a remarkable increase in IL-10 in the vitamin D 
supplemented group and significant increase in Th1 inflammatory cytokines, TNF-α, in non-
vitamin D supplemented congestive heart failure patients [404, 432].  On the other hand, 
weekly doses of 25,000 IU vitamin D3, but not 800 IU/day was effective in influencing Treg 
cell trafficking in patients infected with HIV with an increased level of CCR10 expression, 
while a reduction in CCR4 expression (chemokine required for HIV entry into target cell) in 
HIV infected patients was observed [433]. 
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 Clinical trials on vitamin D regulating serum cytokines in younger population are very limited 
and very little is known about the effect of vitamin D supplementation in healthy children and 
adults [434, 435]. This will be discussed in more detail in Chapter 7.   
 
In summary, scientific studies support an important role for vitamin D in many aspects of the 
immune response.  Clinical evidence from observational studies shows a strong correlation 
between vitamin D deficiency and the development of various immune and infectious 
diseases.  
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*SLE: Systemic lupus erythematosus. AD: Atopic dermatitis. TB: Tuberculosis. AB: Antibiotics. ARIs: Respiratory infections. T1DM: Type 1 diabetes mellitus. 
aOR: Adjusted odds ratio. Data are shown as mean (SD), unless otherwise specified. 
 
 
 
 
 
Table 1-11: Summary of studies reporting association between 25(OH)D and immunity in children (boys and girls). 
 Ref 
Age 
 
n 25(OH)D (nmol/l) 
Outcome 
assessed 
Association 
with outcome 
Comment 
Wright et al. [436] 
16 y 
(median) 
38 44.9 Severity of SLE Yes 
25(OH)D lower in SLE patients (African origin & obese) 
compared with control  (36.8% vs 9.2%, p < 0.001) 
Peroni  et al. 
[437] 
5.6 y 37 
92.1 ± 39.1(Mild AD), 
68.6 ± 21.4 (Moderate), 
51.1 ± 14.7 (Severe AD) 
Severity of AD Yes 
25(OH)D higher in mild AD compared with moderate and severe 
AD (p < 0.05) 
Greer et al. [438] 10.1 ± 0.9 y 56 
81.4 (T1DM), 
70.5 (Newly diagnosed) 
T1DM Yes 
25(OH)D lower in children with T1DM compared with controls 
[mean (95% CI) = 78.7 nmol/l (71.8-85.6) vs. 91.4 nmol/l (83.5-
98.7), p = 0.02] 
 
Allen et al. [439] 
12.7 ± 0.7 
months 
928 - 
Infantile food 
allergy 
 
Yes 
Infants of Australian parents with 25(OH)D ≤ 50 nmol/L were 
more likely to be allergic to peanuts (aOR, 11.51; 95% CI, 2.01-
65.79; p = 0.006) and/or egg (aOR, 3.79; 95% CI, 1.19-12.08; 
p = 0.025) 
 
Interventional studies 
Manaseki-Holland  
et al. [8] 
13.1 ± 9.1 y 224 - 
Reduction of 
pneumonia attack 
Yes 
Children received 100 000 IU vitamin D3 along with AB: 
decreased risk of repeat episode in treatment group (92/204; 
45%) compared with control (122/211; 58%) 
 
Camargo et al. 
[429] 
10.1 ± 0.9y 143 17.47 
ARIs  attack in 
winter 
Yes 
Children received milk fortified with 300 IU of vitamin D3: 
reduction in ARIs attack in treatment group compared with 
control (aOR 0.52 (95% CI: 0.31-0.89) 
 
Manaseki-Holland  
et al. [430] 
1-11 months 
(Range) 
1487 - 
Incidence of 
pneumonia 
 
No 
Children received 100 000 IU vitamin D3 every 3 months for 18 
months:  no effect of vitamin D on the frequency of pneumonia 
episodes 
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1.5 General conclusion  
The evidence from experimental and animal studies continues to accumulate and support a 
link between vitamin D, glucose and immune regulation.  The number of publications 
regarding vitamin D have increased over the last decades, due to widespread vitamin D 
deficiency and suggested therapeutic potential.  Accumulating evidence from observational 
studies has also pointed to vitamin D deficiency and insufficiency as a clinical problem of 
global proportions.  However, interventional studies have produced inconclusive results 
particularly among the younger population. 
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 Chapter 2 
 
Study Objectives and Justification 
The primary aim of this PhD thesis was to conduct an interventional study of vitamin D  
supplementation in vitamin D deficient but otherwise healthy children, to assess the 
association between vitamin D deficiency and  bone status, glucose homeostasis and 
immune function before and after six weeks of receiving vitamin D3 treatment.  The 
research subjects all presented at the endocrine outpatient clinic at the Royal Hospital of 
Sick Children in Glasgow (RHSC).  A second aim of this thesis was to assess the 
effectiveness of electronic surveillance, developed by the Scottish Paediatric Surveillance 
Unit (ScotPSU) to determine the current incidence of hospital-based presentation of 
childhood vitamin D deficiency in Scotland.  As the major biological function of vitamin D 
is to maintain bone health, the third objective was to investigate the relationship between 
bone biochemical profiles with glucose and immune profiles. 
 
To the best of this author’s knowledge, most, if not all, previous interventional studies 
assessing the effect of vitamin D supplementation on glucose homeostasis involve higher-
risk older children and/or adolescents (either obese or pre-diabetes).  At the time of the 
study design there had been no study investigating vitamin D-regulating serum cytokines 
in healthy individuals.  Subsequently, two studies have been conducted on healthy adults, 
and both have failed to observe consistent changes in circulatory cytokines, or their 
corresponding transcription factors [435, 440].  There is limited information available 
concerning the effect of improving vitamin D status on glucose homeostasis and immune 
function, in vitamin D deficient healthy children or infants.  Due to inconsistent evidence, 
we have also examined the association between serum 25(OH)D levels and bone 
remodelling markers, and further explored measurable changes in these markers following 
5000 IU vitamin D3 treatment.  Finally, by linking the results from these studies with 
clinical management, this work will explore any changes in vitamin D related parameters 
following routine vitamin D replacement.  
 
The Institutes of Medicine (IOM) defined the vitamin D deficiency as serum 25(OH)D 
below 50 nmol/l (20 ng/ml), and serum 25(OH)D >14 nmol/l (5.6 ng/ml) considered as 
severe/ profound deficiency.  Vitamin D insufficiency when serum 25(OH)D >75 nmol/l 
(30 ng/ml) .  An expert panel for the IOM recommended that a level of 50 nmol/l was 
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sufficient to optimize musculoskeletal health and serum 25(OH)D levels between 75-100 
nmol/l have been recommended as an optimal range for multiple health outcomes.  
However, it is not known to what degree improving serum levels from 25(OH)D <50 
nmol/l to <75-100 nmol/l is ideal for multiple health outcomes [42, 441, 442].     
 
In Scotland, the incidence of vitamin D deficiency is largely undefined because of 
continual demographic change and the introduction of new public health measures such as 
The Healthy Start Scheme.  However, evidence continues to accumulate, with resultant 
warnings that children presenting symptomatic vitamin D deficiency in Scotland might 
suffer serious consequences, such as seizure and cardiomyopathy in addition to 
developmental delay and increased risk of fractures [5].  There is also a need to institute a 
reliable system to collect data and monitor the incidence of this preventable condition. 
Therefore, this work was designed to estimate the current incidence of vitamin D 
deficiency in children using electronic surveillance systems, and to validate electronic 
surveillance. 
 
Four studies were conducted during the course of my PhD, with specific aims outlined in 
the following section: 
 
2.1 An Electronic Surveillance System for Monitoring 
Nutritional Vitamin D Deficiency in Children in 
Scotland (Chapter 3) 
Hypothesis: An electronic surveillance system can provide reliable data to study the 
epidemiology of vitamin D deficiency.  
Aim: To assess the effectiveness of an electronic surveillance system and determine the 
current incidence of hospital based presentation of childhood vitamin D deficiency in 
Scotland. 
2.2 Effect of Vitamin D3 Supplementation on Bone Status 
(Chapter 5) 
Hypothesis: Six weeks of vitamin D3 supplementation will improve vitamin D status, and 
significantly affect the markers for bone remodelling in vitamin D deficient children aged 
from 3 months to 10 years.  
Aim: To study the baseline and post treatment relationships between serum 25(OH)D and 
bone remodelling markers. 
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2.3 Effect of Vitamin D3 Supplementation on Glucose 
Homeostasis (Chapter 6) 
Hypothesis: Vitamin D supplementation will improve vitamin D status, and accordingly 
will improve the glycaemic status and insulin resistance. 
Aim: To investigate the effect of vitamin D3 supplementation on glycaemic status and 
insulin resistance in vitamin D deficient healthy children. 
 
2.4 Effect of Vitamin D3 Supplementation on Immune 
Function (Chapter 7) 
Hypothesis: Vitamin D3 supplementation will improve vitamin D status, and may promote 
a shift in the balance between T helper 1 (Th1) and T helper 2 (Th2) cells toward Th2 
domination.   
Aim: To assess the effect of short-term vitamin D3 supplementation on main Th1 and Th2 
cytokines, Th17 cytokine, T regulatory cytokine (Treg) and chemokines, linking the 
balance between Th1 and Th2 subsets.  Additionally the association between these 
cytokines and bone remodelling markers before and after vitamin D3 supplementation was 
investigated. 
    
2.5 Research Outcomes 
2.5.1 Primary outcomes 
 The incidence of cases of nutritional vitamin D deficiency presented to hospital-
based pediatricians across Scotland between 2009 and 2011 (Chapter 3). 
 The impact of the short term effects of vitamin D3 replacement on insulin 
resistance in healthy children (Chapter 6).   
 The levels of chemokines / cytokines in plasma, pre- and post- treatment with high 
doses of vitamin D3 (Chapter 7). 
 
2.5.2  Secondary outcomes  
 How effective is the electronic surveillance system (Chapter 3). 
 The range of clinical presentations of vitamin D deficiency in Scotland (Chapter 3). 
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 Whether short-term vitamin D3 replacement has an impact on glycaemic status and 
lipid profile (Chapter 6). 
 The peripheral blood lymphocyte subset profile pre and post vitamin D3 
replenishment in patients presenting with vitamin D deficiency (Chapter 7). 
 Association between peripheral chemokines /cytokines and bone remodelling 
markers (Chapter 7). 
 The impact of short term effects of vitamin D3 replacement on bone remodelling 
markers in vitamin D deficient healthy children (Chapter 5).  
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Chapter 3 
 
 An Electronic Surveillance System for 
Monitoring Nutritional Vitamin D Deficiency in 
Children in Scotland 
 
3.1 Abstract 
Background 
  
Given its geographical position and demography, the population of Scotland is at a 
relatively high risk of vitamin D deficiency.  There is a need to institute a reliable system 
that can monitor the incidence of this preventable condition.  
 
Aim 
 
To assess the effectiveness of an electronic surveillance system to determine the current 
incidence of hospital-based presentation of childhood vitamin D deficiency in Scotland. 
 
Methods  
 
Active surveillance was performed for two years as part of an electronic web-based 
surveillance programme by the Scottish Paediatric Surveillance Unit.  Notifications from 
reporting paediatricians were followed by completion of a questionnaire.  To further 
examine the validity of the system, cases with severe vitamin D deficiency in Glasgow and 
Edinburgh were identified from the regional laboratory and their clinical details were 
checked against those identified through the surveillance system.  Vitamin D deficiency 
was defined as serum 25(OH)D level >50 nmol/l, severe vitamin D deficiency when serum 
25(OH)D >14 nmol/l and vitamin D insufficiency when  serum 25(OH)D >75 nmol/l. 
 
Results 
 
Between September 2009 and August 2011, 163 cases of vitamin D deficiency were 
notified.  The majority of cases (n = 82) were reported in Glasgow with an annual 
incidence of 41 cases per year.  Fourteen cases were reported in Edinburgh during the first 
year of the study and two cases during the second year.  At the time of clinical diagnosis, 
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the median age of the children was 2 years (ranging from 3 months to 16 years).  Cross-
validation of data showed that amongst symptomatic cases who had a measured serum 
vitamin D level of less than 14 nmol/l, 89% of eligible cases had been reported in Glasgow 
and 33% of cases had been reported in Edinburgh. 
 
Conclusion 
 
The incidence of vitamin D deficiency remains high in Scotland.  An electronic 
surveillance system can provide data for studying the epidemiology of vitamin D 
deficiency and may helpful for assessing the effectiveness of public health measures. 
However, it may underestimate the number of positive cases.  
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3.2 Introduction  
Vitamin D deficiency, which is associated with nutritional rickets, is a preventable 
condition that is associated with morbidity in children.  There is a considerable amount of 
emerging data suggesting that low vitamin D levels are associated with a diverse range of 
pathologies.  Children and adults with vitamin D deficiency may be at higher risk of 
morbidity in a number of systems. 
 
The Scottish Paediatric Surveillance Unit (ScotPSU) has recently been developed as an 
electronic version of the British Paediatric Surveillance Unit (BPSU) which has been very 
successful at monitoring the incidence of rare childhood conditions in the UK [443].  A 
monthly survey of symptomatic vitamin D deficiency was launched as part of the Scottish 
Paediatric Surveillance Unit in September 2009 (ScotPSU).  The aims of the current study 
were two-fold: firstly, to study the incidence of cases of nutritional vitamin D deficiency 
that present to hospital-based paediatricians across Scotland and, secondly, to validate the 
electronic surveillance system by cross-referencing cases identified through the clinical 
biochemistry service.  
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3.3 Methods 
As part of the Scottish Paediatric Surveillance Unit (ScotPSU) programme, all 
paediatricians known to the Royal College of Paediatrics and Child Health in Scotland and 
the Scottish Paediatric Society are sent an email each month containing a list of conditions 
being surveyed.  This email notification is linked to the ScotPSU website 
(www.scotpsu.co.uk) where definitions and reporting instructions are given for the 
conditions being surveyed.  The reporting paediatrician is asked to check boxes against any 
of the reportable conditions they have seen in the preceding month, or to check a ‘nil 
return’ box if none have been seen, and return the email to the ScotPSU.  For this study, 
paediatricians were asked monthly from September 2009 – August 2011 to report the 
number of new cases of symptomatic vitamin D deficiency seen in the previous month (see 
Figure 3-1). 
 
 The inclusion criteria were children with symptoms or signs related to vitamin D 
deficiency or symptoms related to hypocalcaemia.  The exclusion criteria were osteopathy 
of prematurity within the previous six months, rickets due to genetic or drug-induced 
defects of phosphate or vitamin D metabolism, and coexistent chronic conditions such as 
chronic malabsorption, liver disease, chronic renal insufficiency and thalassaemia. 
‘Positive returns’ were identified by the ScotPSU's coordinator, and electronically 
forwarded to the study investigator, who then contacted the reporting clinician directly and 
sent the study questionnaire.  The data collection form did not contain any patient 
identifiable information. 
 
The questionnaire was sent to the referring paediatrician, and anonymous details about the 
patient, regarding the presenting features that were ascertained in each case at the time of 
diagnosis, was requested.  The date of birth, as well as centre and mother’s maiden name, 
was requested to allow the identification of duplicate reports (see appendix A-1: ScotPSU/ 
Case Report Form).  If the child had been notified by several paediatricians, one clinician 
was selected to give the clinical details.  Investigators did not make any contact with the 
patients and the ScotPSU did not receive any identifiable data.  For some cases, the 
researcher visited the hospitals in order to collect some missed information directly from 
the reporting clinician.  The study did not collect any recognisable personal patient data 
and was approved as a health service evaluation by the National Research Ethics 
Committee.   
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To examine the validity of the reporting system, cases of vitamin D deficiency in Glasgow 
and Edinburgh where the serum 25 hydroxy-vitamin D (25(OH)D) concentration was 
measured as undetectable at the regional clinical biochemistry laboratory were identified 
and their clinical details were studied.  These cases were then compared to the reporting 
instructions of the ScotPSU survey to check the percentage of eligible cases that were not 
notified.  
 
3.4 Statistical analysis  
All continuous data were described as medians and ranges and categorical data were 
compared using Chi-squared tests (Microsoft Excel 2007).  
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Figure 3-1: Monitoring of nutritional vitamin D deficiency in children in Scotland via the 
Scottish Paediatric Surveillance Unit reporting system. 
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3.5 Results 
3.5.1 Demography  
Over the two-year study period, 163 cases were notified and, of these, 54 were excluded 
for a range of reasons including duplicate notifications (n = 9), failure to return 
questionnaire (n = 16), incorrect notification (n = 16) and coexistence of chronic diseases 
(n = 13) (see figure 3-2).  Of the remaining 109 cases, in 103 (94.5%), details of ethnic 
origin were available: 9 (9%) cases were classed as white whereas the rest were broadly 
classed as non-white (Table 3-1).  Of the 109 cases, 82 (75%) were reported from Glasgow 
and 16 (15%) were reported from Edinburgh.  Based on the total population of white and 
non-white children under the age of 15 years in Scotland as reported by the General 
Register Office for Scotland in 2009 (www.gro-scotland.gov.uk), the incidence of hospital 
presentation of vitamin D deficiency was 0.8/1000 in Glasgow and 0.19/1000 in 
Edinburgh.  The reported incidence in non-white children was greater in Glasgow at 
7/1000 compared to 2.6/1000 in Edinburgh (p = 0.009) when calculated over the two years 
of the study (Table 3-2).  When comparing the two regions over the first year, the 
incidence remained higher in Glasgow, but did not reach statistical significance (p = 0.08). 
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Figure 3-2: The flow diagram of study notifications. 
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Table 3-1: General characteristics of notified cases. 
 N % 
Sex (109)*   
F 49 45 
M 60 55 
Age (107)*   
0-3Y 67 63 
3-6Y 12 11 
6-16Y 28 26 
Ethnic origin (103)*   
South Asian 55 53 
Sub-Saharan African 21 20 
Middle Eastern 9 9 
Caucasian 9 9 
North African 6 6 
Other 2 2 
Chinese 1 1 
Season (103)*   
Autumn 30 29 
Winter 30 29 
Spring 28 27 
Summer 15 15 
Referral source (95)*   
GP 45 47.5 
Orthopaedic 25 26 
Accident and Emergency 13 14 
OPD Medical 9 9.5 
Inpatient Medical 3 3 
Breast Feeding  (67)*   
Yes 57 85 
No 10 15 
Treatment (95)*   
Vitamin D only 37 39 
Ergocalciferol 15  
Cholecalciferol 14  
Alfacalcidol 2  
Not specified 6  
Vitamin D and Calcium 25 26 
Ergocalciferol & Calcium 18  
Cholecalciferol & Calcium   7  
Multivitamin Only  31 33 
Multivitamin and Calcium  2 2 
*Figures in parentheses denote the number of cases for which information was available. 
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Table 3-2: Distribution of reported children from Glasgow, Edinburgh and other centres 
according to year of notification and extent of biochemical vitamin D deficiency. 
 
25(OH)D (nmol/l) 
(Sep 2009 - Aug 2010) 
25(OH)D (nmol/l) 
(Sep 2010 - Aug 2011) 
 
 
<14 
 
14-25 
 
26-50 
 
>50 
 
NK 
 
<14 
 
14-25 
 
26-50 
 
>50 
 
NK* 
Glasgow 
(n=82) 
 
18 
 
10 
 
5 
 
2 
 
7 
 
10 
 
10 
 
6 
 
- 
 
14 
Edinburgh 
(n=16) 
 
7 
 
6 
 
- 
 
- 
 
1 
 
- 
 
- 
 
- 
 
- 
 
2 
Other 
(n=11) 
 
5 
 
2 
 
1 
 
- 
 
- 
 
1 
 
- 
 
- 
 
- 
 
2 
*NK, unknown / unavailable serum (25(OH)D) data in 26 cases. 
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3.5.2 Cross-validation of notification 
To examine the completeness of the notifications, childhood cases of  sever vitamin D 
deficiency (serum 25(OH)D level of <14nmol/l) were identified in Glasgow and Edinburgh 
through the biochemistry laboratory and cross-referenced to those cases notified through 
ScotPSU over the one year period of the study.  
 
In Glasgow, of the 72 children identified through the laboratory records between 
September 2009 and August 2010, 38 had chronic diseases which would have predisposed 
them to vitamin D deficiency and these were excluded.  Of the remaining 34 cases, 10 
cases had not been notified through the ScotPSU survey.  Three of these 10 cases were 
asymptomatic and one was being investigated for failure to thrive and did not have any 
symptoms which could be attributed to vitamin D deficiency.  In two cases, the reason for 
checking 25(OH)D could not be clarified because the medical records were not available. 
In the remaining one case, the test was performed by a general practitioner who would not 
have been included in the ScotPSU survey.  In summary, cross-checking cases of severe 
biochemical vitamin D deficiency in Glasgow over a one year period of the ScotPSU 
survey revealed that of the 34 children with a serum 25(OH)D concentration of <14nmol/l 
who did not have a coexisting chronic disease, only three (11%) cases of clearly 
symptomatic vitamin D deficiency had been missed by the ScotPSU survey (see Figure 3-
3). 
 In Edinburgh, 66 childhood cases of vitamin D deficiency with a serum 25(OH)D of 
<14nmol/l were identified through the biochemistry laboratory and cross-referenced to the 
cases notified through ScotPSU during 2010.  Twenty-nine children had chronic diseases 
which predisposed them to vitamin D deficiency.  Of the remaining 37 cases, 29 cases had 
not been notified to the ScotPSU survey.  Nine of these were asymptomatic and were being 
investigated because of failure to thrive, family concerns and suspected accidental 
ingestion of vitamin D tablets.  In two cases, the medical records were not available. In the 
remaining two cases, the test was performed by a general practitioner.  Thus, of the 37 
children in Edinburgh with a serum 25(OH)D of <14 nmol/l who did not have a coexisting 
chronic disease, 16 (67%) symptomatic cases were not reported through the ScotPSU 
survey (see Figure 3-4).  
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Asymptomatic 
(n=4) 
Chronic disease 
(n=38) 
34 
Referred by GP  
(n=1) 
Notified 
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3 
n=72 
Unable to trace  
(n=2) 
8 
Children in Glasgow with vitamin D <14 nmol/l 
Figure 3-3: An assessment of the reliability of the ScotPSU surveillance system for identifying 
symptomatic cases of vitamin D deficiency presenting to paediatricians in Glasgow. 
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Not notified 
16/24(67%) 
35 
25 
16 
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27 
Children in Edinburgh with vitamin D <14 nmol/l 
Figure 3-4: An assessment of the reliability of the ScotPSU surveillance system for identifying 
symptomatic cases of vitamin D deficiency presenting to paediatricians in Edinburgh. 
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3.5.3 Clinical features  
The median age for the 109 children was 2 years (range, 3 months - 16 years).  In 83 
(76 %) cases, the children had skeletal based clinical suspicion of vitamin D deficiency.  
This included bowed legs or concerns about gait in 41 (38%) children at a median age of 2 
years (7 months - 4 years), bone pain in 27 (25%) children at a median age of 7.7 years (11 
months – 9.5 years), wrist swelling or chest wall deformity in 7 (6%) children at median 
age of 15 months (6 months - 4 years), features of rickets on an x-ray performed at the time 
of a fracture in 4 (4%) children at a median age of 11 months (4 months - 17 months), and 
hypocalcaemic seizure in 4 (4%) children at a median age of 8 months (4 months - 9 
months).  In 11 (10%) children, 10 of whom were from Glasgow and one from elsewhere, 
information about the clinical presentation was not available.  In 7 (6%) children, a family 
history of symptomatic vitamin D deficiency was the sole reason for investigation.  In 8 
(7%) children, there were other causes of referral such as concerns about nutritional status, 
recurrent constipation and general dietary concerns.  The proportions of the different 
categories of presentation were similar between Glasgow and the other centres (see figure 
3-5). 
 
Of the 40 cases that had presented with bowed leg and/or gait disturbance, an x-ray had 
been performed in 32 (80%) children.  There was no information available about the 
radiological image in the remaining eight children.  Of the 32 children who had an x ray 
done, 27 (84%) had radiological signs of rickets.  All four cases of fractures were reported 
from Glasgow and were of South Asian origin, breast fed and had radiological signs of 
rickets with undetectable serum 25(OH)D levels in three of these cases.  Nine children 
(8%) were reported to be white Scottish in origin, of which six were from Glasgow and 
three from other locations in Scotland.  Of these nine cases, bone pain was the presenting 
feature in four cases, bowed leg and/or gait disturbance in two cases and concerns about 
nutritional status in the remainder.  
 
 
  
107 
 
 
Figure 3-5: Proportion of reported presentations in Glasgow and elsewhere 
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Values above the chart represent the actual number of cases in each reported centre. 
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3.5.4 Management of vitamin D deficiency 
Clinical details about the treatment of vitamin D deficiency were available in 95 of 109 
cases notified to the ScotPSU.  Of the 95 children, 34 (36%) received oral vitamin D and 3 
(3%) received intramuscular injection as the sole therapy.  Oral preparations in the 34 
children included ergocalciferol (15) and cholecalciferol (16), with doses ranging from 
1,000-12,000 IU/day for four to nine weeks.  In three cases the oral preparation of vitamin 
D was not known.  Of the 95 children, 25 (26%) received both vitamin D and calcium 
supplements.  In 2 children (2%), multivitamin and calcium supplements were the reported 
treatment regimen and 31 (33%) received multivitamins (Abidec: 10, Dalivit: 15, Healthy 
Start vitamins: 2, unknown: 4).  In 4 cases, vitamin D was administered as Calcit D3, 
Calcichew D3 and 1α-hydroxycholecalcidol.  There was no clear relationship between the 
severity of vitamin D deficiency (clinical or biochemical) and the therapy received (see 
Figure 3-6). 
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Figure 3-6: Types of vitamin D therapy administered categorised according to type of 
presentation.  
 
Figures above the bars represent the actual number of cases in each presentation category. 
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3.6 Discussion 
Vitamin D deficiency rickets has been historically recognized as a widespread health 
problem in the UK [2, 444].  As a consequence, a number of preventative measures have 
been introduced in an attempt to decrease the prevalence of vitamin D deficiency, 
especially among vulnerable groups such as ethnic minorities, and pregnant and lactating 
women.  A Greater Glasgow Health Board campaign was launched in 1979 targeting 
vitamin D supplementation among the Asian community [109, 110].  Although guidelines 
for vitamin D supplementation were issued in the UK in 1994, a survey carried out in 2001 
showed that vitamin D deficiency still exists, raising concern over the ineffectiveness of 
public health measures [106].  
 
Anecdotal reports suggest that vitamin D deficiency occurs across Scotland but the relative 
geographical incidence is unclear [193, 445].  The increase in the occurrence of vitamin D 
deficiency among the population in Scotland has been attributed mainly to its northerly 
location, insufficient dietary intake and population mix [4].  As a result, the Healthy Start 
Scheme was implemented in 2006 but recent surveys indicate that symptomatic vitamin D 
deficiency is still prevalent among children in the UK [5, 446].  However, this survey may 
have underestimated the true incidence.  There is a need for more effective public health 
measures which particularly target the at-risk population in this region, but most 
importantly there is a need for a surveillance system that monitors incidence uniformly 
across Scotland.  
 
The current study also shows that about 10% of symptomatic cases are reported in children 
who are not of a South Asian, African or Middle-Eastern background.  The presenting 
clinical features in this surveillance were also similar to those previously published [5]. 
The ScotPSU survey targets paediatricians but it is possible that children with vitamin D 
deficiency also present to other professionals such as general practitioners and orthopaedic 
surgeons who are not included in the survey [446].  It is, therefore, likely that the actual 
incidence of symptomatic vitamin D deficiency is higher than that identified in this survey. 
 
The reported incidence of vitamin D deficiency was higher in Glasgow than Edinburgh.  It 
is possible that the threshold for notification may have been different in the two centres. 
The children from Glasgow had a varied level of vitamin D deficiency whereas the ones 
from Edinburgh had more severe biochemical deficiency, suggesting that the threshold for 
investigating and reporting cases of vitamin D deficiency may be different between the two 
111 
 
centres.  However, a higher incidence in Glasgow was found even when comparing 
regional differences between these groups of severe cases, although it did not reach 
statistical significance.  Furthermore, the proportion of cases with different clinical 
presentations was also similar when comparing between Glasgow and other centres.  There 
was a marked fall in notifications in cases in Edinburgh compared with Glasgow in the 
second year of the survey.  In the absence of a clear change in public health interventions, 
this may simply reflect a change in enthusiasm for notification.  It is also possible that 
vitamin D deficiency is more prevalent in the west of Scotland compared with the east, 
possibly due to differences in the ethnic variation, climate or nutritional behaviour.  The 
adjustment for ethnic background did not account for detailed ethnic variations but simply 
examined white vs non-white backgrounds and there is a need for further refining of this 
analysis.  Validation of the ScotPSU notification of affected cases by checking a 
proportion of the notified cases through the clinical biochemistry department was helpful 
and revealed that only a minority of symptomatic cases with profound biochemical vitamin 
D deficiency remained unreported in Glasgow.  This exercise was not performed for those 
with milder levels of vitamin D deficiency which would have led to a higher identification 
of unreported cases.  However, amongst similar cases in Edinburgh, there was a much 
higher number of cases which were unreported.  It is, therefore, likely that the lower 
incidence of cases of symptomatic vitamin D deficiency in Edinburgh may have been 
partly due to a lower general rate of reporting these cases.  
 
The recommended method to manage vitamin D deficiency is to provide the child with a 
high dose of vitamin D either as an oral daily dose for 8-12 weeks or as a single oral or 
intramuscular dose [42].  To maintain a sufficient vitamin D level, children should be 
provided with a maintenance dose of 400-800 IU vitamin D per day thereafter, usually as 
part of a multivitamin supplementation [42].  However, this diversity in management of 
severe vitamin deficiency among different practises could be attributed to the absence of a 
clear consensus in the literature regarding treatment regimes of vitamin D deficiency[447]. 
Approximately one third of the children in the current study received suboptimal 
therapeutic doses of vitamin D.  Similar to previous observation; a small number of cases 
were treated with Calcit D3, Calcichew D3 and 1α-hydroxycholecalcidol. 
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The main strength of this study is the use of an established active surveillance system, 
which is further supported with cross-validation.  Musculoskeletal clinical manifestations 
of vitamin D deficiency may present to other professionals such as GPs and orthopaedics, 
and clinical evaluation may be carried out directly at their local clinics.  Therefore, cross-
validation would address this issue.  Our recommendations for future applications of an 
electronic surveillance system is to use an additional independent source for reporting in 
order to make comparisons and to address any lack of reporting, and to assess the 
epidemiology of symptomatic vitamin D deficiency more broadly in the UK. 
 
In summary,  this study represents the first description of an electronic surveillance system 
which could be used for notification of cases of vitamin D deficiency presenting to 
hospitals.  It demonstrated a similar incidence to that reported recently in Glasgow, 
confirming the ongoing presence of profound vitamin D deficiency among children in 
Scotland [5].  Profound vitamin D deficiency, presenting primarily as rickets is a real 
problem in Scotland.  An electronic surveillance system targeted at paediatricians in 
Scotland has confirmed the continued presence of symptomatic vitamin D deficiency in 
children.  The incidence in Glasgow for two consecutive years is similar to that previously 
reported and seems to be higher than in the rest of Scotland.  However, this may have been 
due to changes in levels of awareness of referring clinicians.  Therefore, some of these 
differences may be due to ascertainment bias and future use of such systems needs to  
consider this bias. 
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Chapter 4 
 
 Methodology and Demographics 
Effect of vitamin D supplementation on bone status, glucose homeostasis 
and immune function in children with vitamin D deficiency 
 
 
4.1 Summary 
This chapter includes the research methodology, summary of recruitment procedures, and 
inclusion/exclusion criteria to be applied to Chapters 5, 6, and 7.  It also summarizes 
information obtained by the Study Case Report Form (CRF). 
 
 
4.2 Ethics approval 
The West of Scotland Research Ethics Service (REC3), REC Reference: 11/AL/0291 
approved the studies for the bone (Chapter 5), glucose (Chapter 6), and immune (Chapter 
7) components of the thesis. 
 
4.3 Sample size  
The studies described were performed as pilot studies for a PhD project, and involved 
identifying all children with symptomatic vitamin D deficiency at the Royal Hospital of 
Sick Children in Glasgow (RHSC).  When the study was designed, the researcher was 
unaware of any previous studies examining the impact of high dose of vitamin D 
supplementation on bone biomarkers, glucose homeostasis and cytokines profile in vitamin 
D deficient, healthy children.  It was therefore difficult to calculate the sample size 
adequately and we anticipated that this pilot study will provide novel data as a foundation 
for future studies. 
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4.4 Inclusion and exclusion criteria 
The study included children under 10 years old, referred for evaluation and management of 
suspected vitamin D deficiency at the endocrine clinic at RHSC.  Those individuals taking 
vitamin D supplementation or with a coexisting chronic disease such as chronic 
malabsorption, liver disease, chronic renal insufficiency, osteopathy of prematurity, 
genetic, or drug-induced defects affecting phosphate or vitamin D metabolism or 
thalassaemia were excluded.  
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4.5 Study design 
Eligible participants were identified and recruited by the researcher (the PhD student) from 
the Endocrine Outpatient Clinic at the RHSC during their first clinical visit.  Detailed 
information about the study was discussed privately, and the information sheets were 
handed to potential participants by the researcher at the end of the clinic.  Invitation letters 
with information sheets were posted for those who attended different endocrine clinics at 
the RHSC, at the same time, or who were refered by a different clinic (orthopedics or 
outpatient clinic). 
 
A week or two after the first clinical review, a routine clinical biochemical assessment was 
performed on each patient in a fasting state in the clinical day investigation unit (Ward 1C) 
at the RHSC.  If the child/parent consented, an additional blood sample (5ml) was 
collected during this visit, at the time of the routine venepuncture on Ward 1C.  In 
addition, the child was X-rayed at the RHSC by the consultant pediatric radiology as a 
routine clinical procedure to check for rickets.  At this visit, the children were prescribed 
oral vitamin D3 supplements comprising 5000 IU cholecalciferol to be taken once a day.  
They were then reviewed on Ward 1C six weeks later, when they had a repeat assessment 
and another blood sample collected (Table 4-1). 
 
Routine clinical information about the cases was collected using similar information to that 
detailed in the Case Report Forms provided in the Scottish Paediatric Surveillance Unit 
Study (see appendix B-1).  This included capture data, detailing demographics, ethnic 
background, perinatal history, feeding history, developmental milestones, and previous use 
of supplements.  Additional health information was also gathered, and a full clinical 
examination was carried out to identify any signs of vitamin D deficiency, as listed in the 
ScotPSU’s CRF. 
 
Anthropometry measurements, i.e. weight and height, were also recorded.  Body mass 
index (BMI) was calculated as weight in kilograms (kg) divided by the square of height in 
meters (m2).   According to The National Institute for Health and Care Excellence (NICE) 
recommendations, the most suitable measure to define obesity is BMI ≥ 98th BMI centile 
(>2 SDS above the mean), using the UK 1990 growth chart produced with the LMS 
method (the distribution of BMI at each age by its median (M) and coefficient of variation 
(S), in addition to  a measure of skewness according to the Box-Cox power (L)).  
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Therefore, BMI was expressed as a standard deviation score (BMI SDS), and the BMI SDS 
cut-off for an obese child was > 2.054.  
 
As the BMI is difficult to interpret in infancy and any abnormality in BMI during this 
period should be considered as clinically significant only if it persists after the second year 
of life [448, 449].  Therefore, for the children younger than 24 months, the weight and age 
standard deviation score (Wt SDS) was measured instead of the BMI SDS.  
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Table 4-1: Timetable for investigations and visits. 
 
*Visit 1: routine clinical assessments were carried out by the clinician, and information sheets were 
handed to the patient by the researcher. **Visit 2: routine clinical samples and study samples (if 
consent had been granted) were collected. At this visit patients received the vitamin D3 treatment. 
***Visit 3: six weeks after visit 2, the routine clinical samples and the study samples were collected 
and patients received a letter for their general practitioner recommending prescription of a 
multivitamin supplement. Information about patients' enrolment and treatment, once received, were 
sent directly to the general practitioner by the researcher (see appendix D-2). ****Visit 4: patients 
underwent a routine clinical follow-up by the clinician.  
Procedures Visit 1* Visit 2** Visit 3*** Visit 4**** 
Time intervals 
1-2 weeks 
before tests 
Week 0 
(baseline) 
Week 6 
(end of the study) 
6 months 
Routine clinical visits + + + + 
Study visits   + +  
Information about 
study 
+       
Consent obtained   +     
Clinical blood tests   + +  
Study blood tests   + +   
X-ray   +    
High dose 
Cholecalciferol 
  
5000 IU units 
orally for 6 weeks 
    
Low maintenance 
dose 
    
Daily oral 
supplements of 400 
IU from this visit 
onwards 
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4.6 Recruitment summary  
Figure 4-1 shows a flow chart summarising the study recruitment.  In total, 61 children 
were identified and screened during the 24 months of the study period between 2011 and 
2014.  Of these, 42 met the inclusion criteria and agreed to participate.  Nineteen children 
were excluded, and of those 19 children, six did not meet the inclusion criteria (two 
children were already on high dose vitamin D3 supplementation prescribed by their 
referring clinician prior to the endocrine clinical appointment, two children were older than 
10 years old, one child suffered from a concurrent thyroid illness and one had 
hypophosphatemic rickets).  Of the 42 children who qualified for the study, 37 were 
recruited and attended the first study visit.  Thirty samples were analysed at the first visit, 
for use at different stages of the project.  
 
Thirty samples were analysed for the bone study at baseline, and  25 samples were 
analysed at week 6 (see Chapter 5) for the same study.  Twenty-five samples were 
analysed at week 6 for the glucose study, of which only 19 had full glucose homeostasis 
parameters available at the two time points (see Chapter 6).  All the children who 
participated in the glucose study had an available bone profile and participated in the bone 
study.  Of those 19 children who had their glucose and bone data analysed, 17 children had 
an available cytokine profile.  At the end of the study, during the process of data analysis, 
two children were excluded as both of them showed vitamin D levels within the normal 
reference range at the baseline study visit.  Therefore, only 23 samples were suitable and 
participated in bone and glucose studies.  Eighteen samples were analysed for the cytokine 
assay in the immunity study, of which only 14 were suitable and participated in the study 
(see Chapter 7).  Additionally, five samples were available for further lymphocyte subset 
analysis.  With the exemption of one child, all the children who participated in the immune 
study had an accessible bone and glucose profile.    
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*Sixty-one children were identified through the endocrine clinic.  Forty children were excluded 
during the study period for a variety of reasons as shown in the diagram.   
  
Patients assessed for 
eligibility 
(n=61) 
Identified  
(n=42)  
  
Excluded (n=19) 
Did not meet inclusion 
criteria (n=6) 
Declined to participate    
(n=7) 
Non-attendance (n=3) 
Unable to contact (n=3) 
 
 
  
  
Patients 
attended  
Week 0 
(n=37) 
Excluded (n=7) 
Technical 
difficulties  
(n=7) 
 
Sample analysed  
(n=30)  
Excluded (n=5) 
Non-attendance 
(n=2) 
Withdrawn (n=3) 
Patients 
attended  
Week 6 
 (n=30) 
 
  
Excluded (n=5) 
Technical 
difficulties (n=3) 
Withdrawn (n=2) 
Immunity  
Study 
(n=16) 
  
  
Bone 
Study 
(n=23) 
  
Excluded (n=2) 
Not vitamin D 
deficient at 
baseline (n=2) 
 
Glucose 
Study 
(n=23) 
  
Sample analysed  
(n=25)  
Excluded (n=2) 
Did not meet study 
criteria (n=2) 
 
Immunity  
Study 
(n=14) 
  
Glucose 
Study 
(n=26) 
  
Bone 
Study 
(n=30) 
  
Immunity 
Study 
(n=18) 
  
  
 Figure 4-1: Flow diagram of study recruitment 
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4.7 Baseline characteristics 
4.7.1 Anthropometric and demographic characteristics 
Initially, 37 children appeared to meet the inclusion criteria, consented, and attended the 
first study visit during the 24 months of the study period.  Of these, 17 (46%) were boys 
and 20 (54%) were girls.  The median age for all the participants was 36 months (10 
months - 115 months).  The median age for the boys was 24 months (10 months - 115 
months), while the median age for girls was 41 months (16 months - 115 months).  This 
age difference was non-significant (p = 0.5).  All the study participants had been born in 
the UK and lived there since birth. The median (range) BMI SDS for the participants aged 
24 months or older was 0.49 (-1.45, 2.58), and the Wt SDS for all participants was 0 (-4.5, 
2.88) (Table 4-2). 
 
After selection, the participants were subdivided into groups based on ethnicity for further 
comparison.  The participants had a number of different ethnic backgrounds.  The majority 
of participants were of South Asian origin (38%).  In addition, it should be noted that the 
highest percentage of participants was recruited in winter (40.5%).  Figure 4-2 shows the 
average basal 25(OH)D level of recruited participants, according to ethnic origin and 
season of recruitment.  Children of Sub-Saharan African ethnic origin showed more 
profound vitamin D deficiency throughout the year, compared with other ethnic groups.  
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Table 4-2: Characteristics of recruited children. 
Variables N 
Boys 
(n = 17) 
Girls 
(n = 20) 
Age (months) 37   
  24 (10, 115) 41 (16, 115) 
Anthropometrics     
BMI SDS 25/37 0.73 (-0.68, 2.29) -0.49 (-1.45, 2.42) 
Wt SDS 37/37 -0.16 (-1, 2.88) -0.4 (-4.5, 2.65) 
Ethnic origin 37   
South Asian  14 7 7 
Middle Eastern  7 5 2 
Sub-Saharan African 7 3 4 
Caucasian 8 1 7 
Mixed 1 - 1 
Season of enrolment 37   
Autumn 9 5 4 
Spring 5 2 3 
Summer 8 5 3 
Winter 15 6 9 
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Figure 4-2: Average baseline serum 25(OH)D levels for 35 children, according to ethnic 
origin and season of recruitment.  
 
Two children were excluded from this graph, and both were recruited in winter (one child’s basal 
25(OH)D level was missing (South Asian) and another child had mixed ethnic origin (25(OH)D) < 
14 nmol/l). 
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4.7.2 Dietary data and health information 
The majority (89%) of the participants reported positive for milk intake (cow’s milk or 
breast milk).  No children in the study were taking formula milk. Out of the 37 children 
recruited, 24 (65%) children had never taken a high vitamin D dose or multivitamin 
supplement.  Five children (three boys and two girls) reportedly had been on high doses of 
either vitamin D2 or vitamin D3 supplementation, followed by a low vitamin D dose in the 
form of multivitamins.  Thirteen (35%) children had taken low dose vitamin D as a 
multivitamin prescription (including those who had a high vitamin D dose).  Many parents 
reported that the multivitamin taken was Dalivit and/or Abidec, which provides 400 IU 
vitamin D3, and most of the parents reported their child’s intake as intermittent.  It was 
difficult to obtain information concerning the types of medicines taken from some of the 
parents.  Additionally, 65% of the recruited children were free of any concurrent medical 
condition, and most of the study participants had been either directly or indirectly referred 
from the GP or from Orthopaedics (Table 4-3) 
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Table 4-3: General health information of study participants. 
Variables  N Boys Girls 
Dietary information 37 (17) (20) 
Milk intake    
Breast feeding  5 4 
Cow’s milk  12 12 
No dairy intake  - 4 
Multivitamin supplement    
Yes, previous supplement   4 4 
Yes, current supplement  3 2 
No supplement  10 14 
Prior high dose vitamin D supplement    
Yes  3 2 
No  14 18 
Health information 37 (17) (20) 
No diseases  11 13 
Haematological (iron and B12 deficiency 
anaemia)  
 2 3 
Respiratory (chronic bronchitis, asthma)  2 1 
Allergic (eczema, atopic conditions)  - 3 
Other  2 - 
Referral 37 (17) (20) 
General practitioner (GP)  10 4 
General paediatrician  - 3 
OPD medical   1 2 
Inpatients medical   2 2 
Orthopaedics  4 9 
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4.7.3 Parental health information  
Maternal ages ranged from 20 to 42 years (median 32 years), and 14 (38%) of the mothers 
reported their ethnicity as South Asian.  Other ethnic origins were: Caucasian (UK/other 
European) (9; 24%), Middle Eastern (7; 19%) and Sub-Saharan African (7; 19%). Only 
four (11%) mothers reported having vitamin D deficiency (two of these were having 
vitamin D injections and calcium supplements as treatment), and 78% of mothers did not 
take any vitamin D supplements.  Limited knowledge about vitamin D deficiency affected 
around 46% of the study cohort.  Additionally, 54% of mothers wore clothing that limits 
sun exposure for cultural and/or religious reasons (Table 4-4).  
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Table 4-4: Parental information.  
Variables   
General Information  Yes No 
Postnatal vitamin D supplementation 8 29 
Known maternal vitamin D deficiency 4 33 
Maternal clothing limiting sun exposure 17 20 
Parental understanding of vitamin D deficiency 17 20 
Parental health problems 12 25 
Parental health information (n=37)    
Asthma    
Mother    
Father 
 
 
2 
3 
 
 
35 
34 
Skin disease  
Mother  
Father 
 
1 
2 
 
36 
35 
Allergy   
Mother   
Father 
 
- 
- 
 
- 
- 
Hypertension    
Mother 
Father 
 
- 
2 
 
 
37 
35 
Diabetes  
Mother 
Father 
 
2 
2 
 
35 
35 
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4.7.4 Clinical and radiological data 
The patients’ clinical and radiological findings are summarized in Table 4-5.  Their 
clinicians as well as the research student saw all patients.  Around 54% of the children had 
clinical signs of rickets at the first clinical evaluation, and all of the children with more 
than one clinical sign of rickets were suffering from profound vitamin D deficiency of < 14 
nmol/l, and an elevated serum PTH level.  
 
In older children, clinical presentation of vitamin D deficiency noticeably differs from 
younger children.  They presented with vague manifestations including pain in weight 
bearing joints, thighs and/or calves and muscle cramps.  Children younger than 36 months 
mainly presented with skeletal deformities/ abnormalities including bow legs, wrists 
swelling and fractures (see figure 4-3).  On the basis of concentrations of 25(OH) D alone, 
it was difficult to assess the clinical biochemical consequences of vitamin D deficiency and 
/ or insufficiency (see figure 4-4).  However , all children with abnormal bone biomarkers 
(PTH, ALP, calcium and phosphate) had concurrent clinical and/or radiological signs of 
rickets (Table 4-6). 
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Table 4-5: Clinical and radiological findings. 
Variable N Boy Girls 
Clinical sign of rickets (n = 37) 
Yes 20 11 9 
No 17 6 11 
Clinical sign of rickets on examination (n = 20) 
Bowed legs 13 7 6 
Abnormal gait 2 2 - 
Wrist swelling 14 9 5 
Patent anterior fontanelle 2 1 1 
Rachitic rosary 1 1 - 
Weakness 1 1 - 
Prominent chest cage 1 1 - 
Abnormal dentition - - - 
Frontal bossing 5 3 2 
X-ray performed (n = 37) 
Yes 30 15 15 
No 2 1 1 
No information 5 4 1 
Main X- ray sites (n = 30) 
Wrist 25 15 10 
Ulna and radius 3 3 - 
Hip and tibia 2 2 - 
Clear rickets on X- ray (n = 30) 
Yes 12 6 6 
No 18 9 9 
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Figure 4-3: Clinical presentation of vitamin D deficiency based on age groups. 
 
 
 
 
 
Figure 4-4: Clinical presentation of vitamin D deficiency in 34 children with basal serum 
25(OH)D <75 nmol/l.
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4.7.5 Laboratory data 
Table 4-6 summarizes the available clinical baseline laboratory data for all 37 children 
who were recruited for the vitamin D study.  However, due to technical problems there 
were insufficient blood samples collected, and many children were later excluded, as 
described earlier in this chapter.  By the end of week six of the study period, the number of 
samples available for the bone, glucose and immunity studies were n = 25, n = 25 and n = 
18 respectively.  
 
At baseline, serum 25(OH)D data was available for 36 (97%) children. The basal serum 
25(OH)D level was absent for one child, due to technical difficulties (Patient ID: 25).  A 
high dose of vitamin D3 supplementation was given to this child on the basis of clear 
clinical signs of rickets (bowed legs and wrist swelling), and a family history of nutritional 
rickets (mother and two siblings), and because the patient had not taken any previous 
supplements.  Of the 36 children with available 25(OH)D data at baseline, 18 (50%) 
children had very low serum 25(OH)D levels of < 25 nmol/l, 14 (39%) children had low 
serum 25(OH)D levels between 25-50 nmol/l and two (5.5%) children had insufficient 
serum 25(OH)D levels, between 50-75 nmol/l.  In a further two (5.5%) children, the blood 
results showed normal vitamin D levels at the baseline, and they were excluded from 
further statistical analysis.  These two children were originally referred from a general 
paediatrician, and during the first clinical visit their parents had given imprecise 
information about previous vitamin D supplements. 
 
For the 37 children, baseline serum PTH levels were available for 30 (81%) with high 
basal serum PTH levels reported in 15 (50%) cases with available PTH data.  Alkaline 
phosphatase levels were available in 28 children; of these, the serum ALP was abnormally 
high in just seven (25%) children.  Serum calcium and phosphate were available in 32 
(86.5%) and 28 (76%) children respectively, and abnormally low calcium levels were 
reported in three (9%) children, with low phosphate levels in only one child (3%).    
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Table 4-6: Baseline laboratory data for the 37 children who attended the first study visit. 
Patient 
ID 
Age 
(months) 
Sex 
25(OH)D 
(nmol/l) 
PTH 
(pmol/l) 
ALP 
(u/l) 
Calcium 
(mmol/l) 
Phosphate 
(mmol/l) 
*Study 
1 43 M 33 5.3 99.7 2.36 1.41 1,2,3 
2 23 F 125 6.5 180 2.29 1.15 - 
3 102 M 19 4.3 153 2.51 1.5 1,2 
4 12 M 91 5.4 422 2.44 1.57 - 
5 113 F 44 5.4 270 2.42 1.18 1,2 
6 36 F 29 8.4 219 2.35 1.55 1,2,3 
7 115 F 33 5.5 161 2.37 1.38 1,2,3 
8 46 F 34 4.1 450 2.36 1.43 1,2 
9 78 M <14 4.9 236 2.51 1.27 1,2 
10 79 F <14 6.8 - 2.33 1.43 1,2,3 
11 115 M <14 4.3 251 2.41 1.38 1,2,3 
12 33 F <23 4.1 224 2.52 1.79 1,2,3 
13 24 M <14 6.8 - 2.47 1.62 - 
14 48 M <14 18 - - - - 
15 51 F 33 7.1 - 3.37 1.33 1,2,3 
16 24 M 17 5.1 403 2.43 1.45 - 
17 71 F 20 7.3 102 2.49 - 1,2,3 
18 54 F <14 - - 2.41 1.6 - 
19 24 F <14 19.3 261 2.39 1.81 - 
20 30 F 60 - 2128 2.44 1.24 - 
21 23 F 28 - - - - - 
22 63 F 65 4.1 185 2.48 - 1,2,3 
23 22 F <14 - 194 - - - 
24 84 M <14 - - 2.48 1.68 - 
25 11 M - - - - - - 
26 63 F 34 5.5 178 2.45 1.51 1,2,3 
27 16 M 27 29.8 434 2.44 1.59 1,2,3 
28 16 F 23 36.2 679 2.53 1.57 1,2,3 
29 19 M 26 134.1 2834 2.17 0.81 1,2,3 
30 96 M 49 3.6 226 2.47 1.56 1,2,3 
31 24 M 23 40.4 733 1.82 - - 
32 10 M 18 14.1 864 2.38 1.07 1,2,3 
33 18 M 19 9.7 338 2.52 1.62 1,2,3 
34 66 M 33 5 285 2.25 1.47 1,2 
35 20 F 37 - - - - - 
36 22 F <14 23.9 2551 1.38 1.64 1,2 
37 72 F 31 4.4 181 2.48 1.41 1,2 
Numbers in bold represent abnormal laboratory values. *Study 1: bone (see Chapter 5); Study 2: 
glucose (see Chapter 6); Study 3: immune function (see Chapter 7).  
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4.8 Discussion 
Of the participants in the present study, 39% had low vitamin D levels with serum 
25(OH)D between 25-50 nmol/l, and 50% had more profound vitamin D deficiencies, with 
serum 25(OH)D levels of < 25 nmol/l (total prevalence of vitamin D deficiency was 89%). 
The prevalence of vitamin D deficient status was evenly distributed between boys and 
girls.  In terms of age, children younger than 36 months (3 years) had more profound 
symptomatic vitamin D deficiency, associated with a high rate of bone metabolism 
compared with older children.  Additionally, around 54% of study participants were found 
to have clear signs of rickets upon clinical examination, and 40% who underwent a 
radiological examination showed clear signs of rickets on X-ray.  
 
A number of factors that appear to influence poor vitamin D status were mentioned in our 
study. Since darker skin pigmentation reduces vitamin D synthesis by the sun, due to 
enhanced melanin production, certain ethnicities, such as South Asian and Sub-Saharan 
Africa are more likely to develop vitamin D deficiency.  In our cohort, prevalence rates of 
deficiency were highest among South Asian (38%, n=14).  Due to the fluctuating weather 
conditions in Scotland, evaluating data by isolating individual factors contributing to sun 
exposure was extremely difficult.  However, examination of the distribution of study 
recruitment throughout the year (mainly in winter and autumn), suggested decreased sun 
exposure is an important contributor to lower vitamin D status.  In non-breastfed infants 
and young children, UK dietary surveys show the main contributor to dietary vitamin D 
intake is formula milk, providing an average of 85% of intake for children aged 4-6 
months, 72-80% for those aged 7-11 months, and 29% for those aged 12-18 months [450]. 
Additionally, because plain cow’s milk is not fortified in the UK and breast milk is low in 
vitamin D, dairy intake is likely to be one of the contributors to low vitamin D status in our 
study cohort.  However, full dietary intake data was not collected and so for future studies 
we recommend well-designed questionnaires to assess vitamin D intake.  
 
Around 35% of our study participants had chronic and/or recurrent medical conditions, 
such as asthma, recurrent hospital admissions due to chest infections, atopic dermatitis, 
eczema, and autism.  All of the above-mentioned conditions have been correlated with low 
vitamin D status (as reviewed in the introduction to this thesis).  Parental awareness of 
vitamin D deficiency is relatively low; 54% of parents had no basic understanding about 
vitamin D deficiency.  Covering the skin is known to be an important risk factor for 
vitamin D deficiency, and in our cohort, 46% of mothers were wearing clothing that limits 
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sun exposure for cultural and/or religious reasons.  As 78% of mothers do not take any 
vitamin D supplements, we would expect them to have lower vitamin D levels, possibly 
contributing to the lower vitamin D status in younger breast feeding children. 
In conclusion, a considerable number of children with vitamin D deficiency have been 
identified through the endocrine clinic at RHSC.  This deficiency appears to result from 
poor dietary intake of vitamin D, ethnicity and cultural behaviours.  These findings imply a 
requirement for improved levels of public education, to ensure children have a greater 
opportunity to maintain adequate levels of vitamin D. 
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Chapter 5 
 
 Effect of Vitamin D3 Supplementation on Bone 
Status 
 
5.1 Abstract  
Introduction  
 
Evidence from epidemiological studies on the association between vitamin D status and 
bone remodelling markers were inconsistent.  
 
Objective  
 
To study the effect of six weeks of vitamin D supplementation on bone remodelling 
markers in vitamin D deficient children.  We also aimed to study the baseline and post 
treatment relationships between serum 25(OH)D and these markers. 
 
Method 
 
Twenty-three prepubertal children aged 10 months to 9.5 years (10 boys) were diagnosed 
with vitamin D deficiency and recruited during 24 months of the study period. Treatment 
consisted of 5000 IU vitamin D3 (cholecalciferol) given orally once a day for six weeks. 
At baseline and completion of treatment the following serum levels were measured: 25 
hydroxyvitamin D (25(OH)D), parathyroid hormone (PTH), Alkaline phosphatase (ALP), 
serum osteocalcin (OCN), and bone resorption markers include the C-terminal telopeptide 
of type I collagen (CTX).   
 
Results 
 
The median (range) of serum of 25(OH)D level in 23 children increased significantly in 
response to supplementation, from 27 (14, 65) nmol/l at baseline to 106 (37, 202) nmol/l at 
week 6, p<0.0001.  The median (range) of PTH in 21 children decreased significantly from 
5.5 (3.6, 134.1) pmol/l at baseline to 3.8 (1.9, 6.8) pmol/l at week 6, p<0.0001.  The 
median (range) of ALP in 21 children decreased significantly from 236 (99, 2834) u/l at 
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baseline to 195 (64, 1364) u/l at week 6, p=0.001.  No significant changes were observed 
in the medians of OCN and CTX from baseline to week 6, p=0.5 and p=0.2, respectively. 
 
Conclusion 
 
Short term improvement of vitamin D deficient status significantly increases serum 
25(OH)D levels, decreases serum PTH levels and decreases marker the of bone formation 
ALP.  
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5.2 Introduction 
Vitamin D and the parathyroid hormone (PTH) have long been recognized as significant 
variables required for the maintenance of calcium homeostasis and bone health [451]. 
 
The active form of vitamin D, 1,25(OH)2D can promote intestinal calcium absorption, and 
renal resorption by assisting in the upregulation of various proteins within the intestinal 
and renal epithelial cells [167, 280].  The best-known skeletal action for the active form of 
vitamin D involves regulating both bone formation and resorption, as enacted through 
osteoclastic and osteoblastic cell lineages.  Both 1,25(OH)2D and PTH can induce the 
expression of osteoclast differentiation factor (ODF) or stromal osteoclast forming activity 
(SOFA) by osteoblasts stromal cells which in turn, through cell-to-cell interaction 
stimulate the osteoclast precursors of the monocyte-macrophage lineage to recognize 
ODF/SOFA and further differentiate into osteoclasts, thereby enhancing bone resorption 
[452].  In addition, vitamin D can stimulate bone formation and mineralization either 
indirectly via intestinal and renal regulation of calcium homeostasis or through acting 
directly on osteoblasts, by adjusting the gene expression of various osteoblast 
differentiation and mineralization-associated genes [135, 143]. 
 
In case of serum calcium deficiency, it is suggested that vitamin D exerts a synergistic role 
with PTH, encouraging osteoclast proliferation and bone resorption, while simultaneously 
inhibiting bone mineralization, leading to an increase in calcium bone loss.  When vitamin 
D is also low, the compensatory increase in PTH secretion (secondary 
hyperparathyroidism) can enhance vitamin D synthesis and maintain calcium homeostasis. 
Therefore, serum calcium level may be normal in a vitamin D–deficient infant or child, 
whereas serum phosphate may be normal or reduced, due to the direct influence of PTH on 
the phosphorus reabsorption in the kidney, causing phosphorus to be lost into the urine 
[451, 452].  
 
Although the association between vitamin D status and bone remodelling has been studied 
extensively, studies continue to report inconsistent results, particularly regarding 
measurable changes in the bone remodelling markers following improvement of vitamin D 
status, and the duration of vitamin D treatment necessary to return these markers to the 
normal reference range.  Additionally, results remain inconsistent regarding the association 
between serum 25(OH)D level and bone remodelling markers [453-457].  
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The radiological assessment of the functional consequences of vitamin D deficiency such 
as bone fracture and bone mass require a study designed over a relatively long duration 
with a big sample size.  Therefore, the assessment of biochemical markers for bone 
remodelling can be considered a more practical way to measure the effects of vitamin D 
supplementation on bone.  This part of our project was undertaken to test the hypothesis 
that six weeks of vitamin D supplementation would treat vitamin D deficiency and affect 
the bone remodelling markers in vitamin D deficient children aged between three months 
and 10 years.  We also aimed to study the baseline and post treatment relationships 
between serum 25(OH)D and the bone remodelling markers.  Bone formation markers 
include serum alkaline phosphatase (ALP) and serum osteocalcin (OCN), and bone 
resorption markers include the C-terminal telopeptide of type I collagen (CTX).    
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5.3 Subjects and methods 
5.3.1 Subjects  
Chapter 4 of this thesis described in detail subject characteristics and inclusion/exclusion 
criteria. 
 
5.3.2  Study methods  
The study protocol is detailed in Chapter 4 of this thesis. Briefly, the study design involved 
six weeks of 5000 IU vitamin D3 (cholecalciferol) given orally once a day to children 
referred to the endocrine department at RHSC for vitamin D deficiency.   
 
5.3.3 Blood collection 
Blood samples were collected in Ward 1C at RHSC, in the morning after a six-hour 
overnight fast.  At baseline and completion of treatment, serum 25 hydroxyvitamin D 
(25(OH)D), parathyroid hormone (PTH), alkaline phosphatase (ALP), serum collagen type 
1 cross-linked C-telopeptide (CTX), serum Osteocalcin (OCN), serum calcium and serum 
phosphate were measured. 
 
5.3.4 Biochemical assays 
All blood sampling was performed at the time of routine clinical visits; samples were 
immediately centrifuged at 2600-2800 rev/minute for 10 minutes, and the serum was 
subsequently stored at -80°C until the assays were performed.  Serum 25(OH)D levels 
were assayed using the Abbott Architect Chemiluminescent Microparticle Immunoassay 
(CMIA).  Serum  PTH measurements  were assayed using intact PTH CMIA (Abbott 
Architect).  Serum ALP was measured by Ostase® BAP immunoenzymetric assay 
immunodiagnostic systems Ltd (IDS Ltd, Boldon, Tyne and Wear, UK) with an intra-assay 
CV of 0% to 2.3%.  Serum osteocalcin (OCN) was measured using N-MID® osteocalcin 
ELISA (IDS Ltd, Boldon, Tyne and Wear, UK) with an intra-assay CV of 0.8% to 3.1%. 
Serum CTX  was determined using serum crossLaps® ELISA (IDS Ltd, Boldon, Tyne and 
Wear, UK) with an intra-assay CV of 2.05% to 1.61%.  Dr. McNeilly performed the assays 
for serum 25(OH)D in the Biochemistry Department at Southern General Hospital, 
Glasgow.  The remaining samples were sent directly to the biochemistry laboratory at 
RHSC to test for calcium and phosphate.   
139 
 
5.3.5 Statistical analysis 
All statistical analyses were performed using GraphPad Prism 5 (San Diego California, 
USA) or Mini Tab 17 (Minitab, Coventry, UK) statistical software. The results were 
presented as median and ranges, unless otherwise specified.  The significance of the 
changes in the measurements between baseline and week six for all study participants were 
assessed using the Wilcoxon signed-rank test.  Mann-Whitney U tests were performed to 
analyse the two independent subgroups.  Kruskal-Wallis tests were performed to compare 
three independent subgroups.  A Spearman correlation analysis was also performed, to 
reveal the relationship between vitamin D, PTH and calcium, and changes in the 
relationship between vitamin D, PTH and the bone remodelling markers.  
 
Using SPSS 22 statistical software (USA), a Mixed Effects Model (MEM) analysis was 
employed where appropriate to further explore the confounding effects of independent 
variables.  For the MEM analysis, the log transformed values for 25(OH)D, PTH and ALP 
were used to satisfy the assumption of normal distribution, whereas calcium and CTX 
remained in their original units.  We were unable to perform the MEM for OCN, due to the 
low sample size.  A significance level of p < 0.05 was used to evaluate all the study results.  
Only children with data available at both the baseline and week six of the study period 
were included in the MEM statistical analysis.  Children for whom there was missing data 
recorded at either point in the study period were included in the univariate association 
analysis only.  
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5.4 Results 
5.4.1 Recruitment summary 
In total between 2011 and 2014, during the 24 months of the study period, 61 children 
were identified and screened.  Of these, 42 met the main project inclusion criteria and 
agreed to participate.  24 of the children were excluded before the first visit for several 
reasons (as detailed in chapter 4).  Out of the 42 children who qualified for the study, 37 
attended the first study visit and 12 children were lost over the course of subsequent study 
visits.  At six weeks, 7 children were excluded. Of those 7 children, 5 children were 
excluded due to either non-attendance, or because they withdrew from the study.  In the 
remaining 2 children, the blood results showed normal vitamin D levels at baseline, and 
therefore they were excluded from further analysis.  Both the children who showed normal 
serum 25(OH)D levels at baseline were referred originally from a GP and there was 
inaccuracies in their records concerning previous vitamin D supplementation.  Figure 5-1 
shows the flow diagram for the study recruitment.  
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Figure 5-1: Flow diagram for study recruitment 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The total number of children identified through the endocrine clinic was 61 children. Thirty eight 
children were excluded throughout the study period for a variety of reasons as shown in the diagram. 
  
 
Patient’s attended, 
0 week 
(n=37) 
  
 
Excluded (n=2), 
Not vitamin D deficient at 
baseline (n=2) 
 
Excluded (n=19), 
Not meeting inclusion 
criteria (n=6) 
Declined to participate 
(n=7)  
Not attended (n=3) 
Unable to contact (n=3) 
  
 
Patient assessed for eligibility 
(n = 61) 
 
Identified 
(n=42) 
 
    Excluded (n=5), 
Not attended (n=2) 
Withdrawn (n=3) 
Patient’s attended, 
6 week 
(n=30) 
Excluded (n=7), 
Technical difficulties 
(n=7) 
Excluded (n=5), 
Not attended 
(n=2)  
Withdrawn (n=3) 
  
  
 
Sample Analysed 
(n=30) 
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5.4.2 Demographic characteristics 
There were 23 pre pubertal children, 10 boys with a median age of 55 months (10 to 115 
months) and 13 girls with a median age of 63 months (16 to 115 months) enrolled in the 
study at both time points.  Body Mass Index (BMI) Standard Deviation Score (SDS) (BMI 
SDS) were 0.2 (-0.68, 2.29) and 0.67- (-1.45, 2.42) for the boys and girls respectively. 
Weight Standard Deviation Score (Wt SDS) were 0.05 (-1.02, 2.88) and 0.39 (-4.5, 2.65) 
for the boys and girls respectively.  The main cause of referral was bone pain, with 14 of 
the children recruited for this reason (61%).  Out of those 14 children, 13 were referred 
from an orthopaedic clinic and one child directly from their GP.  Radiological screening 
was performed in 20/23 study participants and we were unable to trace the report for 2 
children referred mainly due to bone pain.  There was one reported x-ray appointment. 
Other causes of referral included bowed legs, seizure, dietary concerns, fracture and family 
history (Table 5-1).  
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     Table 5-1: Characteristics of children who completed the study.  
 N  
   
Age, years  (23) % 
0-2 5 22 
2-6 9 39 
6-10 9 39 
Gender (23) % 
Boy 10 43.5 
Girl 13 56.5 
Race (23) % 
South Asian 10 43.5 
Middle Eastern  4 17.5 
Sub-Saharan African 3 13 
Caucasian 6 26 
Anthropometrics    Median (range) 
BMI SDS  18/23 -0.22(-1.45, 2.42) 
Wt SDS 23/23 -0.25(-4.5, 2.88) 
Vitamin D supplementation  (9) % 
Prior high dose vitamin D supplementation 2 22.2 
Prior multivitamin supplementation 4 44.5 
Current multivitamin supplementation 3 33.3 
Season of enrolment  (23) % 
Autumn 7 30.5 
Spring 6 26 
Summer 6 26 
Winter 4 17.5 
Reason of referral  (23) % 
Bone pain 14 61 
Bowed legs 5 22 
Other 4 17 
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5.4.3 Effects of treatment 
Only children with available data at both time points of the study period, week 0 and week 
6 were included in this analysis.  The median (range) of serum  25(OH)D level in 23 
children increased significantly in response to supplementation, from 27 (14, 65) nmol/l at 
baseline to 106 (37, 202) nmol/l at week 6, p<0.0001.  The median (range) of PTH in 21 
children decreased significantly from 5.5 (3.6, 134.1) pmol/l at baseline to 3.8 (1.9, 6.8) 
pmol/l at week 6, p<0.0001.  The markers of bone remodelling showed variability in 
response to vitamin D3 treatment.  There was a significant reduction in ALP value, from 
236 (99, 2834) u/l at baseline to 195 (64, 1364) u/l at week 6, p=0.001.  No significant 
changes were observed in the medians of OCN and CTX from baseline to week 6, p=0.5 
and p=0.2 respectively.  There was a trend towards an increase in the median value of 
serum calcium level, from 2.38 (2.17, 2.55) mmol/l at baseline to 2.45 (2.33, 2.69) mmol/l 
at week 6, p=0.05 with no change in serum phosphate, p=0.6 (Table 5-2).  
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Table 5-2: Comparison of biochemical measurements of bone remodelling. 
 n 
Baseline 
n 
Week six p-Value 
(from 
baseline 
to 6 
week) 
Normal 
reference 
range 
Median (min, 
max) 
Median (min, 
max) 
25(OH)D (nmol/l) 23 27 (14, 65) 23 106 (37, 202) <0.0001 70-150 
PTH (pmol/l) 21 5.5 (3.6, 134) 21 3.8 (1.9, 6.8) <0.0001 0.9-5.5 
ALP (u/l) 21 236 (99, 2834) 21 195 (64, 1364) 0.001 100-420 
CTX (ng/ml) 19 1.80 (0.9, 3.16) 19 1.72 (0.8, 3.2) 0.2 * 
OCN (ng/ml) 7 39 (16.5, 79) 7 52.8 (19.9, 76) 0.5 * 
Calcium (mmol/l) 19 
2.38 (2.17, 
2.55) 
19 
2.45 (2.33, 
2.69) 
0.05 2.20-2.70 
Phosphate 
(mmol/l) 
19 
1.43 (1.07, 
1.79) 
19 
1.48 (1.23, 
1.89) 
0.6 0.9-1.8 
25(OH)D; 25. hydroxyvitamin D. PTH; parathyroid hormone. ALP; Alkaline phosphatase. CTX; 
Serum cross linked C-telopeptide of type I collagen. OCN; Osteocalcin. * Values for CTX and OCN 
were compared with corresponding age-matched healthy control groups (10th, 90th centiles) in 
children aged from 1year to 10years (internal data obtained by the same assays used in our study). 
Only non-missed values were included in this analysis. 
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5.4.4 Individual changes in bone remodelling markers 
5.4.4.1 Vitamin D (25(OH)D) and Parathyroid hormone (PTH) 
Figure 5-2 shows individual changes in serum 25(OH)D for the 23 children who had 
available 25(OH)D data at both baseline and week 6 of the study period.  Of those 23 
children, 22 children (96%) had basal serum 25(OH)D in the deficiency range (<50 nmol/l) 
and one child (4%) had serum 25(OH)D in the insufficiency range (51-75 nmol/l).  
Following vitamin D3 treatment, there was variability in the serum 25(OH)D response 
among the study participants.  Two children (9%) had final serum of 25(OH)D <50 nmol/l, 
6 (26%) children had final serum 25(OH)D from >50-75 nmol/l, 12 (52%) reached a final 
serum of 25(OH)D >75-150 nmol/l and finally 3 (13%) children exceeded the normal 
reference range with a final 25(OH)D >150 nmol/l.  Figure 5-3 summaries the distribution 
of study participants according to their final serum 25(OH)D level.  
 
Current evidence suggests a difference in growth velocity and rate of bone remodelling 
between infants, older children and adolescents.  For example, there is a higher rate of 
bone remodelling in early infancy and in pre pubertal children, although remodelling is 
generally stable from 4 to10 years of age [458-460].  Due to the key role of both vitamin D 
and PTH in the process of bone turnover, and to further compare the effect of vitamin D3 
supplementation between different age groups, the participants were grouped into three age 
categories; from 10 months to 3 years, from > 3 years to 6 years and from > 6 years to 9.5 
years. 
 
Our results showed that serum 25(OH)D levels increased regardless of patient’s age group 
or basal serum 25(OH)D levels.  The increase in serum 25(OH)D from baseline to 6 week 
was significant in all age groups, with p-value of 0.01, 0.02 and 0.01 for 10 months to 3 
years, > 3 years to 6 years and  > 6 years to 9.5 years respectively.  There were no 
observed significant inter-group differences in the levels of 25(OH)D. 
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Figure 5-2: Individual changes in serum 25(OH)D levels for 23 children before and after 6 
weeks of receiving 5000 IU vitamin D3 treatment. 
 
Significant increase in the median of serum 25(OH)D levels was observed, p <0.0001. Each 
subject’s vitamin D level is represented by a line connecting week 0 with week 6 values. Area 
between two red lines; normal reference ranges for vitamin D.  
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Figure 5-3: Pie chart of response to vitamin D3 supplementation by study participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The distribution of patients according to their serum 25(OH)D reached at week 6, following vitamin 
D supplementation. < 50 nmol/l, vitamin D deficiency; >50-75 nmol/l, vitamin D insufficiency; >75-
150 nmol/l, vitamin D sufficiency; <150nmol/l, exceeded normal reference range. 
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Figure 5-4 shows individual changes observed in serum PTH for the 21 children for whom 
PTH data was available at both time points with a significant reduction in the median of 
serum PTH levels from baseline to week 6, p <0.0001.  Of those 21 children, 12 (57%) 
children had basal serum PTH levels within the normal reference range and 9 (43 %) 
children had basal PTH levels, which exceeded the normal reference range.  After 6 weeks 
of vitamin D3 treatment, PTH levels returned to the normal range in almost all study 
participants, except for two children who remained just above the upper limit of normal. 
 
The highest basal level of serum PTH was observed in the youngest age group (10 months- 
3 years) with a median of 14.1(4.1, 134) pmol/l.  The basal median PTH for those younger 
group differed significantly from the both middle 5(4.1, 7.3) pmol/l and oldest 4.9(3.6, 6.8) 
pmol/l groups, p=0.02.  There was no significante difference in basal PTH between the 
middle and oldest groups, p=0.6. Using a multiple group comparison test, a significant 
difference was observed between the groups (p = 0.02) (see Figure 5-5). 
 
Within the subgroups, serum PTH decreased significantly from baseline to week 6 in both 
the younger age group (10 months- 3 years, p=0.01) and the middle age group (> 3- 6 
years, p =0.01).  No significant reduction in serum PTH was observed in children age > 6-
9.5 years, p=0.1 (see Figure 5-6).  Table 5-3 summaries the percentage change in serum 
25(OH)D and PTH, in study participants from baseline to week 6 grouped according to 
their age group. 
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Figure 5-4: Individual changes in serum PTH levels for 21 children before and after 6 weeks 
of receiving 5000 IU vitamin D3 treatment.  
 
A significant decrease in the median of serum PTH levels was observed, P <0.0001. A line 
connecting week 0 with week 6 values represented each subject’s PTH level. Area between two red 
lines; normal reference ranges for PTH.  
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Figure 5-5: Comparison of basal serum PTH levels (medians) between study participants, as 
grouped by their ages.  
 
The children were grouped into three age categories; from 10 months to 3 years, from >3 years to 6 
years and from >6 years to 9.5 years. Significant differences in the median basal serum PTH levels 
between the youngest and each of older groups was observed, p = 0.02. No significant difference 
was observed between the age groups >3 years to 6 years and >6 years to 9 years, p = 0.6. Basal 
serum PTH levels also differed significantly between the three groups, p = 0.02. The boxes indicate 
quartile values; the whiskers indicate the upper and lower values. The numeric variables for two 
subgroups were compared using the Mann-Whitney U test; comparisons among the three subgroups 
were analysed using the Kruskal-Wallis test (non-parametric).  
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Figure 5-6: Effect of age on serum PTH concentrations before and after 6 weeks of receiving 
5000 IU vitamin D3 treatment.  
 
The median of serum PTH levels decreased significantly in response to vitamin D3 supplementation 
in both children age between 10 months to 3 years and children age > 3 years to 6 years. No 
significance reduction in the median of serum PTH levels in the oldest group, age > 6 years to 9.5 
years. The boxes indicate quartile values; the whiskers indicate the upper and lower values. Wilcoxon 
signed-rank test was used to assess the change from baseline to week six within subgroups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
153 
 
Table 5-3: Individual data for percentage change in serum 25(OH)D and PTH in study 
participants grouped according to age. 
Patient ID 
Age 
(Months) 
Sex % Change 25(OH)D* 
% Change 
PTH* 
 10 months- 3 years 
6 36 Girl 93.1 -51.1 
12 33 Girl 730.4 -21.9 
27 16 Boy 37 * 
28 16 Girl 408.6 -82.3 
29 19 Boy 307.6 -96.4 
32 10 Boy 683.3 -51.75 
33 18 Girl 505.2 -54.6 
36 22 Girl 185.7 -76.1 
Median 
18.5m 
(1.5year) 
- 358% -51.7% 
Patient ID 
Age 
(Months) 
Sex % Change 25(OH)D* 
% Change 
PTH* 
 age > 3 years- 6 years 
1 43 Boy 203 * 
8 46 Boy 394.1 -7.3 
15 51 Girl 284.8 -61.9 
17 71 Girl 200 -41 
22 63 Girl 210.7 -46.3 
26 63 Girl 73.5 -49 
34 66 Boy 269.6 -40 
37 72 Girl 106.4 -56.8 
Median 
63m 
(5.2years) 
- 206% -46.3% 
Patient ID 
Age 
(Months) 
Sex % Change 25(OH)D* 
% Change 
PTH* 
 > 6 years- 9.5 years 
3 102 Boy 268.4 -16.2 
5 113 Girl 163.6 -20.3 
7 115 Girl 130.3 -14.5 
9 78 Boy 971.4 -36.7 
10 79 Girl 371.4 -10.2 
11 115 Boy 857.1 -37.2 
30 96 Boy 89.7 8.3 
Median 
102m 
(8.5years) 
- 268.4% -16.2% 
%  change = [(v2-v1)/v1]*100. 
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5.4.4.2 Markers of bone remodelling (ALP, CTX and OCN) 
By the end of the six-week study period, 21 paired ALP samples were available for 
analysis with a significant change in the median of ALP levels from baseline to week 6, 
p=0.001.  As shown in Figure 5-7, of the 21 children, 15 (71.5%) children had basal serum 
ALP within normal reference range.  Six (28.5%) children showed basal serum ALP levels 
exceeding the normal reference range, which returned to the normal range in 4 children 
and remained high in the remaining 2 children after vitamin D3 supplementation.  
 
Within the subgroups analysis, the reduction in serum ALP was significant in only the 
younger age group (10 months-3 years) with p-value of 0.01.  Non-significant reduction in 
the median of ALP in other groups, 3 to 6 years and > 6 to 9.5 years was observed with P- 
values of 0.07 and 0.1 respectively (see Figure 5-8).  Table 5-4 summarises the percentage 
change in serum ALP concentration from baseline to 6 weeks in study participants, 
grouped according to the age. 
 
 
 
 
 
 
 
 
 
155 
 
Week 0 Week 6
0
100
200
300
400
500
600
700
800
900
1300
1800
2300
2800
Vitamin D3 treatment
A
L
P
(u
/l
)
Week 0 Week 6
0
200
400
600
800
1000
1200
1400
2500
3000
Vitamin D3 treatment
A
L
P
(u
/l
)
A
B
 
Figure 5-7: A; Individual changes in serum alkaline phosphatase (ALP) levels for 21 children 
before and after 6 weeks of receiving 5000 IU vitamin D3 treatment.  
 
A line connecting week 0 with week 6 values represented each subject’s ALP level. Area between 
two red lines; normal reference ranges for ALP. B: Box plot showing distribution of ALP levels 
among the study participants before and after receiving vitamin D3 supplementation. The boxes 
indicate quartile values; the whiskers indicate upper and lower values. A significant increase in the 
median of serum ALP levels was also observed (p < 0.001). 
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Figure 5-8: Effect of age on serum ALP concentrations before and after 6 weeks receiving 
5000 IU vitamin D3 treatment.  
 
The median of serum ALP levels decreased significantly in response to vitamin D3 supplementation 
in children aged between 10 months to 3 years. No significance reduction in serum ALP levels in the 
older groups, children age > 3 years to 6 years and age  > 6 years to 9.5 years, p= 0.07 and 0.1 
respectively. The boxes indicate quartile values; the whiskers indicate the upper and lower values. 
Wilcoxon signed-rank test was used to assess the change from baseline to 6 week within the 
subgroups. 
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Overall, vitamin D3 supplementation had no effect on median concentrations of OCN and 
CTX.  Serum CTX was available for 19 children at the two time points with no significant 
change from baseline to 6 weeks, p=0.2 (see figure 5-9).  Out of those 19 children, 7 (37%) 
children showed low basal CTX levels, 8 (42%) children showed basal CTX levels above 
the normal reference range whereas 4 (21%) children had basal CTX levels within the 
recommended level for corresponding age.  After 6 weeks of vitamin D3 supplementation, 
12 (63%) children had serum CTX within normal reference range, 3 (16%) children 
showed CTX levels above the normal reference range and 4 (21%) children showed low 
serum CTX levels.  Interestingly, the post treatment 25(OH)D levels for the 4 children 
showing low serum CTX levels at 6 weeks was 56, 60, 64 and 168 nmol/l whereas post 
treatment 25(OH)D levels for the 3 children showing high serum CTX levels at 6 weeks 
was 40, 70 and 106 nmol/l (see Figure 5-10).   
 
The subgroup analysis revealed that the younger age group (10 months-3 years) had basal 
serum CTX levels exceeding the  normal reference range for corresponding age in 6/8 
(75%) children whereas 2/8 (25%) children showed basal serum CTX falling within 
normal range.  In contrast, basal serum CTX levels in the middle age group (3- 6 years) 
was below the recommended level for corresponding age group in 5/7 (71.5%) children 
and within the normal reference range in 2/7 (28.5%) children.  In the older age group (> 
6- 9.5 years), the four children showed variability in their basal CTX levels with 2 (50%) 
children higher and 2 (50%) children lower than normal reference range for their 
corresponding age.  There were no significant differences in serum CTX level between the 
subgroups (p = 0.1) (see Figure 5-11).   
 
No significant change was observed in the median for serum OCN levels from baseline to 
week 6, p=0.5.  Serum OCN was available for 7 children at the two time points. Of those 7 
children, 5 showed low basal OCN levels whereas 2 children had basal OCN levels within 
normal reference range for corresponding age.  After supplementation, the OCN levels 
returned to normal reference value in 3 children and remained below reference value in the 
other 2 children, although their 25(OH)D and PTH levels went to the normal reference 
range. Due to lack of samples for OCN we were unable to look at changes based on 
subgroups analysis (see Figure 5-12). 
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Figure 5-9 A; Individual changes in the serum cross linked C-telopeptide of type I 
collagen (CTX)  for 19 children before and after 6 weeks of receiving 5000 IU vitamin D3 
treatment. 
 
 Each subjects’ CTX level is represented by a line connecting week 0 with week 6 values. B; 
Box plot showing distribution of CTX levels among the study participants before and after receiving 
vitamin D3 supplementation. The boxes indicate quartile values; the whiskers indicate the upper 
and lower values. No significant change in the median of serum CTX levels was observed, p 
=0.2. 
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Figure 5-10: Pie chart for the distribution of patients’ CTX levels before and after six weeks 
of receiving vitamin D3 supplements. 
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Figure 5-11: Comparison of basal (A) and 6 weeks (B) serum CTX levels (medians) between 
study participants according to age.  
 
Children were grouped into three age categories; from 10 months to 3 years, from > 3 years to 6 
years and from > 6 years to 9.5 years. No significant differences in the median of basal and week 6 
serum CTX levels between subgroups or within groups. The numeric variables for the two subgroups 
were compared using the Mann-Whitney test; comparisons among the three subgroups were 
analysed using a one-way ANOVA or the Kruskal-Wallis test (non-parametric). Red colours; Children 
with normal CTX level, Blue; High serum CTX levels and Green: Low CTX levels for each 
corresponding age. 
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Figure 5-12: A; Individual changes in serum Osteocalcin (OCN) for 7 children before and 
after 6 weeks of receiving 5000 IU vitamin D3 treatment. 
 
 Each subject’s OCN level is represented by a line connecting 0 week with 6 week values.B: Box plot 
showing distribution of OCN levels among the study participants before and after receiving vitamin 
D3 supplementation. The boxes indicate quartile values; the whiskers indicate upper and lower 
values. The median of serum OCN levels increased but not statistically significant, p =0.5. 
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Table 5-4: Individual data for percentage change in serum ALP and CTX in study 
participants grouped according to their age group. 
Patient ID 
Age 
(Months) 
Sex 
% 
Change ALP 
% 
Change CTX 
 10 months- 3 years  
6 36 Girl -70.3 -37.8 
12 33 Girl -12.5 -31.9 
27 16 Boy -42.3 -42.8 
28 16 Girl -54.9 -46.3 
29 19 Boy -74.2 -4.3 
32 10 Boy -73.9 -26.3 
33 18 Girl -16.2 -24.3 
36 22 Girl -46.5 51.5 
Median  
18.5m (1.5 
year) 
- -54.9% -29.1% 
Patient ID 
Age 
(Months) 
Sex 
% 
Change ALP 
% 
Change CTX 
 age > 3 years- 6 years  
1 43 Boy -9.9 15.4 
8 46 Boy -58.2 -6.9 
17 71 Girl -26.1 -16.6 
22 63 Girl 5.4 107.6 
26 63 Girl -4.4 17.9 
34 66 Boy -26.7 25.8 
37 72 Girl -4.4 3.7 
Median  
63m (5.2 
years) 
- -9.9% 15.5 
Patient ID 
Age 
(Months) 
Sex 
% 
Change ALP 
% 
Change CTX 
 > 6 years- 9.5 years  
3 102 Boy -17.7 -13.8 
5 113 Girl -38.5 * 
7 115 Girl 3.04 4.9 
9 78 Boy 3.3 * 
11 115 Boy -59.7 22.9 
30 96 Boy 0.44 -25.7 
Median  
107m 
(9 years) 
- -8.6% -4.4 
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5.4.4.3 Calcium and phosphate  
In general, vitamin D3 supplementation had no significant effect on the median of calcium 
and phosphate levels.  Figure 5-13 shows individual changes in serum calcium for the 19 
children for whom calcium data was available at the two time points.  Most of the 19 
children (with the exception of one child) had basal calcium level within the normal 
reference range, however, following 6 weeks of vitamin D3 treatment there was an 
increase in the median calcium levels with p-value of 0.05, which was close to statistically 
significance.  Post treatment calcium levels remained within the normal reference range for 
all study participants.  The subgroup analysis showed a non-significant increase in calcium 
levels in children age 10 months- 3 years  and > 3- 6 years, p =0.1 and 0.2 respectively. 
Additionally, treatment with vitamin D3 had no effect on the calcium levels for children in 
the older group (6- 9.5 years) (see Figure 5-14). 
 
Figure 5-15 shows individual changes in serum phosphate levels for the 19 children whose 
was available to the researcher.  All 19 children had basal phosphate levels within the 
normal reference range.  After 6 weeks, no significant effect from vitamin D3 treatment 
was observed, p=0.6.  Post treatment serum phosphate levels remained within the normal 
reference range for nearly all study participants except for one child who showed 6 week 
phosphate level exceeding the normal reference range.  Interestingly, pre-treatment bone 
profile for this child was; 25(OH)D;18 nmol/l, PTH; 6.8 pmol/l, calcium; 2.38 mmol/l, 
phosphate; 1.07 mmol/l, ALP; 864 u/l and CTX; 2.28 ng/ml.  The post-treatment bone 
profile for this child was; 25(OH)D; 141 nmol/l, PTH; 14.1 pmol/l, calcium; 2.45 mmol/l, 
phosphate; 1.89 mmol/l, ALP; 225 u/l and CTX; 1.68 ng/ml. 
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Figure 5-13: A; Individual changes in serum calcium levels for 19 children before and after 6 
weeks of receiving 5000 IU vitamin D3 treatment. 
 
Each subjects’ calcium level is represented by a line connecting week 0 with week 6 values. Area 
between two red lines; normal reference ranges for calcium. B; Box plot showing distribution of 
calcium levels among the study participants before and after receiving vitamin D3 supplementation. 
The boxes indicate quartile values; the whiskers indicate the upper and lower values. No significant 
increase in the median of serum calcium levels was observed, p=0.05. 
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Figure 5-14: Effect of age on serum calcium concentrations before and after receiving 5000 
IU vitamin D3 treatment.  
 
Non-significant increase in the median of serum calcium levels in response to vitamin D3 
supplementation in children age between 10 months to 3 years and age > 3 years to 6 years, p=0.1 
and 0.2 respectively. Non-significant change in the median of calcium levels for children age > 6 
years to 9.5 years, p=1. The boxes indicate quartile values; the whiskers indicate upper and lower 
values. The Wilcoxon signed-rank test was used to assess the change from baseline to week 6 within 
subgroups. 
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Figure 5-15: A; Individual changes in serum phosphate levels for 19 children before and 
after 6 weeks of receiving 5000 IU vitamin D3 treatment.  
 
Each subjects’ phosphate level is represented by a line connecting week 0 with week 6 values. Area 
between two red lines; normal reference ranges for phosphate. B; Box plot showing distribution of 
phosphate levels among the study participants before and after receiving vitamin D3 
supplementation. The boxes indicate quartile values; the whiskers indicate upper and lower values. 
No significant increase in the median of serum phosphate was observed, p =0.6.  
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5.5 Correlation between vitamin D and bone remodelling 
markers 
5.5.1 Relationships between 25(OH)D, parathyroid hormone (PTH) 
and calcium at the baseline and week six of the study 
No significant correlation was observed between serum 25(OH)D and PTH or calcium at 
the baseline and week six of the study.  
 
5.5.2 Relationships between 25 (OH) D, PTH and bone 
biomarkers, ALP, CTX and OCN at baseline and week six 
and between the changes over 6 weeks 
There was no association between baseline and week six serum 25(OH)D with any of the 
bone remodelling markers.  The multivariate analysis further confirmed this (see below).  
There was a significant positive association between PTH and ALP at baseline, r=0.4; 
p=0.02 which become statistically non-significant at week six, p=0.08 (Table 5-5).  There 
was a trend towards a positive association between PTH and CTX, r= 0.4; p=0.08 at study 
baseline.  Changes in serum 25 (OH) D were not associated with changes in any of the 
bone remodelling markers.  However, change in serum PTH was correlated significantly 
with changes in serum ALP, r= 0.5; p=0.01 (see Figure 5-16) (Table 5-6).  
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Table 5-5: Univariate correlation coefficients. 
 
Correlation at 
baseline 
r 
p 
value 
Correlation at 
week six 
r 
p 
value 
Serum 25(OH)D and PTH -0.3 0.08 0.2 0.2 
Serum 25(OH)D and calcium 0.07 0.7 0.05 0.8 
Serum PTH  and calcium -0.1 0.4 0.04 0.8 
Changes in the correlation between 25(OH)D, PTH and calcium from baseline to week six of the 
study period. 
 
 
Table 5-6: Univariate correlation between 25(OH)D, PTH, bone remodelling markers at 
baseline and at week six. 
A 
25(OH)D PTH 
Base line 
Simple regression r p-value r p-value 
Serum ALP -0.2 0.2 0.4 0.02 
Serum CTX -0.2 0.2 0.4 0.08 
Serum OCN 0.1 0.7 -0.3 0.4 
B 
25(OH)D PTH 
Week six 
Simple regression r p-value r p-value 
Serum ALP 0.1 0.5 0.4 0.08 
Serum CTX -0.1 0.6 0.04 0.8 
Serum OCN -0.3 0.4 -0.6 0.3 
C 
25(OH)D PTH 
Change over 6 weeks 
Simple regression 
r 
 
p-value 
r 
 
p-value 
∆  Serum ALP 0.05 0.8 0.5 0.01 
∆ Serum CTX 0.007 0.9 0.09 0.7 
∆  Serum OCN -0.1 0.7 0.08 0.8 
Univariate correlation between change in 25(OH)D, change in PTH and change in markers of bone 
remodelling over 6 weeks. ∆: 6 week value-baseline value.   
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Figure 5-16: The relationship between PTH and ALP at baseline (week 0).  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% confidence limits. A 
significant association was observed, p=0.02. 
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5.5.3 Mixed Effects Model (MEM) 
To conduct further analysis, a Mixed Effects Model (MEM) analysis  (a hierarchical model 
with random intercept and slope) was employed. This analysis only took into account data 
for which values were available at both study time points.  No independent effect between 
vitamin D with any of the bone remodelling parameters, although there was a trend 
towards a significant independent association between vitamin D with both PTH (p=0.08) 
and CTX (p=0.06).  The parathyroid hormone independently associated with ALP and 
CTX with p values of 0.001 and 0.02, respectively.  There was a trend for PTH to be 
independently associated with vitamin D,  p=0.09.  Age was independently associated with 
PTH with p values of 0.001.  Time is independently associated with CTX and vitamin D 
with p values of 0.02 and 0.0001, respectively.  Interestingly, there was a trend for a 
significant independent association between sex and CTX.  The results from MEM are 
summarised in Table 5-7. 
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Table 5-7: Mixed model analysis for vitamin D, PTH and bone remodelling.   
Variables Estimate SE 
95% CI 
(Lower, Upper) 
P-Value 
Log Vitamin D     
Intercept 1.4 0.29 (0.8, 2.07) 0.0001 
Time 0.4 0.06 (0.3, 0.6) 0.0001 
Age -0.002 0.001 (-0.004, 0.0001) 0.7 
Sex -0.08 0.07 (-0.2, 0.06) 0.2 
Race -0.05 0.05 (-0.1, 0.05) 0.2 
Calcium 0.01 0.05 (-0.09, 0.1) 0.4 
Log PTH -0.2 0.12 (-0.4, 0.03) 0.09 
Log PTH     
Intercept 1.79 0.3 (1.1, 2.4) 0.0001 
Time -0.1 0.1 (-0.3, 0.1) 0.3 
Age -0.004 0.001 (-0.006, -0.001) 0.001 
Sex -0.04 0.07 (-0.2, 0.1) 0.6 
Calcium 0.03 0.05 (-0.07, 0.1) 0.5 
Log vitamin D -0.05 0.06 (-0.1, 0.07) 0.08 
Log ALP     
Intercept 2.5 0.39 (1.7, 3.4) 0.0001 
Time 0.03 0.09 (-0.1, 0.2) 0.7 
Age -0.002 0.001 (-0.005, 0.0006) 0.1 
Sex -0.09 0.09 (-0.2, 0.1) 0.3 
Race 0.001 0.06 (-0.1, 0.1) 0.9 
Calcium -0.04 0.06 (-0.1, 0.09) 0.5 
Log vitamin D -0.11 0.1 (-0.4, 0.1) 0.4 
Log PTH 0.4 0.1 (0.2, 0.7) 0.001 
CTX     
Intercept 1.3 0.9 (-0.6, 3.3) 0.1 
Time 0.6 0.2 (0.09, 1.1) 0.02 
Age 0.002 0.003 (-0.003, 0.009) 0.3 
Sex -0.3 0.1 (-0.7, 0.03) 0.07 
Race 0.2 0.1 (-0.03, 0.5) 0.08 
Calcium 0.1 0.1 (-0.1, 0.4) 0.4 
Log vitamin D -0.7 0.3 (-1.5, 0.06) 0.06 
Log PTH 0.7 0.3 (0.08, 1.3) 0.02 
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5.6 Discussion                             
A considerable number of studies have examined vitamin D status and the effect of vitamin 
D supplementation on markers of bone remodelling in the adolescent and adult population 
[461, 462].  Cross-sectional data studying the association of serum 25(OH)D with bone 
remodelling markers in children and young adults shows disagreement.  For example, a 
study in Swiss children and adolescents found no association between bone remodelling 
markers and serum 25(OH)D [453], whereas others in Chinese and Irish adolescents 
demonstrated a significant negative association between serum 25(OH)D and bone 
remodelling markers [454, 455].  In a further interventional study, after 12 weeks of either 
400, 1000, 2000, or 4000 IU of vitamin D3 supplementation daily to healthy pubertal 
multi-ethnic adolescents, neither baseline nor 12 week 25(OH)D levels were associated 
with bone remodelling markers [456].  Supplementation with either 200 IU or 400 IU of 
vitamin D3 over a period of 12 months to 221 vitamin D sufficient girls aged 11-12 years 
did not appear to have any significant effect on markers for bone remodelling.  However, 
there was an effect on bone mineral density for those with the FF VDR genotype, 
indicating an influence from genotype [457].  These results reflect those observed in older 
subjects, aged between 18 and 27 years old, supplemented daily with 600 IU vitamin D3 
and 1500 mg calcium for a period of eight weeks  [463].  Four weeks of supplementation 
for healthy children aged between 6.2 and 13.7 years with 600 IU vitamin D3 does not 
appear to have any significant effect on the rate of bone remodelling [464].  However, 
these observations differ from those for younger vitamin D deficient children, aged 8.5-
10.5 months.  When this group received daily supplements containing 3000-4000 IU of 
vitamin D3, there was a significant effect on serum ALP levels as early as two weeks post 
treatment, and levels returned to normal within eight weeks of treatment [465]. 
Additionally, there was a transient but significant increase in osteocalcin during the first 
two weeks of treatment, which decreased gradually thereafter [465]. 
 
The majority of the available literature concerning vitamin D and bone health in children 
focuses on high-risk groups, i.e. those with rickets due to the very low content of vitamin 
D in breast milk, subjects with special dietary requirements, or those with particular ethnic 
origins [465-468].  However the effect of improving serum 25(OH)D status on markers of 
bone remodelling during infancy and early childhood continuous to be unclear, with a 
limited number of available studies [469, 470].  Such studies are of particular significance 
in Scotland, where people live at high latitude with prolonged winters, during which 
daylight hours are shorter.   
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In our study, short-term vitamin D3 supplementation significantly did reduce the overall 
median level of PTH.  This reduction was most significant in children aged 10 months– 3 
years and 3- 6 years.  The younger group showed higher basal PTH levels and lower basal 
serum calcium.  After supplementation, serum PTH concentrations decreased for all 
participants, regardless of their basal serum 25(OH)D levels.  
 
The suppression of PTH with vitamin D3 supplementation was expected, and is consistent 
with previous observations, which have reported a linear reduction in serum levels of PTH 
at any basal 25(OH)D concentration below 30–40 ng/ml (75–100 nmol/l).  At 25(OH)D 
concentration between 75–100 nmol/l, PTH level is suggested to plateau and remain stable 
[471, 472].  However, PTH concentrations were not elevated at the start of our study in 
many participants particularly in the age group older >6- 9.5 years.  In addition to the 
serum 25(OH)D both serum calcium and age were found to be significant contributors in 
determining PTH level [473].  Therefore, the lack of elevation of PTH despite the lower 
vitamin D status in older children may be attributed to normal serum calcium levels, which 
are one of the main trigger of PTH secretion.   
 
At the baseline, only two children in this study had low serum calcium levels with high 
PTH and very high ALP (Patients IDs: 29 and 36).  Both children are < 24 months in age 
and both are still being exclusively breastfed at the time of study.  Post treatment serum 
25(OH)D levels for those two children reached the normal reference range in one child and 
remained below 50 nmol/l in another child.  Additionally, in both children, there was an 
improvement in serum ALP but this still exceeded the upper normal limit at the end of the 
treatment course.  Both children received a Sandocal tablet (400 mg/1 tablet twice a day). 
Calcium levels returned to the normal range in one child and was not available in the other 
child.  Similarly, one previous study has reported that  normal serum ALP levels and 
complete radiological healing were not observed before 12 weeks of combined vitamin D 
and calcium treatment [474].  Therefore, the response to vitamin D supplementation may 
depend on pre-treatment levels, treatment duration and vitamin D dose. 
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 Rickets due to low dietary calcium intake has been reported in many developing countries 
including Northern Nigeria and parts of India.  In the UK low dietary calcium intakes was 
linked with inappropriate infant feeding, such as using a soy based milk not formulated for 
infant.  The biochemical features that have been used to differentiate dietary calcium 
deficiency rickets from vitamin D deficiency rickets are raised serum 1,25(OH)2D level, 
which nearly doubles in response to a single oral dose of vitamin D (due to high vitamin D 
requirements) and 25(OH)D concentrations being greater than those generally associated 
with vitamin D deficiency [474, 475]. 
 
Several studies report that serum 25(OH)D was inversely associated with PTH.  This 
correlation was not observed in this study [472, 476].  The results from correlation study 
showed an inverse but non-significant relationship between serum PTH and both 25(OH)D 
and calcium.  The lack of significance in the correlating study may be attributed to the 
weak responses to vitamin D3 supplementation in a considerable number of study 
participants (n=7), in addition to low basal PTH levels with minimal non-significant 
change after supplementation [477, 478].   
 
Some reports also suggest that not everyone who is vitamin D deficient has an increased 
PTH level [479, 480].  Interactions between the endocrine and paracrine vitamin D 
network are not yet fully recognised, and this may also explain the apparent lack of a 
relationship between PTH and 25(OH)D levels.  The main production site of vitamin D in 
the kidney, the active form of vitamin D is also produced locally in many organs/tissues. 
Therefore, the possibility of higher or lower serum PTH levels reflecting vitamin D status 
at tissue-level may explain the apparent dissociation between vitamin D and PTH.  For 
example, in one recent study, the prevalence of secondary hyperparathyroidism was 32.5% 
in vitamin D insufficient/deficient critically ill patients, and both secondary 
hyperparathyroidism and vitamin D deficiency were associated with greater disease 
severity although there was no observable correlation between serum 25(OH)D and PTH (r 
= -0.11, p = 0.3) [481]. 
 
Before supplementation, the median serum level for ALP exceeded the normal reference 
range, returning to the normal range following supplementation.  When we conducted a 
subgroup analysis, the median ALP concentration in the younger group (10 months– 3 
years) was significantly higher than in the older groups, possibly indicating increased bone 
remodelling.  However, following supplementation, serum ALP decreased significantly in 
almost all children, regardless of their basal ALP levels.  A similar pattern of ALP 
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reduction in relation to basal vitamin D status for both children and adults is reported 
widely in the literature [465, 482].  Increased levels of serum ALP may be an indication of 
an abnormally late phase of mineralization, and the reduction in ALP, after treatment may 
be a sign of recovery of skeletal abnormality.  However, due to the nature of our study 
which cited data at only two time points and involved one X-ray, we were unable to 
monitor changes in clinical/radiological abnormalities in relation to these biomarkers. 
Monitoring of biomarkers dynamic may be particularly important for children who showed 
very high bone biomarkers levels accompanied with profound clinical/radiological rickets 
at baseline which were not fully recovered after supplementation.  Very high ALP levels 
were evident in just 2 children in our study with basal ALP levels of 2834 and 2551 u/l that 
decreased to 729 and 1364 u/l, respectively, following vitamin D3 supplementation 
(Patients IDs: 29 and 36).  As these bone biomarkers remained above the normal reference 
values, even after supplementation, this might indicate the need for a longer duration of 
vitamin D3 treatment for individuals with profound rickets.  
 
Osteocalcin is the main non collagen protein contained in the organic matrix of bone 
synthesised by the osteoblast.  Few studies have investigated the effects of vitamin D 
supplementation on serum OCN and CTX.  The majority of available studies involve 
adults and the elderly with abnormal bone remodelling such as post-menopausal women at 
risk of developing osteoporosis.  In these studies an alteration in bone remodelling markers 
in response to vitamin D supplementation may be expected [483, 484].  For example, 6 
months daily supplementation for both pre and post-menopausal women with 4000 IU 
vitamin D3 or placebo daily had different effects on rates of bone remodelling.  In 
postmenopausal women, both CTX and OCN levels increased significantly (P=0.001, 
P=0.004 respectively), indicating an augmented rate of bone remodelling.  However, in 
premenopausal women there was no significant response to vitamin D3 supplementation in 
either CTX or OCN [483].  Data linking serum 25(OH)D and bone remodelling markers in 
children and adolescents is inconclusive.  To our knowledge, the majority of accessible 
studies that have explored the effect of vitamin D3 supplementation on OCN and CTX 
have been conducted in either older children or adolescents, with no significant changes 
observed [161, 457, 464] [456, 468]. 
 
A limited numbers of studies have examined the effect of vitamin D3 supplementation on 
OCN and CTX in infants or those in younger age groups [465].  In our study, vitamin D3 
supplementation was found to have no effect on overall and subgroup median OCN and 
CTX levels, and most of the children who were still vitamin D deficient/insufficient, CTX 
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remained above and/ or below the normal reference values.  Low OCN concentrations 
present in many children (5 children or 74%) might reflect suboptimal osteoblastic activity. 
The non-significant effect of vitamin D3 supplementation on both CTX and OCN in our 
study population could be attributed to multiple factors such as small sample size and study 
duration which may not be sufficient to observe a significance change.  Additionally, 
vitamin D itself has been proposed to play a more vital role in bone mineralisation rather 
than bone remodelling [452].  For example, both vitamin D deficient rats and VDR 
knockout mice showed no abnormal intrauterine skeletal development, indicating that 
vitamin D and the VDR might not play an essential role in skeletal formation [485, 486]. 
The wide variation in end point serum 25(OH)D among our study participants could also 
influence the vitamin D threshold suggested to maintain bone metabolism [476, 487].  
 
The results from the univariate correlation and multiple regression analyses performed here 
were consistent with previous observations, showing no significant association between 
vitamin D and bone remodelling markers.  However, our results showed PTH is 
independently correlated with bone remodelling markers, ALP, CTX and OCN.  Therefore, 
secondary hyperparathyroidism, due to vitamin D deficiency, may impose a more 
significant action on bone remodelling rather than vitamin D alone.  Furthermore, there 
was a trend for vitamin D to be an independently associated with CTX, p = 0.06.  The 
results from the mixed linear model also indicated  age, sex and race, as independent 
factors to consider in future studies.  The results from the correlation analysis further 
supported the evidence available for the significant independent role of PTH in the bone 
remodelling process, and in the regulation of serum calcium and phosphate levels.  The 
principal action suggested for PTH in bone is through its main receptors, PTH/PTHrP type 
1 receptor (PTH1R), leading to the activation of multiple signalling pathways, which are 
key regulators of bone metabolism, such as Wnt signalling [488].  
 
Althogh defining the ideal level of vitamin D to optimize musculoskeletal health and 
fructure prevention remains under debate.  However, achieving a level of 25(OH)D 
between 75-150 nmol/l is both safe and effective for multiple health outcomes.  In this 
study there was a variability in the response to 5000 IU daily oral vitamin D3 
supplementation.  For example, 12 (52%) children reached a final serum 25(OH)D level of 
75-150 nmol/l and three (13%) children exceeded the normal reference range with a final 
25(OH)D level of > 150 nmol/l.  Conversely, serum 25(OH)D in eight (35%) children 
remained at < 75 nmol/l.  Therefore, this study could not confirm  whether a dose of six 
weeks 5000 IU vitamin D3 supplementation is effective to increase serum 25(OH)D level 
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of > 75nmol/l in a considerable number of study participants.  Poor compliance may be a 
factor for some children, while misuse of the medication may be the cause for the very 
high level of vitamin D.  An alternative option suggested by other studies to address the 
problem of poor compliance is to use stoss therapy or a high single dose of 100,000-
600,000 IU of oral (capsule, tablet or gel) or intramuscular vitamin D followed by a low 
maintenance dose [489]. 
 
The main strength of this study is the prospective and the interventional nature of the work, 
in addition to its unique population.  However, there are several limitations that should be 
considered.  Firstly, due to ethical issues specifically related to study design we were not 
able to construct a control group without vitamin D3 supplementation.  Absence of a 
control group is a critical limitation of this part of the project.  This study did not 
contribute to several potential confounding variables such as feeding practices, sun 
exposure and physical activity which may affect the individual responses to vitamin D3 
treatment.  Further, observed changes in the bone turnover markers possibly reflected high 
bone turnover during the infancy and early childhood, effect of vitamin D3 
supplementation, or most likely, a combination of both.  Finally, compliance might be 
affected by a combination of two possible confounding factors: a liquid form of vitamin D 
supplement and parental ambivalence regarding treatment.   
  
In conclusion, supplementation of children with 5000 IU of vitamin D3 for six weeks 
significantly increased serum 25(OH)D levels and affected the level of bone formation 
marker, ALP.  The effect of vitamin D3 supplementation on bone remodelling biomarkers 
may depend on the age in addition to on pre-treatment level and treatment duration.  The 
results from this study, as well as previous studies have suggested ALP as a reliable marker 
for monitoring patients with nutritional vitamin D deficiency than CTX and OCN in 
addition to an indicate that  PTH might have an independent role to play in bone 
remodelling process.  Finally, an additional randomized control trial are needed to confirm 
the effectiveness vitamin D dose and to validate the clinical significance of our results and 
longer durations of high-dose vitamin D treatment, involving multiple doses at measurable 
intervals are advised for future studies. 
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Chapter 6 
 
 Effect of Vitamin D3 Supplementation on 
Glucose Homeostasis 
 
6.1 Abstract  
Introduction  
 
Observational studies point to an association between lower circulating 25(OH)D status 
and an increased risk of diabetes mellitus.  Interventional studies are inconclusive, and the 
effect of improving vitamin D status on glucose homeostasis in vitamin D deficient, 
otherwise healthy children is still unclear.  
 
Objective  
 
To investigate the effect of vitamin D3 supplementation on glycaemic status in vitamin D 
deficient children. 
 
Method 
 
Twenty-three pre-pubertal children aged 10 months to 9.5 years (10 boys) were diagnosed 
with vitamin D deficiency [25(OH)D level >50 nmol/l] and  insufficiency [25(OH)D 
level >73 nmol/l] and recruited during 24 months of the study period.  Treatment consisted 
of 5000 IU vitamin D3 (cholecalciferol) given orally once a day for six weeks.  At baseline 
and completion of treatment the following were measured: 25 hydroxyvitamin D 
(25(OH)D), parathyroid hormone (PTH), glycated haemoglobin (HbA1c), sex hormone 
binding globulin (SHBG), fasting insulin, fasting glucose, homeostasis model assessment 
index - estimated insulin resistance (HOMA IR) and lipid profile. 
 
Results 
 
In 17 patients for whom glucose, insulin and HOMA IR data were available, median 
(range) serum 25(OH)D increased significantly from 26.5 (14, 49) nmol/l at the baseline to 
96 (37, 191) nmol/l at week six (p < 0.0001).  Serum PTH concentrations decreased 
significantly from a median of 6.3 (3.6, 134) pmol/l at the baseline to 4 (1.9, 6.8) pmol/l at 
week six (p < 0.0001).  HOMA IR decreased significantly from a median of 2.18 (0.56, 
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20.29) at the baseline to 1.59 (0.37, 12.5) at week six (p = 0.04). Fasting serum insulin 
decreased from a median of 11.1 (2.46, 99.2) µiu/ml at the baseline to 8.1 (1.8, 66.6) 
µiu/ml (p = 0.05).     
  
Conclusion 
 
Short term improvement of vitamin D deficient status was associated with improvement in 
insulin resistance.  Further interventional studies are still needed. 
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6.2 Introduction  
As described earlier in the introduction of this thesis, there has been increased research on 
the effects of vitamin D on glucose homeostasis and conditions preceding type 2 diabetes,  
such as insulin resistance and impaired β cell function [490].  Epidemiological studies have 
linked low vitamin D status with impaired glucose tolerance and an increased risk of 
diabetes mellitus [256, 266, 491].  However, the majority of studies which involved the 
younger population have failed to prove relevant vitamin D effects on glucose homeostasis 
and insulin resistance.  
 
Impaired insulin secretion and decreased glucose tolerance have been reported in VDR 
mutant mice compared with those with functional receptors, suggesting a direct role of 
vitamin D in the regulation of insulin secretion [229].  Evidence from non-genomic studies 
have also pointed to an indirect role of vitamin D in insulin secretion through regulation of 
intracellular calcium concentrations, known as the main stimulator for glucose-induced 
insulin secretion [490].  In peripheral tissues such as skeletal muscle, the active form of 
vitamin D is suggested to improve free fatty acid–induced insulin resistance accompanied 
by an increase in insulin responsive-ness for glucose transport in cultured myocytes (i.e., 
improved glucose uptake) [236, 237].   
 
It has been suggested that combined assessment of both vitamin D status and PTH is 
needed for optimal evaluation of the impact of vitamin D on glucose homeostasis.  There is 
evidence showing that PTH is positively correlated with the prevalence of type 2 diabetes. 
For example, PTH treatment of cultured adipocytes has been shown to induce a reduction 
in insulin-stimulated glucose uptake and to down regulate the insulin secretion signalling 
pathway [492].  Additionally, primary hyperparathyroidism has been suggested as a risk 
factor for insulin insensitivity and β cell dysfunction [493].  However, epidemiological 
studies which examined the effect of PTH on abnormal glucose homeostasis still show 
conflicting findings [494, 495].  
 
To my knowledge, most, if not all, available interventional studies assessing the effect of 
vitamin D supplementation on glucose homeostasis involve higher-risk older children 
and/or adolescents (either obese or pre-diabetes).  There is little information available 
about the effect of improving vitamin D status in vitamin D deficient healthy young 
children or infants or when raising serum 25(OH)D from < 50 nmol/l  to > 75 nmol/l.  In 
one interventional study, which aimed to treat obese children and adolescents (basal 
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25(OH)D < 56 nmol/l) with 20000 IU vitamin D2 daily for 28 days, both insulin sensitivity 
and glucose tolerance, but not insulin secretion, were improved [161].  
 
This chapter aims to investigate the short term effects of vitamin D3 supplementation on 
insulin resistance in vitamin D deficient healthy children in addition to glycaemic status 
and lipid profile.  This chapter also looked at the association between markers of glucose 
homeostasis and markers of bone remodelling.   
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6.3  Subjects and methods 
6.3.1 Subjects 
Chapter 4 of the thesis described in detail subject characteristics and inclusion/exclusion.   
 
6.3.2 Study methods 
Study protocol was detailed in Chapter 4 of this thesis.  Briefly, the study design involved 
six weeks of 5000 IU vitamin D3 (cholecalciferol) given orally once a day to children 
referred to the endocrine department at RHSC for vitamin D deficiency.   
 
6.3.3 Blood collection 
Blood samples were collected in Ward 1C at RHSC, in the morning after a six-hour 
overnight fast. At baseline and completion of treatment, serum 25 hydroxyvitamin D 
(25(OH)D), parathyroid hormone (PTH), alkaline phosphatase (ALP), serum collagen type 
1 cross-linked C-telopeptide (CTX), glycated haemoglobin (HbA1c), sex hormone binding 
globulin (SHBG), fasting serum insulin, fasting blood glucose, and homeostasis model 
assessment index  estimated insulin resistance (HOMA IR) were measured.  The original 
HOMA IR from Matthew et al. was used to assess the outcomes of the intervention [218]. 
This model employs a simple linear equation based on the combination of fasting serum 
glucose (FSG) and fasting serum insulin (FSI) to exhibit a measure for insulin resistance: 
HOMA IR = (FSI[mu/l] × FSG[mmol/l])/22.5.  This method is simple, cheap and has been 
compared with other well validated methods of measuring insulin resistance and β cell 
function such as glycemic clamps [496].   
 
6.3.4  Biochemical assays 
All blood sampling was performed at the time of routine clinical visits; samples were 
immediately centrifuged at 2600-2800 rev/minute for 10 minutes, and the serum was 
subsequently stored at -80°C until the assays were performed. Serum 25(OH)D levels were 
assayed using the Abbott Architect Chemiluminescent Microparticle Immunoassay 
(CMIA).  Parathyroid hormone measurements were assayed using intact PTH CMIA 
(Abbott Architect). Insulin was measured by enzyme immunoassay for the quantitative 
measurement of insulin in human serum (DRG Instruments, GmbH DRG International, 
Inc., Germany) with an intra-assay CV of 1 to 1.22%.  Cholesterol measurements were 
183 
 
assayed using the Abbott ARCHITECT enzymatic cholesterol esterase method. 
Triglyceride measurements were assayed using the Abbott ARCHITECT glycerol 
phosphate oxidase method.  The ELISA for the insulin was performed by Mr McMillan in 
the Department of Child Health at RHSC, Glasgow. Dr. McNeilly performed the assays for 
serum 25(OH)D and lipids profile in the Biochemistry Department at Southern General 
Hospital, Glasgow.  The remaining samples were sent directly to the biochemistry 
laboratory at RHSC to test for fasting blood glucose, serum HbA1c and serum SHBG. 
HbA1c was measured using high performance liquid chromatography (HPLC). SHBG and 
fasting glucose were measured using an immunoassay analyser and glucose reagent kit 
respectively (ARCHITECT ci8200 System, Abbott Laboratories). 
 
6.3.5  Statistical analysis 
All statistical analyses were performed using GraphPad Prism 5 (San Diego, California, 
USA) or Mini Tab 17 (Minitab, Coventry, UK) statistical software and the results are 
presented as median and ranges, unless otherwise specified.  The significance of the 
changes in the measurements between baseline and week six for all study participants were 
assessed using the Wilcoxon signed-rank test.  Mann-Whitney U test were performed to 
analyse the two independent subgroups.  A Spearman correlation analysis was also 
performed to reveal the relationship between vitamin D, bone remodelling and glucose 
homeostasis parameters.  Using SPSS 22 Statistical Software (USA), a mixed model was 
employed where appropriate to explore the confounding effects of independent variables. 
For Mixed Effects Model analysis, the transformed values for 25(OH)D, PTH, glucose, 
insulin, HOMA, SHBG and HbA1c were used to satisfy the assumption of normal 
distribution. A significance level of p < 0.05 was used to evaluate all the study results.  
 
Only children with data available at both the baseline and week six of the study period 
were included in the MEM statistical analysis.  Children for whom there was missing data 
recorded at either point in the study period were included in the univariate association 
analysis only.   
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6.4 Results 
6.4.1 Recruitment summary  
A total of 61 children were identified and screened during the 24 months of the study 
period between 2011 and 2014. Forty-two children met the main project inclusion criteria 
and agreed to participate.  Thirty-seven children attended the first study visit, of whom 12 
children were excluded due to difficulty with venous access, lack of patients/parents 
cooperation or insufficient blood sample volume.  Twenty-six children's samples were 
analysed at the baseline and 25 samples at week six of the study.  There was difficulty in 
obtaining full investigations for every child, particularly in the younger age group. This 
was mainly due to technical difficulties such as venous access, in addition to lack of 
cooperation from both parents and children.  Figure 6-1 shows a flow diagram of study 
recruitment.   
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Figure 6-1: Flow diagram of study recruitment. Sixty-one children were identified through 
the endocrine clinic 
 
 
*Thirty-eight children were excluded throughout the study period due to a variety of reasons as 
shown in the diagram.   
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6.4.2 Demographic characteristics  
 
Twenty-three pre-pubertal children, 10 boys with a median age of 55 months (10 to 115 
months) and 13 girls with a median age of 63 months (16 to 115 months) enrolled at the 
two time points of the study.  Height (Ht) and body mass index (BMI) were converted into 
SDS using the 1990 British childhood standards [448, 449].  Standard Deviation Score 
(SDS) (BMI SDS) were 0.2 (-0.68, 2.29) and 0.67- (-1.45, 2.42) for boys and girls 
respectively.  Weight Standard Deviation Score (Wt SDS) were 0.05 (-1.02, 2.88) and 0.39 
(-4.5, 2.65) for boys and girls respectively.  The main reason for referral was bone pain, 
with 14 children in total (61%) being referred for this reason.  Out of those 14 children, 13 
children were referred from the orthopaedic clinic and one child was referred directly from 
the general practitioner (GP).  Radiological screening was performed in 20 study 
participants and we were unable to trace the reports in two children who were referred 
mainly due to bone pain.  One other child did not have an X-ray due to parental preference. 
Other causes for referral included bowed leg, seizure, dietary concern, fracture and family 
history.  Table 6-1 summarises the details of the 23 children enrolled in the study.  
 
Childhood obesity has been suggested to be associated with impaired glucose tolerance and 
insulin resistance [497].  Therefore, increased BMI among study participants was 
identified and represented in a separate table.  Three obese children (13%) were identified 
and their detailed information is provided in 6-2. 
   
 
 
  
187 
 
Table 6-1: Characteristics of recruited children. 
 N  
Age (years)  (23) % 
0-2 5 22 
2-6 9 39 
6-10 9 39 
Gender (23) % 
Male 10 43.5 
Female 13 56.5 
Race (23) % 
South Asian 10 43.5 
Middle Eastern  4 17.5 
Sub-Saharan African 3 13 
Caucasian 6 26 
Anthropometrics    Median (range) 
BMI SDS  18/23 -0.22 (-1.45, 2.42) 
Wt SDS 23/23 -0.25 (-4.5, 2.88) 
Vitamin D supplementation  (8) % 
Prior high dose vitamin D3 supplementation 2 25 
Prior multivitamin supplementation 4 50 
Current multivitamin supplementation 2 25 
Season of enrolment (23) % 
Autumn 7 30.5 
Spring 6 26 
Summer 6 26 
Winter 4 17.5 
Reason for referral  (23) % 
Bone pain 14 61 
Bowed legs 5 22 
Other 4 17 
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Table 6-2: Baseline laboratory and demographic characteristics of the three obese children 
enrolled in the study. 
Numbers in bold represent values outside the reference range (arrows indicate either above or 
below the reference range).  
Patient ID 34 30 7 
BMI SDS 2.3 2.1 2.4 
Wt SDS 2.8 2.2 2.7 
Age (years) 7 8 9.5 
Gender Male Male Female 
Race Middle Eastern Middle Eastern South Asian 
Referral  General paediatrician Orthopaedics General practitioner 
Reason for referral  Bone pain Bone pain Bone pain 
Season of referral  Summer Summer Autumn 
Vitamin D supplementation  Multivitamin No No 
25(OH)D, nmol/l 33 (↓↓) 49 (↓↓) 33 (↓↓) 
PTH 5 3.6 5.5 
Glucose (mmol/l) 5.7 4.4 4.1 
Insulin (µiu/ml) 11.3 11.1 99.2 (↑↑) 
HOMA IR 2.86 (↑↑) 2.18 20.2 (↑↑) 
HbA1c (mmol/mol) 38 31 39 
SHBG 31 (↓↓) - 17 (↓↓) 
Cholesterol (mmol/l) 4.1 4 4.4 (↑↑) 
Triglycerides (nmol/l) 2.2 (↑↑) 0.7 1.5 
HDL (mmol/l) 1.1 (↓↓) 2.4 0.9 (↓↓) 
Cholesterol/ HDL 3.7 1.7 4.9 (↑↑) 
Non-HDL cholesterol level 
(mmol/l) 
3.5 3 2.3 
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6.4.3 Effects of treatment  
For the 23 children included in this study, the median (range) of serum 25(OH)D levels 
increased significantly from 27 (14, 65) nmol/l at the baseline to 106 (37, 202) nmol/l at 
week six (p < 0.0001).  The median (range) of PTH levels in 21 children decreased 
significantly from 5.5 (3.6, 134.1) pmol/l at the baseline to 3.8 (1.9, 6.8) pmol/l at week six 
(p < 0.0001).  
 
Compared with week 0, there was a significant reduction in HOMA IR (p = 0.04) and a 
trend towards a reduction in serum insulin was noticed at week six (p = 0.05).  No 
significant changes in blood glucose, HbA1c and SHBG parameters, and any of the lipid 
profile measures were noticed after six weeks of supplementation (Table 6-3). 
 
The median of the changes between week six and baseline (week six – baseline) for 
glucose, insulin, HOMA IR and SHBG parameters showed a reduction after six weeks of 
vitamin D3 treatment whereas HbA1c showed an increase.  No change was observed in the 
lipid profile except for the cholesterol/HDL ratio which showed an increase following 
supplementation.  Table 6-4 summarises the outcome variables expressed as difference 
/changes and percentage change between the baseline and the week-six visits.  
 
For the 17 children whose insulin and HOMA IR data were available at the two time 
points, serum 25(OH)D increased significantly from 26.5 (14, 49) nmol/l at the baseline to 
96 (37, 191) nmol/l at week six (p < 0.0001 ) (see Figure 6-2).  Out of those 17 children, 
PTH data at week six was not obtained for two children due to insufficient samples, and 
serum PTH concentrations decreased significantly in the remaining 15 children from 6.3 
(3.6, 134) pmol/l to 4 (1.9, 6.8) pmol/l at week six (p < 0.0001) (see Figure 6-3). 
Additionally, children showed variability in their responses to vitamin D3 treatment.  For 
example, out of  the 17 children with available HOMA IR at the two time points, 6 (35%) 
children had 25(OH)D of < 75 nmol/l at the end point, with a median (range) percentage 
change of  PTH of -50.1(-76, -16)%.  Eleven (65%) children reached a final 25(OH)D of > 
75 nmol/l, with a median (range) percentage change of PTH of -45 (-96, 8.3)%.    
 
High prevalence of abnormal glucose homeostasis in obese/overweight children, and 
significant associations between 25(OH)D level and measurements of glucose homeostasis 
were reported by several studies [263, 498].  Therefore the participants were grouped 
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according to their BMI SDS, to compare the study parameters between obese and normal 
weight children.  Obese children showed a significant reduction in their HOMA IR  
from baseline to week six (p=0.007). However, the result showed no significant difference 
in HOMA IR between normal weight and obese children at week six, p=0.1.  Additionally, 
a significant increase in serum 25(OH)D level and a significant decrease in serum PTH 
levels was observed in the normal weight group (p = 0.001 and < 0.0001 for 25(OH)D and 
PTH respectively).  However, there was no difference observed between normal weight 
and obese children when we compared the change in both 25(OH)D and PTH from 
baseline to week six (Table 6-5 and Table 6-6). 
 
At the baseline, a high cholesterol/HDL ratio was reported in three children.  The first 
child was a 9.5 year old obese girl (Patient ID: 7) with a basal cholesterol/HDL ratio of 4.9. 
The other two children were 10 and 16 months normal-weight boys (Patient IDs: 27 and 
32), with basal serum cholesterol/HDL ratio of 4.4 and 6.2.  At week six, vitamin D3 
treatment was successful in improving serum 25(OH)D in Patients 7 and 32, and their 
cholesterol/HDL also returned to normal range. The other child (Patient ID: 27), had a final 
serum 25(OH)D of 37 nmol/l, and showed an increase in cholesterol/HDL ratio from 4.4 at 
baseline to 5.1 at week six (Table 6-7). Abnormal triglyceride levels were reported in two 
children: 2.4 nmol/l in a normal-weight child (Patient ID: 32), and 2.2 nmol/l in an obese 
child (Patient ID: 34). After supplementation, both children showed an increase in final 
serum 25(OH)D to the normal levels.  However, only Patient 34 showed a reduction in 
triglyceride level to the normal reference range, while serum triglyceride for the other child 
reduced slightly to 2.3 nmol/l (Table 6-7). 
 
Finally, basal serum cholesterol was above the normal reference range in two children, 
Patient ID: 7 and Patient ID: 27, with basal serum cholesterol level of 4.4 and 4.8 mmol/l 
respectively.  At week six, vitamin D3 treatment was successful in raising serum 25(OH)D 
in Patient ID 7, and serum cholesterol for this patient returned to normal range (4.1 
mmol/l).  The other child (Patient ID: 27) had final serum 25(OH)D of 37 nmol/l, and 
showed an increase in cholesterol level from 4.8 nmol/l at baseline to 5.1 nmol/l at week 
six (Table 6-7). 
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Table 6-3: Comparison of the biochemical and lipid profile measurements for the 23 
participants enrolled in the study over two points of the study period. 
 N 
Baseline 
median 
(min, max) 
N 
Week 6 
median 
(min, max) 
Baseline vs 
week 6 
p-value 
Normal 
value 
25(OH)D 
(nmol/l) 
23 27 (14, 65) 23 106 (37, 202) <0.0001 70-150 
PTH  
(pmol/l) 
21 5.5 (3.6, 134.1) 21 3.8(1.9, 6.8) <0.0001 0.9-5.5 
Metabolic N 
Baseline 
median 
(min, max) 
N 
Week 6 
median 
(min, max) 
Baseline vs 
week 6 
p-value 
Normal 
value 
Glucose 
(mmol/l) 
22 4.5 (2.9, 5.7) 22 4.4 (3.2, 5) 0.3 3.9-7 
 Insulin 
(µiu/ml) 
 
17 
 
11.1 (2.46, 99.2) 17 8.1 (1.8, 66.6) 0.05 * 
 HOMA IR 17 2.18 (0.56, 20.29) 17 1.59 (0.37, 12.5) 0.04 * 
  
HbA1c 
(mmol/mol) 
21 33 (29, 39) 21 34 (25, 42) 0.1 20-42 
  
SHBG (nmol/l) 
16 141 (17, 207) 16 115 (18, 223) 0.2 60-209 
Lipids  N 
Baseline 
median 
(min, max) 
N 
Week 6 
median 
(min, max) 
Baseline vs 
week 6 
p-value 
Normal 
value 
  
Cholesterol 
(mmol/l) 
 
17 
 
4 (3.3, 4.8) 
 
17 
 
3.9 (2.9, 5.2) 
 
0.8 
 
≥4.3 
  
Triglycerides 
(nmol/l) 
 
17 
 
0.9 (0.5, 2.4) 
 
17 
 
0.9 (0.4, 2.3) 
 
0.6 
 
≥1.7 
  
HDL 
(mmol/l) 
 
17 
 
1.2 (0.6, 2) 
 
17 
 
1.2 (0.6, 1.9) 
 
0.4 
 
≤1.5 
  
Cholesterol/ 
HDL 
 
17 
 
3.2 (2, 6.2) 
 
17 
 
3.5 (2.2, 6) 
 
0.2 
 
≥4 
Non-HDL 
cholesterol 
(mmol/l) 
 
17 
 
2.6 (3.7, -1.9) 
 
17 
 
2.8 (4.1, 1.7) 
 
0.5 
 
>3.5 
25(OH)D: 25 hydroxy vitamin D. PTH: Parathyroid hormone. HOMA IR: Homeostasis model 
assessment index - estimated insulin resistance. SHBG: Sex hormone binding globulin. HbA1c: 
Glycated haemoglobin. HDL: High density lipoprotein.  Normal reference values for insulin and 
HOMA IR were compared with age- and sex-specific paediatric reference interval as indicated in 
references [499, 500]. 
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Table 6-4: Summary statistics of differences/changes (week 6– baseline) and percentage 
changes (% = ([(v2-v1)/v1]*100) values after six weeks of vitamin D3 supplementation. 
Metabolic N Change (min, max) % change (min, max) 
Glucose 22 -0.1(-1, 1.5) mmol/l -2.2 (-23.8, 51.7) 
Insulin 17 -0.7(-32.5, 8.97) µiu/ml -9.3 (-64.5, 141.3) 
HOMA IR 17 -0.21(-7.80, 1.4) -13.6 (-71.4, 142) 
HbA1c 21 1 (-4, 4) mmol/mol 2.63 (-13.8, 12.9) 
SHBG 16 -3 (-87, 93) nmol/l -3.5 (-53, 78.7) 
Lipids N Change (min, max) % change (min, max) 
Cholesterol 17 0 (-0.4, 1) mmol/l 0 (-12, 23.8) 
Triglycerides 17 0 (-1.1, 0.5) nmol/l 0 (-55, 50) 
HDL 17 -0.1 (-0.3, 0.3) mmol/l -5 (-30, 25) 
Cholesterol/HDL 17 2.6 (-35.6, 53.7) 8 (-25, 46) 
Results are shown as median (range). 
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Figure 6-2: Individual changes in the 25(OH)D concentrations for 17 children with available 
insulin and HOMA IR data before and after six weeks of receiving 5000 IU cholecalciferol 
treatment. 
 
Significant increase in the median of vitamin D levels was observed (p < 0.0001). Each subject’s 
vitamin D level is represented by a line connecting week 0 with week 6 values. Area between two 
red lines; normal reference ranges for vitamin D.  
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Figure 6-3: Individual changes in the PTH concentrations for 15 children with available 
insulin and HOMA IR data before and after six weeks of receiving 5000 IU cholecalciferol 
treatment.  
 
Significant decrease in the median of PTH levels was observed (p < 0.0001). Each subject’s PTH 
level is represented by a line connecting week 0 with week 6 values. Area between two red lines; 
normal reference ranges for PTH.  
  
 
194 
 
Table 6-5: Changes from baseline to six weeks of primary outcome measures for the study 
participants divided according to BMI SDS.  
 N Normal  weight 
p-value 
(Baseline 
vs  
week six) 
N Obese 
p-value 
(Baseline 
vs  
week six) 
 
p-value 
(Difference 
between 
groups at  
week six) 
25(OH)D (nmol/l) 
 
Baseline 
Week six 
Change: End-Baseline 
% change 
20 
20 
 
 
23 (14, 33) 
103 (37,191) 
73.5 (10,168) 
277 (37, 857) 
 
0.001 
    3 
 3 
 
 
33 (33, 49) 
93 (76, 122) 
44 (43, 89) 
130 (89, 269) 
0.1 0.9 
PTH (pmol/l) 
 
Baseline 
Week six 
Change: End-Baseline 
% change 
18 
18 
 
 
6.18 (4,134) 
3.9 (1.9, 6.8) 
-2.7 (-129, -0.3) 
-46 (-96, -7.3) 
 
<0.0001 
    3 
 3 
 
 
5 (3.6, 5.5) 
3.9 (3, 4.7) 
-0.8 (-2, -0.3) 
-14.5 (-40, -8) 
 
0.4 
 
0.9 
Metabolic        
Glucose (mmol/l) 
 
Baseline 
Week six 
Change: End-Baseline 
% change 
19 
19 
 
 
4.4 (2.9, 5.1) 
4.4 (3.2, 5) 
-0.1 (-1,1.5) 
-2 (-23,51.7) 
 
0.5 
3 
3 
 
 
4.5 (4.4, 5.7) 
4.6 (4.1, 5) 
-0.2 (-0.7, 0.3) 
-4.3 (-12, 6.8) 
0.4 0.3 
Insulin (µiu/ml) 
 
Baseline 
Week six 
Change: End-Baseline 
% change 
14 
14 
 
 
7.9 (2.4, 20) 
7.8 (1.8,11) 
-0.9 (-12, 6.4) 
-14 (-64,141) 
 
0.1 
3 
3 
 
 
11 (6, 99) 
10 (5.9, 66) 
-5.4 (-32.5, -1.3) 
-32 (-47, -12) 
 
0.1 
 
0.4 
HOMA IR 
 
Baseline 
Week six 
Change: End-Baseline 
% change 
14 
14 
 
 
1.5 (0.56, 3.89) 
1.4 (0.37, 2.4)      
-0.23(-2.7,1.5) 
-16.6 (-71,142) 
 
0.1 
3 
3 
 
 
2.86 (2.28, 20) 
2.1 (1.31, 12.5) 
-1.55 (-7.7, -0.2) 
-38 (-54,-6.41) 
 
0.007 
 
0.1 
HbA1c (mmol/mol) 
 
Baseline 
Week six 
Change: End-Baseline 
% change 
18 
18 
 
 
32.5 (29, 38) 
33.5 (25, 39) 
1 (-4, 4) 
2.7 (-13.7,12.9) 
 
0.1 
3 
3 
 
 
38 (31, 39) 
7 (31, 42) 
0 (-1, 3) 
0 (-2.6, 7.7) 
 
0.1 
 
0.5 
SHBG (nmol/l) 
 
Baseline 
Week six 
Change: End-Baseline 
% change 
15 
15 
 
 
141 (17, 207) 
115 (76, 223) 
-3 (-87, 93) 
-3.5 (-53,78.7) 
 
0.1 
 
- 
 
 
NA 
 
NA 
 
- 
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Table 6-6: Changes from baseline to six weeks of secondary outcome measures for the 
study participants divided according to BMI SDS.  
 
 
 
 
 
 
 
 
 
 
 
 
 N Normal weight 
p-value 
(Baseline 
vs 
week six) 
N Obese 
p-value 
(Baseline 
vs 
week six) 
 
p-value 
(Difference 
between groups 
at 
week six ) 
Lipids        
Cholesterol (mmol/l) 
 
Baseline 
Week six  
Change: End-Baseline 
% change 
14 
14 
 
 
3.8 (3.3, 4.8) 
3.8 (2.9, 5.2) 
0.05 (-0.4,1) 
1.2 (-12, 23.8) 
 
0.5 
3 
3 
 
 
4.1 (4, 4.4) 
4 (3.7, 4.2) 
-0.3 (-0.4, 0) 
-6.8 (-9.7, 0) 
 
0.3 
 
0.9 
 
Triglycerides (nmol/l) 
 
Baseline 
Week six  
Change: End-Baseline 
% change 
 
14 
14 
 
 
 
0.85 (0.5, 2.4) 
0.9 (0.4, 2.3) 
0 (-0.5, 0.5) 
0 (-55, 50) 
 
 
0.8 
 
3 
3 
 
 
 
1.5 (0.7, 2.2) 
1.1 (0.8,1.1) 
-0.4 (-1.1, 0.1) 
-26.6 (-50,14) 
 
 
0.4 
 
 
0.4 
HDL (mmol/l) 
 
Baseline 
Week six  
Change: End-Baseline 
% change 
 
14 
14 
 
 
1.2 (0.6, 2) 
1.2 (0.6, 1.9) 
-0.1 (-0.3, 0.3) 
-6 (-30, 25) 
 
0.6 
 
3 
3 
 
 
 
1.1 (0.9,1.7) 
1.1 (0.9,1.6) 
-0.1 (-0.2, 0) 
-5.8 (-18, 0) 
 
0.3 
 
0.5 
Cholesterol/ HDL 
 
Baseline 
Week six  
Change: End-Baseline 
% change 
14 
14 
 
 
3.2 (2, 6.2) 
3.4 (2.2, 6) 
0.25 (0.8,1.9) 
8.7 (-25, 46) 
 
0.2 
3 
3 
 
 
 
3.7 (2.4, 4.9) 
4.1 (2.5, 4.6) 
-0.1 (-0.3, 0.4) 
4.1 (-6.1,10.8) 
 
0.7 
 
0.5 
Non-HDL Cholesterol 
(mmol/l) 
 
Baseline 
Week six  
Change: End-Baseline 
% change  
 
14 
14 
 
 
 
2.5 (3.7, 1.9) 
2.75 (-4.1, 1.7) 
0.1 (0.8, 0.5) 
4.3 (19.2, 30.4) 
 
 
0.3 
 
3 
3 
 
 
 
3 (3.5, 2.3) 
2.8 (3.2, 2.4) 
0.2 (0.2, 0.3) 
6.6 (8.5, 4.3) 
 
 
0.4 
 
 
0.7 
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Table 6-7: Abnormal lipid parameters reported in four patients. Numbers in bold represent 
values outside a reference range.  
Patient ID 7 27 32 34 
Age 7 years 16 months 10 months 7 years 
Gender Female Male Male Male 
Race South Asian Middle Eastern Caucasian Middle Eastern 
Anthropometrics 2.4 (BMI SDS) -0.5 (WT SDS) > -2 ( WT SDS) 2.3 (BMI SDS) 
Main presentation Bone Pain 
 
Fracture/Clear 
rickets on X-ray 
 
Wrist swelling/Clear 
rickets on X-ray 
Bone Pain 
Patient’s medical 
history 
Clear 
 
Iron deficiency 
anaemia/Poor 
feeding 
B12 deficiency 
anaemia/Poor feeding 
Clear 
Family history 
Hypertension/High 
cholesterol (Father) 
Clear Clear 
Asthma (Father) 
Diabetes (Mother) 
25(OH)D 
(nmol/l) 
    
Baseline 33 27 18 33 
Week six 76 37 141 122 
Cholesterol 
(mmol/l) 
    
Baseline 4.4 4.8 3.3 4.1 
Week six 4.1 5.1 2.9 3.7 
Triglycerides 
(nmol/l) 
    
Baseline 1.5 1 2.4 2.2 
Week six 1.1 1.5 2.3 1.1 
HDL 
(mmol/l) 
    
Baseline 0.9 1.1 0.6 1.1 
Week six 0.9 1 0.6 0.9 
Cholesterol/ HDL     
Baseline 4.9 4.4 6.2 3.7 
Week six 4.6 5.1 5.5 4.1 
Non-HDL 
cholesterol 
(mmol/l) 
    
Baseline 3.5 3.7 3.1 3 
Week six 3.2 4.1 2.7 2.8 
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6.4.4 Individual changes in markers of glucose homeostasis  
6.4.4.1 Insulin   
Seventeen paired samples were available for insulin analysis at the two time points of the 
study period.  There was no significant change in the median of insulin levels after six 
weeks of vitamin D3 supplementation (p = 0.05).  Abnormal baseline insulin levels were 
identified in four children (Patient IDs: 7, 12, 15 and 28).  After supplementation, insulin 
levels returned to the normal reference range in three children (Patient IDs: 12, 15 and 28), 
and remained above the normal reference range in one child (Patient ID: 7) (see Figure 6-4 
and Table 6-8). 
 
When the 17 children was divided into two groups based on their final 25(OH)D 
concentrations, children with final 25(OH)D  levels of ≥ 75 nmol/l had a significant 
reduction in the median of  serum insulin (p = 0.02), whereas those who were still vitamin 
D deficient after six weeks of vitamin D3 supplementation showed no significant change 
(p = 0.8) (see Figure 6-5).  There was no significant difference in the percentage change of 
insulin levels between the two groups (p = 0.05) (see Figure 6-6).  Vitamin D3 treatment 
was successful to reach serum 25(OH)D concentrations of ≥ 75 nmol/l in 11 children.  The 
median of the insulin levels for those children who achieved serum 25(OH)D 
concentrations of ≥ 75 nmol/l at the end of the study was significantly decreased from 13.2 
(2.46, 99.2) µiu/ml at the baseline to 9.3 (1.8, 66.67) µiu/ml at week six (p = 0.02) (Table 
6-8).  
 
The percentage changes in serum insulin were compared with percentage changes in serum 
25(OH)D (see Figure 6-7).  With the exception of two children (Patient IDs: 29 and 33), 
participants who reached a serum 25(OH)D of ≥ 75 nmol/l at week six showed a reduction 
in serum insulin.  One of those two children (Patient ID: 29) showed a 141% increase in 
serum insulin after supplementation compared with the baseline.  This was an 18-month-
old male who had co-existing vitamin B12 deficiency anaemia.  Additionally, markers of 
bone remodelling (ALP and CTX) for this child showed abnormal levels even after 
supplementation.  The other child (Patient ID: 33) was a 19-month-old male who had a 
15% increase in serum insulin after supplementation compared with the baseline, and had 
no significant medical background. 
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Figure 6-4: Individual changes in serum insulin for 17 children before and after six weeks of 
receiving 5000 IU cholecalciferol treatment.  
 
No significant change in the median of serum insulin levels was observed (p = 0.05). Each subject’s 
insulin level is represented by a line connecting week 0 with week 6 values. Red dots represent 
values exceeding normal reference range for serum insulin. Abnormally high insulin was observed 
in four children at baseline and in one child at week six. 
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Figure 6-5: Changes in serum insulin from baseline to week six in 17 children grouped by 
serum 25(OH)D concentration reached by the end point.  
 
Significant reduction in serum insulin was observed for the children with final 25(OH)D concentration 
of ≥ 75 nmol/l (p = 0.02) and no significant change in serum insulin was observed in those who were 
still vitamin D deficient after six weeks of supplementation (p = 0.8). 
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Figure 6-6: The percentage changes in serum insulin in 17 children grouped by serum 
25(OH)D concentration at the end point.  
 
Children who reached a final 25(OH)D concentration of ≥ 75 nmol/l showed a trend towards a 
significant decrease in % change of serum insulin compared with those who had a final 25(OH)D of 
< 75nmol/l (p = 0.05).  
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Figure 6-7: The percent changes in serum insulin in 17 children in relation to the percent 
changes in serum 25(OH)D concentration. 
 
Green dots represent children who reached a final 25(OH)D level of ≥ 75 nmol/l while black dots 
represent children who reached a final 25(OH)D < 75nmol/l.  With an exception of two children 
(patients IDs: 29 and 33). Children with a sufficient final 25(OH)D concentration showed a trend 
toward a significant decrease in % serum insulin compared with those who were still vitamin D 
deficient/insufficient at week six.   
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6.4.4.2 Glucose 
Twenty-two paired samples were available for glucose analysis at the two time points of 
the study period. They showed no significant change in the median of blood glucose levels 
after six weeks of vitamin D3 supplementation (p = 0.3) (see Figure 6-8).  Low basal blood 
glucose (defined by a serum glucose) of < 3.9 mmol/l was observed in one child (Patient 
ID: 22), whereas another child (Patient ID: 8) showed a low week-six blood glucose level 
(Table 6-8). 
 
When the 22 children with available glucose data at the two time points were divided into 
two groups based on their final 25(OH)D concentrations (25(OH)D ≥ 75 nmol/l (n = 14) 
and < 75 nmol/l (n = 8)), no significant change in the medians of blood glucose levels from 
baseline to week six in either groups was observed (p = 0.5 and p = 1 respectively).  Out of 
the 22 children with available glucose data, vitamin D3 treatment was successful to reach 
serum 25(OH)D concentrations of ≥ 75 nmol/l in 14 children.  The median glucose levels 
for those 14 children who achieved serum 25(OH)D concentration of ≥ 75 nmol/l at the 
study end was 4.6 (2.9, 5.7) mmol/l at the baseline and non-significantly decreased to 4.55 
(3.2, 5) mmol/l at week six (p = 0.2).  Additionally, there was no significant difference in 
the percentage change of blood glucose between children who reached a final 25(OH)D 
concentration of ≥ 75 nmol/l compared with those who had a final 25(OH)D concentration 
of < 70 nmol/l (see Figure 6-9). 
 
In order to examine the change in blood glucose in relation to the change in vitamin D 
levels individually for each child, the percentage change of blood glucose was compared 
with percentage change of serum 25(OH)D.  Out of 14 children who were vitamin D 
deficient at the baseline and reached  final 25(OH)D concentrations of ≥ 75 level nmol/l at 
week six, 9 children had a reduction in the % of glucose, four children showed an elevation 
in % of glucose while glucose level remained unchanged in one child (see Figure 6-10). 
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Figure 6-8: Individual changes in blood glucose for 22 children before and after six weeks of 
receiving 5000 IU cholecalciferol treatment. 
 
No significant change in the median fasting glucose level was observed (p = 0.3). Each subject’s 
glucose level is represented by a line connecting week 0 with week 6 values. Area between two red 
lines; normal reference ranges for blood glucose. Low blood glucose level was observed in two 
children. 
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Figure 6-9: The percentage change in blood glucose in 22 children grouped by the end point 
vitamin D concentration.  
 
No significant difference in % change of fasting glucose was found between the two groups (p = 
0.3).   
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Figure 6-10: The percentage changes in blood glucose in 22 children in relation to the 
percentage changes in serum 25(OH)D concentration.  
 
Green dots represent children who reached a final 25(OH)D level of ≥ 75 nmol/l, while black dots 
represent children who reached a final 25(OH)D level of < 75nmol/l.   
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6.4.4.3 Homeostasis model assessment index - estimated insulin resistance 
(HOMA IR) 
Seventeen paired samples were available for HOMA IR analysis at the two time points of 
the study period.  They had a significant reduction in the median of HOMA IR levels after 
six weeks of vitamin D3 supplementation (p = 0.04) (see figure 6-11).  Abnormal baseline 
HOMA IR was observed in four children (Patient IDs: 7, 12, 15 and 28).  Following 
supplementation, HOMA IR declined to the normal reference range in three children 
(Patient IDs: 12, 15 and 28) and remained above the normal reference range in one child 
(Patient ID: 7) (Table 6-8).  
 
When the 17 children were divided into two groups, based on their final 25(OH)D levels, a 
significant reduction in HOMA IR was observed in children with final 25(OH)D 
concentrations of ≥ 75 nmol/l (p = 0.02), whereas no significant change in HOMA IR was 
observed in those who were still vitamin D deficient after six weeks of vitamin D3 
supplementation (p = 0.8) (see Figure 6-12).  There was no significant difference in the 
percentage change of HOMA IR between the two groups (p = 0.05) (see Figure 6-13). 
Vitamin D3 treatment was successful in 11 children.  The HOMA IR for those children 
who achieved 25(OH)D concentrations of ≥ 75 nmol/l at the study end was significantly 
decreased from 2.23 (0.56, 20.29) at the baseline to 1.34 (0.72, 12.5) at week six (p = 0.02) 
(Table 6-8).  The percentage changes in HOMA IR were compared with the percentage 
changes in serum 25(OH)D.  Only two of the children who reached serum 25(OH)D levels 
of ≥ 75 nmol/l at week six did not show a reduction in HOMA IR (Patient IDs: 29 and 33) 
(see Figure 6-14). 
 
 
 
 
 
207 
 
Week 0 Week 6
0
1
2
3
4
5
12
15
18
21
Vitamin D3 treatment
H
O
M
A
 I
R
 
 
 
Figure 6-11: Individual changes in HOMA IR for 17 children before and after six weeks of 
receiving 5000 IU cholecalciferol treatment. 
 
Significant reduction in the median of HOMA IR levels was observed (p = 0.04). Each subject’s 
HOMA IR level is represented by a line connecting week 0 with week 6 values. Red dots represent 
values exceeding normal reference ranges for HOMA IR. Abnormal HOMA IR was observed in four 
children at baseline and in one child at week six. 
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Figure 6-12: Changes in HOMA IR from baseline to week six in 17 children grouped by the 
end point serum 25(OH)D concentration. 
 
A significant reduction in HOMA IR was observed for children with final 25(OH)D concentration of ≥ 
75 nmol/l (p = 0.02) and no significant change was observed in those who were still vitamin D 
deficient after six weeks (p = 0.8). 
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Figure 6-13: The percentage changes in HOMA IR in 17 children grouped by the end point 
serum 25(OH)D concentration. 
 
Children who reached a final 25(OH)D concentration of ≥ 75 nmol/l showed a trend toward a 
significant reduction in % HOMA IR compared with those who had a final 25(OH)D level of < 75nmol/l 
(p = 0.05). 
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Figure 6-14: The percentage change in HOMA IR in 17 children in relation to the percentage 
changes in serum 25(OH)D concentration. 
 
Green dots represent children who reached a final 25(OH)D level of ≥ 75 nmol/l, while black dots 
represent children who reached a final  25(OH)D level of < 75 nmol/l.  With an exception of two 
children (Patient IDs: 29 and 33), children with sufficient final 25(OH)D concentration showed a trend 
towards a significant decrease in % HOMA IR compared with those who were still vitamin D 
deficient/insufficient at six weeks. 
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Table 6-8: Summary data of age (months), fasting blood glucose, fasting serum insulin and 
HOMA IR of the 17 children  with available glucose, insulin and HOMA IR data at the two 
time points divided according to their final 25(OH)D level. 
End points 25(OH)D ≥ 75 nmol/l 
No Age 
Glucose 
Week 0 
Glucose 
Week 6 
*p- 
value 
Insulin 
Week 0 
Insulin 
Week 6 
*p- 
value 
HOMA 
IR 
Week 0 
HOMA 
IR 
Week 6 
*p- 
value 
1 43 3.9 4.2 
0.1 
13.2 9.3 
0.02 
2.29 1.37 
0.02 
7 115 4.6 4.1 99.2 66.6 20.29 12.5 
11 115 4.1 4.4 13.5 11.3 2.9 2.33 
12 33 4.6 3.7 19 6.7 3.89 1.11 
15 51 4.7 4.6 17.3 6.2 3.63 1.29 
28 16 4.2 4 20.3 11.4 3.63 2.13 
29 19 4.9 4.9 4.5 11 0.99 2.4 
30 96 4.4 4.7 11.1 9.7 2.18 2.04 
32 10 5.1 4.6 2.4 1.8 0.56 0.37 
33 18 4.8 4.5 3.1 3.5 0.66 0.72 
34 115 5.7 5 11.3 5.9 2.86 1.31 
Median  4.6 4.5  13.2 9.3  2.23 1.34  
End points 25(OH)D < 75 nmol/l  
No Age 
Glucose 
Week 0 
Glucose 
Week 6 
*p- 
value 
Insulin 
Week 0 
Insulin 
Week 6 
*p- 
value 
HOMA 
IR 
Week 0 
HOMA 
IR 
Week 6 
*p- 
value 
3 102 4.5 4.4 
1 
11.8 11 
0.8 
2.37 2.16 
0.8 
6 36 4.1 4.4 6.6 6.8 1.21 1.33 
17 16 4.5 4.4 9.2 8.1 1.84 1.59 
27 16 4.2 4.2 4.1 7.5 0.78 1.4 
36 70 4.7 4.9 5.8 4.2 1.21 0.92 
37 21 5.1 4.6 5.4 9.2 1.32 1.88 
Median  4.5 4.4  6.2 7.3  1.26 1.49  
*p-values refer to the change in the median of each parameter within each group. Numbers in bold 
represent values above the normal reference range.  
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6.4.4.4 Sex Hormone Binding Globulin (SHBG) and Glycated Haemoglobin 
(HbA1c)  
Sixteen paired samples were available for SHBG analysis and 21 samples were available 
for HbA1c analysis at the two time points of the study period.  There were no significant 
changes in the medians of these parameters following six weeks of vitamin D3 
supplementation (p = 0.2 and p = 0.1 for SHBG and HbA1c, respectively) (see Figure 6-15 
and Figure 6-16). 
 
 At the baseline, HbA1c levels were within the normal reference range for all participants. 
At week six, one child showed HbA1c at the upper limit of the normal range (Patient ID: 
7) (see Figure 6-15).  Out of the 21 children with available HbA1c data, vitamin D3 
treatment was successful in increasing 25(OH)D concentrations to  ≥ 75 nmol/l in 14 
children, while seven children had final 25(OH)D concentrations of < 75nmol/l.  The 
median percentage change in HbA1c levels from week 0 to week 6 was compared between 
those two groups of children, with no significant difference in % change of HbA1c 
between children who had final 25(OH)D concentrations of ≥75 nmol/l and those with 
final 25(OH)D concentrations of <75 nmol/l (p = 0.7) (see Figure 6-17). 
 
At the baseline, SHBG levels were within the normal reference range except for one child 
(Patient ID: 7) who had a basal SHBG below the normal reference range, and still had low 
SHBG after six weeks.  A high SHBG level was reported in one child at week six (Patient 
ID: 9) (see Figure 6-16).  Of the 16 children who had available SHBG data, vitamin D3 
treatment was successful in increasing 25(OH)D concentrations to ≥ 75 nmol/l in 11 
children, while five children had a final 25(OH)D levels of < 75nmol/l.  Median percentage 
change in SHBG levels from week 0 to week 6 was compared between those two groups of 
children, with no significant difference in % change of SHBG between children who had a 
final 25(OH)D concentrations of ≥ 75 nmol/l and those with a final 25(OH)D 
concentrations of < 75 nmol/l ( p = 0.4) (see figure 6-18). 
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Figure 6-15: Individual changes in glycated haemoglobin (HbA1c) for 21 
children before and after six weeks of receiving 5000 IU cholecalciferol 
treatment.  
 
No significant change in the median of HbA1c levels was observed (p = 0.1). Each 
HbA1c’s level is represented by a line connecting week 0 with week 6 values. Area 
between two red lines; normal reference ranges for HbA1c. 
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Figure 6-16: Individual changes in sex hormone binding globulin (SHBG) 
for 16 children before and after six weeks of receiving 5000 IU 
cholecalciferol treatment.  
 
No significant change in the median of SHBG levels was observed (p = 0.2). Each 
subject’s SHBG level is represented by a line connecting week 0 with week 6 
values. Area between two red lines; normal reference ranges for SHBG. Low 
SHBG was observed in one child and high SHBG level was observed in one child 
(red dots).   
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Figure 6-17: The percentage change in HbA1c in 21 children grouped by 
end point vitamin D concentration (children who had final 25(OH)D ≥ 75 
nmol/l and those with final 25(OH)D < 75 nmol/l).  
 
No significant difference in % change of HbA1c was found between the two 
groups (p = 0.7).   
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Figure 6-18: The percentage change in SHBG for 16 children grouped by 
end point of vitamin D concentration (children who had final 25(OH)D ≥ 75 
nmol/l and those with final 25(OH)D < 75 nmol/l).  
 
No significant difference in % change of SHBG was found between the two 
groups (p = 0.4).   
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6.4.5  Correlation between glucose homeostasis parameters: 
SHBG, HbA1c, glucose, insulin and HOMA IR 
Fasting measurements of SHBG, HbA1c, glucose, insulin and HOMA IR levels were 
examined for correlations.  
 
 A significant negative association was observed between SHBG and HbA1c levels at 
baseline (r = -0.4; p = 0.04) and after six weeks of vitamin D3 treatment (r = -0.5; p = 0.03) 
(see Figure 6-19 and Figure 6-20).  No significant association was observed between 
HOMA IR and HbA1c at baseline (r = 0.3; p = 0.1) and after six weeks of vitamin D3 
treatment (r = 0.2; p = 0.2) (see Figure 6-21 and Figure 6-22).  A non-significant negative 
association was observed between HOMA IR and SHBG at baseline (r = -0.4; p = 0.1), and 
after six weeks of vitamin D3 treatment (r = -0.3; p = 0.2) (see Figure 6-23 and Figure 6-
24).  There was no significant association observed between glucose and HbA1c levels at 
baseline (r = 0.003; p = 0.9), and after six weeks of vitamin D3 treatment (r = -0.1; p = 
0.5).  Similarly, no significant association was observed between glucose and SHBG at 
baseline (r = 0.4; p = 0.1) and after six weeks of vitamin D3 treatment (r = -0.01; p = 0.9) 
(Table 6-9).  No significant association was observed between insulin and HbA1c levels at 
baseline (r = 0.3; p = 0.1), and after six weeks of vitamin D3 treatment (r = 0.3; p = 0.2).  
There was also no significant association observed between insulin level and SHBG at 
baseline (r = -0.4; p = 0.1) and after six weeks of vitamin D3 treatment (r = -0.4; p = 0.1) 
(Table 6-9). 
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Figure 6-19: The relationship between SHBG and HbA1c in 16 vitamin D 
deficient children at the baseline.  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% 
confidence limits. A significant association was observed (r = -0.4; p = 0.04). 
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Figure 6-20: The relationship between SHBG and HbA1c in 16 children 
following six weeks of vitamin D3 supplementation. 
 
Green dots represent children who reached a final 25(OH)D level of ≥ 75 nmol/l. 
Black dots represent children with a final 25(OH)D level of < 75nmol/l. The black 
line indicates the line of best fit, and the blue lines indicate the 95% confidence 
limits. A significant association was observed (r = -0.5; p = 0.03). 
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Figure 6-21: The relationship between HOMA IR and HbA1c in 17 vitamin D 
deficient children at the baseline.  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% 
confidence limits. No significant association was observed (r = 0.3; p = 0.1). 
 
 
Figure 6-22: The relationship between HOMA IR and HbA1c in 15 children 
following six weeks of vitamin D3 supplementation.  
 
Green dots represent children who reached a final 25(OH)D level of ≥ 75 nmol/l 
whereas black dots represent children who reached a final 25(OH)D level of < 
75nmol/l. The black line indicates the line of best fit, and blue lines indicate the 
95% confidence limits. No significant association was observed (r = 0.2; p = 0.2). 
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Figure 6-23: The relationship between HOMA IR and SHBG in 11 vitamin D 
deficient children at the baseline.  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% 
confidence limits. No significant association was observed (r = -0.4; p = 0.1). 
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Figure 6-24: The relationship between HOMA IR and SHBG in 12 children 
following six weeks of vitamin D3 supplementation.  
 
Green dots represent children who reached a final 25(OH)D level of ≥75 nmol/l 
whereas black dots represent children reached a final 25(OH)D level of < 75nmol/l. 
The black line indicates the line of best fit, and blue lines indicate the 95% 
confidence limits. No significant association was observed (r = -0.3; p = 0.2). 
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            Table 6-9: Univariate correlation coefficients: Changes in correlation between different glucose homeostasis parameters from baseline to week 
            six. 
 
 
 
 
 
 
 
 
 
 
 
` 
 
                                                                                 At baseline   
 
N 
Fasting glucose 
(mmol/l) 
N 
 
Fasting insulin 
(µiu/ml) 
N HOMA IR N 
SHBG 
(nmol/l) 
 r (p)  r (p)  r (p)  r (p) 
SHBG (nmol/l) 15 0.1 (0.4) 11 -0.4 (0.1) 11 -0.4 (0.1) - - 
HbA1c (mmol/mol) 22 0.003 (0.9) 17 0.3 (0.1) 17 0.3 (0.1) 16 -0.4 (0.04) 
                                                                          At week six   
 
N 
Fasting glucose 
(mmol/l) 
N 
Fasting insulin 
(µiu/ml) 
N HOMA IR N 
SHBG 
(nmol/l) 
 r (p)  r (p)  r (p)  r (p) 
SHBG (nmol/l) 17 -0.01 (0.9) 11 -0.4 (0.1) 12 -0.3 (0.2) - - 
HbA1c (mmol/mol) 21 -0.1 (0.5) 15 0.3 (0.2) 15 0.2 (0.2) 16 -0.5 (0.03) 
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6.4.6  Correlation of vitamin D with markers of glucose 
homeostasis 
No significant correlation was observed between  25(OH)D and PTH in the 17 children 
whose 25(OH)D and PTH data were available at both week 0 and week 6 of the study 
period (r = -0.01; p = 0.9 and r = -0.1; p = 0.7 at baseline and week 6 respectively).  
 
6.4.6.1 Changes in correlation between serum 25(OH)D, glucose 
homeostasis parameters and bone remodelling markers from 
baseline to week six.  
Univariate correlation coefficients between study parameters are shown in Table 6-10.  No 
significant correlations were found between serum 25(OH)D and any of the glucose 
homeostasis parameters throughout the study period.  At the baseline, PTH was 
significantly and negatively correlated with HOMA IR (r = -0.5; p = 0.03).  PTH was 
significantly and positively correlated with cholesterol/HDL ratio (r = 0.5; p = 0.04). 
Additionally, there was a significant positive correlation between SHBG and ALP (r = 0.5; 
p = 0.03).  At week six, there was a significant positive correlation observed between 
serum PTH and triglyceride levels (r = 0.5; p = 0.03) (see Figure 6-26, Figure 6-27, Figure 
6-28, Figure 6-29, Figure 6-30, Figure 6-31, Figure 6-32). 
 
6.4.6.2 Mixed Effects Model (MEM) 
The mixed effects model (MEM) were employed for further analysis.  Out of 17 patients 
whose glucose, insulin and HOMA IR data were available, only parameters with available 
data at the two time points are included in this analysis.  The results from the MEM are 
summarised in Table 6-11.  The MEM showed that both HOMA IR and glucose  are 
independently correlated with vitamin D after correction for other covariance such as BMI 
SDS, age and PTH.  Additionally, HbA1c independently correlated with PTH and time.
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Table 6-10: Univariate correlation coefficients. 
At baseline 
 
 
Glucose 
(mmol/l) 
 
Insulin 
(µiu/ml) 
 HOMA IR  Chol/HDL  
Triglycerides 
(mmol/l) 
 
SHBG 
(nmol/l) 
 
HbA1c 
(mmol/mol) 
N r (p) N r (p) N r (p) n r (p) N r (p) N r (p) N r (p) 
25(OH)D 22 -0.3(0.08) 17 0.2(0.2) 17 0.3(0.2) 17 -0.007(0.9) 17 -0.1(0.4) 17 -0.4(0.09) 23 -0.1(0.3) 
PTH 22 0.1(0.4) 15 -0.4(0.08) 17 -0.5(0.03) 17 0.5(0.04) 17 0.3(0.2) 17 0.2(0.2) 23 -0.1(0.4) 
Calcium 18 -0.1(0.6) 14 0.2(0.3) 14 0.2(0.3) 15 -0.16(0.5) 15 -0.2(0.4) 15 -0.1(0.4) 20 -0.007(0.9) 
ALP 20 0.3(0.1) 16 -0.4(0.07) 16 -0.4(0.08) 15 0.1(0.6) 15 0.09(0.7) 15 0.5(0.03) 21 -0.3(0.1) 
CTX 19 0.2(0.2) 16 -0.2(0.4) 16 -0.2(0.3) 15 0.2(0.3) 15 0.2(0.4) 13 0.4(0.07) 19 -0.09(0.6) 
At week six 
 
 
Glucose 
(mmol/l) 
 
Insulin 
(µiu/ml) 
 HOMA IR  Chol/HDL  
Triglycerides 
(mmol/l) 
 
SHBG 
(nmol/l) 
 
HbA1c 
(mmol/mol) 
N r (p) N r (p) N r (p) N r (p) N r (p) N r (p) N r (p) 
25(OH)D 
22 -0.02(0.8) 17 -0.1 (0.6) 17 0.1-(0.5) 17 -0.2(0.2) 17 -0.2(0.2) 17 0.1(0.6) 21 0.05(0.8) 
PTH 
20 0.1(0.5) 15 -0.07(0.7) 15 -0.1(0.6) 15 0.4(0.07) 15 0.5(0.03) 17 -0.02(0.9) 20 -0.003(0.9) 
Calcium 
19 0.1(0.7) 13 -0.1(0.6) 13 -0.1(0.5) 15 -0.02(0.9) 15 0.2(0.4) 16 0.2(0.9) 19 -0.2(0.3) 
ALP 
19 0.3(0.1) 16 -0.3(0.1) 16 -0.1(0.5) 15 0.04(0.7) 15 0.1(0.5) 14 0.3(0.1) 20 -0.1(0.4) 
CTX 
19 0.4(0.05) 16 0.2(0.3) 16 0.3(0.2) 15 -0.2(0.3) 15 0.04(0.8) 14 0.4(0.1) 18 0.1(0.6) 
Changes in correlation between serum 25(OH) D, glucose homeostasis parameters and bone remodelling markers from baseline to week six. Non-paired samples were 
included in this analysis. Significant results are represented in bold.
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Figure 6-25: The relationship between HOMA IR and PTH in 17 vitamin D 
deficient children at the baseline.  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% 
confidence limits. A significant negative association was observed (r = -0.5; p = 
0.03). 
 
 
 
 
Figure 6-26: The relationship between HOMA IR and PTH in 15 children 
following six weeks of vitamin D3 supplementation.  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% 
confidence limits. Green dots represent children who reached a final 25(OH)D level 
of ≥ 75 nmol/l, whereas black dots represent children who reached a final 25(OH)D 
level of < 75nmol/l. No significant association was observed (r = -0.1; p = 0.6). 
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Figure 6-27: The relationship between cholesterol/HDL ratio and PTH in 17 
vitamin D deficient children at the baseline.  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% 
confidence limits. A significant association was observed (r = 0.5; p = 0.04). 
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Figure 6-28: The relationship between cholesterol/HDL ratio and PTH in 15 
children following six weeks of vitamin D3 supplementation.  
 
Green dots represent children who reached a final 25(OH)D level of ≥75 nmol/l 
whereas black dots represent children who reached a final 25(OH)D level of < 
75nmol/l. The black line indicates the line of best fit, and the blue lines indicate the 
95% confidence limits. No significant association was observed (r = 0.4; p = 0.07). 
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Figure 6-29: The relationship between Triglycerides and PTH in 17 vitamin 
D deficient children at the baseline.  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% 
confidence limits. No significant association was observed (r = 0.3; p = 0.2). 
 
 
 
Figure 6-30: The relationship between triglycerides and PTH in 15 children 
following six weeks of vitamin D3 supplementation.  
 
Green dots represent children who reached a final 25(OH)D level of ≥ 75 nmol/l 
whereas black dots represent children who reached a final  25(OH)D level of < 
75nmol/l. The black line indicates the line of best fit, and the blue lines indicate the 
95% confidence limits. A significant association was observed (r = 0.5; p = 0.03).   
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Figure 6-31: The relationship between SHBG and ALP in 15 vitamin D 
deficient children at the baseline.  
 
The black line indicates the line of best fit, and the blue lines indicate the 95% 
confidence limits. A significant association was observed (r = 0.5; p = 0.03). 
 
 
 
 
Figure 6-32: The relationship between SHBG and ALP in 14 vitamin D 
deficient children. 
 
 Green dots represent children who reached a final 25(OH)D level of ≥ 75 nmol/l 
whereas black dots represent children who reached a final  25(OH)D level of < 
75nmol/l. The black line indicates the line of best fit, and the blue lines indicate the 
95% confidence limits. No significant association was observed (r = 0.3; p = 0.1).   
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Table 6-11: Mixed model analysis to identify predictors of vitamin D, PTH and glucose 
homeostasis parameters. 
Variables Estimate SE p-value 
95% CI 
(Lower, Upper) 
Log vitamin D     
Intercept 4.46 3.67 0.2 (-3.01,11.93) 
Time 0.56 0.05 0.0001 (0.44,0.67) 
Log HOMA IR 1.01 2.82 0.7 (-4.72,6.75) 
Log insulin -1.13 2.80 0.6 (-6.82,4.54) 
Log glucose -4.11 3.08 0.1 (-10.35,2.12) 
Log SHBG -0.041 0.30 0.8 (-0.63,0.55) 
Log HbA1c -0.009 0.19 0.9 (-0.60,0.58) 
Log PTH     
Intercept -10.79 7.24 0.1 (-26.22,4.63 
Time -0.40 0.10 0.001 (-0.62,-0.18 
Log HOMA IR -9.87 5.55 0.09 (-21.63,1.88) 
Log insulin 9.35 5.50 0.1 (-2.31,21.01) 
Log glucose 9.20 5.89 0.1 (-3.15,21.56) 
Log SHBG -0.10 0.53 0.8 (-1.17,0.96) 
Log HbA1c -0.06 0.28 0.8 (-0.77, 0.63) 
Log HOMA IR*     
Intercept 0.83 0.95 0.4 (-1.55,3.22) 
Time 0.11 0.09 0.3 (-0.15,0.38) 
BMI SDS -0.02 0.30 0.9 (-0.75,0.71) 
Age 0.002 0.03 0.9 (-0.06,0.06) 
Log vitamin D -0.51 0.18 0.02 (-0.95,-0.07) 
Log PTH 0.03 0.16 0.8 (-0.38,0.44) 
Log insulin     
Intercept 1.29 0.99 0.19 (-0.67, 3.25) 
Time 0.09 0.10 0.4 (-0.30, 0.49) 
BMI SDS -0.02 0.31 0.9 (-0.64, 0.60) 
Age 0.003 0.03 0.9 (-0.06,0.07) 
Log vitamin D -0.40 0.18 0.1 (-0.96, 0.14) 
Log PTH 0.12 0.16 0.5 (-0.44,0.68) 
Log glucose     
Intercept 0.78 0.1 0.0001 (0.4,1.147) 
Time 0.04 0.01 0.02 (0.005,0.08) 
BMI SDS -0.001 0.06 0.9 (-0.12,0.12) 
Age -0.0004 0.005 0.9 (-0.01,0.01) 
Log PTH -0.04 0.03 0.3 (-0.12,0.04) 
Log vitamin D -0.09 0.03 0.005 (-0.16,-0.02) 
Race 0.001 0.01 0.8 (-0.02,0.02) 
Log SHBG     
Intercept 1.83 0.97 0.08 (-0.26, 3.93) 
Time 0.06 0.08 0.5 (-0.31,0.44) 
BMI SDS -0.06 0.34 0.8 (-0.77,0.65) 
Age 0.0003 0.02 0.9 (-0.05, 0.05) 
Log vitamin D -0.08 0.11 0.5 (-1.39,1.21) 
Log PTH 0.31 0.16 0.1 (-0.28,0.90) 
Log HbA1c     
Intercept 0.35 0.77 0.6 (-1.38,2.09) 
Time 0.21 0.05 0.0001 (0.1,0.32) 
BMI SDS -0.01 0.33 0.9 (-0.79,0.77) 
Age 0.01 0.01 0.5 (-0.02,0.051) 
Log PTH 1.01 0.12 0.0001 (0.76,1.25) 
Log vitamin D -0.131 0.08 0.14 (-0.31,0.051) 
Vitamin D independently correlated with HOMA IR and glucose. PTH independently correlated with 
HbA1c. * Race could not be added to HOMA IR, insulin and SHBG due to low sample size. 
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6.5 Discussion 
Epidemiological studies suggest an inverse relationship between vitamin D status and 
glycaemic parameters, such as fasting glucose, fasting insulin and HbA1c [265, 266]. 
Several clinical intervention studies have supported the hypothesis that vitamin D 
replacement improves insulin sensitivity/resistance indices, and may had a positive impact 
on glycaemic control in patients with (or at high risk of developing) type 2 diabetes 
mellitus [279, 282].  Therefore, we hypothesized that these effects were likely to be more 
evident in vitamin D deficient individuals.  
 
 A dose of 5000 IU of vitamin D3 for 4-8 weeks is the suggested minimum dose that is 
effective to achieve optimal serum 25(OH)D concentrations of ≥ 75 nmol/l for 
musculoskeletal benefit in vitamin D deficient healthy adults [501].  Additionally, serum 
25(OH)D levels between 75-100 nmol/l have been suggested as in the ideal range for 
multiple health outcomes [441].  A daily vitamin D3 dose of 4000 IU was successful in 
improving HOMA IR and decreasing plasma insulin at six months, but not at three months, 
in obese adolescents [282].  In the present study, daily treatment of vitamin D deficient 
children without diabetes mellitus with 5000 IU of vitamin D3 for six weeks had a 
significant effect on insulin resistance.  
 
Although we found no effect from the correction of vitamin D status on fasting glucose, 
HbA1c, SHBG and lipid profile,  results from the study reveal favourable effects from oral 
vitamin D3 supplementation on insulin resistance and fasting serum insulin levels.  A 
significant reduction in insulin resistance (p = 0.04), and a trend towards a significant 
reduction in fasting serum insulin (p = 0.05) was observed for the 17 children for whom 
glucose, insulin and HOMA IR data was available at both baseline and week six of the 
study period.  This improvement in insulin resistance and the reduction in serum insulin 
was more apparent in children who responded well to vitamin D3 supplementation and 
who had an end point serum 25(OH)D level of ≥ 75 nmol/l.  In one child (Patient ID: 7), 
both HOMA IR and serum insulin decreased remarkably from baseline to week six, 
although still remaining outside the normal reference range.  The improvement in insulin 
resistance at the end point serum 25(OH)D level of ≥ 75 nmol/l was consistent with 
previous observations in adults.   In a cross sectional study by Chiu et al 2004, involving 
126 glucose-tolerant healthy non obese adults, a positive association between serum 
25(OH)D and insulin sensitivity indices was observed, and an improvement in insulin 
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sensitivity of 60% was demonstrated when serum 25 (OH)D increased from  24.96 to75 
nmol/l [258].  
 
Observational studies exploring the relationship between vitamin D status and markers of 
glucose homeostasis also show conflicting data. Several studies support an inverse 
relationship between 25(OH)D status and insulin resistance [265, 266].  On the other hand, 
other studies have failed to prove that relationship [264, 502]. For example, no association 
was found between 25(OH)D with measures of glucose homeostasis and β cell function in 
175 obese youths (aged 9-20 years) who had either normal glucose tolerance, impaired 
glucose tolerance or had type 2 diabetes mellitus [502].  Another study involving both 
obese and normal weight girls aged between 12-18 years found that PTH, but not 
25(OH)D, was correlated inversely with HOMA IR and positively with QUICKI only in 
obese girls [503].   
 
The limited number of published interventional studies evaluating the effects of vitamin D 
replacement on insulin resistance in paediatric populations are inconsistent.  The 
discrepancy among studies may be attributed to the differences in vitamin D dose, basal 
and end points serum 25(OH)D levels and a variable risk of bias.  Additionally, the 
majority of the available clinical trial data is based on trials targeting obese and/or high 
risk children.  Six months, but not three months, of daily supplementation of 4000 IU 
vitamin D in obese adolescents showed a significant improvement in both HOMA IR and 
QUICKI compared with a placebo [282].  Using the HOMA to measure insulin resistance, 
two recent randomised trials including obese adolescents have reported conflicting results.  
In the first trial, a 2000 IU daily oral vitamin D3 supplementation in 20 healthy adolescents 
for 12 weeks did not have any effect on the lipid profile and markers for insulin resistance 
[504].  On the other hand, weekly 300000 IU oral vitamin D3 supplementation for 12 
weeks in 21 obese adolescents with metabolic syndrome improved the lipid profile and 
markers for insulin resistance [283].  When comparing the last study with our study, there 
are important differences in baseline vitamin D levels (mean baseline 25(OH)D level in the 
last study was 45 nmol/l compared with 28 nmol/l in our study) and study population.  
Additionally, the mean HOMA IR in the last study was 3.21 which decreased following 
oral vitamin D3 supplementation by 0.4 to 2.81 whereas in our study the mean HOMA IR 
was 3.09 which decreased following vitamin D treatment by 0.9 to 2.19.  
 
In older children and adolescents, lower 25(OH)D status has been linked to a higher risk of 
metabolic syndrome, including increased triglyceride level and insulin resistance [283].  
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Few available studies have considered the association between vitamin D and serum lipids 
specific to a younger age group.  One cross-sectional study, which included 1961 children 
aged between 1 and 5 years reported a significant association between serum 25(OH)D and 
non-HDL cholesterol, as well as non-fasting triglycerides and total cholesterol ( even after 
adjustment for specific confounders) [505].  Both triglycerides and non-HDL cholesterol 
are known predictors, used to identify the risk of cardiovascular disease in healthy adults.  
The association between serum 25(OH)D and lipids still needs to be confirmed in an 
interventional study.  If an association between vitamin D and lipid parameters in early 
childhood exists, this may provide a basis for early life stage interventions to decrease 
future cardiovascular risk.  
 
In the present work, vitamin D3 treatment was not found to improve the median lipids 
profile.  However, when examining individual data for a small number of children with an 
abnormal lipid profile, demonstrable improvement in lipids, particularly in obese children, 
occurred following vitamin D3 supplementation.  
 
The link between lower vitamin D status and obesity is well-documented [86].  Obese 
children generally have low vitamin D status compared with normal weight children [85]. 
Clinical trials have linked obesity to lower vitamin D status, which in turn seems to have 
negative consequences on insulin resistance and glucose homeostasis [265, 266].  In the 
present study, three obese children were identified.  The three children had basal serum 
25(OH)D levels of < 50 nmol/l, and two showed an alarmingly abnormal metabolic profile 
(increased insulin resistance, low basal SHBG level and an abnormal lipid profile). 
Additionally, both of those children with abnormal metabolic profiles had a positive family 
history of either diabetes or hypertension with high cholesterol level.  Following 
supplementation, the metabolic profile returned to normal level in one child while it 
improved (but remained abnormal) in the other.  Therefore, the study participants were 
divided into two groups based on their BMI, to compare the effect of vitamin D 
supplementation between normal weight children and obese children.  The results showed 
a significant reduction in HOMA IR in obese children following vitamin D supplementaion 
(p = 0.007). 
 
The correlation study found a significant association between HOMA IR and PTH r(p): - 
0.5(0.03), which was also reported in another study [503].  Previous reports suggest PTH 
may have a role on glucose-mediated insulin secretion [506, 507].  The proposed role 
concerned the ability of PTH to impair insulin release mechanisms, involving ATP 
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depletion and increasing resting calcium concentrations [508].  In addition, PTH has been 
suggested to either directly increase insulin resistance, or to at least be linked to a 
deterioration in insulin resistance [509, 510].  However, the effect of lowering serum PTH 
by vitamin D supplementation on glucose homeostasis requires further evaluation.  
 
There was no association between 25(OH)D and measures of glucose homeostasis was 
found in the universal correlation analysis.  However, the results from MEM analysis 
revealed vitamin D as an independent predictor of HOMA IR and glucose levels, after 
correction for other variables such as time, BMI SDS, age, PTH, and race.  The association 
between vitamin D and glycaemia markers has been reported previously in both adults and 
children [265, 511].  
 
Although the results do not demonstrate any significant effect of vitamin D3 treatment on 
serum SHBG level, those from the universal correlation analysis showed a significant 
association between HbA1c and SHBG at the baseline, as well as at the end of the study. 
Additionally, MEM analysis suggested PTH as an independent predictor for HbA1c, which 
may further supports reports that correlate hyperparathyroidism with the prevalence of 
hyperglycaemia.  
 
Finally, several children (n = 6) demonstrated low final serum 25(OH)D levels.  Since 
patient compliance was only assessed verbally and may not reflect actual intake, the wide 
range in the end point of serum 25(OH)D may indicate poor compliance.  A larger study 
may have disclosed a significant effect from vitamin D intervention on other glucose 
homeostasis parameters.  Additionally, since vitamin D3 treatment lasted only six weeks, 
we could not assess any long-term effects on glucose and lipid parameters or the safety of 
the 5000 IU vitamin D3 dose.   
 
The main strength of this study is the prospective and interventional nature of our work.  In 
contrast to other available interventional studies, our study involved younger and healthy 
children.  However, this part of the thesis has several limitations.  Firstly, several children 
were still vitamin D deficient following vitamin D replacement, which may limit our 
ability to detect significant changes in some parameters.  However, it could be 
hypothesised that the relationship between vitamin D status and these parameters is 
dependent on other factors such as age, production of sex hormone and diabetic risk and 
the absence of the significant association between 25(OH)D and these measurements is due 
to the nature of study participants: pre-pubertal non-obese children at lower risk of diabetes 
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mellitus.  Secondly, our study involved only a small number of participants and a larger 
study may have disclosed a positive effect of vitamin D intervention on other glucose 
homeostasis parameters.  An additional limitation is that there was no control group which 
may limits our ability to attribute the changes exclusively to the intervention and to 
eliminate the confounding effects of age, sex, race, BMI, nutritional status and family 
history.  Finally, since vitamin D3 treatment lasted only six weeks, we cannot assess the 
long-term effects of vitamin D3 supplementation on glucose and lipid parameters.  
 
In summary, six weeks of vitamin D3 supplementation has a favourable effect on key 
glucose homeostasis parameters, HOMA IR and fasting serum insulin in healthy children 
with low vitamin D level.  Although our results may not have any immediate implication in 
term of clinical practice and public health, a larger sample size with a longer period of 
follow-up would possibly have obtained more favourable results and the correction of poor 
vitamin D status may be considered as an additional effective measure to decrease the 
insulin resistance and/or improve glycemic status.  
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Chapter 7 
 
 Effect of Vitamin D3 Supplementation on 
Immune Function 
 
7.1 Abstract  
Introduction 
 
The immunomodulatory function of vitamin D is not fully understood. One key 
mechanism through which vitamin D influences human immune responses may be related 
to the regulation of specific cytokines and chemokines produced by antigen-presenting 
cells. Additionally, some reports suggest that vitamin D may play a central role in 
alterations to the balance of different T helper cell subsets, and may affect the tissue-
specific lymphocyte homing capability. Finally, several immune cell-secreting cytokines 
have been suggested as mediators for the bone remodelling process, and as regulators of 
bone cell development and activity. 
 
Objective 
 
The effect of short-term vitamin D3 supplementation on main T helper 1 (Th1) and T 
helper 2 (Th2) cytokines, Th17 cytokine, T regulatory cytokine (Treg) and chemokines 
linking the balance between the Th1 and Th2 subset was assessed. Additionally, an 
association between these cytokines and bone remodelling markers before and after 
vitamin D3 supplementation was also investigated. 
 
Method 
 
Children deficient in vitamin D were treated with daily 5000 IU Cholecalciferol (vitamin 
D3) for six weeks. Baseline and end of treatment serum 25 hydroxyvitamin D (25(OH)D), 
parathyroid hormone (PTH), alkaline phosphatase (ALP) and serum collagen type 1 cross-
linked C-telopeptide (CTX) were measured. Leukocyte subset analysis was performed for 
T and B cells and T regulatory cells and a Luminex assay was used to measure Th1 
cytokines (IL-2, TNF-α, INF-γ), Th2 cytokines (IL-4, IL-5, IL-6), Th17 cytokine (IL-17), 
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Treg cytokine (IL-10) and the Th1/Th2 subset balance linked to chemokines/cytokines 
and/or differentiation (IL-8, IL-12, EOTAXIN, MIP-1β, IP-10, RANTES, MCP-1). 
 
Results 
 
A total of 14 children were enrolled in the study, with a median (range) age of five years 
(10 months, 9.5 years). Over a six-week period, 25(OH)D increased from 24.5 (14, 49) 
nmol/l at the baseline to 103 (37, 191) nmol/l at the week six (p = 0.0001). Serum PTH 
concentrations decreased from 7.2 (3.6, 134) pmol/l at the baseline to 4.3 (2.7, 6.8) pmol/l 
at week six (p = 0.006). No significant alteration in measured lymphocyte subsets in 
response to vitamin D3 treatment was detected, although there was a significant increase in 
the main Th2 secreted cytokine IL-4 (p = 0.001) and a tendency towards a significant 
increase in other Th2 secreted cytokines (IL-5, p = 0.05 and IL-6, p = 0.05) following 
vitamin D3 supplementation. The results from the Mixed EffectsModel (MME) study 
showed that IL-17 is independently correlated with PTH. Additionally, IL-6, IL-8, IL-12, 
IL-10, IL-17 and IFN-γ are independently correlated with bone remodelling markers.  
 
Conclusion 
 
Six weeks vitamin D3 supplementation in vitamin D deficient children is associated with 
an alteration in multiple cytokines. However, it is unclear whether serum 25(OH)D in these 
children or the response to vitamin D treatment are directly associated with a change in 
these cytokines. The results also showed a significant association between inflammation 
and bone remodelling markers in vitamin D deficient children.  
  
 
 
 
 
 
 
  
234 
 
 
7.2 Introduction  
As described in the introduction, it has become increasingly clear that hosts’ defences 
against harmful events require complex communication between the innate and adaptive 
sides of the immune system [287].  Signals from innate immune cells, stimulated by 
infectious agents and inflammatory stimuli, prompt naive CD4-positive T helper 
(CD4+Th) cells to proliferate and differentiate into one of several T cell effectors.  These 
included T helper 1(Th1), T helper 2 (Th2), T helper 17 (Th17) and regulatory T (iTreg) 
cells, as determined by the specific effector cytokines produced by antigen-presenting cells 
(APCs) [294, 296].  
 
CD4-positive T helper cells are also important manufacturers of a range of cytokines that 
determine the features of immune responses [294].  Type 1 helper cells produce pro-
inflammatory cytokines such as IL-2, IFN-γ and tumour necrosis factor-alpha (TNF-
α).Type 2 helper cells are generally considered to be anti-inflammatory and produce 
cytokines such as IL-4, IL-5, IL-13 and IL-6 [302, 512].  T regulatory cells suppress the 
activation of the immune system and therefore maintain self-tolerance [513].  T helper 17 
cells produce IL-17 and IL-22 and have been suggested to play a key role in resistance to 
extracellular pathogens [514].  Other cytokines, such as IL-8, IL-10 and IL-12, can 
influence T-cell activation and/or differentiation. For example, IL-10 inhibits IL-2 
production by activating human T cells and down-regulates Th1 secreted cytokines [515], 
and both  IL-8 and IL-12 are essential for Th1 development. Additionally, IL-12 is 
suggested as a regulator of Th1/ Th17 balance [516-518]. 
 
Upon activation, CD4+Th cells are able to express a variety of chemokine receptors, 
depending upon the cellular context in which they are activated.  T helper 1 cells are able 
to express chemokine receptors such as CCR5 (RANTES and MIP-1β), CXCR3 (IP-10) 
and CCR2 (MCP-1), which play a role in the differentiation of Th1 cells and/or in assisting 
their migration into different inflammatory tissue sites [519-521].  The activation of Th2 
cells is associated with an expression of CCR3 (Eotaxin) receptors on Th2 cells, promoting 
their migration into target sites, such as sites of allergic reaction in the airways [364, 522]. 
 
Ideally, humans should produce a well-balanced Th1 and Th2 response suited to the 
immune challenge [513, 523].  A key role of cytokines is the maintenance of a proper 
balance between Th1 and Th2 cellular subsets.  Any dysregulation of the Th1/Th2 balance 
may cause a disruption in immune system’s responses to infections (immunodeficiency), or 
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excessive and incorrect immune responses to harmless environmental antigens (atopy) or 
self-antigens (autoimmunity) [513, 524].  Both Treg and Th17 can play a role in Th1 and 
Th2 activity and function.  For example, IL-4 signaling through the IL-4 receptor in naive 
CD4+T cells maintains the Th2/Treg balance via activation of transcription factor fork 
head box P3 (FoxP3) and signal transduction and activator 6 (STAT6) [304].  Improper 
Th1/Th17 cell balance has been linked with the development of inflammatory bowel 
disease [305].   
 
Experimental reports have shown that vitamin D may play a critical role in determining 
immune response through an alteration in the functional status of CD4+ Th cells subsets. It 
has been suggested that vitamin D may affect Th cell polarization by enhancing Th2 cell 
and/or inhibiting Th1 development.  For example, it has been found that vitamin D3 
enhances the production of Th2 cytokine IL-4, and inhibits the production of Th1 
cytokines IL-2, IFN-γ and TNF-α [401, 525-527].  Additionally, vitamin D3 has been 
suggested as a direct inducer of T regulatory cell development via the regulation of FoxP3 
expression and has been shown to inhibit IL-17 secretion by Th17 cells [528, 529].  
 
Both the immune system and bone remodelling process are interrelated with a complex 
overlapping regulatory network [530, 531].  Osteoblasts regulate the haematopoietic stem 
cell niche, which gives rise to all blood and immune cells [532], whereas osteoclasts 
originate mainly from the same myeloid precursor cells that produce macrophages and 
myeloid dendritic cells [533]. Evidence from experimental studies has suggested that 
cytokines such as IL-2, IL-6, IL-8, IL-10, IL-12, INF-γ and TNF-α  may act as regulators 
of bone cell metabolism and skeletal remodelling [530].  Bone remodelling factors such as 
vitamin D and PTH may also play a key role in the process of systemic inflammation and 
the modulation of cytokine secretion [197, 534, 535].  
 
Based on available evidence, the impact of vitamin D supplementation on different T cell 
subsets remains unclear, particularly among both the healthy and the younger population. 
This study was designed to test the hypothesis that vitamin D can influence Th1/Th2 
skewing by examining the effect of short-term vitamin D3 supplementation on main T 
helper 1 (Th1) and T helper 2 (Th2) cytokines, Th17 cytokine, T regulatory cytokine 
(Treg) and chemokines linking the balance between the Th1 and Th2 subsets.  An 
additional objective was to determine whether these cytokines are associated with markers 
of bone remodelling before and after vitamin D3 supplementation. 
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This study also aimed to document the change in the peripheral blood lymphocyte subset 
following vitamin D supplementation by examining the relative percentages of B cells 
(CD19+), T cells ( CD4+/CD8+/CD3+) and T regulatory cells (CD4+CD25+FoxP3+) 
using Multi-Parameter Flow Cytometry (FACS).  
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7.3 Subjects and methods 
7.3.1 Patient methods 
7.3.1.1 Ethics approval and funding  
This study was given a favourable ethical opinion by the West of Scotland Research Ethics 
Service (REC3) (REC Reference: 11/AL/0291) and received additional funding from 
TENOVUS (sponsored research project no. S11/37).  
 
7.3.1.2 Recruitment of Subjects   
A total of 18 children aged between 10 months and 9.5 years, who had been referred for 
evaluation and management of suspected vitamin D deficiency, were investigated.  These 
cases were recruited in the outpatient clinical endocrinology department of the Royal 
Hospital for Sick Children (RHSC). All patients had already consented to participate in the 
bone and glucose parts of this study.  
 
7.3.1.3 Inclusion/Exclusion criteria  
All vitamin D-deficient children aged 10 years or under were eligible for this study. In 
addition to the main exclusion criteria listed earlier in Chapter 4.  Patients with a history of 
any chronic inflammatory condition or atopy were further excluded in this chapter. The 
study protocol is described in Chapter 4.  
 
7.3.1.4 Blood collection 
Blood samples were collected on Ward 1C at RHSC. Serum 25(OH)D and PTH levels 
were obtained as a part of routine clinical care, and an additional 3ml of peripheral blood 
was collected in EDTA vacuettes for the immune study.  For 25(OH)D, samples were 
collected in lithium heparin vacuettes and immediately centrifuged at 2600-2800 
rev/minute for 10 minutes. The serum was subsequently stored at -80C until the assay was 
performed.  Samples for PTH were collected in lithium heparin vacuettes and sent directly 
on the same day to the biochemistry laboratory at RHSC. Blood samples for the immune 
analysis were collected into two EDTA vacuettes.  The first blood sample was immediately 
centrifuged at 2600-2800 rev/minute for 10 minutes, and the plasma fraction stored in 
aliquots at -80oC until the end of the recruitment period for the study in order to perform 
the Luminex Multiplexed Cytokine Assay.   The second sample was transferred directly to 
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the research unit at the Institute of Infection, Immunity and Inflammation for the 
lymphocyte subset analysis.     
 
7.3.2 Routine laboratory measurements 
The assay for serum 25(OH)D levels was performed by Dr Jane McNeilly in the 
Biochemistry Department at the Southern General Hospital, Glasgow using an Abbott 
Architect Chemiluminescent  Microparticle Immunoassay (CMIA).  Parathyroid hormone 
(PTH) measurements were assayed by the biochemistry laboratory at RHSC using intact 
PTH CMIA (Abbott Architect). 
 
7.3.3 Molecular biology: Luminex Multiplexed Cytokine Assay 
This assay was performed at the laboratory of the Institute of Infection, Immunity and 
Inflammation at the University of Glasgow.  All samples were assayed on the same plate at 
the same time in duplicates. 
 
Luminex assay, an alternative to classical ELISA, enables the simultaneous detection and 
quantification of multiple cytokines in a single well of a 96-well plate.  The advantages of 
Luminex over ELISA are the smaller sample volume requirement and a lower protein 
detection limit in addition to the production of more reliable results [536].  In this study, 
the cytokines and chemokines IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17, 
EOTAXIN, MIP-1β, IP-10, TNF-α, IFN-γ, RANTES and MCP-1 were simultaneously 
examined in each sample from the study participants using a custom made Bio-Plex Pro 
Human Cytokine Group I, 15-plex assay.  The immunoassay reagents were purchased from 
Bio-Rad laboratories (Hemel Hempstead, Hertfordshire, UK) and the method was 
performed according to the manufacturer’s instructions.   
 
This method involves the use of a capture antibody-antigen sandwich to detect the marker 
of interest, as described in Figure 7-1.  Briefly, standards and reagents were prepared 
following the manufacturer’s instructions.  After thawing, 50 μl of each patient’s sample, 
various concentrations of the assay standards and the control were added to a 96-well plate 
containing magnetic beads and pre-wet with assay buffer.  The magnetic beads were pre-
coated with analyte/biomarker-specific capture antibodies and had distinctive fluorescence 
wavelengths for each antibody.  The plate was then incubated for 30 minutes before a wash 
step was applied. Subsequently, 25 µl of a biotinylated detection antibody specific to the 
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biomarker of interest was added to each well and incubated on a plate shaker for one hour 
at room temperature.  Following the incubation, 50 µl of diluted reporter streptavidin-PE 
antibody was added, followed by incubation for a further 30 minutes, agitation at room 
temperature and washing.  Finally, 125 µl assay buffer was added to each well and analysis 
was performed using a Bio-Plex 100 multiplex plate reader (Bio-Rad).  A standard curve 
was obtained using the different concentrations of the assay standards.  Concentrations of 
target proteins were calculated by matching each value to the standard curves.  Data were 
analysed using Bio-Plex Manager software v6.1 (Biorad). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-1: Luminex Multiplexed Cytokine Assays. 
 
Magnetic bead pre-coated with analyte-specific capture antibody and biotinylated detection antibody 
specific to the biomarker of interest form an antibody-antigen sandwich. This is followed by the 
addition of phycoerythrin (PE)-conjugated streptavidin and read by a detection instrument. 
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7.3.4 Cell based assays 
7.3.4.1 Cell purification 
Lymphocytes (CD4+ T cells) were indirectly isolated from whole blood by layering over 
the Ficoll-Paque density medium (Sigma-Aldrich) using the RosetteSep™ CD4+ T cell 
enrichment cocktail (Stem Cell Technologies).  This cocktail contains a combination of 
monoclonal antibodies directed against cell surface antigens on human leukocytes (CD16, 
CD19, CD36, CD56, CD66b) and glycophorin A on RBCs, which crosslink unwanted 
haematopoietic cells. The method was performed according to the manufacturer’s 
instructions as described in Figure 7-2. 
 
7.3.4.2 T reg Detection (Miltenyi Treg detection kit) 
Following the purification steps, cells were washed and surface-stained with CD4-FITC, 
CD25-APC and CD127-BV421 (all BioLegend). Dead cells were labelled using fixable 
viability stain eFluor780 (eBioscience).  Cells were fixed and permeabilized using the 
eBioscience fixation and permeabilization kit (as per the manufacturer’s instructions), 
before incubation with Foxp3-PE (eBioScience) antibody.  Finally, cells were resuspended 
in cold PEF buffer (flow cytometry buffer: PBS + 0.5% FCS + 2mM EDTA).  Samples 
were acquired on the MACSQuant flow cytometer and analysed using the MACSQuantify 
software v2.4 (Miltenyi Biotec).  
 
7.3.4.3 Lymphocyte analysis (T/B cells) 
Lymphocyte analysis (T/B cells) was performed following an addition of 1ml of RBC lysis 
buffer (Miltenyi Biotec) to 100 μL of whole blood.  After 10 minutes of incubation, 
centrifuging at 300g/5 minutes and removing the supernatant, cells were washed and 
suspended in 200 µL PEF, and  labelled with 5 µL of CD19-PE (B cells; BioLegend), 
CD3-FITC (T cells; BioLegend), CD4-Vioblue (Miltenyi Biotec) and CD8-APC (Miltenyi 
Biotec) antibodies.  Dead cells were labelled using 1 µL DRAQ7 (BioStatus).  
Samples were acquired on the MACSQuant flow cytometer and analysed using the 
MACSQuantify software v2.4 (Miltenyi Biotec). 
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Figure 7-2: Schematic diagram showing the main steps used for isolation of CD4+ T cells 
using  the Human CD4+T Cell Enrichment cocktail. 
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7.3.4.4 Flow Cytometry 
Flow cytometry is a technology that enables researchers to simultaneously examine, count, 
and sort cells by detecting surface or intracellular markers of interest via measuring the 
fluorescence signals emitted from cells.  The process starts with the preparation of a cell 
suspension and labelling with fluorescently conjugated antibodies.  The suspension is then 
forced to pass through a complex tubing system in a liquid jet stream followed by 
excitation with a laser beam to emit light at different wavelengths (depending on the 
fluorophore used).  Several detectors are carefully placed around the stream at a point 
where the fluid passes through the laser beam.  One of these detectors is in line with the 
laser beam and is used to measure Forward Scatter (FSC).  Another detector is placed 
perpendicular to the stream and is used to measure Side Scatter (SSC).  Light scatter and 
fluorescence released from fluorochromes are detected by these detectors and used to 
provide a multiparametric analysis of the physical and chemical characteristics of single 
cells.  For example, both FSC and SSC together can provide information about cell size 
and granularity, while markers of interest can be evaluated via fluorescence.  In this 
chapter, flow cytometry was employed for the lymphocyte subset analysis [537]. 
 
7.3.5 Statistical analysis 
Statistical analyses were performed with GraphPad Prism 5 (San Diego California, USA) 
or Mini Tab 17 (Minitab, Coventry, UK) statistical software.  Results are presented as 
median and ranges unless stated otherwise.  The significance of changes in cytokine and 
lymphocyte measurements from the baseline to the week six was assessed using the 
Wilcoxon signed-rank test.  Spearman correlation analysis was performed to reveal the 
association of 25(OH)D levels and markers of bone remodelling with laboratory 
parameters.  Using IBM SPSS 22 statistical software, the Mixed Effectsmodel (MEM) was 
employed where appropriate to explore the confounding effects of independent cytokines. 
For MEM analysis, the laboratory measures were transformed with logarithmic 
transformation to obtain a more normal distribution (as data were skewed, a natural log 
transformation was applied).  All study results were evaluated at the level of significance p 
< 0.05. 
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7.4 Results 
7.4.1 Recruitment summary 
A total of 61 children were identified and screened during the 24-month study period 
between 2011 and 2014, of whom 42 met the main project inclusion criteria and agreed to 
participate.  In total, 37 children attended the first study visit, of whom 19 were excluded 
due to difficulty with venous access, lack of patient/parent cooperation or insufficient 
blood sample volume.  Samples from 18 children were available for cytokine analysis and 
10 for lymphocyte subset analysis at the baseline.  At week six of the study, 18 samples 
were available for cytokine analysis and only five samples were available for lymphocyte 
subset analysis.  The main reason for the drop-out at week six was the difficulty in 
obtaining a sufficient blood sample during venipuncture due to either difficult venous 
access or parental refusal.  During the process of data analysis, four children were excluded 
as two of them showed vitamin D levels within the normal reference range at the baseline 
study visit.  A further two patients were excluded due to the coexistence of chronic 
inflammatory/atopic conditions, chronic eczema and cow’s milk allergy (see figure 7-3, 
flow diagram of study recruitment). 
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Figure 7-3 Flow diagram of study recruitment 
 
 
Sixty-one children were identified through the endocrine clinic. Forty-seven children were excluded 
throughout the study period due to a variety of reasons as shown in the diagram.   
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7.4.2 Demographic characteristics  
At the baseline, the median age (range) of the children was four years (10 months to 9.5 
years).  Height (Ht) and body mass index (BMI) were converted into SDS using 1990 
British childhood standards [448, 449].  The main cause of referral was bone pain (six 
children; 43%).  Other causes included bowed legs, seizures, dietary concern fractures and 
family history.  Table 7-1 summaries the details of the 14 children enrolled in the study. 
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Table 7-1: Characteristics of recruited children. 
 
 
 
 
 
 
Variables  N % 
Age (years)  (14)  
0-2 5 36 
2-6 5 36 
6-10 4 28 
Gender (14)  
Male 7 50 
Female 7 50 
Race (14)  
South Asian 6 43 
Middle Eastern  3 21.5 
Sub-Saharan African 2 14 
Caucasian 3 21.5 
Anthropometrics    Median (range) 
BMI SDS  9/14 0.5(-1.4, 2.4) 
Wt SDS 14/14 0.09(-4.5, 2.6) 
Vitamin D supplementation  (14) % 
Prior high dose vitamin D3 supplementation 1 7 
Prior multivitamin supplementation 3 21.5 
No supplementation 10 71.5 
Season of enrolment  (14) % 
Autumn 6 43 
Spring 3 21.5 
Summer 3 21.5 
Winter 2 14 
Reason for referral  (14) % 
Bone pain 6 43 
Bowed leg  4 28.5 
Other 4 28.5 
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7.4.3 Individual changes in cytokines 
As previously described, in order to examine the effect of short-term vitamin D3 
supplementation on Th1/Th2 cytokine skewing, Th17 cytokine, Treg cytokine and 
chemokines linking the balance between the Th1 and Th2 subsets, the cytokine profiles 
from the serum of 14 children was studied at the baseline and following six weeks of 
vitamin D3 supplementation. Table7-8 and Table 7-9 show the baseline and week six 
cytokine profiles for the 14 children. Table 7-2 shows the median and median percent 
changes for each individual’s cytokines.  
 
The researcher is not aware of any scientific data specifying what level of change in serum 
cytokines is considered to be clinically meaningful. An increase in the cytokine serum 
level from the baseline value was therefore defined as a positive change, while a decrease 
was defined as a negative change, regardless of magnitude.In order to further compare the 
effect of the response to vitamin D3 supplementation on circulatory cytokines, children 
were grouped according to their final serum 25(OH)D, 25(OH)D  > 75 and 25(OH)D < 75 
nmol/l. Data were represented according to these figures. However, the representation was 
not found to affect the interpretation of the results. 
 
For the Th1-secreting cytokines, the results showed a borderline trend towards an increase 
in IL-2 levels from 16.6 pg/ml at baseline to 40.5 pg/ml at week 6 (p = 0.09). However, 
patients’ responses to high-dose vitamin D3 were not homogenous. While 10 patients 
(71.5%) had increased serum IL-2 levels after six weeks, three patients (21.5%) showed 
decreased IL-2 levels after the same period of high dose supplementation. Due to a 
technical error in the Luminex machine, the IL-2 value for one patient (7%) was 
unavailable at week 6 and was excluded from further analysis. No significant changes were 
noticed in other Th1 secreted cytokines IFN-γ and TNF-α (see figure 7-4). 
 
A significant increase in serum IL-4 from 7.3 pg/ml at baseline to 10.8 pg/ml at week six 
(p = 0.001) was detected. Additionally, there were increases in the other Th2 secreting 
cytokines (IL-5 and IL-6) after supplementation (18.3 to 24.6 pg/ml; p = 0.05 and 19.2 to 
30.5 pg/ml; p = 0.05), although this was not statistically significant. However, serum IL-4, 
IL-5 and IL-6 response to high dose vitamin D3 was non-homogenous. Of the 14 patients 
included in the analysis, one patient (7%) showed an 18% reduction in serum IL-4 value 
after six weeks of supplementation, while the other 13 patients showed an increase. A total 
of 11 patients (78.5%) had increased serum IL-5 and IL-6 levels after six weeks. Three 
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patients (21.5%) had lower IL-5 and IL-6 levels after the same period of high dose 
supplementation (see figure 7-5). 
 
No significant change was noted in the other cytokines or chemokines related to other Th 
cell subtype activity and Th1/Th2 balance (see figure 7-6 and see figure 7-7). 
 
A non-significant change in serum chemokines related to Th1 function and activity was 
noted: RANTES, IP-10, MCP-1 and MIP-1β levels as shown in figure 7-8 see figure 7-9. 
The serum level of EOTAXIN, a chemokine related to Th2 activity, also showed no 
significant change after supplementation (see figure 7-10). 
 
Interestingly, one child (Patient ID: 33) had an inconsistent/different response to vitamin 
D3 supplementation compared with other children. This patient experienced a substantial 
drop in both pro- and anti-inflammatory cytokines, although there was an increase in IFN-γ 
and an almost steady IL-4 level. Although the immunological profile for this child had a 
significant impact on the study results, the child had no coexisting medical/ immunological 
condition. 
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Figure 7-4: T helper 1 (Th1) secreted cytokines: IL-2, IFN-γ and TNF-α. 
For illustration purposes, on the line graphs children were divided according to the final 25(OH)D 
reached. Green lines represent children who were still vitamin D deficient after supplementation; 
black lines represent children who were vitamin D sufficient after supplementation. Increases in 
serum IL-2, IFN-γ and TNF-α of study participants after six weeks of supplementation were not 
significant (p = 0.09, 0.4 and 0.7 respectively). 
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Figure 7-5: T helper 2 secreted cytokines (Th2); IL-4, IL-5 and IL-6.  
For illustration purposes, on the line graphs children were divided according to the final 25(OH)D 
reached. Green lines represent children who were still vitamin D deficient after supplementation; 
black lines represent children who were vitamin D sufficient after supplementation. Significant 
increases in serum IL-4 level after six weeks of supplementation was noted (p = 0.001).  
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Figure 7-6: Cytokines involved in the development and function of Th1 effector cells IL-8 
and IL-12.  
For illustration purposes, on the line graphs children were divided according to the final 25(OH)D 
reached. Green lines represent children who were still vitamin D deficient after supplementation; 
black lines represent children who were vitamin D sufficient after supplementation. There was no 
significant change in serum IL-8 and IL-12 levels (p = 0.1 and 0.1 respectively). 
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Figure 7-7: Cytokines involved in Th effector cell functions: IL-10 (Th2 and Treg secreted 
cytokine) and IL-17 (Th17 secreted cytokine).  
For illustration purposes, the line graphs represent children divided according to the final 25(OH)D 
reached. Green lines represent children who were still vitamin D deficient after supplementation; 
black lines represent children who were vitamin D sufficient after supplementation. No significant 
change in serum IL-10 or IL-17 levels was noted (p = 0.2 and 0.4 respectively). 
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Figure 7-8: Other inflammatory chemokines are RANTES and IP-10 (associated with Th1 
tissue recruitment and/or promoting Th1 differentiation). 
 For illustration purposes, the line graphs show the final 25(OH)D reached. Green lines represent 
children who were still vitamin D deficient after supplementation; black lines represent children who 
were vitamin D sufficient after supplementation. No significant change in serum RANTES and IP-10 
was noted (p = 0.1 and 0.4 respectively). 
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Figure 7-9: Other inflammatory chemokines: MCP-1 and MIP-1β (associated with Th1 tissue 
recruitment and/or promoting Th1 differentiation).  
For illustration purposes, the line graphs show the final 25(OH)D reached. Green lines represent 
children who were still vitamin D deficient after supplementation; black lines represent children who 
were vitamin D sufficient after supplementation. There was no significant change in serum MCP-1 
and MIP-1β levels (p = 0.4 and 0.7 respectively). 
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Figure 7-10: Other inflammatory chemokines: EOTAXIN (associated with Th2 tissue 
recruitment). 
 For illustration purposes, on the line graphs children were divided according to the final 25(OH)D 
reached. Green lines represent children who were still vitamin D deficient after supplementation; 
black lines represent children who were vitamin D sufficient after supplementation. No significant 
change in serum EOTAXIN was noted (p = 0.4).  
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Table 7-2: Summary statistics of differences/changes (week 6 – baseline) and percentage 
changes after six weeks of vitamin D3 supplementation. 
Cytokines 
Baseline value 
(pg/ml) 
Week six value 
(pg/ml) 
Percent change over 
six weeks (%) 
Th1 secreted 
cytokines 
   
IL-2 16.6 40.5 65.2 
INF-γ 779.3 895.8 29.4 
TNF-α 28.2 29.6 12.7 
Th2 secreted 
cytokines 
   
IL-4 7.3 10.8 22.9 
IL-5 30.5 24.6 23.5 
IL-6 19.2 30.5 36.1 
Other cytokines/ 
chemokines 
  
IL-8 39.1 65.4 32.7 
Il-12 88.7 148.9 48.9 
IL-10 29.4 43.2 33.7 
IL-17 81.9 208.5 25 
EOTAXIN 235.8 352.1 25.1 
IP-10 1213.8 993 -20.1 
MCP-1 61.4 78.3 16.1 
MIP-1β 183.6 173.2 -4.7 
RANTES 51611.7 58790 20.2 
Results are shown as median. 
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7.4.4 Changes in the lymphocyte subsets before and after vitamin 
D treatment: 
Lymphocyte (T/B cells) and Treg analysis and gating are illustrated in Figure 7-11 and 
Figure 7-12.  No significant changes were seen in the lymphocyte and Treg levels after 
vitamin D3 treatment (Table 7-3 and Table 7-4).  However, an examination of the 
individual changes in those who responded well to vitamin D treatment shows a general 
trend towards an increase in both Treg and CD4 levels and a decrease in CD19 (see Figure 
7-13). 
 
 
Figure 7-11: Total lymphocyte number and gating using flow cytometry.  
Cells were isolated from fresh blood. Lymphocyte analyses (T/B cells) were labelled using CD19-PE, 
CD3-FITC, CD4-Vioblue and CD8-APC antibodies. Dead cells were labelled using DRAQ7. (Note: 
flow cytometry analysis was performed Dr Michelle Le Brocq, Institute of Infection, Immunology and 
Inflammation).  
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Figure 7-12: Isolation and counting of T regulatory cells (Tregs) using flow cytometry.  
Cells were isolated from fresh blood and stained with an immunofluorescent for Treg surface 
markers. (Note: flow cytometry analysis was performed Dr Michelle Le Brocq, Institute of Infection, 
Immunology and Inflammation).  
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Table 7-3: Effect of vitamin D3 treatment on peripheral lymphocytes. 
Patient 
ID 
Age 
(months) 
Sex 
Vitamin D 
Week 0 
(nmol/l) 
Vitamin D 
Week 6 
(nmol/l) 
Treg 
Week 0 
 
Treg 
Week 6 
 
CD19 
Week 0 
 
CD19 
Week 6 
 
CD3 
Week 0 
 
CD3 
Week 6 
 
CD4 
Week 0 
 
CD4 
Week 6 
 
CD8 
Week 0 
 
CD8 
Week 6 
 
27H 16 Male 27 37 6.5 6.3 16.4 21.5 23.8 36.4 56.8 56.1 33.3 37.2 
28H 16 Female 23 117 8.4 10.6 11.6 6.8 23.8 14.2 45.5 48.5 46.7 40.2 
29R 19 Male 26 106 13.4 13.3 9.8 6.6 58.2 56.5 66.2 68.2 29.3 26.6 
30H 96 Male 49 93 2.9 6.6 4.7 2.5 34.2 21.8 45.2 46.5 41.4 38.6 
34T 84 Male 33 122 3.4 5.1 3.3 2.5 21.7 9.2 50.5 52.8 37.4 38.1 
Median 19  27 106 6.4 6.5 8.5 5.71 
 
23.8 
 
24.9 53.6 54.5 35.3 37.6 
P-Value 
(wk 0 vs 
wk 6) 
  0.05 0.3 0.6 0.6 0.1 0.6 
 
 
 
Table 7-4:  Effect of vitamin D3 treatment in % change of peripheral lymphocytes. 
Patient 
ID 
Age 
(months) 
Sex 
% change vitamin D over 
six weeks 
% change Treg over 
six weeks 
% change CD19 over 
six weeks 
% change CD3 over 
six weeks 
% change CD4 over 
six weeks 
% change CD8 over 
six weeks 
27H 16 Male 37 -2.9 31.3 53.1 98.9 11.7 
28H 16 Female 408 26.6 -41.3 -40 106.5 -13.9 
29R 19 Male 307.6 -0.5 -32.9 -2.9 103 -8.9 
30H 96 Male 89.7 121.8 -46.3 -36.2 102.8 -6.6 
34T 84 Male 89.7 121.8 -46.3 -36.2 102.8 -6.6 
Median 19  269.6 13.3 -32.8 -19.6 103.7 -2.3 
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Figure 7-13: Individual change in peripheral lymphocytes following vitamin D3 
supplementation from baseline to week six. 
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7.4.5 Cytokines and bone remodelling 
The regulatory effects of vitamin D on the immune system and bone remodelling (as 
described in the introduction of this thesis) and the suggested role of cytokines as 
significant mediators of bone remodelling and bone cell metabolism may therefore directly 
and/or indirectly affect vitamin D function in vitamin D deficient children.  This section 
examines the association between vitamin D, cytokines and bone remodelling markers for 
the 14 participants at the baseline and following six weeks of vitamin D3 supplementation. 
 
7.4.5.1 Individual changes in bone remodelling markers 
Individual details of markers of bone remodelling in the 14 participants included in the 
immunity study are summarised in Table 7-10.  In these participants, median (range) serum 
25(OH)D increased significantly after vitamin D3 supplementation from 24.5 (14, 49) 
nmol/l at the baseline to 103 (37, 191) nmol/l after six weeks (p = 0.0001).  Serum PTH 
concentrations also decreased significantly from a median of 7.2 (3.6, 134) pmol/l at the 
baseline to 4.3 (2.7, 6.8) pmol/l after six weeks (p = 0.006) and serum ALP decreased 
significantly from a median of 238 (99.7, 2834) to 210 (64.9, 729) u/l, p = 0.03. 
Additionally, serum C- terminal telopeptide of type I collagen (CTX) decreased from a 
median of 2.2 (1.3, 3.1) ng/ml to 1.7 (0.8, 3.03) ng/ml. However, this reduction was not 
statistically significant (p = 0.1).   
 
7.4.5.2 Association of bone remodelling markers and cytokines 
Univariate correlation analysis at the week six point showed that 25(OH)D was 
significantly correlated only with INF-γ, (p = 0.03; r = -0.5), whereas no correlation was 
found with any cytokines at the baseline.  Parathyroid hormone (PTH) was significantly 
correlated with IL-17 and IP-10 at baseline (p = 0.02; r = -0.5, p = 0.01; r = 0.6 
respectively), and with Eotaxin at week six (p = 0.003; r = −0.7).  C-terminal telopeptide of 
type I collagen (CTX) was found to be significantly correlated with IL-2, IL-5, IL-6, IL-8, 
IL-12, IL-10 and  IL-17, (p = 0.02; r = -0.2, p = 0.02; r = -0.6, p  =  0.04; r  =  -0.5, p = 
0.03; r  = -0.6, p = 0.01; r = -0.6, p = 0.04; r = -0.6, p = 0.01; r = -0.7 respectively) at the 
baseline.  Finally, ALP was significantly correlated with IL-4, IL-5, IL-8 and IL-17, (p = 
0.01; r = -0.6, p = 0.04; r = -0.5, p = 0.03; r = -0.6, p = 0.04; r = -0.5 respectively) at the 
baseline and with IL-2, IL-4, IL-5, IL-6, IL-8, IL-12, IL-10 and IL-17,(p = 0.02; r = -0.6, p 
= 0.01; r = -0.7, p = 0.001; r = -0.8, p = 0.001; r = -0.8, p = 0.0001; r = -0.8, P = 0.006; r = 
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-0.7, p = 0.002; r = 0.7, p = 0.02; r = -0.6 respectively) at week six (Table 7-5; Figures 
from 7-14 to 7-21).  After Bonferroni adjustment , IL-5, IL-6 and IL-8 were only 
significantly correlated with ALP  
 
 
 
 
 
 
 
 
 
 
 
  
263 
 
 
Table 7-5: Association of bone remodelling markers and cytokines. 
Baseline 25 (OH)D (n = 14) PTH (n = 14) CTX (n = 12) ALP (n = 12) 
Correlation  
Th1 cytokines r (p value) r (p value) r (p value) r (p value) 
IL-2 -0.1(0.5) -0.1 (0.5) -0.2(0.02) -0.5 (0.07) 
INF-γ -0.1(0.5) 0.3(0.2) -0.04(0.8) 0.03 (0.9) 
TNF-α -0. 2(0.3) 0.3(0.1) -0.04(0.8) 0.1(0.7) 
Th2 cytokines r (p value) r (p value) r (p value) r (p value) 
IL-4 0.07(0.8) -0.4(0.1) -0.5(0.07) -0.6(0.01) 
IL-5 -0.2(0.4) -0.3(0.1) -0.6(0.02) -0.5(0.04) 
IL-6 -0.2(0.3) -0.1(0.5) -0.5(0.04) -0.4(0.1) 
Other 
chemokines  
r (p value) r (p value) r (p value) r (p value) 
IL-8 -0.08(0.7) -0.3(0.2) -0.6(0.03) -0.6(0.03) 
IL-12 -0.2(0.4) -0.4(0.07) -0.6(0.01) -0.5(0.06) 
IL-10 -0.3(0.2) -0.1(0.7) -0.6(0.04) -0.4(0.1) 
IL-17 -0.1(0.6) -0.5(0.02) -0.7(0.01) -0.5(0.04) 
EOTAXIN 0.2(0.3) -0.4(0.1) -0.3 (0.2) -0.5(0.07) 
IP-10 -0.4(0.1) 0.6(0.01) 0.5(0.09) 0.4(0.1) 
MCP-1 0.2(0.4) -0.2(0.4) -0.2(0.4) -0.2(0.4) 
MIP-1β -0.07(0.7) 0.2(0.4) -0.1(0.6) 0.1(0.6) 
RANTES -0.1(0.6) -0.1(0.6) -0.4(0.1) -0.2(0.4) 
Week six 25 (OH)D (n = 14) PTH (n = 12) CTX (n = 12) ALP (n = 12) 
Correlation 
Th1 cytokines r (p value) r (p value) r (p value) r (p value) 
IL-2 -0.08(0.7) -0.2(0.5) -0.2(0.4) -0.6(0.02) 
INF-γ -0.5(0.03) 0.5(0.06) -0.09(0.7) 0.09(0.7) 
TNF-α -0.4(0.1) 0.4(0.1) -0.1(0.6) 0.1(0.6) 
Th2 cytokines r (p value) r (p value) r (p value) r (p value) 
IL-4 -0.2(0.4) 0.004(0.9) -0.4(0.1) -0.7(0.01) 
IL-5 -0.1(0.5) -0.07(0.8) -0.4(0.1) -0.8(0.001*) 
IL-6 0.004(0.9) -0.2(0.4) -0.3(0.3) -0.8(0.001*) 
Other cytokines/ 
chemokines 
r (p value) r (p value) r (p value) r (p value) 
IL-8 -0.2(0.3) -0.04(0.8) -0.2(0.3) -0.8(0.0001*) 
IL-12 -0.2(0.2) -0.1 (0.6) -0.3(0.3) -0.7(0.006) 
IL-10 -0.2(0.3) -0.06(0.8) -0.4(0.1) 0.7(0.002) 
IL-17 -0.3(0.1) 0.06(0.8) -0.4 (0.1) -0.6(0.02) 
EOTAXIN 0.04(0.8) -0.7(0.003) 0.01(0.9) -0.4(0.1) 
IP-10 -0.1(0.5) 0.1(0.6) 0.05(0.8) -0.02(0.9) 
MCP-1 -0.2(0.3) -0.2(0.3) -0.06(0.8) -0.5(0.08) 
MIP-1β 0.3(0.2) 0.2(0.3) -0.1(0.6) 0.1(0.7) 
RANTES 0.1(0.5) -0.02(0.9) -0.09(0.7) -0.1(0.5) 
* IL-5, IL-6 and IL-8 were significantly correlated with ALP 
*Significance of P<0.001 after Bonferroni adjustment
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Figure 7-14: Relationship between serum 25(OH)D and INF-γ in 14 children presenting with 
vitamin D deficiency at baseline (A) and after six weeks (B) of high dosage vitamin D3 
supplementation.  
The green dots in graph B represent children who remained vitamin D deficient after six weeks. A 
significant association was found at week six (p = 0.03; r = -0.5). 
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Figure 7-15: Relationship between serum PTH and IL-17, IP-10 and Eotaxin in 14 children 
presenting with vitamin D deficiency at the baseline (A,C and E) and in 12 children after six 
weeks (B,D and F) of a high dosage of vitamin D3 supplementation.  
The green dots in the right-hand side panel represent children who remained vitamin D deficient 
after six weeks. A significant association was found at week 0 between PTH and both IL-17(p = 
0.02; r = -0.5) and IP-10 (p = 0.01; r = 0.6), and at week six between PTH and Eotaxin (p = 0.003; r 
= -0.7). 
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Figure 7-16: Relationship between serum CTX and IL-2, IL-5 and IL-6 in 12 children presenting 
with vitamin D deficiency at the baseline (A,C and E) and after six weeks (B,D and F) of high 
dosage vitamin D3 supplementation.  
The green dots on the right-hand side panel represent children who remained vitamin D deficient 
after six weeks. A significant association was found at week 0 between CTX and IL-2 (p = 0.02; r = 
-0.2) and IL-5 (p = 0.02; r = -0.6), and IL-6 (p = 0.04; r = -0.6). 
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Figure 7-17: Relationship between serum CTX and both IL-8 and IL-12 in 12 children 
presenting with vitamin D deficiency at the baseline (A and C) and after six weeks (B and D) 
of high dosage vitamin D3 supplementation.  
The green dots on the right-hand side panel represent children who remained vitamin D deficient 
after six weeks. A significant association was found at week 0 between CTX and IL-8 (p = 0.03; r = 
-0.6) and between CTX and IL-12 (p = 0.01; r = -0.6). 
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Figure 7-18: Relationship between serum CTX and both IL-10 and IL-17 in 12 children 
presenting with vitamin D deficiency at the baseline (A and C) and after six weeks (B and D) 
of high dosage of vitamin D3 supplementation. 
 The green dots on the right-hand side panel represent children who remained vitamin D deficient 
after six weeks. A significant association was found at 0 weeks between CTX and IL-10 (p = 0.04; r 
= -0.6) and between CTX and IL-17 (p = 0.01; r = -0.7). 
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Figure 7-19: Relationship between serum ALP and IL-2, IL-4 and IL-5 in 12 children 
presenting with vitamin D deficiency at the baseline (A,C and E) and after six weeks (B,D 
and F) of high dosage vitamin D3 supplementation.  
The green dots on the right-hand side panel represent children who remained vitamin D deficient 
after six weeks. A significant association was found at week 0 between ALP and IL-4 (p = 0.01; r = 
-0.6) and IL-5 (p = 0.04; r = -0.5). At week six, a significant association was found between ALP 
and IL-2 (p = 0.02; r = -0.6), IL-4 (p = 0.01; r = -0.7) and IL-5 (p = 0.001; r = -0.8). 
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Figure 7-20: Relationship between serum ALP and IL-6, IL-8 and IL-10 in 12 children 
presenting with vitamin D deficiency at the baseline (A,C and E) and after six weeks (B,D 
and F) of high dosage vitamin D3 supplementation.  
The green dots on the right-hand side panel represent children who remained vitamin D deficient 
after six weeks. A significant association was found at week 0 between ALP and IL-8 (p = 0.03; r = 
-0.6). At week six, a significant association was found between ALP and IL-6 (p = 0.001; r = -0.8) 
and IL-8 (p = 0.0001; r = -0.8) and IL-10 (p = 0.002; r = 0.6). 
271 
 
 
0 150 300 450 600 750 900
0
50
100
150
200
250
300
2500 3000
n = 12
r = -0.5
p = 0.06
ALP (week 0)
u/l
IL
-1
2
p
g
/m
l
0 50 100 150 200 250 300 350
0
50
100
150
200
250
300
350
700 750 800
n = 12
r = -0.7
p = 0.006
ALP (week 6)
u/l
IL
-1
2
p
g
/m
l
0 150 300 450 600 750 900
0
50
100
150
200
250
300
2500 3000
n = 12
r = -0.5
p = 0.04
ALP (week 0)
u/l
IL
-1
7
p
g
/m
l
0 50 100 150 200 250 300 350
0
100
200
300
400
500
700 750 800
n = 12
r = -0.6
p = 0.02
ALP (week 6)
u/l
IL
-1
7
p
g
/m
l
A B
C D
 
Figure 7-21: Relationship between serum ALP and both IL-12 and IL-17 in 12 children 
presenting with vitamin D deficiency at the baseline (A and C) and after six weeks (B and D) 
of high dosage vitamin D3 supplementation.  
The green dots on the right-hand side panel represent children who remained vitamin D deficient 
after six weeks. A significant association was found at week 0 between ALP and IL-17 (p = 0.04; r 
= -0.5). At week six, a significant association was found between ALP and both IL-12 (p = 0.006; r 
= -0.7) and IL-17 (p = 0.02; r = -0.6). 
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7.4.5.3 Mixed Effects Model (MEM) 
In order to investigate whether the serum levels of selected cytokines, IL-8, IL-12, INF-γ, 
TNF-α, IP-10 and IL-17, IL-4, IL-6 and IL-10, which have been suggested to play a role in 
the process of bone remodelling were independently related to vitamin D level and markers 
of bone remodelling, a Mixed Effects Model (MEM) was employed for further analysis. 
This type of analysis only takes into account data with available values at both time points 
of the study (no missed value). 
 
 Due to the low sample size (n = 14),  it was not possible to perform an MEM analysis for 
each cytokine including all bone remodelling markers simultaneously.  Therefore, in order 
to increase the sample size and perform an MEM analysis, the two children who were 
excluded from the study analysis due to coexistent chronic inflammatory conditions were 
included in the MEM.  Similar results were obtained when the MEM analysis was 
performed using the whole cohort (n = 18). 
 
The results of MEM using cytokine levels as dependent variables shows that both INF-γ 
and IL-6 are independently correlated with serum CTX, with p values of 0.006 and 0.03, 
respectively.  Additionally, IL-17 was independently correlated with PTH with a p value of 
0.01.  Furthermore, this analysis shows that IL-8, IL-12, IL-17, IL-6 and IL-10 are 
independently correlated with ALP, with p values of 0.0001, 0.01, 001, 0.04 and 0.02, 
respectively (Table 7-6 and Table 7-7). 
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Table 7-6: Mixed model analysis to identify predictors of selected cytokines.  
  Variables Estimate SE p value 
95% CI 
(Lower, Upper) 
Log IL-8     
Intercept 3.5 0.528655 0.0001 (2.4,4.6) 
Time 0.03 0.081907 0.6 (-0.1,0.2) 
Log vitamin  D -0.1 0.141928 0.4 (-0.4,0.2) 
Log PTH 0.1 0.107403 0.2 (-0.09,0.3) 
CTX 0.03 0.052775 0.4 (-0.07,0.1) 
Log ALP -0.7 0.149424 0.0001 (-1.04,-0.4) 
     
Log IL-12     
Intercept 3.4 0.5 0.002 (2.05,4.8) 
Time 0.05 0.09 0.5 (-0.1,0.2) 
Log vitamin  D -0.1 0.1 0.4 (-0.4,0.2) 
Log PTH 0.1 0.1 0.2 (-0.09,0.4) 
CTX 0.04 0.05 0.4 (-0.06,0.1) 
Log ALP -0.7 0.2 0.01 (-1.2,-0.3) 
     
Log INF-γ     
Intercept 4.1 0.7 0.01 (1.7,6.5) 
Time 0.2 0.1 0.1 (-0.3,0.8) 
Log vitamin  D -0.5 0.2 0.1 (-1.3,0.2) 
Log PTH -0.2 0.1 0.2 (-0.5,0.2) 
CTX -0.4 0.08 0.006 (-0.6,-0.2) 
Log ALP 0.2 0.2 0.4 (-0.5,0.9) 
     
 Log Eotaxin     
Intercept 3.2 0.7 0.05 (-0.3,6.8) 
Time -0.06 0.1 0.7 (-1.4,1.3) 
Log vitamin  D 0.1 0.2 0.5 (-0.8,1.2) 
Log PTH 0.2 0.1 0.3 (-0.8,1.4) 
CTX 0.2 0.07 0.08 (-0.04,0.4) 
Log ALP -0.7 0.2 0.05 (-1.3,0.02) 
     
Log IL-17     
Intercept 5.4 0.9 0.005 (2.8,8.1) 
Time 0.2 0.1 0.3 (-0.2,0.5) 
Log vitamin  D -0.5 0.3 0.09 (-1.1,0.09) 
Log PTH 0.5 0.2 0.01 (0.1,0.97) 
CTX -0.01 0.09 0.8 (-0.2,0.2) 
Log ALP -1.2 0.3 0.01 (-2.02,0.4) 
This table shows that INFγ is independently correlated with CTX. IL-8, IL-12 and IL-17 are 
independently correlated with ALP. IL-17 is independently correlated with PTH 
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Table 7-7: Mixed model analysis to identify predictors of selected cytokines (IL-4, IL-6 and 
IL-10). 
Variables Estimate SE p value 
95% CI 
(Lower, Upper) 
Log IL-4     
Intercept 2.1 0.5 0.4 (-1493.9,1498.2) 
Time -0.03 0.08 0.7 (-0.7,0.6) 
Log vitamin  D 0.10 0.1 0.6 (-18.4,18.6) 
Log PTH -0.0004 0.1 0.9 (-3.7,3.7) 
CTX -0.007 0.05 0.9 (-0.3,0.3) 
Log ALP -0.5 0.2 0.4 (-615.7,614.6) 
     
Log IL-6     
Intercept 2.7 0.8 0.06 (-0.3,5.7) 
Time -0.1 0.1 0.4 (-0.6,0.3) 
Log vitamin  D 0.3 0.2 0.1 (-0.2,0.9) 
Log PTH 0.4 0.3 0.2 (-0.3,1.09) 
CTX 0.2 0.09 0.03 (0.01,0.4) 
Log ALP -1.03 0.3 0.04 (-2.01,-0.06) 
     
Log IL-10     
Intercept 3.2 0.6 0.003 (1.6,4.8) 
Time 0.1 0.1 0.3 (-0.1,0.3) 
Log vitamin  D -0.2 0.2 0.1 (-0.6,0.1) 
Log PTH 0.2 0.2 0.3 (0-.3,0.7) 
CTX 0.07 0.06 0.2 (-0.05,0.2) 
Log ALP -0.7 0.2 0.02 (-1.2,-0.1) 
This table shows that IL-6 is independently correlated with CTX and ALP. IL-10 is independently 
correlated with ALP 
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7.5  Discussion  
The main finding of this study is that following six weeks of vitamin D3 supplementation 
of vitamin D deficient children, there was a significant increase in serum 25(OH)D and IL-
4, and a closely approximating significant increase in IL-5 and IL-6 levels.  In addition, a 
significant independent association between inflammatory cytokines and bone remodelling 
markers was suggested.  
 
This study did not demonstrate an effect of vitamin D3 supplementation on the circulating 
levels of several cytokines.  As indicated in experimental evidence, it was expected that the 
levels of Th1 cytokines TNF-α and INF-γ would decrease, while the levels of Th2 
cytokines IL-5 and IL-6 were expected to increase following supplementation [526, 527, 
538].  Additionally, with an exception of the week six significant negative association 
between 25(OH)D and INF-γ, cytokine levels/or changes in cytokine levels were not found 
to be associated with serum 25(OH)D levels.  Moreover, lymphocyte subsets do not appear 
to significantly change. 
 
Immunoglobulin E (IgE) antibodies are known as the main effector molecules of 
type I allergic diseases, such as asthma, food allergy and urticaria.  Evidence has shown 
that IL-4, in addition to CD40L and IL-13, is the classical signal to enhance B cell class 
switching to generate IgE [539, 540].  Additionally, IL-5 produced by Th2 cells has been 
also suggested as a significant factor promoting the maturation and differentiation of 
eosinophils in humans [541].  It may, therefore, be reasonable to suggest that skewing 
towards a Th2 phenotype cell may be a significant contributor in the pathophysiology of 
allergic disease [542].  Interleukins-2 produced by naive CD4+ T cells following their 
activation by antigens have been suggested to be a mediator for CD4+ T cell differentiation 
into effector Th2 cells, and as an essential factor for the maintenance of the balance of both 
Th1/Th2 and Treg/Th17 cells [543, 544].  Finally, IL-6 has been shown to promote Th17 
differentiation while blocking regulatory T cell (Treg) differentiation [545]. 
 
The results showed a significant increase in the main Th2 secreted cytokine IL-4 (p = 
0.001) and a tendency for a significant increase in other Th2 secreted cytokines IL-5 (p = 
0.05) and IL-6 (p = 0.05) following vitamin D3 supplementation.  The results were 
therefore consistent with the experimental evidence that supports the role of vitamin D in 
shifting Th1/Th2 polarization towards the Th2 phenotype [301, 546, 547].  Furthermore, 
experimental evidence showed that naive CD4+ Th cells could differentiate into Th2 cells 
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if both cytokines IL-4 and IL-2 were present at the time of stimulation [548-550].  The 
results from this study support this proposal by showing a significant increase in IL-4 and a 
trend towards an increase in IL-2 levels.  
 
Clinical trials on vitamin D-regulating serum cytokines in healthy individuals are very 
limited, with inconsistent results.  Two studies conducted on healthy adults have failed to 
observe consistent changes in either circulatory Th1 or Th2 associated cytokines or their 
corresponding transcription factors following vitamin D supplementation.  In a three-
month placebo-controlled randomized trial of vitamin D3 supplementation in healthy 
vitamin D insufficient adults, 50 µg (2000 IU) vitamin D did have an effect in some 
circulating cytokines, including GM-CSF, IFN-γ, IL-4, IL-8, IL-10 and IL-13.  On the 
other hand, no significant effect of vitamin D3 supplementation was observed in IL-2, IL-
5, IL-6 and TNF-α cytokines [435, 440].  In another trial, 25 g (1000 IU) vitamin D3 
supplementation of vitamin D-deficient adult patients with multiple sclerosis (MS) led to 
significantly increased serum levels of TGF-β1, while no effect on TNF-α, IFN-γ, and IL-
13 was observed [404].  
 
In children, a recent cross-sectional and interventional trial showed that children with 
atopic dermatitis had higher levels of circulating cytokines (except TNF-α) compared with 
a healthy control group.  Following three months of 25 µg (1000 IU) vitamin D3 treatment, 
there was a significant reduction in the clinical severity of atopic dermatitis (p < 0.001) and 
a statistically significant reduction in cytokines, including IL-2, IL-4, IL-6 and IFN-γ (p < 
0.01), but not TNF-α. The levels of these cytokines approached that of the healthy control 
group after supplementation [434].  The researcher is not aware of any available 
interventional study examining the effect of vitamin D3 supplementation on vitamin D-
deficient healthy children. 
 
The conflicting evidence from available clinical trials on both adults and children may be a 
result of several factors, mainly relating to study design.  Firstly, most available trials used 
a relatively low dose of vitamin D3 of < 2000 IU, which may not be sufficient to stimulate 
innate immunity [434, 435].  Additionally, the duration of some studies may not have been 
sufficient to observe an effect.  One trial involved a healthy young female given a 
relatively high dose of vitamin D.  However, there were several limitations in this trial 
relating to sample size and the main study design, as it was specially designed for another 
primary object.  Accordingly, measurement was only performed at the baseline and after 
six months of vitamin D3 treatment [440].  Secondly, most of available studies had either 
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basal 25(OH)D at an insufficient level (50-70 nmol/l) [432, 434, 435] or a non-significant 
change in final serum 25(OH)D compared with the basal level [435] (a final 25(OH)D 
concentration of < 75-100 nmol/l has been suggested as an ideal range for multiple health 
outcomes).  Thirdly, the measurement of cytokines in most available trials was carried out 
only before and after vitamin D intervention and did not take into account the 
possible transient effect of vitamin D on circulatory cytokines.  For example, a transient 
inverse relationship between vitamin D and inflammatory Th1 cytokines was reported in 
athletes during the period of exercise, suggesting that vitamin D deficient status contributes 
to the injury risk for this population [551].  Finally, most of the available interventional 
studies involved unhealthy populations with a variety of pathological conditions, such as 
multiple sclerosis and allergic or cardiac disease [404, 432, 434].  The response to vitamin 
D treatment in such populations may depend on the corresponding disease-specific original 
cytokine profile and the nature of immunological disorder.  For example, MS is associated 
with the increased production of Th1-associated cytokines, including IL-2, INF-γ and 
TNF-α, whereas the T cell cytokines profile in adults with atopic dermatitis showed a 
heterogeneous alteration in Th1 and Th2 or Naive Th cell related cytokines [552, 553].  
 
T regulatory cells (Tregs) are characterized as CD4+CD25++ T cells with expression of 
the FoxP3 and low or absent expression of CD127 [513, 554, 555].  Experimental evidence 
has shown the ability of the active form of vitamin D3 to up-regulate FoxP3 expression 
and inhibit the proliferation of human peripheral B cells.  Additionally, Treg induction 
requires the presence of IL-2 [410, 528, 556].  Both IL-2 and IL-4 have been suggested to 
play a significant role in enhancing FoxP3 expression and maintaining CD4+CD25+ Treg 
development and function [557].  Clinically, in healthy adults, 140,000 IU of vitamin D3 
supplementation at the baseline and after four weeks significantly increased the percentage 
of Treg (4.8 ±1.4 at the baseline to 5.6 ±1.4 at 8 week (p < 0.001) [403].  Furthermore, 
daily supplementation of HIV-infected patients (who already have underlying T cell 
dysfunction) with either 800 IU of vitamin D3 for three months or 25,000 IU weekly for 
two months showed a different effect.  The higher dose (25,000) had a significant effect on 
skin-homing markers on Treg. On the other hand, vitamin D of 800 IU units has failed to 
either correct the vitamin D-deficient status or to exert any immunomodulatory effects in 
HIV-infected patients [433].  The results from the clinical trials described above may 
indicate the defending effects of vitamin D against T cell-related pathology and 
autoimmunity, which need further exploration in the clinical field.  The researcher is not 
aware of any other studies that have investigated the effect of vitamin D on the Treg 
population as a primary target in younger children. 
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In this study, there were no consistent changes in peripheral blood lymphocyte analysis, 
namely B cells (CD19+), CD4/CD8 T cells and T regulatory cells (CD4+CD25+FoxP3+). 
This may have been due to the small sample size and wide ranges of final serum vitamin D 
response, in addition to the wide age range of the children involved.  Only five patients’ 
samples were available for peripheral blood lymphocyte subset analysis.  Of those five 
patients, one was still vitamin D deficient after supplementation and no change in his T reg 
cell profile was observed.  Most of the other four patients had an increase in their T reg 
cells after six weeks of vitamin D3 supplementation.  A similar observation was noted in 
CD19 cells.  The patient whose final vitamin D level was still low showed an increase in 
CD19 cells, whereas the other four showed a reduction in their CD19.  Despite the low 
sample size, this study was therefore able to demonstrate some changes in Treg and 
CD19+ cells for each individual patient.    
 
Osteoimmunology is the study of the influence of the immune system on skeletal dynamics 
and homeostasis, including study of the development of immune cells in bone marrow and 
the interaction between the immune and skeletal systems in health and disease.  Cytokines 
secreted by lymphocytes and macrophages have been suggested to be powerful mediators 
that play a significance role in maintaining skeletal integrity and bone remodelling [558].  
 
In this study, an independent correlation have been reported between ALP and pro-
inflammatory cytokines including IL-8, IL-12, IL-17, IL-10 and IL-6, between CTX and 
both INF-γ and IL-6, and between PTH and IL-17. The univariate analysis demonstrated  
significant relationships between ALP and IL-5, IL-6 and IL-8 at the week 6 of vitamin D3 
treatment.  However, this is not a proof of causality. 
 
The precise roles of IFN-γ and IL-17 in the bone remodelling process are controversial for 
several reasons, mainly related to the differences in study models and target cell types in 
experimental studies [559].  Interleukin-17 has been suggested to mainly act as a potent 
stimulator of osteoclastogenesis (bone resorption) by targeting the osteogenic 
differentiation of mesenchymal stem cells and osteoblast [560, 561].  Generally, based on 
the available evidence, IFN-γ can be considered to be a potent anti-osteoclastogenic agent 
through mechanisms that involve interfering with the receptor activator of NF-κB ligand 
(RANKL)-receptor activator of the NF-κB (RANK) signalling pathway, which mediates its 
anti-resorptive function [562, 563].  Similarly, IL-12 has been suggested to inhibit of 
osteoclast differentiation through indirect mechanisms mediated by IFN-γ [564]. 
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In this study, the MEM did not reveal any independent association between serum levels of 
IFN-γ and 25(OH)D.  In MEM, however, IFN-γ was found to be independently and 
negatively associated with CTX (a marker of bone resorption).  Additionally, the result 
from MEM showed that IL-17 is positively and independently associated with PTH (which 
stimulates bone resorption by acting directly on osteoblasts/ stromal cells and indirectly via 
enhancing osteoclastogenesis) [565], and negatively independently associated with ALP (a 
marker of bone formation).  Since VDR knockout mice showed up regulation of IL-17 and 
IFN-γ production more than wild-type mice [566], an indirect association between serum 
25(OH)D and inflammatory cytokines may therefore be suggested.  Additionally, the 
results from univariate correlation revealed the significant negative correlation between IL-
12 and CTX in vitamin D deficient status (at the baseline), and between IL-12 and ALP 
after six weeks of vitamin D3 treatment. 
 
Current evidence regarding the exact role of IL-6 in bone remodelling is inconsistent [567, 
568].  Generally, it has been suggested that IL-6 may be regarded as a stimulator of 
osteoclastogenesis through a mechanism involving the stimulation of osteoblastic/stromal 
cell-mediated osteoclast differentiation.  The result from MEM showed an independent 
negative association between IL-6 and ALP (p = 0.04).  IL-10 has been suggested to 
suppress bone resorption by inhibiting osteoclastogenesis through mechanisms involved in 
the regulation of osteoprotegerin (OPG) expression, and down-regulation of RANKL and 
colony-stimulating factor-1 (CSF-1) expression [569].  Moreover, its potent anti-
inflammatory effect enables IL-10 to indirectly inhibit infection-stimulated bone 
resorption, mediated through pro-inflammatory cytokines such as TNF-α (bone absorptive 
factors) [559].  Additionally, IL-10 has been suggested to promote osteoblastic 
differentiation, which promotes bone formation [570].  The result from MEM showed an 
independent negative association between IL-10 and ALP (p = 0.02).  These results are 
inconsistent with the experimental evidence which support the role of IL-10 in promoting 
bone loss and suppressing bone formation. 
 
In summary, results from correlation studies may indicate that circulatory cytokines play a 
role in maintaining the bone remodelling imbalance.  Lower vitamin D status and an 
associated higher PTH level may lead to a high bone remodelling rate, which in turn 
depends on the integrated effects of a variety of local and systemic factors, including the 
cytokines.  The inconsistency in the correlations between different cytokines and markers 
of bone remodelling, CTX and ALP, at the baseline and six weeks, may reflect the balance 
in the bone remodelling process during the vitamin D deficiency status.  Additionally, the 
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results of this study show associations between most of the cytokines and either a 
decreased rate of bone formation or an increased rate of bone resorption.  Several clinical 
studies have linked the systemic and/or local inflammatory pathological conditions with 
disturbance in the bone remodelling process, which in turn may contribute to the loss of 
bone mass.  For example, pro-inflammatory cytokines, such as IL-6, IL-17 and IFN-γ, have 
been shown to be significant contributors to the development of bone-related diseases such 
as osteoporosis and rheumatic arthritis [571-573].  Finally, a small number of clinical 
studies have examined the association between circulatory cytokines and markers of bone 
remodelling. In one study of healthy adults, IL-6, IL-10, IL-17 and IFN-γ were found to be 
correlated with markers of bone remodelling, which are consistent with the observations 
made in this study [574]. 
 
The main strength of this study is that, to our opinion, it is the first interventional study 
examining the effect of vitamin D3 supplementation on vitamin D-deficient healthy 
children.  However, there are several limitations to this study that may affect its ability to 
detect significant changes in other cytokines and lymphocytes following vitamin D3 
supplementation.  Firstly, 5000 IU /day may not be sufficient to stimulate innate immunity, 
and/or the duration of the study may not have been long enough to detect a significant 
effect of some cytokines and/or chemokines.  Secondly, the results showed that following 
vitamin D3 supplementation in vitamin D-deficient children, only 68% achieved final 
vitamin D levels greater than 75nmol/l and the difference between baseline and six-week 
vitamin D levels may not be sufficient to exert an immunomodulatory effect for many 
cytokines.  For example, Zhang et al. (2012) demonstrated that a level of 75 nmol/l was 
required to inhibit TNF-α and IL-16 [575].  Furthermore, the participants were illness-free 
at the time of study and the correlation between vitamin D and other cytokines/chemokines 
may be evident when the immune system is stimulated by sepsis or infection.  Despite their 
good response to vitamin D3 treatment, some children in the study population showed an 
inconsistent cytokine profile compared with the other children.  This inconsistency may 
suggest the possibility of an effect caused by ethnic diversity, minor unreported illnesses, 
different nutritional behaviours and the variety of the age groups.  Moreover, only the 
circulatory level of cytokines was measured; it may be that changes for some cytokines are 
more evident at the tissue or organ level.  For example, it has been reported that some of 
inflammatory cytokines are variably changed in serum and synovial fluid in patients with 
rheumatic arthritis [576].   Another limitation  is that there was no control group who did 
not have any vitamin D supplementation which may have a critical impacts on the results.   
However, by confining the analysis to children with symptomatic vitamin D deficiency, 
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and testing the children pre- and post-treatment, each child may able to act as their own 
control to reduce the risk of confounding factors such as minor illnesses, different 
nutritional patterns and the variety of age groups, which may all affect serum cytokines 
levels [577-580].  Finaly, the sample size of this work must be considered as it may limits 
the power to properly control for confounding variables and determine true association 
between cytokiens and bone biomarkers.  
 
In conclusion, increasing evidence from experimental and observational studies supports 
the role of vitamin D in human defence mechanisms.  Theoretically, cytokines are 
multifunctional molecules secreted by human cells in response to immunological 
challenges and play direct roles in human responses to infection, inflammation, trauma, 
sepsis and cancer.  These molecules involve in several pathophysiological conditions, and 
their measurement in the body fluids and /or circulation can be used as significant clinical 
and laboratory measures for monitoring diseases activity.  Whilst this pilot work has shown 
that vitamin D3 treatment is associated with an alteration in multiple cytokines, it is 
unclear whether serum 25(OH)D in these children or response to vitamin D3 treatment are 
directly associated with a change in these cytokines.  The results from our study suggest 
that vitamin D may modulate the immune system through a mechanism involving mainly 
the Th2 cytokines and there were independent correlations between systemic inflammation 
and markers of bone remodelling.  Therefore, our findings support previous studies which 
indicated to the possible beneficial effects of supplementary vitamin D with respect to 
infectious and autoimmune diseases.  However, the effect of vitamin D3 supplementation 
on the cytokines profile need further exploration in well-designed clinical trials involving a 
strictly controlled environment with either experimental animals and/or healthy adults. 
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Table 7-8:  Pre-treatment levels of inflammatory and anti- inflammatory cytokines in the serum of 14 children presenting with vitamin D deficiency. 
Patient 
ID 
Baseline (week 0) 
Th2 
(Pro-inflammatory) 
Other pro-inflammatory cytokines 
Th1 
(Anti-inflammatory) 
 IL-2 IFN-γ TNF-α IL-8 IL-12 IL-10* IL-17 IP-10 Eotaxin RANTES MIP-β MCP-1 IL-4 IL-5 IL-6* 
1 13.84 556.33 15.36 33.99 55.25 25.19 55.47 1211.15 429.8 52005.61 233.4 86.83 5.81 17.18 15.72 
6 26.95 1815.49 58.1 54.38 115.22 41.94 149.59 786.58 191.71 64660.54 204.94 93.29 10.77 28.03 26.97 
7 36.1 2404.22 83.53 76.39 189.18 42.41 207.02 1141.39 175.6 48603.31 134.22 53.1 14.59 33.44 32.03 
10 13.05 1726.21 62.45 40.88 84.02 32.54 75.09 1546.32 135.43 51217.93 115.23 60.78 9.19 24.69 22.01 
11 22.8 825.88 33.15 37.36 285.51 29.41 266.18 900.3 311.87 66348.53 160.17 52.12 5.46 18.41 14.2 
12 29.06 418.86 15.06 77.01 141.28 65.07 161.45 1207.86 449.94 58035.2 235.38 100.22 15.03 47.28 48.01 
15 9.61 622.21 18.95 32.38 40.05 20.34 57.93 1121.46 280.06 65961.8 239.31 55.61 5.46 12.9 11.44 
17 32.78 462.85 15.96 67.29 138.52 58.92 192.93 1250.54 521.91 44245.43 162.42 66.87 13.73 36.58 43.41 
27 16.95 1373.66 45.74 49.16 93.47 28.47 71.83 1778.9 190 32257.51 150.97 43.12 8.83 18.24 21.44 
28 13.71 1074.93 34.33 30.93 54.58 24.09 48.05 1679.4 90.63 69528.95 350.11 38.28 4.86 15.17 12.58 
29 2.06 503.11 20.14 18.18 28.26 7.83 29.69 1221.84 403.24 23069.98 149.95 99.09 2.51 6.71 4.11 
30 11.07 161.42 *5.50 28.5 73.93 21.91 88.86 717.97 326.49 33956.48 143.9 69.18 5.77 15.77 12.11 
32 16.43 732.78 23.41 23.62 48.62 24.88 51.35 1468 166.82 15953.47 214.3 62.12 2.33 9.23 17.06 
33 30.8 1133.99 50.69 55.8 116.58 57.03 150.38 1216.5 174.44 71917.53 259.69 55.53 11.83 37.9 37.09 
*IL-6 can be considered to either block or promote inflammation and IL-10 as anti-inflammatory.  
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Table 7-9: Post-treatment levels of inflammatory and anti- inflammatory cytokines in the serum of 14 children presenting with vitamin D deficiency. 
Patient ID 
End of the study (week six) 
Th2 
(Pro-inflammatory) 
Other  pro-inflammatory cytokines 
Th1 
(Anti-inflammatory) 
 IL-2 IFN-γ TNFα IL-8 IL-12 IL-10* IL-17 IP-10 Eotaxin RANTES MIP-β MCP-1 IL-4 IL-5 IL-6* 
1 43.17 1714.28 57.09 92.64 169.66 69.97 207.81 2333.39 526.42 66083.04 228.87 103.27 17.74 47.01 46.76 
6 66.2 1880.7 59.41 128.49 313.56 118.1 485.18 1354.46 468.96 46369.72 166.7 120.98 22.9 64.54 80.29 
7 48.13 1513.16 49.68 72.94 191.98 65.55 213.28 907.63 237.15 59688.87 168.12 93.36 14.79 37.95 43.22 
10 12.79 895.86 32.12 36.56 89.41 21.44 89.67 1077.69 131.7 74364.99 146.71 49 7.49 17.42 16.68 
11 576.35 291.1 13.56 71.69 244.85 51.36 209.37 1321.55 1838.65 62538.82 147.17 79.75 9.44 23.61 266.64 
12 48.01 381.31 7.96 87.64 187.78 75.36 210.93 1015.51 576.37 68335.27 211.52 91.05 18.4 54.64 57.9 
15 8.94 864.11 27.11 29.15 32.18 14.72 52.17 729.28 391.74 68698.46 176.29 76.91 5.54 14.46 11.92 
17 40.5 867.29 24.74 91.08 229.97 74.72 270.06 696.14 378.71 44312.7 175.07 75.86 16.44 43.45 48.68 
27 47.89 1788.75 62.16 67.76 237.05 59.24 353.28 2481.83 559.53 57891.2 184.76 101.85 10.91 25.71 29.45 
28 17.2 2674.81 101.34 40.24 90.09 32.23 72.65 1859.52 178.5 85646.67 765.88 46.83 7.04 20.56 23.34 
29 7.04 895.86 18.65 32.87 61.9 17.53 14.33 970.57 325.49 32791.25 171.47 83.9 6.28 12.78 11.92 
30 8.4 435.83 10.84 32.06 62.57 17.06 68.57 549 256.96 26691.67 133.16 46.66 6.24 15.41 10.11 
32 31.29 576.17 19.25 63.21 128.22 35.04 262.31 792.78 193.98 32015.85 218.27 63.92 10.7 28.87 31.55 
33 * 1458.72 62.45 16.69 21.76 10.96 7.32 860.42 45.54 27536.32 165.99 31 11.88 7.22 6.97 
*IL-6 can be considered to either block or promote inflammation and IL-10 as anti-inflammatory. 
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Table 7-10: Markers of bone remodelling for 14 children enrolled in the immunity study. 
   
Bone markers/ 
Baseline 
Bone markers/ 
Week six 
Patient 
ID 
Sex 
Age 
(months) 
Vitamin D 
mmol/l 
(n=14) 
PTH 
pmol/l 
(n=14) 
ALP 
u/l 
(n=12) 
CTX 
ng/ml 
(n=12) 
Vitamin D 
mmol/l 
(n=14) 
PTH 
pmol/l 
(n=12) 
ALP 
u/l 
(n=12) 
CTX 
ng/ml 
(n=12) 
1 M 43 33 5.3 99.79 2.014 100 * 89.9 2.33 
6 F 36 29 8.4 219 1.30 56 4.1 64.9 0.81 
7 F 115 33 5.5 161.1 2.17 76 4.7 166 2.28 
10 M 79 14 6.8 * * 66 6.1 * * 
11 M 115 14 4.3 251 1.55 134 2.7 101 1.91 
12 F 33 23 4.1 224 1.57 191 3.2 196 1.07 
15 F 51 33 7.1 * * 127 2.7 * * 
17 F 71 20 7.3 102 1.39 60 4.3 75.3 1.16 
27 F 16 27 29.8 434 3.01 37 * 250 1.72 
28 F 16 23 36.2 679 2.50 117 6.4 306 1.34 
29 M 18 26 134 2834 3.16 106 4.7 729 3.03 
30 M 96 49 3.6 226 2.46 93 3.9 227 1.82 
33 F 18 18 14.1 864 2.28 141 6.8 225 1.68 
32 M 10 19 9.7 338 2.26 115 4.4 283 1.71 
 
285 
 Chapter 8 
 
Discussion, Conclusion and Recommendations 
for Future Research 
 
8.1 An electronic surveillance system for monitoring 
nutritional vitamin D deficiency in children in 
Scotland 
Despite the national recommendations and the interventional measures in the UK to 
address the problem of vitamin D deficiency during early childhood, anecdotal reports still 
showing that there are increasing numbers of symptomatic cases of vitamin D deficiency 
[5, 105].  There is a need to institute a reliable system to prospectively collect data and 
monitor the incidence of this preventable condition.  Accordingly, a monthly survey of 
symptomatic vitamin D deficiency was launched using the established electronic ScotPSU 
methodology, with two aims. The first aim was to estimate the current incidence of vitamin 
D deficiency in children in Scotland.  The second aim was to validate the electronic 
surveillance system and to look at the range of clinical presentations of vitamin D 
deficiency in Scotland. 
 
Over the two years of the survey, the reported incidence of vitamin D deficiency in non-
white children was greater in Glasgow at 7/1000 compared with 2.6/1000 in Edinburgh (p 
= 0.009).  However, it is likely that the true incidence of vitamin D deficiency was 
underestimated, due to the significant numbers of unreported cases identified from the 
regional laboratory data in the cross-validation study.  In Glasgow, 82 cases were 
identified through ScotPSU services over the two years of the study, while only 16 cases 
were identified in Edinburgh during the same period.  The increasing incidence of 
symptomatic vitamin D deficiency in Glasgow suggests that current public health measures 
have not yet had a beneficial effect on prevention of vitamin D deficiency.  However, 
during the second year only two cases had been reported in Edinburgh whereas 40 cases 
were reported in Glasgow during the same period, which may simply reflect a change in 
enthusiasm for notification in the second year in Edinburgh. 
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As expected, children with Asian and Sub-Saharan African ethnic origin have a much 
higher risk for profound symptomatic vitamin D deficiency with 76 (74%) cases reported 
through ScotPSU during the two years. The high prevalence of profound symptomatic 
vitamin D deficiency in these ethnic groups was also reported previously in Glasgow [5]. 
In addition to that, the results from our survey showed that symptomatic vitamin D 
deficiency was also prevalent among other populations such as Caucasian children.  A 
recent survey conducted through the British Paediatric Surveillance Unit (BPSU) 
confirmed our observations by reporting 91 confirmed or probable cases of hypocalcaemic 
seizures secondary to vitamin D deficiency in children in the UK and Ireland, including 11 
(12%) children of Caucasian origin [581].  In our survey, skeletal or bone mineral-based 
clinical suspicion of vitamin D deficiency represented the main presenting features of 
vitamin D deficiency, which is consistent with previous observations in Glasgow [5].  
Hypocalcaemic seizure, which is one of the most serious complications of nutritional 
rickets, was reported in four (4%) children in our survey.  A considerable proportion of 
children had unusual presentations such as concerns about nutritional status and recurrent 
constipation.  In summary, vitamin D deficiency is very common in Scotland due to the 
variations in ethnic demography and low vitamin D intake, in addition to insufficient 
sunlight exposure.  Although it is a preventable condition, people seem to be unaware of, 
or disregard, government advice regarding vitamin D supplementation for high-risk 
groups.  The results from this survey show that ScotPSU may provide reliable data for 
monitoring symptomatic vitamin D deficiency and may be helpful for assessing the 
effectiveness of public health measures.   
 
8.2 Effect of vitamin D supplementation on bone status, 
glucose homeostasis and immune function in 
children with symptomatic vitamin D deficiency 
Three different studies were conducted in an attempt to explore the effects of vitamin D3 
supplementation on bone remodelling, glucose homeostasis and immune function.  In 
summary, the main objectives of these studies were: 
 
 To study the effect of six weeks of vitamin D supplementation on bone remodelling 
markers.  To study the baseline and post-treatment relationships between serum 
25(OH)D levels and the bone remodelling markers. 
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 To investigate the effect of vitamin D3 supplementation on glycaemic status and 
insulin resistance in vitamin D deficient healthy children.  
 To assess the effect of short-term vitamin D3 supplementation on the main Th1 and 
Th2 cytokines, Th17 cytokine, T regulatory cytokine (Treg) and chemokines 
linking the balance between the Th1 and Th2 subsets.  
 
Generally, our recruitment summary showed that symptomatic vitamin D deficiency is 
common among breastfeeding infants and older children of non-Caucasian ethnic origin. 
The increasing number of overall study participants also raised questions about public 
awareness about the problem of vitamin D deficiency.   
 
8.2.1 Effect of vitamin D3 supplementation on bone status 
The effect of six weeks of vitamin D3 supplementation on bone remodelling markers was 
explored in chapter 5.  The results of this study suggest that short-term vitamin D3 
supplementation significantly increases serum 25(OH)D levels, and may affect bone 
remodelling in children, possibly by suppressing PTH levels.  Both PTH level and ALP 
decreased significantly with treatment.  However, no significant response emerged 
following supplementation, effecting either CTX or OCN 
 
A recent review of the laboratory assessments of vitamin D status, vitamin D dosing and 
various supplementation options for the treatment of vitamin D deficiency in the paediatric 
population, recommended doses of vitamin D ranging between 1000 to 5000 IU daily for 
infants 1 to 12 months old, and a daily dose of 5000 IU vitamin D for patients over 12 
months old to correct nutritional vitamin D deficiency.  The study also advised this regime 
for a period of 4–8 weeks, although the radiological evidence of healing occurs within 2 to 
4 weeks of treatment [582].  
 
In our study there were individual differences in treatment responses.  A daily dose of 5000 
IU oral vitamin D3 was insufficient to increase the serum 25(OH)D level to a normal 
reference range of  35% in our study participants.  However,  this part of the study has 
several limitations, as detailed previously in Chaper 5.  A better designed study with a 
longer duration of high-dose vitamin D treatment, involving multiple doses at measurable 
intervals, is advised for future studies.   
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As discussed in Chapter 5, short-term vitamin D3 supplementation significantly reduced 
the overall median level of PTH, which was most significant in children aged 10 months–3 
years and 3–6 years. This younger group also showed a lower 25(OH)D level,  higher basal 
PTH levels, higher basal ALP and lower basal serum calcium compared to other older 
groups.  This may indicate that infants and young children are at an increased risk for 
nutritional rickets than the older children due to prolonged breast feeding, indoor activity, 
age and race, for example.  Therefore,  it is also recommended that future studies measure 
patient compliance, and take into account the nutritional status, indoor activity and 
differences in the rate of bone remodelling biomarkers in different age groups and races. 
 
The regression analysis suggested that PTH could have an independent role in the bone 
remodelling process .  Furthermore, although some of the children in the present study 
were already on a low dose of multivitamin supplementation before starting the higher 
dose vitamin D treatment, their basal ALP and PTH showed persisting abnormalities, 
indicating that a high dose of vitamin D is necessary for better skeletal response.  Few 
studies have assessed the effects of vitamin D supplementation on serum  ALP, 
osteocalcin, and CTX in healthy children [464, 465].  The results from our study, as well as 
previous studies, did not find any significant response in either CTX or OCN and 
concluded that ALP is a more reliable marker for diagnosing and monitoring patients with 
nutritional vitamin D deficiency in children than CTX and OCN.  However, further studies 
are required to explore the the dynamics of biochemical bone markers during vitamin D 
supplementation. 
 
8.2.2 Effect of vitamin D3 supplementation on glucose 
homeostasis 
Lower circulating 25(OH)D status has been correlated with an increased risk of diabetes 
mellitus.  Interventional studies, however, are inconclusive, and the effect of improving 
vitamin D status on glucose homeostasis in healthy children remains unclear.  This study 
aimed mainly to investigate the effect of short-term vitamin D replacement on glucose 
homeostasis parameters in vitamin D deficient healthy children. Homeostatic model 
assessment (HOMA IR) was employed to assess insulin resistance from fasting glucose 
and fasting insulin measurements.  
 
The participants in this study were normal, healthy and mostly non-obese children.  It was 
expected that their blood glucose parameters were within the normal range.  Any 
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abnormality in HOMA IR measurement was therefore likely to be due to an abnormality in 
insulin concentration rather than hyperglycaemic status.   Accordingly, the high basal 
HOMA IR measurements which were noted in a few participants in this study were 
attributed to either a reduction in insulin sensitivity or increased insulin resistance rather 
than a defect in insulin secretion.   Consistent with some other studies conducted in obese 
and/or high risk populations, this study also observed that vitamin D3 supplementation in 
vitamin D deficient healthy children was associated with an improvement in insulin 
resistance, as indicated by HOMA IR [266, 283].  This reduction in fasting insulin 
following vitamin D supplementation suggests that the abnormality in HOMA IR was due 
to the reduction in insulin sensitivity, and there may have been an improvement in insulin 
uptake following vitamin D supplementation.   Furthermore, given the fact that most of our 
study population was not at risk of diabetes and did not have any predisposing factors such 
as obesity, abnormal lipid profiles or abnormal glycaemic indices, the improvement in 
vitamin D status could therefore be one of the contributors to the improvement in HOMA 
IR following vitamin D3 supplementation.  This was further supported by the observation 
that the children whose final serum 25(OH)D was higher than 75nmol/l had a significant 
improvement in HOMA-IR compared with those who were still deficient/insufficient 
following supplementation.  Consistent with this observation, Von Hurst et al. (2010) 
reported the greatest improvement in insulin sensitivity and/or insulin secretion following 
4000 IU vitamin D3 supplementation occurred when endpoint serum 25(OH)D reached 80 
nmol/l or higher.   However, the study group in this study was completely different, and 
consisted of South Asian women at high risk of type 2 diabetes mellitus [279].    
 
The remarkable difference we observed in serum insulin and insulin resistance, when 
children were grouped according to their final serum 25(OH)D may also indicate the 
significance of a vitamin D dose in obtaining desirable outcomes.  Additionally, the lack of 
significant effects of vitamin D3 supplementation (which we observed in the obese child 
with abnormal lipid profiles and a family history of hypertension and 
hypercholesterolemia) may suggest a need for a larger dose and/or longer duration of 
treatment in high risk children.  Unlike studies conducted in adult populations, no changes 
and/or associations were noticed in this study between serum 25(OH)D level and other pre-
diabetic parameters such as lipid profile, fasting glucose, HbA1c or SHBG.  It could be 
hypothesised that the relationship between vitamin D status and these measurements are 
dependent on other factors such as age, production of sex hormone and diabetic risk, and 
the lack of significant association between 25(OH)D and these measurements is due to the 
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nature of study participants: pre-pubertal non-obese children at lower risk of diabetes 
mellitus.  In summary, six weeks of vitamin D3 supplementation of vitamin D deficient 
children does have a favourable effect on key glucose homeostasis parameters, HOMA IR 
in normal-weight, low-diabetic-risk children.  A further study of a longer duration, 
involving multiple vitamin D doses and a larger sample size is required.  
 
8.2.3 Effect of vitamin D3 supplementation on immune function 
One key mechanism by which vitamin D influences human immune responses may be 
related to the regulation of specific cytokines and chemokines produce by antigen 
presenting cells (APCs).  Additionally, some reports suggest that vitamin D may play a 
central role in the alteration of different T-helper-cell subset balances.  At present there are 
no published paediatric studies assessing the effect of vitamin D supplementation in 
cytokines in healthy children.  Therefore, we assessed the effect of short term vitamin D3 
supplementation on main T helper 1 (Th1) and T helper 2 (Th2) cytokines, Th17 cytokine, 
T regulatory cytokine (Treg) and chemokines linking the balance between Th1 and Th2 
subsets.  In addition, we determined whether these cytokines were associated with markers 
of bone remodelling before and after vitamin D3 supplementation. 
 
The main finding from this pilot work is that six weeks of vitamin D3 supplementation in 
vitamin D deficient children is associated with a significant increase in the main Th2 
secreted cytokine, IL-4 (p = 0.001) and a tendency towards a significant increase in other 
Th2 secreted cytokines, IL-5 (p = 0.05) and IL6 (p = 0.05).  However, it is unclear if serum 
25(OH)D in these children or their response to vitamin D3 treatment are directly associated 
with a change in these cytokines. This finding from the present study was consistent with 
the experimental evidence which suggested that IL-4 may stimulate naive Th cell response 
to differentiate towards the Th2 effector phenotype. T helper 2 (Th2) cells in turn can also 
secrete more IL-4 and IL-5 [550]. This proposal is further supported by other evidence 
which indicates that APCs such as dendritic cells (can also secrete IL-4) are able to express 
vitamin D receptor (VDR), and the active form of vitamin D is a potential target for these 
cells [374].  Finally, Th2 response and Th2- related cytokines have been correlated with 
the incidence of allergic airway diseases which are further connected with low vitamin D 
status [409].  For example, low levels of IL-4 have been found in vitamin D deficient  
asthmatic patients compared with healthy controls (p = 0.003) and lower vitamin D status 
was correlated with the severity of asthma [583].  Finally, our results suggest that vitamin 
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D may associated with a skewing of the immune response to a Th2 phenotype, with an 
increase in IL-4 secretion and pointed to the significant association between systemic 
inflammation and markers of bone remodelling. These finding may further support the 
possible beneficial effects of supplementary vitamin D with respect to infectious and 
autoimmune diseases. 
 
8.3 Limitations and general conclusion: Effect of vitamin 
D supplementation on bone status, glucose 
homeostasis and immune function in children with 
symptomatic vitamin D deficiency 
The main strength of this thesis is the prospective and interventional nature of our work, in 
addition to its unique population.  However, there are general limitations in our study. 
Firstly, it was not a randomized controlled trial and we are unable to confirm whether any 
of observed changes were due to the intervention.  Secondly, the sample size was relatively 
small which may limit our ability to detect significant changes in some biomarkers. 
Thirdly, for ethical reasons, collection of blood samples for the study was performed at the 
same time as the clinical samples, which limited our ability to carry out sufficient 
investigation in many cases. The fourth limitation was the variability in age distribution 
among study participants.  Furthermore, it was very difficult to assess compliance for the 
treatment among study participants; compliance was assessed verbally from parents and 
may not reflect the actual intake.   Finally, sun exposure, physical activity and food intake 
were not measured in our study.  Due to the multi-ethnic population of our study, food 
intake may be one of the significant contributors to the lower vitamin D status.   
 
Our work was performed as a pilot study, since no prior research existed regarding the 
impact of high dose of vitamin D supplementation on bone biomarkers, glucose 
homeostasis and cytokines profile in children when we embarked on this project.  
It was therefore difficult to calculate the sample size adequately.  However, now that we 
have undertaken this preliminary work,  we now able to calculate the numbers required to 
design a sufficiently powered study in the future.  For instance, based on our results in the 
glucose study (chapter 6), a sample of 149 children would provide 80% power to detect a 
treatment difference of 1.04 in mean change of insulin resistance (HOMA IR) in healthy,  
vitamin D deficient children which would be significant at p<0.05. 
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In summary, the result from the second part of this thesis were consistent with the findings 
in our ScotPSU study in the first section which revealed a high prevalence of vitamin D 
deficiency and insufficiency among children in Glasgow.  The current work also provided 
some evidence that vitamin D deficiency and insufficiency among healthy children may be 
associated with a disturbance in immune and glucose profiles, in addition to a well-
established musculoskeletal effect.  Therefore, six weeks of daily supplementation with 
5000 IU vitamin D3 to healthy children led to a significant increase in median serum 
25(OH)D, significant decreases in serum PTH and ALP, a significant improvement in 
insulin resistance and a possible improvement in cytokines profile. 
 
 
8.4 Recommendations for future research  
1. Investigation of the long term effect of vitamin D3 supplementation on bone 
remodelling, glucose homeostasis and immune function using multiple point 
measurements, to further explore the effect of improving vitamin D status on 
glucose and immune profile measurements.  
2. The effect of improving vitamin D status on bone remodelling, glucose homeostasis 
and immune function should be further investigated in a larger population to 
control for potential bias such as age, ethnicity, diet and BMI.  
3. More studies are needed in this research area, and measurement of sun exposure, 
and vitamin D and calcium intake, should be considered in any future study.  It 
would be helpful to investigate whether these confounders have any effect on 
vitamin D level.  
4. Basal serum 25(OH)D concentration and/or the end point of serum 25(OH)D 
achieved should be considered as a significant contributor for the study outcomes. 
5. In immunity studies, the effect of vitamin D3 supplementation in cytokine profiles 
is still contradictory and may need further exploration.  Well-designed clinical trials 
under strictly controlled environments involving experimental animals and/or 
healthy adults may be needed in order to minimize the risk of confounders such as 
the effect of age variability, minimal illness and physical activity. 
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Appendix A–1- ScotPSU/ Case Report Form 
Symptomatic Vitamin D Deficiency In Scotland 
Case Report Form 
 
 ScotPSU Register Number:  
 
  
REPORTING CLINICIAN 
1.   Dr’s Name (please print)    ………………………   
2.   Month/Year of Report      /    
3.   Date diagnosis considered      /    /      
 
CHILD’S DETAILS 
4.   First Letter of Forename                      
5.   Month and year of birth        /    
6.   Gender                  M  F   
7.   Postal code           
8.   Gestation (wks) 
   
 
BIRTH MOTHER'S DETAILS 
9.  First Letter of MAIDEN SURNAME          
10. Current Age …………………….   
11. Country of Birth 
12. Ethnic Origin:  South Asia  North -African             Other Africa 
Middle- Eastern Chinese                Caucasian  
Other……………………………………………  
_____________________________________________________________ 
PRESENTATION 
Date of Clinic:          Date of referral:            Hospital: 
 
Source of referral:   A&E 
GP 
      Inpatient Medical 
OPD Medical 
Orthopaedic 
Other…………………… 
 
Reasons for referral:            Gait disturbance               Delayed walking                                 
                                                Bowed leg                         FHx of Vit D def 
                                                Known Rickets                 Seizure 
                                                Pain                                   Abnormal blood results      
                                                Fractures           Dietary Concerns 
                                                Swollen Wrists                  Abnormal X ray 
                                                Other 
      
        
X-Ray Abnormal findings…………………………………………… 
      
Blood abnormal findings…………………………………………… 
_______________________________________________________________ 
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MATERNAL VITAMIN D STATUS 
Antenatal supplementation: Name:  Start Month/Yr:   Dose: 
 Recommended By:        HV        GP        Other 
Other…………………………………… 
 
Current supplementation: Name:    Start Month/Yr;   
Dose: 
 
 Recommended By:        HV        GP        Other 
Other…………………………………… 
 
Known Mat Vit D Def:       Yes              No                
 
Maternal Clothing that limits sun exposure:             Yes              No 
  
Parental Understanding of Vit D:       None           Some            Complete 
_______________________________________________________________ 
 
CHILD’S NUTRITIONAL & VITAMIN D STATUS 
 
Prior Vitamin supplementation: Name:        Duration:       Dose: 
 
 Recommended by:         HV        GP        Other   
Other…………………………………… 
 
Breast feeding duration:     
 
Age at weaning:  
 
Diet at presentation:  Breast Milk (BM) only 
  Formula milk (FM) only 
  BM + FM 
  BM + solids 
  FM + solids 
           Other
 Other………………………………………………………….. 
 
Dietary problems:  None 
          Yes 
Details………………………………………………………………… 
 
Coexisting conditions:………………………………………………………….. 
_______________________________________________________________ 
CHILD’S EXAMINATION FINDINGS AT PRESENTATION 
Age at walking:                                                  Not walking yet 
Weight:  Height:  OFC: 
 
Bowed Legs           Abnormal gait            Wrist Swelling             Frontal Bossing       
                                                                                                    
Rachitic rosary          Abnormal Dentition      Bone pain                   Weakness                                                                 
 
 Patent Ant Fontanelle      Other…………………………………… 
______________________________________________________________ 
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RESULTS OF FIRST INVESTIGATIONS  
Biochemistry Ca PO PTH ALP 25(OH)D 
Date      
Result      
Reference Range      
Measurement unit      
 
 X-rays Specify site Clear 
Rickets 
Healing 
Rickets 
No 
Rickets 
Site 1      
Site 2      
Site 3      
______________________________________________________________ 
 
TREATMENT OF VITAMIN D DEFICIENCY 
Drug Name Start 
Date 
Dose Administration 
Method 
Stop Date 
Drug 1      
Drug 2      
Drug 3      
Other      
 
 
 
_______________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Case Of Any Queries About Completing This Form, Contact: 
Dr S Faisal Ahmed 0141 201 0571 or s.f.ahmed@clinmed.gla.ac.uk 
Dr Nagla E lfakhri : n.el-fakhri.1@research.gla.ac.uk.  
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Appendix B–1- Vitamin D deficiency and its potential 
effect on bone status, glucose homeostasis and immune 
function among children in Scotland/Case report form 
Vitamin D deficiency and its potential effect on bone status, immune and 
glucose homeostasis among children in Scotland. 
 
Case Report Form 
Hospital Number: 
Study Number: 
Date of first visit: 
 
REPORTING CLINICIAN 
1.   Dr’s Name (please print)    ………………………   
2.   Month/Year of Report      /    
3.   Date diagnosis considered      /    /      
 
CHILD’S DETAILS 
4.   First Letter of Forename                      
5.   Month and year of birth        /    
6.   Gender       M  F   
7.   Postal code                     
8.   Gestation  (wks) 
   
BIRTH MOTHER'S DETAILS            
9. Current Age …………………….   
10. Country of Birth 
11. Ethnic Origin:  South Asia  North -African             Other Africa 
Middle- Eastern  Chinese    Caucasian  
Other……………………………………………  
PRESENTATION 
Date of Clinic:         Date of referral:   
 
Source of referral:   A&E 
GP 
      Inpatient Medical 
OPD Medical 
Orthopaedic 
Other…………………… 
 
Reasons for referral:             Gait disturbance               Delayed walking                                 
                                                 Bowed leg                         Family history of Vit D def 
                                                 Known Rickets                 Seizure 
                                                 Pain                                   Abnormal blood results      
                                                 Fractures            Dietary Concerns 
                                                 Swollen Wrists                  Abnormal X ray 
                                                 Other 
     
   Abnormal X-Rays findings…………………………………………… 
Abnormal blood findings………………………………………………… 
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MATERNAL VITAMIN D STATUS 
Antenatal supplementation: Name:  Start Month/Yr:   Dose: 
 Recommended By:        HV         GP       Other 
Other…………………………………… 
 
Current supplementation: Name:  Start Month/Yr   Dose: 
 
 Recommended By:         HV        GP        Other 
Other…………………………………… 
 
Known Mat Vit D Def:        Yes             No                
 
Maternal Clothing that limits sun exposure:              Yes              No  
  
Parental Understanding of Vit D:       None          Some            Complete 
_______________________________________________________________ 
PARENT CLINICAL DETAILS 
Asthma                       Mother       Father 
 
Skin disease               Mother        Father 
 
Allergy                       Mother       Father 
 
Hypertension             Mother        Father 
 
Diabetes                     Mother        Father           Other……………………….. 
--------------------------------------------------------------------------------------------------- 
CHILD’S NUTRITIONAL & VITAMIN D STATUS 
Prior Vitamin supplementation: Name:     Duration: 
                        Dose: 
 
 Recommended by:          HV        GP       Other 
Other…………………………………… 
Breast feeding duration: ………….    
Age at weaning:  
Diet at presentation:  Breast Milk (BM) only 
  Formula milk (FM) only 
  BM + FM 
  BM + solids 
  FM solids 
 
 Other………………………………………………………….. 
Dietary problems:  None 
          Yes* 
*Details………………………………………………………………… 
Coexisting conditions:   -------------------------------------------
_________________________________________________________________ 
CHILD’S CLINICAL DETAILS 
Asthma                  
Skin disease         
Allergy                   
Diabetes                        Others……………………….. 
_________________________________________________________________ 
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CHILD’S EXAMINATION FINDINGS AT PRESENTATION 
Age at walking:                                                  Not walking yet 
Weight:  Height:  OFC: 
 
Bowed Legs  Abnormal Dentition     Wrist Swelling Weakness                                                                                                  
Rachitic rosary Patent Ant Fontanelle      Bone pain  Abnormal gait                                                                                       
Frontal Bossing      Other…………………… ………………………… 
_________________________________________________________________________ 
 
TREATMENT RECEVING OF VITAMIN D DEFICIENCY 
Drug Name Start 
Date 
Dose Administration 
Method 
Stop Date 
Drug 1      
Drug 2      
Drug 3      
Other      
_________________________________________________________________________ 
 
RESULTS OF INVESTIGATIONS BEFORE VITAMIN D TREATMENT 
 
Biochemistry Ca PO PTH ALP 25(OH)D 
Date      
Result      
Reference Range      
Measurement unit      
 
Biochemistry Glucose Insulin HbA1c SHBG 
Date of blood taken     
Result      
Reference Range     
Measurement unit     
 
Biochemistry Total 
cholesterol 
HDL LDL 
Date of blood taken    
Result    
Reference Range    
Measurement unit    
 
 X-rays Specify site Clear 
Rickets 
Healing 
Rickets 
No 
Rickets 
Site 1      
Site 2      
Site 3      
___________________________________________________________________ 
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Vitamin D deficiency and its potential effect on bone status, immune and glucose 
homeostasis among children in Scotland. 
 
Six Week visit  
Hospital Number: 
 
Study Number: 
 
Date of the visit: 
 
Weight ……. Height …….. 
                                          
Any change in the medical history 
………………………………………………………………………………………………
……………………………………………………………………………………………… 
Any medication 
………………………………………………………………………………………………
……………………………………………………………………………………………… 
Adverse effect 
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
RESULTS OF INVESTIGATIONS AFTER VITAMIN D TREATMENT 
 
Biochemistry Ca PO PTH ALP 25(OH)D 
Date      
Result      
Reference Range      
Measurement unit      
 
Biochemistry Glucose Insulin HbA1c SHBG 
Date of blood taken     
Result      
Reference Range     
Measurement unit     
 
Biochemistry Total 
cholesterol 
HDL LDL 
Date of blood taken    
Result    
Reference Range    
Measurement unit    
 
 
______________________________________________________________ 
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Appendix C–1- Child information sheet 
Department of Child Health 
Royal Hospital for Sick Children 
Yorkhill, Glasgow 
G3 8SJ, United Kingdom 
faisal.ahmed@glasgow.ac.uk 
 
    
A STUDY LOOKING AT GLUCOSE CONTROL AND IMMUNE FUNCTION IN 
CHILDREN WITH VITAMIN D DEFICIENCY 
 
       NEW PATIENT 
 
INFORMATION SHEET FOR CHILDREN (6-9 YRS) 
 
- You are being asked if you would like to take part in some work which we are 
doing at Yorkhill hospital. 
 
- This work is looking at the effects of something called ‘Vitamin D’. 
 
- Because your Vitamin D level is low you need some blood tests and some 
treatment. 
 
- These tests will be done when you start Vitamin D and then after a few weeks to 
check the treatment. 
 
- We would like to take an extra blood sample when you come for these tests. 
_____________________________________________________________________ 
 
Please read this sheet and talk to your family about it. Take your time and ask us if 
anything is not clear. 
- If you do take part, please make sure you do not eat or drink any milk or juice before 
coming for your tests. 
 
- If you do take part, we will take a sample at the same time as your other tests. You 
will not have an extra jag.  
 
 
- We will use special cream for the jag to make sure you don’t feel any pain. 
 
You do not need to take part in this work if you don’t want to. 
Please ask your parents, the doctors or nurses anything you want to know about the study.   
 
THANK YOU FOR READING THIS 
Appendix C–2- Child consent form 
Study Number:  
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Patient Identification Number: 
  
 CONSENT/ASSENT FORM FOR CHILDREN 6-9 YEARS 
A STUDY LOOKING AT GLUCOSE CONTROL AND IMMUNE FUNCTION IN 
CHILDREN WITH VITAMIN D DEFICIENCY 
 
Name of Researcher: Dr …………………………        
I have read the Information Sheet (Please take a copy with you to keep)  
I have asked questions about the study   
My questions have been answered  
I have spoken to the following people about the study (Please add name below) 
………………………………………………………………………………………
……………………………………………………………………………………… 
 
I agree to for an addition blood sample to be taken. 
     
Name of patient  Date (Day / Month 
/ Year) 
 Signature 
(Childs)ASSENT 
     
Name of parent / guardian 1  Date (Day / Month 
/ Year) 
 Signature (parent 
guardian) 
     
Name of parent / guardian 2  
(if applicable) 
 Date (Day / Month 
/ Year) 
 Signature(parent 
guardian) 
     
Investigator  Date (Day / Month 
/ Year) 
 Signature (investigator) 
     
Name of person taking 
consent (if different from 
investigator) 
 Date (Day / Month 
/ Year) 
 Signature(researcher if 
different from investigator 
THANK YOU FOR YOUR HELP 
Investigator to keep original form; 1 copy to be given to patient; 1 copy to be kept with hospital notes 
(Please initial boxes) 
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Appendix C–3- Parent information sheet 
 
Department of Child Health 
Royal Hospital For Sick Children 
Yorkhill, Glasgow 
G3 8SJ, United Kingdom 
faisal.ahmed@glasgow.ac.uk 
 
       
A STUDY LOOKING AT GLUCOSE CONTROL AND IMMUNE FUNCTION IN 
CHILDREN WITH VITAMIN D DEFICIENCY 
 
   
PARENT INFORMATION SHEET FOR NEW CHILDREN 
 
We are asking you and your child’s help with a study. This leaflet explains the study, so 
please read it carefully and asks any questions. You can discuss the leaflet with anybody you 
want. If you have any difficulty understanding the information, we can arrange for an 
interpreter to help you.  
 
What Is The Purpose Of This Study 
There is some suggestion that Vitamin D may help how the body controls the sugar levels 
in blood. Vitamin D may also be helpful in fighting infection and how the body copes with 
allergies. We would like to find out whether children with Vitamin D deficiency have any 
of these features. We would also like to know whether these features change with 
treatment. 
 
Why Has My Child Been Chosen? 
There is a very strong suspicion that your child has Vitamin D deficiency and your child 
needs treatment with Vitamin D. Your child will be attending the hospital for tests and for 
the first dose of Vitamin D.  
 
What Will Happen To My Child & I In The Study? 
We will first discuss the study with you when you bring your child to the clinic. We will 
provide you with the information sheet and go through it with you in the clinic. When you 
and your child come to the hospital in two weeks for a blood test and treatment for Vitamin 
D deficiency, we will take some extra blood sample, if you are agreed to take part. The 
amount of sample will be about two tea-spoons. For the study, we are requesting that, on 
the day of the blood test, you bring your child to the hospital in the morning before your 
child has the first meal or milk feed. We will do this again when your child returns for a 
check of Vitamin D treatment. 
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What Do I Need To Do In The Study? 
If you agree to participate, we will collect extra blood sample from your child when your 
child attends for the test. On the day of the tests, you need to make sure that your child 
does not have the morning meal or feed. Please remember, that if you decide not to take 
part in the study, your child will still have the tests and the Vitamin D. We will just not 
take the extra sample for the study. 
 
Will The Study Cause Any Discomfort Or Inconvenience 
You and your child will need to attend the ward first thing in the morning; we will arrange 
transport if you have any difficulties in attending and will discuss this with you 
beforehand. Your child may feel hungry in the morning when attending the ward but will 
be able to eat as soon as the blood test is completed. You may have to wait to have the tests 
done but we will make sure that they get done as soon as possible. For the blood your child 
will need a jag and we will make sure that these procedures are as painless as possible by 
using a local anaesthetic cream.  
 
What Will Happen To My Child & I After The Study? 
After the study, you will continue to come to the routine clinic at the hospital until there is 
a clear improvement in your child’s condition. Your child may need further xrays, tests or 
scans but this will be decided by the doctors in the clinic. When the results of the study are 
published, you or your child’s name will not be shown, so there is no way of anyone 
knowing that you have taken part unless you tell them.  
 
What Will Happen To My Child If Any Of The Study Tests Show Any Abnormality? 
We are not expecting that any of the study tests will show any abnormality that requires 
any action. We think that if there will be any abnormalities than they will be very mild. 
The team of doctors who are doing the research are specialists and will discuss any 
important results with you in the clinic. 
 
Are There Any Benefits To My Child Of Taking Part In The Study? 
There are no obvious benefits of taking part in the study as your child will still have the 
treatment whether your child takes part or does not take part in the study. 
 
Do I Have To Take Part? 
YOU DO NOT HAVE TO SAY ‘YES’ to taking part in this study if you do not want to, and 
you can come out of the study at any time if you are unhappy. 
 
What If Something Goes Wrong? 
We will take every care in the course of this study but we are not expecting any problems. 
However, if you are not happy about anything about this study, talk to other members of your 
family, your family doctor and ask them to speak to us. If your child is harmed due to 
someone's negligence, then you may have grounds for a legal action but may have to pay for 
it. Regardless of this, if you wish to complain, or have any concerns about any aspect of the 
way your child has been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you. Taking part in 
this study would not affect your child's legal rights. 
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Will My Taking Part In This Study Be Kept Confidential? 
All information which is collected about your child during the course of the research will be 
kept strictly confidential.  Any information about you that leaves the hospital will have name 
and address removed so that your child cannot be recognised from it. 
 
Who Is Organising The Study? 
The study is being organised by a group of doctors who look after children with Vitamin d 
deficiency at Yorkhill. You will find the main doctors’ details below. 
 
Who Is Helping These Doctors With The Study? 
This study is being performed as an educational project by a doctor who is doing her PhD. 
She is supported by an educational grant from the Government of Libya.  
 
What Will Happen To The Results Of The Study? 
The results of this study will be discussed with other doctors who work with children. They 
will be discussed at meetings and written up as articles. Do let us know if you would like to 
see a copy of these results. The results will also be used to design future studies of Vitamin 
d deficiency. 
 
Who Has Looked At his Study? 
The study has also been checked and approved by a number of organisations including the:-  
- NHS Research Ethics Committee in Glasgow 
- NHS Research & Development Dept in Glasgow 
-  
Who Can I Contact For Further Information? 
If you want to discuss the study further with one of the research team, please contact: 
Professor SF Ahmed - 0141 201 0571, faisal.ahmed@glasgow.ac.uk 
Dr Nagla El-Fakhri - 0141 201 0502, n.el-fakhri.1@research.gla.ac.uk 
If you want to discuss the study with a doctor who is not directly linked to the study, please 
contact: Dr MG Shaikh- 0141 201 1889, guftar.shaikh@nhs.net  
 
A copy of this information sheet and consent form will be given to you to keep. If you have 
any further questions about the study, please feel free to ask the doctor or nurse at the clinic 
your child attends at Yorkhill. 
 
 
THANK YOU FOR READING THIS 
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Appendix C–4- Parent consent form 
Study Number:  
Patient Identification Number: 
 
PARENT / LEGAL GUARDIAN CONSENT ASSENT FORM 
A STUDY LOOKING AT GLUCOSE CONTROL AND IMMUNE FUNCTION IN 
CHILDREN WITH VITAMIN D DEFICIENCY 
 
Name of Researcher: Dr …………………………. 
        
I agree for an additional blood sample to be taken 
     
Name of patient  Date (Day / Month / 
Year) 
 Signature 
     
Name of parent / guardian 1  Date (Day / Month / 
Year) 
 Signature 
     
Name of parent / guardian 2  
(if applicable) 
 Date (Day / Month / 
Year) 
 Signature 
     
I have read the Parent / Guardian Information Sheet (Please take a copy 
with you to keep) 
 
I have had the opportunity to discuss the study and ask questions   
I have received satisfactory answers to all my questions  
I have received enough information about the study  
I have spoken to the following people about the study (Please add name 
below) 
…………………………………………………………………………… 
 
I understand that my child can withdraw from the study at any time 
without giving a reason and without affecting their medical care 
 
I give permission for my child’s family doctor to be told of my child’s 
involvement in the study  
 
(Please initial) 
boxes) 
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Investigator  Date (Day / Month / 
Year) 
 Signature 
     
Name of person taking 
consent (if different from 
investigator) 
 Date (Day / Month / 
Year) 
 Signature 
 
THANK YOU FOR YOUR HELP 
Investigator to keep original form; 1 copy to be given to patient; 1 copy to be kept with hospital notes  
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Appendix D–1- Clinic check list for eligible participant for 
the study 
 
Bone status, glucose homeostasis and immune function in children with 
vitamin D deficiency  
 
Clinic check list for eligible participant for the study 
 
 
 
1. Exclusion and inclusion criteria  
2. Information sheet handed 
3. Verbal explanation  
 
4. Investigation requested: 
 
 
5. A: Routine (Hospital 
 laboratory)                                                          
 
 
U&E’s 
PTH 
Bone profile 
Full blood count 
25(OH) D 
 
4. C: Department of child health (DCH) 
 
 
 
 
 
 
 
 
 
6. Participant needs x- ray and/or echo 
 
7. Vitamin D prescription prepared 
 
8. Appointment for the result discussion  
 
9. Patient notified 4 days before the date of the first test 
 
10.  Alert the nurses  
  
 
 
 
 
 
 
 
 
4. B: Blood sugar profile (Hospital 
laboratory)  
 
Fasting blood sugar 
HbA1c 
SHBG 
  
Lipid profile  
Insulin 
Urine 
Immunie study 
Cytokines 
Lymphocytes 
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Appendix D–2- A letter for a general practitioner (GP) 
 
Royal Hospital for Sick Children, Dalnair Street, Glasgow, G3 8SJ 
 
Endocrine Services 
 
Consultants: Dr A Mason        Professor S F Ahmed       Dr M G Shaikh  Dr H McDevitt  
Specialist Nurses:             Ethel McNeill          Vicky Campbell 
Occupational Therapist:  Liz Dougan 
Dietician:       Jill Morrison        
    
*Contact Details 
 0141 201 0000 (Main Switchboard)  
 0141 201 0767 (Professor Ahmed’s Secretary) 
 0141 201 0571 (Professor Ahmed direct line)    
 
kathleen.gibson2@ggc.scot.nhs.uk  
 0141 201 0245 (Specialist Endocrine Nurses)    
 0141 201 0149 (Occupational Therapist)  
 0141 201 9368 (Dietitian)  
 
Fax: +44 (0) 141 201 0562  
 
 
Date---------- 
GP name---------- 
GP address--------- 
 
 
Dear Dr -------------- 
 
Child name -----, DOB ---/--/--, Address----------, CHI-------- 
 
 
The above patient has been participating in the Vitamin D - Metabolic and Immune study. A 
summary of this patient’s involvement in the study is outlined below. 
 
First study visit date: 15/04/2014 
1. Clinical samples collected – YES 
2. Study samples collected – YES 
3. Vitamin D (cholecalciferol) - Solgar 5000IU daily for 6 weeks- YES 
 
Second study visit date: 29/05/2014 
1. Clinical samples collected – YES  
2. Study samples collected – YES 
3. Multivitamin prescription-YES 
 
Follow Up Clinic Consultant: ---------------- Date: --/---/--- 
 
Yours sincerely  
 
Nagla  El-fakhri 
PhD student, Child Health 
Cc Doctor ------------- Consultant Paediatrician  
310 
 
 
 
List of References 
 
1. Ford JA, Colhoun EM, McIntosh WB, Dunnigan MG. Rickets and osteomalacia in the 
Glasgow Pakistani community, 1961-71. Br Med J 1972; 2(5815):677-680. 
2. Benson PF, Stroud CE, Mitchell NJ, Nicolaides A. Rickets in immigrant children in 
London. Br Med J 1963; 1(5337): 1054-1056. 
3. Rhein HM.Vitamin D deficiency in Scotland. Br Med J 2014; 22; 348: g2821. 
4. Zgaga L, Theodoratou E, Farrington SM, Agakov F, Tenesa A, Walker M, Knox S, 
Wallace AM, Cetnarskyj R, McNeill G, Kyle J, Porteous ME, Dunlop MG, Campbell H. 
Diet, environmental factors, and lifestyle underlie the high prevalence of vitamin D 
deficiency in healthy adults in Scotland, and supplementation reduces the proportion that 
are severely deficient. J Nut 2011;141(8):1535-1542.  
5. Ahmed SF, Franey C, McDevitt H, Somerville L, Butler S, Galloway P, Reynolds L, 
Shaikh MG, Wallace AM. Recent trends and clinical features of childhood vitamin D 
deficiency presenting to a children's hospital in Glasgow. Arch Dis Child 2011; 96(7):694-
695. 
6. Ashraf, S. and M.Z. Mughal, The prevalence of rickets among non-Caucasian children. 
Arch  Dis Child 2002; 87(3):263–264.  
7. Hyppönen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth 
cohort: the role of obesity. Diabetes Care 2006 ;29(10):2244-2246. 
8. Manaseki-Holland S, Qader G, Isaq Masher M, Bruce J, Zulf Mughal M, Chandramohan 
D, Walraven G. Effects of vitamin D supplementation to children diagnosed with 
pneumonia in Kabul:a randomised controlled trial. Tropical Medicine and International 
Health 2010 ;15(10):1148-1155. 
9.  Ashraf AP, Alvarez JA, Gower BA, Saenz KH, McCormick KL. Associations of serumm 
25-hydroxyvitamin D and components of the metabolic syndrome in obese adolescent  
females. Obesity (Silver Spring) 2011; 19(11):2214-2221. 
10.  Dunn PM. Soranus of Ephesus (circa AD 98-138) and perinatal care in Roman times. Arch  
Dis Child 1995; 73:F51-F52. 
11. Glisson F. A treatise of the rickets: being a disease common to children. Culpeper N, 
translated and –edited (london): P Cole; 1651. 
12. Dunn PM. Glisson F. (1597-1677) and the "discovery" of rickets. Arch Dis Child (Fetal 
Neonatal Edition)1998; 78(2):F154-F155.  
13. Mellanby E. An experimental investigation on rickets 1919. Nutrition 1989; 5(2):81-86. 
14. McCollum EV, Simmonds N, Becker  J E, Shipley  PG. Studies on experimental rickets. 
XXI. An experimental demonstration of the existence of a vitamin which promotes calcium 
deposition. J Biol Chem 1922; 53: 293-312. 
15. Hess AF, Unger LJ, Pappenheimer AM. Experimental Rickets in Rats : Vii. The 
Prevention of Rickets by Sunlight, by the Rays of the Mercury Vapor Lamp, and by the 
Carbon Arc Lamp. J  Exp Med 1922; 30;36(4):427-446. 
16. Chick H, Dalyell  EJH, Hume EM., Mackay HMM, Henderson-Smith H. The aetiology of 
rickets in infants: prophylactic and curative observations at the Vienna University 
Kinderklinik. The Lancet 1922; ii:7–11. 
311 
 
 
 
17. Askew FA, Bourdillon BR, Bruce HM, Jenkins RGC, Webster TA. The distillation of 
vitamin D.  Proc R Soc London1 931; 107:76–90. 
18. Windaus, A. The chemistry of irradiated ergosterol. Proc R Soc London 1931; 108:568-
575. 
19. Esvelt RP, Schnoes HK, DeLuca HF. Vitamin D3 from rat skins irradiated in vitro with 
ultraviolet light. Arch Biochem Biophys 1978 ;188(2):282-286.   
20. Holick MF. Environmental factors that influence the cutaneous production of 
            vitamin D. Am J Clin Nutr. 1995 ;61(3):638S-645S. Review.  
 
21. Logan VF, Gray AR, Peddie MC, Harper MJ, Houghton LA. Long-term vitamin D3 
supplementation is more effective than vitamin D2 in maintaining serum 25-
hydroxyvitamin D status over the winter months. Br J Nutr 2013; 28;109(6):1082-1088. 
22. Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of 
vitamin D after its endogenous synthesis. J Clin Invest 1993 ;91(6):2552-2555. 
23. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3):266-281. Review. 
24. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune 
diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80(6 Suppl):1678S- 
88S. Review. 
25. Vatanparast H, Calvo MS, Green TJ, Whiting SJ. Despite mandatory fortification   of 
staple foods, vitamin D intakes of Canadian children and adults are inadequate. J Steroid 
Biochem Mol Biol 2010; 121(1-2):301-303.  
26. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in 
humans. J Clin Endocrinol Metab 2004; 89(11):5387-5391. 28.  
27. Grossmann RE, Tangpricha V. Evaluation of vehicle substances on vitamin D 
bioavailability: a systematic review. Mol Nutr Food Res 2010; 54(8):1055-1061.  
28. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu 
RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA: The 
2011 report on dietary reference intakes for calcium and vitamin d from the institute of 
medicine: What clinicians need to know. J Clin Endocrinol Metab 2011; 96:53-58. 
29. Lee GJ, Birken CS, Parkin PC, Lebovic G, Chen Y, L'Abbé MR, Maguire JL; TAR Get 
Kids! Collaboration. Consumption of non-cow's milk beverages and serum vitamin D  
levels in early childhood. CMAJ 2014; 186(17):1287-1293. 
30. Natri AM, Salo P, Vikstedt T, Palssa A, Huttunen M, Kärkkäinen MU, Salovaara H, 
Piironen V, Jakobsen J, Lamberg-Allardt CJ. Bread fortified with cholecalciferol increases 
the serum 25-hydroxyvitamin D concentration in women as effectively as a cholecalciferol 
supplement. J Nutr 2006; 136(1):123-127. 
31. Tangpricha V, Koutkia P, Rieke SM, Chen TC, Perez AA, Holick MF. Fortification of 
orange juice with vitamin D: a novel approach for enhancing vitamin D nutritional health. 
American J Nutr 2003; 77(6):1478-1483. 
32. Hill KM, Jonnalagadda SS, Albertson AM, Joshi NA, Weaver CM. Top food sources  
contributing to vitamin D intake and the association of ready-to-eat cereal and breakfast 
consumption habits to vitamin D intake in Canadians and United States Americans. J Food 
Sci 2012; 77(8):H170-5. 
33. Hess FA, The Role of Activated Milk in the Anti-Rickets Campaign. Am J Public Health 
Nations Health 1932; 22(12):1215-1219 
312 
 
 
 
34. Calvo MS, Whiting SJ. Vitamin  D Forti fication in North America: Current Status and 
Future Considerations, in Handbook of Food Fortification and Health: From Concepts to 
Public Health. Preedy, R. Srirajaskanthan and V.B. Patel (Editors). Springer New York 
Heidelberg Dordrecht London: New York: 2013; 259-275. 
35. Committee on Medical Aspects of Food and Nutrition Policy; Panel on Child and  
            Maternal Nutrition of the Committee on Medical Aspects of Food and Nutrition 
            Policy. Scientific review of the Welfare Food Scheme. Reports of Health and Social subject 
(london) 2002;(51):i-xxi, 1-147. Review. 
 
36. Ross SG. Vitamin D intoxication in infancy; a report of four cases. J Pediatr 
1952;41(6):815-822.  
37. The national  archive [Internet]. UK. Department of Health.  Healthy start proposals for 
reform of the Welfare Food Scheme 2002;[cited Janury 2016] Available from 
[http://webarchive.nationalarchives.gov.uk/20081105143757/http://dh.gov.uk/en/Consultat
ions/Closedconsultations/DH_4087874]  
38. Gov.UK[Internet].UK. Department of Health. Fortified Foods Guidance to compliance 
with European Regulation (EC) No. 1925/2006 on the addition of vitamins and minerals 
and certain other substances to food 2011; [updated 2013 May; cited 2016 January]. 
Available from [https://www.gov.uk/government/publications/fortified-foods-guidance-to-
compliance-with-european-regulation-ec-no-1925-2006-on-the-addition-of-vitamins-and-
minerals-and-certain-other-substances-to-food]. 
39. Cribb VL, Northstone K, Hopkins D, Emmett PM. Sources of vitamin D and calcium in the 
diets of preschool children in the UK and the theoretical effect of food fortification. J Hum 
Nutr Diet  2015; 28(6):583-592.  
40. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M. Vitamin d deficiency in 
children and its management: Review of current knowledge and recommendations. 
Pediatrics 2008; 122:398-417. 
41. Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher 
JC, Gallo RL, Jones G, Kovacs CS, Manson JE, Mayne ST, Ross AC, Shapses SA, Taylor 
CL. IOM committee members respond to endocrine society vitamin d guideline. J Clin 
Endocrinol Metab 2012; 97:1146-1152. 
42. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, 
Murad MH, Weaver CM. Evaluation, treatment, and prevention of vitamin d deficiency: 
An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911-
1930. 
43. Pettifor JM, Bikle DD, Cavaleros M, Zachen D, Kamdar MC, Ross FP. Serum levels of 
free 1,25-dihydroxyvitamin D in vitamin D toxicity. Ann Intern Med 1995; 122(7):511-
513. 
44.  Blank S, Scanlon KS, Sinks TH, Lett S, Falk H. An outbreak of hypervitaminosis D 
associated with the overfortification of milk from a home-delivery dairy. Am J Public 
Health 1995; 85(5):656-659. 
45. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88(2):582S-586S. 
Review. 
46. Shephard RM, Deluca HF. Plasma concentrations of vitamin D3 and its metabolites in the 
rat as influenced by vitamin D3 or 25-hydroxyvitamin D3 intakes. Arch Biochem Biophys 
1980; 202(1):43-53. 
47. Deluca HF, Prahl JM, Plum LA. 1,25-Dihydroxyvitamin D is not responsible for toxicity 
caused by vitamin D or 25-hydroxyvitamin D. Arch Biochem Biophys 2011; 505(2):226-
230. 
313 
 
 
 
48.  Bouillon R, Van Cromphaut S, Carmeliet G. Intestinal calcium absorption: Molecular 
vitamin D mediated mechanisms. J Cell Biochem 2003; 1;88(2):332-339. 
49. Atabek ME, Pirgon O, Sert A. Oral alendronate therapy for severe vitamin D intoxication 
of the infant with nephrocalcinosis. J Pediatr Endocrinol Metab 2006; 19(2):169-172. 
50.  Vogiatzi MG, Jacobson-Dickman E, DeBoer MD; Drugs, and Therapeutics Committee  of 
The Pediatric Endocrine Society. Vitamin D supplementation and risk of toxicity in 
pediatrics: a review of current literature. J Clin Endocrinol Metab 2014; 99(4):1132-1141. 
51.  Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: 
implications for establishing a new effective dietary intake recommendation for vitamin D. 
J Nutr 2005; 135(2):317-322. Review. 
52. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D 
insufficiency into perspective. Br J Nutr  2005; 94(4):483-492. Review.  
53. Sjöden G, Lindgren U. The effect of prednisolone on kidney calcification in vitamin D-
treated rats. Calcif Tissue Int 1985; 37(6):613-616. 
54. Moore CE, Radcliffe JD, Liu Y. Vitamin D intakes of children differ by race/ethnicity, sex, 
age, and income in the United States, 2007 to 2010. Nutr Res 2014; 34(6):499-506. 
55.  Burrows TL, Martin RJ, Collins CE. A systematic review of the validity of dietary 
assessment methods in children when compared with the method of doubly labeled water. J 
Am Diet Assoc 2010; 110(10):1501-1510. 
56. Roman-Viñas B, Ortiz-Andrellucchi A, Mendez M, Sánchez-Villegas A, Peña Quintana L, 
Aznar LA, Hermoso M, Serra-Majem L. Is the food frequency questionnaire suitable to 
assess micronutrient intake adequacy for infants, children and adolescents? Matern Child 
Nutr 2010; 6 Suppl 2:112-121. 
57. Nucci AM, Russell CS, Luo R, Ganji V, Olabopo F, Hopkins B, Holick MF, Rajakumar K. 
The effectiveness of a short food frequency questionnaire in determining vitamin D intake 
in children. Dermatoendocrinol. 2013; 5(1):205-510. 
58. Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, Moshfegh AJ, Sempos CT, 
Picciano MF. Estimation of total usual calcium and vitamin D intakes in the United States. 
J Nutr 2010; 140(4):817-22. 
59. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann 
Epidemiol 2009; 19(2):73-8. 
60. Lips, P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: 
consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001; 
22(4): 477-501. 
61. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, Hewison M.   
Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol 
Metab 2001; 86(2):888-894. 
62. Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerström G, Westin 
G. 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological 
parathyroid glands. J Clin Endocrinol Metab. 2002; 87(6):2967-2972. 
63. Tangpricha V, Flanagan JN, Whitlatch LW, Tseng CC, Chen TC, Holt PR, Lipkin MS, 
Holick MF. 25-hydroxyvitamin D-1alpha-hydroxylase in normal and malignant colon 
tissue. Lancet. 2001 ; 26;357(9269):1673-1674. 
314 
 
 
 
64. Tsugawa N, Suhara Y, Kamao M, Okano T. Determination of 25-hydroxyvitamin D in 
human plasma using high-performance liquid chromatography--tandem mass spectrometry. 
Anal Chem. 2005; 77(9):3001-3007. 
65. Bunch  DR , Miller AY, Wang S. Development and validation of a liquid chromatography-
tandem mass spectrometry assay for serum 25-hydroxyvitamin D2/D3 using a turbulent 
flow online extraction technology. Clin Chem Lab Med 2009; 47(12): 1565-1572. 
66. Snellman G, Melhus H, Gedeborg R, Byberg L, Berglund L, Wernroth L, Michaëlsson K. 
Determining vitamin D status: a comparison between commercially available assays. PLoS 
One 2010;5(7):e11555. 
67. Lai JK, Lucas RM, Banks E, Ponsonby AL; Ausimmune Investigator Group. Variability in 
vitamin D assays impairs clinical assessment of vitamin D status. Intern Med J 2012; 
42(1):43-50. 
68. Carter GD, Berry JL, Gunter E, Jones G, Jones JC, Makin HL, Sufi S, WheelerMJ. 
Proficiency testing of 25-hydroxyvitamin D (25-OHD) assays. J Steroid Biochem Mol Biol 
2010; 121(1-2):176-179. 
69. Carter  GD. 25-Hydroxyvitamin D assays: the quest for accuracy. Clin Chem 2009; 55(7): 
1300-1302. 
70. Wallace AM, Gibson S, de la Hunty A, Lamberg-Allardt C, Ashwell M. Measurement of 
25-hydroxyvitamin D in the clinical laboratory: current procedures, performance 
characteristics and limitations. Steroids  2010; 75(7):477-488. 
71. Andersson S, Jörnvall H. Sex differences in cytochrome P-450-dependent 25-
hydroxylation of C27-steroids and vitamin D3 in rat liver microsomes. J Biol Chem 1986; 
261(36):16932-6. 
72. Wikvall  K. Cytochrome P450 enzymes in the bioactivation of vitamin D to its hormonal 
form (Review). International Journal of Molecular Medicine 2001; 7(2): 201-209. 
73. Lund J, DeLuca HF. Biologically active metabolite of vitamin D3 from bone, liver, and 
blood serum. J Lipid Res 1966; 7(6):739-744. 
74. Henry HL. Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 
2011; 25(4): 531-541. 
75. Anderson  PH , May BK, Morris HA. Vitamin D metabolism: new concepts and clinical 
implications. The Clinical biochemist. Reviews / Australian Association of Clinical 
Biochemists. 2003; 24(1): 13-26. 
76. Anderson PH, O'Loughlin PD, May BK, Morris HA. Quantification of mRNA for the  
vitamin D metabolizing enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney 
using real-time reverse transcriptase- polymerase chain reaction. J Mol Endocrinol 
2003;31(1):123-32. 
77. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995; 
15;83(6):841-850. Review. 
78. Haussler MR, Whitfield GK, Haussler CA, Hsieh JC, Thompson PD, Selznick SH, 
Dominguez CE, Jurutka PW. The nuclear vitamin D receptor: biological and molecular 
regulatory properties revealed. J Bone Miner Res 1998; 13(3):325-349 
79. Takeshita A, Ozawa Y, Chin WW. Nuclear receptor coactivators facilitate vitamin D 
receptor homodimer action on direct repeat hormone response elements. Endocrinology 
2000; 141(3):1281-1284. 
315 
 
 
 
80. Christakos S, Ajibade DV, Dhawan P, Fechner AJ, Mady LJ. Vitamin D: metabolism. 
Endocrinol Metab Clin North Am  2010; 39(2):243-253 
81. Mizwicki MT, Norman AW. The vitamin D sterol-vitamin D receptor ensemble model 
offers unique insights into both genomic and rapid-response signaling. Sci Signal 2009; 
16;2(75):re4. Review. 
82. Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort 
study of dietary and lifestyle predictors. Am J Clin Nutr 2007; 85(3):860-868. 
83. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis 
of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote 
vitamin D3 synthesis in human skin. J Clin Endocrinol Metab1988; 67(2):373-378. 
84. Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence an associations of 
25-hydroxyvitamin D deficiency in US children: NHANES 2001-2004. Pediatrics 2009; 
124(3):e362-370. 
85. Smotkin-Tangorra M, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S. Prevalence 
of vitamin d insufficiency in obese children and adolescents. J Pediatr Endocrinol Metab 
2007; 20:817-823. 
86.  McGill AT, Stewart JM, Lithander FE, Strik CM, Poppitt SD. Relationships of low serum 
vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in 
overweight and obesity. Nutr J 2008; 28;7:4. 
87. Holick MF,  MacLaughlin JA,  Doppelt SH. Regulation of cutaneous previtamin D3 
photosynthesis in man: skin pigment is not an essential regulator. Science 1981;  
6;211(4482):590-593. 
88. Armas LA, Dowell S, Akhter M, Duthuluru S, Huerter C, Hollis BW, Lund R, Heaney RP. 
Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: the effect of UVB 
dose and skin color. J Am Acad Dermatol 2007; 57(4):588-593. 
89. Gallagher JC, Jindal PS, Smith LM. Vitamin D supplementation in young White and 
African American women. J Bone Miner Res 2014; 29(1):173-181. 
90.  Sayre RM, Dowdy JC. Darkness at noon: sunscreens and vitamin D3. Photochem 
Photobio 2007; 83(2):459-463. 
91. Ward M, Berry D, Power C, Hyppönen E. Working patterns and vitamin D status in mid-
life: a cross-sectional study of the 1958 British birth cohort. Occup Environ Med 2011; 
68:902-907. 
92. Kaplan FS, Soriano S, Fallon MD, Haddad JG. Osteomalacia in a night nurse. Clinical 
Orthopaedics and Related Research 1986 ;(205):216-221. 
93. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am 
J Clin Nutr 1999; 69(5):842-856. Review.  
94.  Awumey EM, Mitra DA, Hollis BW, Kumar R, Bell NH. Vitamin D metabolism is altered 
in Asian Indians in the southern United States: a clinical research center study. J Clin 
Endocrinol Metab 1998; 83(1):169-173.  
95. El Rifai NM, Abdel Moety GA, Gaafar HM, Hamed DA. Vitamin D deficiency in 
Egyptian mothers and their neonates and possible related factors. J Matern Fetal Neonatal 
Med 2014; 27(10):1064-1068. 
96. Leerbeck E, Søndergaard H. The total content of vitamin D in human milk and cow's    
milk. Br J Nutr 1980; 44(1):7-12. 
316 
 
 
 
97. Henderson A. Vitamin D and the breastfed infant. J Obstet Gynecol Neonatal Nurs 2005; 
34(3):367-372. Review. 
98. Goswami R, Gupta N, Goswami D, Marwaha RK, Tandon N, Kochupillai N. Prevalence 
and significance of low 25-hydroxyvitamin D concentrations in healthy subjects in Delhi. 
Am J Clin Nutr 2000; 72(2):472-475. 
99.  Alsuwadia AO, Farag YM, Al Sayyari AA, Mousa DH, Alhejaili FF, Al-Harbi AS, 
Housawi AA, Mittal BV, Singh AK. Prevalence of vitamin D deficiency in Saudi adults. 
Saudi Med J 2013; 34(8):814-818. 
100.    Shea MK, Benjamin EJ, Dupuis J, Massaro JM, Jacques PF, D'Agostino RB, Ordovas 
JM, O'Donnell CJ, Dawson-Hughes B, Vasan RS, Booth SL. Genetic and non-genetic 
correlates of vitamins K and D. Eur J Clin Nutr 2009; 63(4):458-464. 
101.   Hunter D, De Lange M, Snieder H, MacGregor AJ, Swaminathan R, Thakker RV, 
Spector TD. Genetic contribution to bone metabolism, calcium excretion, and vitamin D 
and parathyroid hormone regulation. J Bone Miner Res 2001; 16(2):371-380. 
102.   Dastani Z, Li R, Richards B. Genetic regulation of vitamin D levels. Calcif Tissue Int 
2013; 92(2):106-117. 
103.   Laaksonen M, Kärkkäinen M, Outila T, Vanninen T, Ray C, Lamberg-Allardt C. Vitamin 
D receptor gene BsmI-polymorphism in Finnish premenopausal and postmenopausal 
women: its association with bone mineral density, markers of bone  turnover, and intestinal 
calcium absorption, with adjustment for lifestyle factors. J Bone Miner Metab 
2002;20(6):383-390. 
104. 105. Ford L, Graham V, Wall A, Berg J. Vitamin D concentrations in an UK inner-city 
multicultural outpatient population. Ann Clin Biochem  2006; 43(Pt 6):468-473.  
105.   Purdon G, Comrie F,  Rutherford L, Marcinkiewicz A (2013). Vitamin D status of 
Scottish adults: Results from the 2010 & 2011 Scottish Health Surveys.  Retrieved from 
Food Standards Agency in Scotland website. 
[http://www.foodstandards.gov.scot/sites/default/files/845 
11545_FSA_Vit_D_2011_report_final.pdf] 
106. Callaghan AL, Moy RJ, Booth IW, Debelle G, Shaw NJ. Incidence of symptomatic vitamin 
D deficiency. Arch Dis Child 2006; 91(7):606-607. 
107.  Moy RJ, McGee E, Debelle GD, Mather I, Shaw NJ. Successful public health action to 
reduce the incidence of symptomatic vitamin D deficiency. Arch Dis Child 2012; 
97(11):952-954. 
108.   Department of Health and Social Security. Rickets and osteomalacia: Report of the 
Working Party on Fortification of  Food with Vitamin D, Committee on Medical Aspects 
of Food Policy. Reports on health and social subjects (London)1980; 19:i-xii, 1-66. 
Review. 
109.  Dunnigan MG, McIntosh WB, Sutherland GR, Gardee R, Glekin B, Ford JA, Robertson I. 
Policy for prevention of Asian rickets in Britain: a preliminary assessment of the Glasgow 
rickets campaign. Br med J (Clinical research ed.)1981; 31;282(6261):357-360. 
110.   Dunnigan MG, Glekin BM, Henderson JB, McIntosh WB, Sumner D, Sutherland GR. 
Prevention of rickets in Asian children: assessment of the Glasgow campaign. Br med J 
(Clinical research ed.)1985; 291(6490):239-242. 
111.  Henderson JB, Dunnigan MG, McIntosh WB, Abdul-Motaal AA, Gettinby G, Glekin BM. 
The importance of limited exposure to ultraviolet radiation and dietary factors in the 
aetiology of Asian rickets: a risk-factor model. Q J Med 1987; 63(241):413-425. 
317 
 
 
 
112.  Dunnigan MG, Henderson JB. An epidemiological model of privational rickets and 
osteomalacia. Proc Nutr Soc 1997; 56(3):939-956. Review 
113. Henderson JB, Dunnigan MG, McIntosh WB, Abdul Motaal A, Hole D. Asian 
osteomalacia is determined by dietary factors when exposure to ultraviolet radiation is 
restricted: a risk factor model. Q J Med 1990; 76(281):923-933. 
114.   Gov.UK [Internet].UK. Department of Health. The National Diet and Nutrition Survey 
(NDNS). Results from Years 1, 2, 3 and 4 (combined) of the Rolling Programme 
(2008/2009 – 2011/2012). 2014  [cited 2016 12 August ]; Available 
from:https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/31099
5/NDNS_Y1_to_4_UK_report.pdf. 
115.  LeFevre ML; U.S. Preventive Services Task Force. Screening for vitamin D deficiency  in 
adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 
2015; 20;162(2):133-140 
116.  Joiner TA,  Foster C,  Shope T. The many faces of vitamin D deficiency rickets. Pediatr 
Rev 2000; 21(9):296-302. 
117.  Goel KM, Sweet EM, Logan RW, Warren JM, Arneil GC, Shanks RA. Florid and 
subclinical rickets among immigrant children in Glasgow. Lancet 1976; 1(7970):1141-
1145. 
118.  Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, 
and adolescents. Pediatrics 2008; 122(5):1142-1152. 
119. Eastwood JB, de Wardener HE, Gray RW, Lemann JL Jr. Normal plasma-1,25-(OH)2-
vitamin-D concentrations in nutritional osteomalacia. Lancet 1979; 1(8131):1377-8. 
120.  LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D 
deficiency in postmenopausal US women with acute hip fracture. JAMA 1999; 
281(16):1505-11. 
121.  Martini  FH, Nath JL, Bartholomew EF. Fundamentals of Anatomy & Physiology. 9 ed. 
2011, USA: Pearson Education 
122. Hadjidakis DJ, Androulakis  II.  Bone remodeling. Ann N Y Acad Sci 2006; 1092: 385-96. 
123. Kierszenbaum AL, Tres LL. Connective tissue in Histology and Cell Biology. M. Hyde, 
2012, USA: Elsevier Saunders: 111-149. 
124. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, 
Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ. Cbfa1, a candidate gene for 
cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone 
development. Cell 1997 ;30;89(5):765-771.  
125. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011; 26(2):229-238. 
           Review. 
 
126.  Hughes, D.E., D.M. Salter, and R. Simpson, CD44 expression in human bone: a novel 
marker of osteocytic differentiation. J Bone Miner Res 1994; 9(1): 39-44. 
127.  Lu Y, Yuan B, Qin C, Cao Z, Xie Y, Dallas SL, McKee MD, Drezner MK, Bonewald LF, 
Feng JQ. The biological function of DMP-1 in osteocyte maturation is mediated by its 57-
kDa C-terminal fragment. J Bone Miner Res 2011 Feb;26(2):331-340. 
128. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23  
             in Hyp mice. Am J Physiol Endocrinol Metab 2006 ;291(1): E38-49. 
 
318 
 
 
 
129. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of 
osteoclast differentiation and function by the new members of the tumor necrosis factor 
receptor and ligand families. Endocr Rev 1999;20(3):345-357. Review. 
130. Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in 
action. Trends Cell Biol 2004;14(11):628-638. Review. 
131. Manolagas, S.C., Birth and death of bone cells: basic regulatory mechanisms and 
implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21(2): 
115-137. 
132. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC. Osteoblast programmed 
cell death (apoptosis): modulation by growth factors and cytokines.  J Bone Miner Res 
1998;13(5):793-802. 
133. Rucci N, Molecular biology of bone remodelling. Clin Cases Miner Bone Metab 2008; 
5(1): 49-56. 
134. Lieben L, Masuyama R, Torrekens S, Van Looveren R, Schrooten J, Baatsen P, Lafage-
Proust MH, Dresselaers T, Feng JQ, Bonewald LF, Meyer MB, Pike JW, Bouillon R, 
Carmeliet G. Normocalcemia is maintained in mice under conditions of calcium 
malabsorption by vitamin D-induced inhibition of bone mineralization.  J Clin Invest 
2012;122(5):1803-1815. 
135. Atkins GJ, Anderson PH, Findlay DM, Welldon KJ, Vincent C, Zannettino AC, 
O'Loughlin PD, Morris HA. Metabolism of vitamin D3 in human osteoblasts: evidence for 
autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 
2007;40(6):1517-1528. 
136. Kogawa M, Findlay DM, Anderson PH, Ormsby R, Vincent C, Morris HA, Atkins GJ. 
Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of 
bone resorption. Endocrinology 2010;151(10):4613-4625. 
137. Gardiner EM, Baldock PA, Thomas GP, Sims NA, Henderson NK, Hollis B, White CP, 
Sunn KL, Morrison NA, Walsh WR, Eisman JA. Increased formation and decreased 
resorption of bone in mice with elevated vitamin D receptor in mature cells of the 
osteoblastic lineage. FASEB J 2000 ;14(13):1908-1916. 
138. Amling M, Priemel M, Holzmann T, Chapin K, Rueger JM, Baron R, Demay MB. Rescue 
of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal 
mineral ion homeostasis: formal histomorphometric and biomechanical analyses. 
Endocrinology 1999 ;140(11):4982-4987. 
139. Lian J, Stewart C, Puchacz E, Mackowiak S, Shalhoub V, Collart D, Zambetti G,  Stein G. 
Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. 
Proc Natl Acad Sci U S A 1989 ;86(4):1143-1147. 
140. Reinholt FP, Hultenby K, Oldberg A, Heinegård D. Osteopontin--a possible anchor of 
osteoclasts to bone. Proc Natl Acad Sci U S A.1990 ;87(12):4473-4475.  
141. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, Goldberg HA. Bone 
sialoprotein expression enhances osteoblast differentiation and matrix mineralization in 
vitro. Bone 2007 ;41(3):462-473. 
142. Anderson HC. Molecular biology of matrix vesicles. Clin Orthop Relat Res 1995; 314:266-
280. Review. 
143. oeckel VJ, Alves RD, Swagemakers SM, Eijken M, Chiba H, van der Eerden BC, van 
Leeuwen JP. 1Alpha,25-(OH)2D3 acts in the early phase of osteoblast differentiation to 
enhance mineralization via accelerated production of maturematrix vesicles. J Cell Physiol 
2010 ;225(2):593-600. 
319 
 
 
 
144. Tang WJ, Wang LF, Xu XY, Zhou Y, Jin WF, Jin WF, Wang HF, Gao j. 
Autocrine/Paracrine Action of Vitamin D on FGF23 Expression in Cultured Rat 
Osteoblasts. Calcified Tissue International 2010; 86(5): 404-410. 
145. Yoshiko Y, Wang H, Minamizaki T, Ijuin C, Yamamoto R, Suemune S, Kozai K, Tanne 
K, Aubin JE, Maeda N. Mineralized tissue cells are a principal source of FGF23. Bone. 
2007 ;40(6):1565-1573. 
146. Quarles LD, Role of FGF23 in vitamin D and phosphate metabolism: implications in 
chronic kidney disease. Exp Cell Res 2012;  318(9): 1040-1048. 
147. Boivin G, Mesguich P, Pike JW, Bouillon R, Meunier PJ, Haussler MR, Dubois PM, Morel 
G. Ultrastructural immunocytochemical localization of endogenous 1,25-dihydroxyvitamin 
D3 and its receptors in osteoblasts and osteocytes from neonatal mouse and rat calvaria. 
Bone Miner 1987 ;3(2):125-136. 
148. Fermor B, Skerry TM. PTH/PTHrP receptor expression on osteoblasts and osteocytes but 
not resorbing bone surfaces in growing rats. J Bone Miner Res 1995;10(12):1935-1943. 
149. Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O'Loughlin PD, Nicholson 
GC, Briffa KH, Eisman JA, Gardiner EM. Vitamin D action and regulation of bone 
remodeling: suppression of osteoclastogenesis by the mature osteoblast. J Bone Miner Res 
2006 ;21(10):1618-1626. 
150. Anh DJ, Dimai HP, Hall SL, Farley JR. Skeletal alkaline phosphatase activity is primarily 
released from human osteoblasts in an insoluble form, and the net release is inhibited by 
calcium and skeletal growth factors. Calcif Tissue Int1998 ;62(4):332-340. 
151. Harris H, The human alkaline phosphatases: what we know and what we don't know. Clin 
Chim Acta 1990; 186(2): 133-50. 
152. Weiss, M.J., et al., Structure of the human liver/bone/kidney alkaline phosphatase gene. J 
Biol Chem, 1988. 263(24): p. 12002-10. 
 
153. Millan, J.L., Molecular cloning and sequence analysis of human placental alkaline 
phosphatase. J Biol Chem, 1986. 261(7): p. 3112-5. 
 
154. Berger, J., et al., Cloning and sequencing of human intestinal alkaline phosphatase cDNA. 
Proc Natl Acad Sci U S A, 1987. 84(3): p. 695-8. 
 
155. Seibel, M.J., Biochemical markers of bone turnover: part I: biochemistry and variability. 
Clin Biochem Rev, 2005. 26(4): p. 97-122. 
 
156. Hauschka, P.V., et al., Osteocalcin and matrix Gla protein: vitamin K-dependent proteins 
in bone. Physiol Rev, 1989. 69(3): p. 990-1047. 
 
157. Price, P.A., J.G. Parthemore, and L.J. Deftos, New biochemical marker for bone 
metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of 
normal subjects and patients with bone disease. J Clin Invest, 1980. 66(5): p. 878-83. 
 
158. Ivaska, K.K., et al., Release of intact and fragmented osteocalcin molecules from bone 
matrix during bone resorption in vitro. J Biol Chem, 2004. 279(18): p. 18361-9. 
 
159. Villafan-Bernal, J.R., S. Sanchez-Enriquez, and J.F. Munoz-Valle, Molecular modulation 
of osteocalcin and its relevance in diabetes (Review). Int J Mol Med, 2011. 28(3): p. 283-
93. 
 
160. Ferron, M., et al., Osteocalcin differentially regulates beta cell and adipocyte gene 
expression and affects the development of metabolic diseases in wild-type mice. Proc Natl 
Acad Sci U S A, 2008. 105(13): p. 5266-70. 
320 
 
 
 
161. Poomthavorn, P., et al., Effects of correction of vitamin D insufficiency on serum 
osteocalcin and glucose metabolism in obese children. Clin Endocrinol (Oxf), 2014. 80(4): 
p. 516-23. 
 
162. Ferron, M., et al., Intermittent injections of osteocalcin improve glucose metabolism and 
prevent type 2 diabetes in mice. Bone, 2012. 50(2): p. 568-75. 
 
163. Delmas, P.D., et al., The use of biochemical markers of bone turnover in osteoporosis. 
Committee of Scientific Advisors of the International Osteoporosis Foundation. 
Osteoporos Int, 2000. 11 Suppl 6: p. S2-17. 
 
164. Christakos, S., et al., Vitamin D and intestinal calcium absorption. Mol Cell Endocrinol, 
2011. 347(1-2): p. 25-9. 
 
165. Nijenhuis, T., J.G. Hoenderop, and R.J. Bindels, TRPV5 and TRPV6 in Ca(2+) 
(re)absorption: regulating Ca(2+) entry at the gate. Pflugers Arch, 2005. 451(1): p. 181-92. 
 
166. Pike, J.W., et al., Molecular actions of 1,25-dihydroxyvitamin D3 on genes involved in 
calcium homeostasis. J Bone Miner Res, 2007. 22 Suppl 2: p. V16-9. 
 
167. Ko, S.H., et al., Dietary calcium and 1,25-dihydroxyvitamin D3 regulate transcription of 
calcium transporter genes in calbindin-D9k knockout mice. J Reprod Dev, 2009. 55(2): p. 
137-42. 
 
168. Fujita, H., et al., Tight junction proteins claudin-2 and -12 are critical for vitamin D-
dependent Ca2+ absorption between enterocytes. Mol Biol Cell, 2008. 19(5): p. 1912-21. 
 
169. Wakabayashi, T., Mechanism of the calcium-regulation of muscle contraction--in pursuit 
of its structural basis. Proc Jpn Acad Ser B Phys Biol Sci, 2015. 91(7): p. 321-50. 
 
170. Mundy, G.R. and T.A. Guise, Hormonal control of calcium homeostasis. Clin Chem, 1999. 
45(8 Pt 2): p. 1347-52. 
 
171. Gensure, R.C., T.J. Gardella, and H. Juppner, Parathyroid hormone and parathyroid 
hormone-related peptide, and their receptors. Biochem Biophys Res Commun, 2005. 
328(3): p. 666-78. 
 
172. Pettifor, J.M., Nutritional Rickets, in Pediatric Bone (Second Edition) Biology & Diseases, 
F.H. Glorieux, J.M. Pettifor, and H. JÜppner, Editors. 2011, Elsevier's Science & 
Technology: USA. p. 625-646. 
 
173. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis 
of vitamin D3: exposure to winter sunlight in Boston and Edmonton will  not promote 
vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988 Aug;67(2):373-8. 
174. Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF. Sunscreens suppress 
cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab. 1987 Jun;64(6):1165-8. 
175. Matsuoka LY, Wortsman J, Dannenberg MJ, Hollis BW, Lu Z, Holick MF. Clothing 
prevents ultraviolet-B radiation-dependent photosynthesis of vitamin D3. J Clin Endocrinol 
Metab. 1992 Oct;75(4):1099-103. 
176. Ozkan, B., Nutritional rickets. J Clin Res Pediatr Endocrinol, 2010. 2(4): p. 137-43. 
 
177. Hosseinpour, F., et al., Phenobarbital suppresses vitamin D3 25-hydroxylase expression: a 
potential new mechanism for drug-induced osteomalacia. Biochem Biophys Res Commun, 
2007. 357(3): p. 603-7. 
 
321 
 
 
 
178. Takeda, E., et al., Vitamin D-dependent rickets type I and type II. Acta Paediatr Jpn, 1997. 
39(4): p. 508-13. 
 
179. Ruppe, M.D., X-Linked Hypophosphatemia, in GeneReviews(R), R.A. Pagon, et al., 
Editors. 1993: Seattle (WA). 
 
180. Sahay, M. and R. Sahay, Renal rickets-practical approach. Indian J Endocrinol Metab, 
2013. 17(Suppl 1): p. S35-44. 
 
181. Haque, S.K., G. Ariceta, and D. Batlle, Proximal renal tubular acidosis: a not so rare 
disorder of multiple etiologies. Nephrol Dial Transplant, 2012. 27(12): p. 4273-87. 
 
182. Batlle, D. and S.K. Haque, Genetic causes and mechanisms of distal renal tubular acidosis. 
Nephrol Dial Transplant, 2012. 27(10): p. 3691-704. 
 
183. Raisz, L.G., et al., 1,25-dihydroxycholecalciferol: a potent stimulator of bone resorption in 
tissue culture. Science, 1972. 175(4023): p. 768-9. 
 
184. Rodriguez, L., et al., Extracellular calcium and parathyroid hormone-related peptide 
signaling modulate the pace of growth plate chondrocyte differentiation. Endocrinology, 
2005. 146(11): p. 4597-608. 
 
185. Lidor, C., et al., Healing of rachitic lesions in chicks by 24R,25-dihydroxycholecalciferol 
administered locally into bone. J Bone Miner Res, 1987. 2(2): p. 91-8. 
 
186. Berry, J.L., et al., Growth plate chondrocyte vitamin D receptor number and affinity are 
reduced in avian tibial dyschondroplastic lesions. Bone, 1996. 19(2): p. 197-203. 
 
187. Nilsson, O., et al., Endocrine regulation of the growth plate. Horm Res, 2005. 64(4): p. 
157-65. 
 
188. Dean, D.D., et al., Effect of 1alpha,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin 
D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo. 
Endocrine, 2001. 14(3): p. 311-23. 
 
189. Lucey, M.R., et al., Osteomalacia--a clinical review of 46 cases. Ir J Med Sci, 1985. 
154(12): p. 449-54. 
 
190. Bhan, A., A.D. Rao, and D.S. Rao, Osteomalacia as a result of vitamin D deficiency. 
Endocrinol Metab Clin North Am, 2010. 39(2): p. 321-31, table of contents. 
 
191. Binkovitz, L.A., P. Sparke, and M.J. Henwood, Pediatric DXA: clinical applications. 
Pediatr Radiol, 2007. 37(7): p. 625-35. 
 
192. Watts, N.B., Clinical utility of biochemical markers of bone remodeling. Clin Chem, 1999. 
45(8 Pt 2): p. 1359-68. 
 
193. Rennie, L.M., et al., Incidental radiological diagnosis of rickets. Emerg Med J, 2005. 22(8): 
p. 534-7. 
 
194. Heaney, R.P., et al., Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin 
Endocrinol Metab, 2011. 96(3): p. E447-52. 
 
195. Holick, M.F., et al., Vitamin D2 is as effective as vitamin D3 in maintaining circulating 
concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab, 2008. 93(3): p. 677-81. 
 
196. Gordon, C.M., et al., Treatment of hypovitaminosis D in infants and toddlers. J Clin 
Endocrinol Metab, 2008. 93(7): p. 2716-21. 
322 
 
 
 
 
197. Gysemans, C.A., et al., 1,25-dihydroxyvitamin D3 modulates expression of chemokines 
and cytokines in pancreatic islets: Implications for prevention of diabetes in nonobese 
diabetic mice. Endocrinology, 2005. 146(4): p. 1956-1964. 
 
198. Cutolo, M., C. Pizzorni, and A. Sulli, Vitamin D endocrine system involvement in 
autoimmune rheumatic diseases. Autoimmunity Reviews, 2011. 11(2): p. 84-87. 
 
199. Scarlett, J.M. and M.W. Schwartz, Gut-brain mechanisms controlling glucose homeostasis. 
F1000Prime Rep, 2015. 7: p. 12. 
 
200. Weiss, R., Childhood metabolic syndrome: must we define it to deal with it? Diabetes 
Care, 2011. 34 Suppl 2: p. S171-6. 
 
201. Zimmet, P., et al., The metabolic syndrome in children and adolescents - an IDF consensus 
report. Pediatr Diabetes, 2007. 8(5): p. 299-306. 
 
202. Samuel, V.T. and G.I. Shulman, Mechanisms for insulin resistance: common threads and 
missing links. Cell, 2012. 148(5): p. 852-71. 
 
203. Bryant, N.J., R. Govers, and D.E. James, Regulated transport of the glucose transporter 
GLUT4. Nat Rev Mol Cell Biol, 2002. 3(4): p. 267-77. 
 
204. Weinstein, S.P., et al., Regulation of GLUT2 glucose transporter expression in liver by 
thyroid hormone: evidence for hormonal regulation of the hepatic glucose transport system. 
Endocrinology, 1994. 135(2): p. 649-54. 
 
205. Csorba, T.R., Proinsulin: biosynthesis, conversion, assay methods and clinical studies. Clin 
Biochem, 1991. 24(6): p. 447-54. 
 
206. Trout, K.K., C. Homko, and N.C. Tkacs, Methods of measuring insulin sensitivity. Biol 
Res Nurs, 2007. 8(4): p. 305-18. 
 
207. Rutter, G.A., Visualising insulin secretion. The Minkowski Lecture 2004. Diabetologia, 
2004. 47(11): p. 1861-72. 
 
208. Saltiel, A.R. and C.R. Kahn, Insulin signalling and the regulation of glucose and lipid 
metabolism. Nature, 2001. 414(6865): p. 799-806. 
 
209. Chang, L., S.H. Chiang, and A.R. Saltiel, Insulin signaling and the regulation of glucose 
transport. Mol Med, 2004. 10(7-12): p. 65-71. 
 
210. Rui, L., Energy metabolism in the liver. Compr Physiol, 2014. 4(1): p. 177-97. 
 
211. Riganti, C., et al., The pentose phosphate pathway: an antioxidant defense and a crossroad 
in tumor cell fate. Free Radic Biol Med, 2012. 53(3): p. 421-36. 
 
212. Draznin, B., Molecular mechanisms of insulin resistance: serine phosphorylation of insulin 
receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. 
Diabetes, 2006. 55(8): p. 2392-7. 
 
213. Turner, N., Mitochondrial Metabolism and Insulin Action, in Type 2 diabetes, P.K. Masuo, 
Editor. 2013, InTech Croatia p. 44. 
 
214. DeFronzo, R.A., J.D. Tobin, and R. Andres, Glucose clamp technique: a method for 
quantifying insulin secretion and resistance. Am J Physiol, 1979. 237(3): p. E214-23. 
215. Arslanian, S.A., Clamp techniques in paediatrics: what have we learned? Horm Res, 2005. 
64 Suppl 3: p. 16-24. 
323 
 
 
 
 
216. Muniyappa, R., et al., Current approaches for assessing insulin sensitivity and resistance in 
vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab, 
2008. 294(1): p. E15-26. 
 
217. Cobelli, C., et al., Assessment of beta-cell function in humans, simultaneously with insulin 
sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol 
Endocrinol Metab, 2007. 293(1): p. E1-E15. 
 
218. Matthews, D.R., et al., Homeostasis model assessment: insulin resistance and beta-cell 
function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 
1985. 28(7): p. 412-9. 
 
219. Conwell, L.S., et al., Indexes of insulin resistance and secretion in obese children and 
adolescents: a validation study. Diabetes Care, 2004. 27(2): p. 314-9. 
 
220. Uwaifo, G.I., et al., Indices of insulin action, disposal, and secretion derived from fasting 
samples and clamps in normal glucose-tolerant black and white children. Diabetes Care, 
2002. 25(11): p. 2081-7. 
 
221. Nguyen, Q.M., et al., Utility of childhood glucose homeostasis variables in predicting adult 
diabetes and related cardiometabolic risk factors: the Bogalusa Heart Study. Diabetes Care, 
2010. 33(3): p. 670-5. 
 
222. Conwell, L.S. and J.A. Batch, Oral glucose tolerance test in children and adolescents: 
positives and pitfalls. J Paediatr Child Health, 2004. 40(11): p. 620-6. 
 
223. Aydin, B. and S.J. Winters, Sex Hormone-Binding Globulin in Children and Adolescents. J 
Clin Res Pediatr Endocrinol, 2016. 8(1): p. 1-12. 
 
224. Li, C., et al., Association of Testosterone and Sex Hormone-Binding Globulin With 
Metabolic Syndrome and Insulin Resistance in Men. Diabetes Care, 2014. 33(7): p. 1618-
1624. 
 
225. Perry, J.R., et al., Genetic evidence that raised sex hormone binding globulin (SHBG) 
levels reduce the risk of type 2 diabetes. Hum Mol Genet, 2010. 19(3): p. 535-44. 
 
226. Schneider LE, Schedl HP, McCain T, Haussler MR. Experimental diabetes reduces 
circulating 1,25-dihydroxyvitamin D in the rat. Science. 1977 Jun 24;196(4297):1452-4 
227. Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin 
D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin 
Pract. 1995 Mar;27(3):181-8. 
228. Behall KM, Scholfield DJ, Hallfrisch JG, Kelsay JL, Reiser S. Seasonal variation in plasma 
glucose and hormone levels in adult men and women. Am J Clin Nutr. 1984 Dec;40(6 
Suppl):1352-6. 
229. Zeitz, U., et al., Impaired insulin secretory capacity in mice lacking a functional vitamin D 
receptor. FASEB J., 2003. 17(3): p. 509-511. 
 
230. Maestro, B., et al., Transcriptional activation of the human insulin receptor gene by 1,25-
dihydroxyvitamin D-3. Cell Biochem  Funct., 2002. 20(3): p. 227-232. 
 
231. Bourlon, P.M., B. Billaudel, and A. Faure-Dussert, Influence of vitamin D-3 deficiency 
and 1,25 dihydroxyvitamin D-3 on de novo insulin biosynthesis in the islets of the rat 
endocrine pancreas. Journal of Endocrinology, 1999. 160(1): p. 87-95. 
 
324 
 
 
 
232. Lee S, Clark SA, Gill RK, Christakos S. 1,25-Dihydroxyvitamin D3 and pancreatic beta-
cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology. 
1994 Apr;134(4):1602-10. 
233. Riachy, R., et al., 1,25-dihydroxyvitamin D-3 protects RINm5F and human islet cells 
against cytokine-induced apoptosis: Implication of the antiapoptotic protein A20. 
Endocrinology, 2002. 143(12): p. 4809-4819. 
 
234. Riachy, R., et al., 1,25-dihydroxyvitamin D-3 protects human pancreatic islets against 
cytokine-induced apoptosis via down-regulation of the fas receptor. Apoptosis, 2006. 
11(2): p. 151-159. 
 
235. Kawashima, H. and A. Castro, Effect of 1 alpha-hydroxyvitamin D3 on the glucose and 
calcium metabolism in genetic obese mice. Res Commun Chem Pathol Pharmacol, 1981. 
33(1): p. 155-61. 
 
236. Zhou, Q.G., et al., 1,25-Dihydroxyvitamin D improved the free fatty-acid-induced insulin 
resistance in cultured C2C12 cells. Diabetes Metab Res Rev., 2008. 24(6): p. 459-464. 
 
237. Maestro, B., et al., Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression 
and insulin responsiveness for glucose transport in U-937 human promonocytic cells. 
Endocr J, 2000. 47(4): p. 383-91. 
 
238. McCarty, M.F., Vitamin D, parathyroid hormone, and insulin sensitivity. American Journal 
of Clinical Nutrition, 2004. 80(5): p. 1451-1452. 
 
239. Sadeghi, K., et al., Vitamin D3 down-regulates monocyte TLR expression and triggers 
hyporesponsiveness to pathogen-associated molecular patterns. Eur J  Immunol., 2006. 
36(2): p. 361-370. 
 
240. Baker, R.G., M.S. Hayden, and S. Ghosh, NF-kappa B, Inflammation, and Metabolic 
Disease. Cell Metab., 2011. 13(1): p. 11-22. 
 
241. Teegarden, D. and S.S. Donkin, Vitamin D: emerging new roles in insulin sensitivity. Nutr 
Res Rev., 2009. 22(1): p. 82-92. 
 
242. Cheng, S., et al., Adiposity, cardiometabolic risk, and vitamin D status: the Framingham 
Heart Study. Diabetes, 2010. 59(1): p. 242-8. 
 
243. Barrera, D., et al., Estradiol and progesterone synthesis in human placenta is stimulated by 
calcitriol. J Steroid Biochem Mol Biol, 2007. 103(3-5): p. 529-32. 
 
244. Maestro, B., et al., Identification of a Vitamin D response element in the human insulin 
receptor gene promoter. J Steroid Biochem Mol Biol. , 2003. 84(2-3): p. 223-230. 
 
245. Bland, R., et al., Expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase in pancreatic 
islets. J Steroid Biochem Mol Biol., 2004. 89-90(1-5): p. 121-125. 
 
246. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits 
pancreatic secretion of insulin. Science. 1980 Aug 15;209(4458):823-5 
 
247. Jeddi, S., et al., The effects of vitamin d on insulin release from isolated islets of rats. Int J 
Endocrinol Metab, 2015. 13(1): p. e20620. 
 
248. Billaudel, B., L. Barakat, and A. Faure-Dussert, Vitamin D-3 deficiency and alterations of 
glucose metabolism in rat endocrine pancreas. Diabetes & Metabolism, 1998. 24(4): p. 
344-350. 
325 
 
 
 
 
249. Riachy, R., et al., Beneficial effect of 1,25 dihydroxyvitamin D-3 on cytokine-treated 
human pancreatic islets. J Endocrinol., 2001. 169(1): p. 161-168. 
 
250. Simpson, R.U., G.A. Thomas, and A.J. Arnold, Identification of 1,25-dihydroxyvitamin D3 
receptors and activities in muscle. J Biol Chem, 1985. 260(15): p. 8882-91 
. 
251. Li, Y., et al., Regulation of insulin secretion and GLUT4 trafficking by the calcium sensor 
synaptotagmin VII. Biochem Biophys Res Commun, 2007. 362(3): p. 658-64. 
 
252. Gray, E., et al., Activation of the extracellular calcium-sensing receptor initiates insulin 
secretion from human islets of Langerhans: involvement of protein kinases. J Endocrinol, 
2006. 190(3): p. 703-10. 
 
253. Beaulieu, C., et al., Calcium is essential in normalizing intolerance to glucose that 
accompanies vitamin D depletion in vivo. Diabetes, 1993. 42(1): p. 35-43. 
 
254. Thomas, D.M., et al., Modulation of glucose transport by parathyroid hormone and insulin 
in UMR 106-01, a clonal rat osteogenic sarcoma cell line. J Mol Endocrinol, 1995. 14(2): 
p. 263-75. 
 
255. Orwoll E, Riddle M, Prince M. Effects of vitamin D on insulin and glucagon secretion in 
non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1994 May;59(5):1083-7. 
256. Boucher, B.J., et al., Glucose-intolerance and impairment of insulin-secretion in relation to 
vitamin-d deficiency in East London Asians. Diabetologia, 1995. 38(10): p. 1239-1245. 
 
257. Baynes, K.C.R., et al., Vitamin D, glucose tolerance and insulinaemia in elderly men. . 
Diabetologia, 1997. 40(3): p. 344-347. 
 
258. Chiu, K.C., et al., Hypovitaminosis D is associated with insulin resistance and beta cell 
dysfunction. Am J Clin Nutr. , 2004. 79(5): p. 820-825. 
 
259. Kamycheva, E., et al., Insulin sensitivity in subjects with secondary hyperparathyroidism 
and the effect of a low serum 25-hydroxyvitamin D level on insulin sensitivity. J  
Endocrinol Investigat., 2007. 30(2): p. 126-132. 
 
260. Scragg, R., M. Sowers, and C. Bell, Serum 25-hydroxyvitamin D, diabetes, and ethnicity in 
the Third National Health and Nutrition Examination Survey. Diabetes Care, 2004. 27(12): 
p. 2813-2818. 
 
261. Forouhi, N.G., et al., Baseline serum 25-hydroxy vitamin D is predictive of future 
glycemic status and insulin resistance - The Medical Research Council Ely Prospective 
Study 1990-2000. Diabetes, 2008. 57(10): p. 2619-2625. 
 
262. Song, Y., et al., Blood 25-Hydroxy Vitamin D Levels and Incident Type 2 Diabetes: A 
meta-analysis of prospective studies. Diabetes care, 2013. 36(5): p. 1422-1428. 
 
263. Reinchr, T., et al., Vitamin D status and parathyroid hormone in obese children before and 
after weight loss. Eur J  Endocrinol., 2007. 157(2): p. 225-232. 
 
264. Poomthavorn, P., et al., Vitamin D status and glucose homeostasis in obese children and 
adolescents living in the tropics. Int J Obes., 2012. 36(4): p. 491-495. 
265. Olson, M.L., et al., Vitamin D deficiency in obese children and its relationship to glucose 
homeostasis. J Clin Endocrinol Metab, 2012. 97(1): p. 279-85. 
 
266. Roth, C.L., et al., Vitamin D deficiency in obese children and its relationship to insulin 
resistance and adipokines. J Obes., 2011. 2011: p. 495101. 
326 
 
 
 
 
267. Nsiah-Kumi, P.A., et al., Vitamin D Insufficiency Is Associated With Diabetes Risk in 
Native American Children. Clin Pediatr (Phila). , 2012. 51(2): p. 146-153. 
 
268. Delvin, E.E., et al., Vitamin D Status Is Modestly Associated with Glycemia and Indicators 
of Lipid Metabolism in French-Canadian Children and Adolescents. J Nutr., 2010. 140(5): 
p. 987-991. 
 
269. Ford, E.S., et al., Associations Between Concentrations of Vitamin D and Concentrations 
of Insulin, Glucose, and HbA(1c) Among Adolescents in the United States. Diabetes Care, 
2011. 34(3): p. 646-648. 
 
270. Kelly, A., et al., A cross-sectional study of vitamin D and insulin resistance in children. 
Arch Dis Child., 2010. 96(5): p. 447-452. 
 
271. Olson, M.L., et al., Vitamin D Deficiency in Obese Children and Its Relationship to 
Glucose Homeostasis. J Clin Endocrino Metab., 2011. 97(1): p. 279-285. 
 
272. Gedik O, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon 
secretion in man. Diabetologia. 1986 Mar;29(3):142-5. 
273. I Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T. Effect of 1 alpha (OH)-vitamin 
D3 on insulin secretion in diabetes mellitus. Bone Miner. 1986 Jun;1(3):187-92 
274. Ljunghall S, Lind L, Lithell H, Skarfors E, Selinus I, Sørensen OH, Wide L. Treatment 
with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose 
tolerance--a prospective randomized double-blind study. Acta Med Scand. 
1987;222(4):361-7. 
275. Nyomba BL, Auwerx J, Bormans V, Peeters TL, Pelemans W, Reynaert J, Bouillon R, 
Vantrappen G, De Moor P. Pancreatic secretion in man with subclinical vitamin D 
deficiency. Diabetologia. 1986 Jan;29(1):34-8. 
276. Zofková I, Stolba P. Effect of calcitriol and trifluoperazine on glucose stimulated B cell 
function in healthy humans. Exp Clin Endocrinol. 1990 Nov;96(2):185-91. 
277. Grimnes, G., et al., Vitamin D, Insulin Secretion, Sensitivity, and Lipids Results From a 
Case-Control Study and a Randomized Controlled Trial Using Hyperglycemic Clamp 
Technique. Diabetes, 2011. 60(11): p. 2748-2757. 
 
278. Tai, K., et al., Glucose tolerance and vitamin D: Effects of treating vitamin D deficiency. 
Nutrition, 2008. 24(10): p. 950-956. 
 
279. von Hurst, P.R., W. Stonehouse, and J. Coad, Vitamin D supplementation reduces insulin 
resistance in South Asian women living in New Zealand who are insulin resistant and 
vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr, 2010. 103(4): p. 
549-55. 
 
280. Mitri, J., et al., Effects of vitamin D and calcium supplementation on pancreatic beta cell 
function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium 
and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin 
Nutr., 2011. 94(2): p. 486-494. 
281. Krul-Poel, Y.H., et al., Effect of Vitamin D Supplementation on Glycemic Control in 
Patients With Type 2 Diabetes (SUNNY Trial): A Randomized Placebo-Controlled Trial. 
Diabetes Care, 2015. 38(8): p. 1420-6. 
 
282. Belenchia, A.M., et al., Correcting vitamin D insufficiency improves insulin sensitivity in 
obese adolescents: a randomized controlled trial. Am J Clin Nutr., 2013. 97(4): p. 774-781. 
 
327 
 
 
 
283. Kelishadi, R., et al., Effects of vitamin D supplementation on insulin resistance and 
cardiometabolic risk factors in children with metabolic syndrome: a triple-masked 
controlled trial. J Pediatr (Rio J), 2014. 90(1): p. 28-34. 
 
284. Murphy, K., P. Travers, and M. Walport, Janeway's immunobiology. Seventh Edition ed. 
2008, USA: Garland Science. 928. 
 
285. Parker, D. and A. Prince, Innate immunity in the respiratory epithelium. Am J Respir Cell 
Mol Biol, 2011. 45(2): p. 189-201. 
 
286. Takeuchi, O. and S. Akira, Pattern recognition receptors and inflammation. Cell, 2010. 
140(6): p. 805-20. 
 
287. Iwasaki, A. and R. Medzhitov, Control of adaptive immunity by the innate immune system. 
Nat Immunol, 2015. 16(4): p. 343-53. 
 
288. Birchler, T., et al., Human Toll-like receptor 2 mediates induction of the antimicrobial 
peptide human beta-defensin 2 in response to bacterial lipoprotein. European Journal of 
Immunology, 2001. 31(11): p. 3131-3137. 
 
289. Jones, B.W., et al., Differential roles of Toll-like receptors in the elicitation of 
proinflammatory responses by macrophages. Annals of the Rheumatic Diseases, 2001. 60: 
p. III6-III12. 
 
290. Koyasu, S. and K. Moro, Type 2 innate immune responses and the natural helper cell. 
Immunology, 2011. 132(4): p. 475-81. 
 
291. Nutt, S.L., et al., The generation of antibody-secreting plasma cells. Nat Rev Immunol, 
2015. 15(3): p. 160-71. 
 
292. Mills, D.M. and J.C. Cambier, B lymphocyte activation during cognate interactions with 
CD4+ T lymphocytes: molecular dynamics and immunologic consequences. Semin 
Immunol, 2003. 15(6): p. 325-9. 
 
293. Nelms, K., et al., The IL-4 receptor: signaling mechanisms and biologic functions. Annu 
Rev Immunol, 1999. 17: p. 701-38. 
 
294. Zhu, J., H. Yamane, and W.E. Paul, Differentiation of effector CD4 T cell populations (*). 
Annu Rev Immunol, 2010. 28: p. 445-89. 
 
295. Luckheeram, R.V., et al., CD4(+)T cells: differentiation and functions. Clin Dev Immunol, 
2012. 2012: p. 925135. 
 
296. Sad, S. and T.R. Mosmann, Single IL-2-secreting precursor CD4 T cell can develop into 
either Th1 or Th2 cytokine secretion phenotype. J Immunol, 1994. 153(8): p. 3514-22. 
 
297. Wurster, A.L., T. Tanaka, and M.J. Grusby, The biology of Stat4 and Stat6. Oncogene, 
2000. 19(21): p. 2577-84. 
 
298. Szabo, S.J., et al., A novel transcription factor, T-bet, directs Th1 lineage commitment. 
Cell, 2000. 100(6): p. 655-69. 
299. Lee, H.J., et al., GATA-3 induces T helper cell type 2 (Th2) cytokine expression and 
chromatin remodeling in committed Th1 cells. J Exp Med, 2000. 192(1): p. 105-15. 
 
300. Dorfman, D.M., et al., Differential expression of T-bet, a T-box transcription factor 
required for Th1 T-cell development, in peripheral T-cell lymphomas. Am J Clin Pathol, 
2003. 120(6): p. 866-73. 
 
328 
 
 
 
301. Li, Z., Y. Zhang, and B. Sun, Current understanding of Th2 cell differentiation and 
function. Protein Cell, 2011. 2(8): p. 604-11. 
 
302. Abbas, A.K., K.M. Murphy, and A. Sher, Functional diversity of helper T lymphocytes. 
Nature, 1996. 383(6603): p. 787-793. 
 
303. Boonstra, A., et al., 1 alpha,25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T 
cells to enhance the development of Th2 cells. Journal of Immunology, 2001. 167(9): p. 
4974-4980. 
 
304. Chapoval, S., et al., Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) 
balance by IL-4 and STAT6. J Leukoc Biol, 2010. 87(6): p. 1011-8. 
 
305. Olsen, T., et al., TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory 
bowel disease, and their potential to mediate the inflammation. Cytokine, 2011. 56(3): p. 
633-40. 
 
306. Finotto, S., et al., Development of spontaneous airway changes consistent with human 
asthma in mice lacking T-bet. Science, 2002. 295(5553): p. 336-8. 
 
307. Neurath, M.F., et al., The transcription factor T-bet regulates mucosal T cell activation in 
experimental colitis and Crohn's disease. J Exp Med, 2002. 195(9): p. 1129-43. 
 
308. Harrington, L.E., et al., Interleukin 17-producing CD4+ effector T cells develop via a 
lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 2005. 6(11): p. 
1123-32. 
 
309. Korn, T., et al., IL-17 and Th17 Cells. Annu Rev Immunol, 2009. 27: p. 485-517. 
 
310. Yang, X.O., et al., T helper 17 lineage differentiation is programmed by orphan nuclear 
receptors ROR alpha and ROR gamma. Immunity, 2008. 28(1): p. 29-39. 
 
311. Durant, L., et al., Diverse targets of the transcription factor STAT3 contribute to T cell 
pathogenicity and homeostasis. Immunity, 2010. 32(5): p. 605-15. 
 
312. Fossiez, F., et al., T cell interleukin-17 induces stromal cells to produce proinflammatory 
and hematopoietic cytokines. J Exp Med, 1996. 183(6): p. 2593-603. 
 
313. Ye, P., et al., Requirement of interleukin 17 receptor signaling for lung CXC chemokine 
and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host 
defense. J Exp Med, 2001. 194(4): p. 519-27. 
 
314. Pelletier, M., et al., Evidence for a cross-talk between human neutrophils and Th17 cells. 
Blood, 2010. 115(2): p. 335-43. 
 
315. Liang, S.C., et al., Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and 
cooperatively enhance expression of antimicrobial peptides. J Exp Med, 2006. 203(10): p. 
2271-9. 
 
316. Kebir, H., et al., Preferential recruitment of interferon-gamma-expressing TH17 cells in 
multiple sclerosis. Ann Neurol, 2009. 66(3): p. 390-402. 
317. Lee, Y.K., et al., Late developmental plasticity in the T helper 17 lineage. Immunity, 2009. 
30(1): p. 92-107. 
 
318. Rizzo, A., et al., Smad7 induces plasticity in tumor-infiltrating Th17 cells and enables 
TNF-alpha-mediated killing of colorectal cancer cells. Carcinogenesis, 2014. 35(7): p. 
1536-46. 
 
329 
 
 
 
319. Cosmi, L., et al., Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ 
T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum, 
2011. 63(8): p. 2504-15. 
 
320. Wing, J.B. and S. Sakaguchi, Foxp3(+) T(reg) cells in humoral immunity. Int Immunol, 
2014. 26(2): p. 61-9. 
 
321. Sakaguchi, S., Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in 
immunological tolerance to self and non-self. Nat Immunol, 2005. 6(4): p. 345-52. 
 
322. Curotto de Lafaille, M.A. and J.J. Lafaille, Natural and adaptive foxp3+ regulatory T cells: 
more of the same or a division of labor? Immunity, 2009. 30(5): p. 626-35. 
 
323. Hori, S., T. Nomura, and S. Sakaguchi, Control of regulatory T cell development by the 
transcription factor Foxp3. Science, 2003. 299(5609): p. 1057-61. 
 
324. Piccirillo, C.A., Regulatory T cells in health and disease. Cytokine, 2008. 43(3): p. 395-
401. 
 
325. Venken, K., et al., Compromised CD4+ CD25(high) regulatory T-cell function in patients 
with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of 
FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology, 
2008. 123(1): p. 79-89. 
 
326. Apostolou, I., et al., Origin of regulatory T cells with known specificity for antigen. Nat 
Immunol, 2002. 3(8): p. 756-63. 
 
327. Akbar, A.N., et al., The peripheral generation of CD4+ CD25+ regulatory T cells. 
Immunology, 2003. 109(3): p. 319-25. 
 
328. Roncarolo, M.G., et al., Interleukin-10-secreting type 1 regulatory T cells in rodents and 
humans. Immunol Rev, 2006. 212: p. 28-50. 
 
329. Asseman, C., et al., An essential role for interleukin 10 in the function of regulatory T cells 
that inhibit intestinal inflammation. J Exp Med, 1999. 190(7): p. 995-1004. 
 
330. Martinez-Forero, I., et al., IL-10 suppressor activity and ex vivo Tr1 cell function are 
impaired in multiple sclerosis. Eur J Immunol, 2008. 38(2): p. 576-86. 
 
331. Chen, W., et al., Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ 
regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 2003. 
198(12): p. 1875-86. 
 
332. Ohkura, N., et al., T cell receptor stimulation-induced epigenetic changes and Foxp3 
expression are independent and complementary events required for Treg cell development. 
Immunity, 2012. 37(5): p. 785-99. 
 
333. Sakaguchi, S., et al., Immunologic self-tolerance maintained by activated T cells 
expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-
tolerance causes various autoimmune diseases. J Immunol, 1995. 155(3): p. 1151-64. 
334. Ohkura, N., Y. Kitagawa, and S. Sakaguchi, Development and maintenance of regulatory T 
cells. Immunity, 2013. 38(3): p. 414-23. 
 
335. Wei, S., I. Kryczek, and W. Zou, Regulatory T-cell compartmentalization and trafficking. 
Blood, 2006. 108(2): p. 426-31. 
 
336. Allakhverdi, Z., et al., Expression of CD103 identifies human regulatory T-cell subsets. J 
Allergy Clin Immunol, 2006. 118(6): p. 1342-9. 
330 
 
 
 
 
337. Kleinewietfeld, M., et al., CCR6 expression defines regulatory effector/memory-like cells 
within the CD25(+)CD4+ T-cell subset. Blood, 2005. 105(7): p. 2877-86. 
 
338. Schneider, M.A., et al., CCR7 is required for the in vivo function of CD4+ CD25+ 
regulatory T cells. J Exp Med, 2007. 204(4): p. 735-45. 
 
339. Law, J.P., et al., The importance of Foxp3 antibody and fixation/permeabilization buffer 
combinations in identifying CD4+CD25+Foxp3+ regulatory T cells. Cytometry A, 2009. 
75(12): p. 1040-50. 
 
340. Chen, X. and J.J. Oppenheim, Resolving the identity myth: key markers of functional 
CD4+FoxP3+ regulatory T cells. Int Immunopharmacol, 2011. 11(10): p. 1489-96. 
 
341. Duggleby, R.C., et al., CD27 expression discriminates between regulatory and non-
regulatory cells after expansion of human peripheral blood CD4+ CD25+ cells. 
Immunology, 2007. 121(1): p. 129-39. 
 
342. Kraczyk, B., R. Remus, and C. Hardt, CD49d Treg cells with high suppressive capacity are 
remarkably less efficient on activated CD45RA- than on naive CD45RA+ Teff cells. Cell 
Physiol Biochem, 2014. 34(2): p. 346-55. 
 
343. Modeling immunity to enteric pathogens (MIEP). Schematic representation of the 
cytokines and transcription factors controlling CD4+ T cell differentiation Model 2014 
(image) [viewed 2016 12 August]; Available from: http://miepdev.vbi.vt.edu/models/cd4-t-
cell-model-archive/. 
  
344. Gaffen, S.L. and K.D. Liu, Overview of interleukin-2 function, production and clinical 
applications. Cytokine, 2004. 28(3): p. 109-23. 
 
345. Wang, Y. and H. Thorlacius, Mast cell-derived tumour necrosis factor-alpha mediates 
macrophage inflammatory protein-2-induced recruitment of neutrophils in mice. Br J 
Pharmacol, 2005. 145(8): p. 1062-8. 
 
346. Reefman, E., et al., Cytokine secretion is distinct from secretion of cytotoxic granules in 
NK cells. J Immunol, 2010. 184(9): p. 4852-62. 
 
347. Balkwill, F., TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev, 
2006. 25(3): p. 409-16. 
 
348. Peng, S.L., S.J. Szabo, and L.H. Glimcher, T-bet regulates IgG class switching and 
pathogenic autoantibody production. Proc Natl Acad Sci U S A, 2002. 99(8): p. 5545-50. 
 
349. Agrati, C., et al., Interferon-gamma-mediated antiviral immunity against orthopoxvirus 
infection is provided by gamma delta T cells. J Infect Dis, 2006. 193(11): p. 1606-7; author 
reply 1607-8. 
 
350. Luzina, I.G., et al., Regulation of inflammation by interleukin-4: a review of "alternatives". 
J Leukoc Biol, 2012. 92(4): p. 753-64. 
 
351. Marcenaro, E., et al., IL-12 or IL-4 prime human NK cells to mediate functionally 
divergent interactions with dendritic cells or tumors. J Immunol, 2005. 174(7): p. 3992-8. 
352. Kouro, T. and K. Takatsu, IL-5- and eosinophil-mediated inflammation: from discovery to 
therapy. Int Immunol, 2009. 21(12): p. 1303-9. 
 
353. Scheller, J., et al., The pro- and anti-inflammatory properties of the cytokine interleukin-6. 
Biochim Biophys Acta, 2011. 1813(5): p. 878-88. 
 
331 
 
 
 
354. Trinchieri, G., Cytokines acting on or secreted by macrophages during intracellular 
infection (IL-10, IL-12, IFN-gamma). Curr Opin Immunol, 1997. 9(1): p. 17-23. 
 
355. Couper, K.N., D.G. Blount, and E.M. Riley, IL-10: the master regulator of immunity to 
infection. J Immunol, 2008. 180(9): p. 5771-7. 
 
356. Iwakura, Y., et al., The roles of IL-17A in inflammatory immune responses and host 
defense against pathogens. Immunol Rev, 2008. 226: p. 57-79. 
 
357. Jin, W. and C. Dong, IL-17 cytokines in immunity and inflammation. Emerg Microbes 
Infect, 2013. 2(9): p. e60. 
 
358. Taub, D.D., et al., The effects of human recombinant MIP-1 alpha, MIP-1 beta, and 
RANTES on the chemotaxis and adhesion of T cell subsets. Adv Exp Med Biol, 1993. 351: 
p. 139-46. 
 
359. Bonecchi, R., et al., Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC 
chemokines by IFN-gamma in human neutrophils. J Immunol, 1999. 162(1): p. 474-9. 
 
360. Gu, L., et al., Control of TH2 polarization by the chemokine monocyte chemoattractant 
protein-1. Nature, 2000. 404(6776): p. 407-11. 
 
361. Liu, M., et al., CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic 
implications. Cytokine Growth Factor Rev, 2011. 22(3): p. 121-30. 
 
362. Heath, H., et al., Chemokine receptor usage by human eosinophils. The importance of 
CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest, 1997. 99(2): 
p. 178-84. 
 
363. Yamada, H., et al., Eotaxin is a potent chemotaxin for human basophils. Biochem Biophys 
Res Commun, 1997. 231(2): p. 365-8. 
 
364. Sallusto, F., C.R. Mackay, and A. Lanzavecchia, Selective expression of the eotaxin 
receptor CCR3 by human T helper 2 cells. Science, 1997. 277(5334): p. 2005-7. 
 
365. Miyamasu, M., et al., Th1-derived cytokine IFN-gamma is a potent inhibitor of eotaxin 
synthesis in vitro. Int Immunol, 1999. 11(6): p. 1001-4. 
 
366. Baggiolini, M., A. Walz, and S.L. Kunkel, Neutrophil-activating peptide-1/interleukin 8, a 
novel cytokine that activates neutrophils. J Clin Invest, 1989. 84(4): p. 1045-9. 
 
367. Osawa, Y., et al., Tumor necrosis factor alpha-induced interleukin-8 production via NF-
kappaB and phosphatidylinositol 3-kinase/Akt pathways inhibits cell apoptosis in human 
hepatocytes. Infect Immun, 2002. 70(11): p. 6294-301. 
 
368. Magram, J., et al., IL-12-deficient mice are defective in IFN gamma production and type 1 
cytokine responses. Immunity, 1996. 4(5): p. 471-81. 
 
369. Chan, T.Y.K., Vitamin D deficiency and susceptibility to tuberculosis. Calcified Tissue 
International, 2000. 66(6): p. 476-478. 
 
370. Mangelsdorf DJ, Koeffler HP, Donaldson CA, Pike JW, Haussler MR. 1,25-
Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line 
(HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol. 1984 
Feb;98(2):391-398. 
332 
 
 
 
371. Abe E, Miyaura C, Sakagami H, Takeda M, Konno K, Yamazaki T, Yoshiki S, SudaT. 
Differentiation of mouse myeloid leukemia cells induced by 1alpha,25-dihydroxyvitamin 
D3. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4990-4994. 
372. Dam, T.N., et al., The vitamin D3 analog calcipotriol suppresses the number and antigen-
presenting function of Langerhans cells in normal human skin. The journal of investigative 
dermatology. Symposium proceedings / the Society for Investigative Dermatology, Inc. 
[and] European Society for Dermatological Research, 1996. 1(1): p. 72-7. 
 
373. White, J.H., Vitamin D metabolism and signaling in the immune system. Reviews in 
Endocrine & Metabolic Disorders, 2012. 13(1): p. 21-29. 
 
374. Hewison, M., et al., Differential regulation of vitamin D receptor and its ligand in human 
monocyte-derived dendritic cells. Journal of Immunology, 2003. 170(11): p. 5382-5390. 
 
375. Liu, P.T., et al., Convergence of IL-1 beta and VDR Activation Pathways in Human 
TLR2/1-Induced Antimicrobial Responses. Plos One, 2009. 4(6). 
 
376. Tiosano, D., et al., The Role of Vitamin D Receptor in Innate and Adaptive Immunity: A 
Study in Hereditary Vitamin D-Resistant Rickets Patients. Journal of Clinical 
Endocrinology & Metabolism, 2013. 98(4): p. 1685-1693. 
 
377. Kong, J., et al., Novel role of the vitamin D receptor in maintaining the integrity of the 
intestinal mucosal barrier. American Journal of Physiology-Gastrointestinal and Liver 
Physiology, 2008. 294(1): p. G208-G216. 
 
378. Yin, Z., et al., Vitamin D Enhances Corneal Epithelial Barrier Function. Investigative 
Ophthalmology & Visual Science, 2011. 52(10): p. 7359-7364. 
 
379. Clairmont, A., et al., Induction of gap junctional intercellular communication by vitamin D 
in human skin fibroblasts is dependent on the nuclear vitamin D receptor. Carcinogenesis, 
1996. 17(6): p. 1389-1391. 
 
380. Gniadecki, R., B. Gajkowska, and M. Hansen, 1,25-dihydroxyvitamin D3 stimulates the 
assembly of adherens junctions in keratinocytes: involvement of protein kinase C. 
Endocrinology, 1997. 138(6): p. 2241-8. 
 
381. Palmer, H.G., et al., Vitamin D-3 promotes the differentiation of colon carcinoma cells by 
the induction of E-cadherin and the inhibition of beta-catenin signaling. Journal of Cell 
Biology, 2001. 154(2): p. 369-387. 
 
382. Hewison, M., Vitamin D and innate immunity. Current Opinion in Investigational Drugs, 
2008. 9(5): p. 485-490. 
 
383. Yim, S., et al., Induction of cathelicidin in normal and CF bronchial epithelial cells by 
1,25-dihydroxyvitamin D-3. Journal of Cystic Fibrosis, 2007. 6(6): p. 403-410. 
 
384. Hertting, O., et al., Vitamin D Induction of the Human Antimicrobial Peptide Cathelicidin 
in the Urinary Bladder. Plos One, 2010. 5(12). 
 
385. Weber, G., et al., Vitamin D induces the antimicrobial protein hCAP18 in human skin. 
Journal of Investigative Dermatology, 2005. 124(5): p. 1080-1082. 
386. Gombart, A.F., N. Borregaard, and H.P. Koeffler, Human cathelicidin antimicrobial 
peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-
regulated in myeloid cells by 1,25-dihydroxyvitamin D-3. Faseb Journal, 2005. 19(9): p. 
1067-1077. 
 
333 
 
 
 
387. Liu, P.T., et al., Toll-like receptor triggering of a vitamin D-mediated human antimicrobial 
response. Science, 2006. 311(5768): p. 1770-1773. 
 
388. Aung, G., et al., Catestatin, a neuroendocrine antimicrobial peptide, induces human mast 
cell migration, degranulation and production of cytokines and chemokines. Immunology, 
2011. 132(4): p. 527-539. 
 
389. Chertov, O., et al., Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell 
chemoattractant proteins released from interleukin-8-stimulated neutrophils. Journal of 
Biological Chemistry, 1996. 271(6): p. 2935-2940. 
 
390. Zughaier, S.M., W.M. Shafer, and D.S. Stephens, Antimicrobial peptides and endotoxin 
inhibit cytokine and nitric oxide release but amplify respiratory burst response in human 
and murine macrophages. Cellular Microbiology, 2005. 7(9): p. 1251-1262. 
 
391. Lai, Y., et al., The Antimicrobial Protein REG3A Regulates Keratinocyte Proliferation and 
Differentiation after Skin Injury. Immunity, 2012. 37(1): p. 74-84. 
 
392. Zhang, J.-Z., et al., Production and secretion of platelet-derived growth factor AB by 
cultured human keratinocytes: Regulatory effects of phorbol 12-myristate 13-acetate, 
etretinate, 1,25-dihydroxyvitamin D-3, and several cytokines. Journal of Dermatology 
(Tokyo), 1995. 22(5): p. 305-309. 
 
393. Chandra, G., et al., Effect of vitamin D-3 on phagocytic potential of macrophages with live 
Mycobacterium tuberculosis and lymphoproliferative response in pulmonary tuberculosis. 
Journal of Clinical Immunology, 2004. 24(3): p. 249-257. 
 
394. Tanaka, H., et al., Human monocyte-derived dendritic cells induce naive T cell 
differentiation into T helper cell type 2 (Th2) or Th1/Th2 effectors. Role of 
stimulator/responder ratio. J Exp Med, 2000. 192(3): p. 405-12. 
 
395. Kuwana, M., Induction of anergic and regulatory T cells by plasmacytoid dendritic cells 
and other dendritic cell subsets. Hum Immunol, 2002. 63(12): p. 1156-63. 
 
396. Adorini, L. and G. Penna, Induction of tolerogenic dendritic cells by vitamin D receptor 
agonists. Handbook of experimental pharmacology, 2009(188): p. 251-73. 
 
397. Ferreira, G.B., et al., 1,25-Dihydroxyvitamin D-3 alters murine dendritic cell behaviour in 
vitro and in vivo. Diabetes-Metabolism Research and Reviews, 2011. 27(8): p. 933-941. 
 
398. Penna, G. and L. Adorini, 1 alpha,25-dihydroxyvitamin D-3 inhibits differentiation, 
maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell 
activation. Journal of Immunology, 2000. 164(5): p. 2405-2411. 
 
399. D'Ambrosio, D., et al., Inhibition of IL-12 production by 1,25-dihydroxyvitamin D-3 - 
Involvement of NF-kappa B downregulation in transcriptional repression of the p40 gene. 
Journal of Clinical Investigation, 1998. 101(1): p. 252-262. 
 
400. Hewison, M., et al., Vitamin D and barrier function: a novel role for extra-renal 1 alpha-
hydroxylase. Molecular and Cellular Endocrinology, 2004. 215(1-2): p. 31-38. 
 
401. Provvedini, D.M., et al., 1,25-dihydroxyvitamin D3 receptors in human leukocytes. 
Science, 1983. 221(4616): p. 1181-3. 
 
402. Baeke, F., et al., The Vitamin D Analog, TX527, Promotes a Human 
CD4(+)CD25(high)CD127(low) Regulatory T Cell Profile and Induces a Migratory 
Signature Specific for Homing to Sites of Inflammation. Journal of Immunology, 2011. 
186(1): p. 132-142. 
334 
 
 
 
 
403. Prietl, B., et al., Vitamin D Supplementation and Regulatory T Cells in Apparently Healthy 
Subjects: Vitamin D Treatment for Autoimmune Diseases? Israel Medical Association 
Journal, 2010. 12(3): p. 136-139. 
 
404. Mahon, B.D., et al., Cytokine profile in patients with multiple sclerosis following vitamin 
D supplementation. Journal of Neuroimmunology, 2003. 134(1-2): p. 128-132. 
 
405. Staeva-Vieira, T.P. and L.P. Freedman, 1,25-dihydroxyvitamin D-3 inhibits IFN-gamma 
and IL-4 levels during in vitro polarization of primary murine CD4(+) T cells. Journal of 
Immunology, 2002. 168(3): p. 1181-1189. 
 
406. Higashimoto, Y., et al., 1 alpha,25-dihydroxyvitamin D3 and all-trans-retinoic acid inhibit 
the growth of a lung cancer cell line. Anticancer Research, 1996. 16(5A): p. 2653-2659. 
 
407. Chang, S.H., Y. Chung, and C. Dong, Vitamin D Suppresses Th17 Cytokine Production by 
Inducing C/EBP Homologous Protein (CHOP) Expression. Journal of Biological 
Chemistry, 2010. 285(50): p. 38751-38755. 
 
408. Cantorna, M.T., J. Zhao, and L. Yang, Symposium 3: Vitamin D and immune function: 
from pregnancy to adolescence Vitamin D, invariant natural killer T-cells and experimental 
autoimmune disease. Proceedings of the Nutrition Society, 2012. 71(1): p. 62-66. 
 
409. Camargo, C.A., Jr., et al., Cord-Blood 25-Hydroxyvitamin D Levels and Risk of 
Respiratory Infection, Wheezing, and Asthma. Pediatrics, 2011. 127(1): p. E180-E187. 
 
410. Chen, S., et al., Modulatory effects of 1,25-dihydroxyvitamin D-3 on human B cell 
differentiation. Journal of Immunology, 2007. 179(3): p. 1634-1647. 
 
411. Muhe, L., et al., Case-control study of the role of nutritional rickets in the risk of 
developing pneumonia in Ethiopian children. Lancet, 1997. 349(9068): p. 1801-1804. 
 
412. Laaksi, I., et al., An association of serum vitamin D concentrations < 40 nmol/L with acute 
respiratory tract infection in young Finnish men. American Journal of Clinical Nutrition, 
2007. 86(3): p. 714-717. 
 
413. Gibney, K.B., et al., Vitamin D deficiency is associated with tuberculosis and latent 
tuberculosis infection in immigrants from Sub-Saharan Africa. Clinical Infectious 
Diseases, 2008. 46(3): p. 443-446. 
 
414. McDermott, A.M., The Role of Antimicrobial Peptides at the Ocular Surface. Ophthalmic 
Research, 2009. 41(2): p. 60-75. 
 
415. Kaur, I., A. Saraswat, and B. Kumar, Comparison of calcipotriol and coal tar in 
conjunction with sun exposure in chronic plaque psoriasis: A pilot study. Journal of 
Dermatology, 2001. 28(8): p. 448-450. 
 
416. Howell, M.D., et al., Selective killing of vaccinia virus by LL-37: Implications for eczema 
vaccinatum. Journal of Immunology, 2004. 172(3): p. 1763-1767. 
 
417. Asgari, M.M., et al., Association of Prediagnostic Serum Vitamin D Levels with the 
Development of Basal Cell Carcinoma. Journal of Investigative Dermatology, 2010. 
130(5): p. 1438-1443. 
 
418. Cantorna, M.T. and B.D. Mahon, Mounting evidence for vitamin D as an environmental 
factor affecting autoimmune disease prevalence. Experimental Biology and Medicine, 
2004. 229(11): p. 1136-1142. 
 
335 
 
 
 
419. Munger, K.L., et al., Vitamin D intake and incidence of multiple sclerosis. Neurology, 
2004. 62(1): p. 60-5. 
 
420. Kamen, D.L., et al., Vitamin D deficiency in systemic lupus erythematosus. Autoimmun 
Rev, 2006. 5(2): p. 114-7. 
 
421. Stene, L.C., G. Joner, and G. Norwegian Childhood Diabetes Study, Use of cod liver oil 
during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: 
a large, population-based, case-control study. Am J Clin Nutr, 2003. 78(6): p. 1128-34. 
 
422. Bergman, P., et al., Vitamin D3 supplementation in patients with frequent respiratory tract 
infections: a randomised and double-blind intervention study. BMJ open, 2012. 2(6). 
 
423. Murdoch, D.R., et al., Effect of Vitamin D-3 Supplementation on Upper Respiratory Tract 
Infections in Healthy Adults The VIDARIS Randomized Controlled Trial. Jama-Journal of 
the American Medical Association, 2012. 308(13): p. 1333-1339. 
 
424. Avenell, A., et al., Vitamin D supplementation to prevent infections: a sub-study of a 
randomised placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). 
Age Ageing, 2007. 36(5): p. 574-7. 
 
425. Salahuddin, N., et al., Vitamin D accelerates clinical recovery from tuberculosis: results of 
the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A 
randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with 
pulmonary tuberculosis'. Bmc Infectious Diseases, 2013. 13. 
 
426. Wejse, C., et al., Vitamin D as Supplementary Treatment for Tuberculosis A Double-blind, 
Randomized, Placebo-controlled Trial. American Journal of Respiratory and Critical Care 
Medicine, 2009. 179(9): p. 843-850. 
 
427. Pozuelo-Moyano, B., et al., A Systematic Review of Randomized, Double-Blind, Placebo-
Controlled Trials Examining the Clinical Efficacy of Vitamin D in Multiple Sclerosis. 
Neuroepidemiology, 2013. 40(3): p. 147-153. 
 
428. Urashima, M., et al., Randomized trial of vitamin D supplementation to prevent seasonal 
influenza A in schoolchildren. American Journal of Clinical Nutrition, 2010. 91(5): p. 
1255-1260. 
 
429. Camargo, C.A., Jr., et al., Randomized Trial of Vitamin D Supplementation and Risk of 
Acute Respiratory Infection in Mongolia. Pediatrics, 2012. 130(3): p. E561-E567. 
 
430. Manaseki-Holland, S., et al., Effect on the incidence of pneumonia of vitamin D 
supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled 
superiority trial. Lancet, 2012. 379(9824): p. 1419-1427. 
 
431. Hayes, C.E., et al., Vitamin D Actions on CD4(+) T Cells in Autoimmune Disease. Front 
Immunol, 2015. 6: p. 100. 
 
432. Schleithoff, S.S., et al., Vitamin D supplementation improves cytokine profiles in patients 
with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J 
Clin Nutr, 2006. 83(4): p. 754-9. 
 
433. Khoo, A.L., et al., High-dose vitamin D3 supplementation is a requisite for modulation of 
skin-homing markers on regulatory T cells in HIV-infected patients. AIDS Res Hum 
Retroviruses, 2013. 29(2): p. 299-306. 
 
336 
 
 
 
434. Di Filippo, P., et al., Vitamin D Supplementation Modulates the Immune System and 
Improves Atopic Dermatitis in Children. International Archives of Allergy and 
Immunology, 2015. 166(2): p. 91-96. 
 
435. Yusupov, E., et al., Vitamin d and serum cytokines in a randomized clinical trial. Int J 
Endocrinol, 2010. 2010. 
 
436. Wright, T.B., et al., Hypovitaminosis D is Associated with Greater Body Mass Index and 
Disease Activity in Pediatric Systemic Lupus Erythematosus. Journal of Pediatrics, 2009. 
155(2): p. 260-265. 
 
437. Peroni, D.G., et al., Correlation between serum 25-hydroxyvitamin D levels and severity of 
atopic dermatitis in children. British Journal of Dermatology, 2011. 164(5): p. 1078-1082. 
 
438. Greer, R.M., et al., Serum vitamin D levels are lower in Australian children and 
adolescents with type 1 diabetes than in children without diabetes. Pediatric Diabetes, 
2013. 14(1): p. 31-41. 
 
439. Allen, K.J., et al., Vitamin D insufficiency is associated with challenge-proven food allergy 
in infants. Journal of Allergy and Clinical Immunology, 2013. 131(4): p. 1109-+. 
 
440. Das, M., et al., Effect of vitamin D supplementation on cathelicidin, IFN-gamma, IL-4 and 
Th1/Th2 transcription factors in young healthy females. Eur J Clin Nutr, 2014. 68(3): p. 
338-43. 
 
441. Bischoff-Ferrari, H.A., Optimal serum 25-hydroxyvitamin D levels for multiple health 
outcomes. Adv Exp Med Biol, 2008. 624: p. 55-71. 
 
442. Nowson, C.A., et al., Vitamin D and health in adults in Australia and New Zealand: a 
position statement. Med J Aust, 2012. 196(11): p. 686-7. 
 
443. Verity, C. and M. Preece, Surveillance for rare disorders by the BPSU. The British 
Paediatric Surveillance Unit. Arch Dis Child, 2002. 87(4): p. 269-71. 
 
444. Preece, M.A., et al., Vitamin-D Deficiency among Asian Immigrants to Britain. Lancet, 
1973. 1(7809): p. 907-910. 
 
445. Williamson, S. and S. Greene, Rickets: Prevention message is not getting through. BMJ, 
2007. 334(7607): p. 1288. 
 
446. Davies, J.H., et al., Epidemiology of vitamin D deficiency in children presenting to a 
pediatric orthopaedic service in the UK. J Pediatr Orthop, 2011. 31(7): p. 798-802. 
 
447. Gupta, K. and J.T. Warner, Inappropriate and inconsistent modalities of treatment of 
vitamin D deficiency in children. Arch Dis Child, 2011. 96(8): p. 787. 
 
448. Cole, T.J., J.V. Freeman, and M.A. Preece, Body mass index reference curves for the UK, 
1990. Arch Dis Child, 1995. 73(1): p. 25-9. 
 
449. Freeman, J.V., et al., Cross sectional stature and weight reference curves for the UK, 1990. 
Arch Dis Child, 1995. 73(1): p. 17-24. 
 
450. Gov.UK[Internet].UK. Department of Health. Diet and Nutrition Survey of Infants and 
Young Children, 2011; [cited 2016 4 March]. Available 
fromhttps://www.gov.uk/government/uploads/system/uploads/attachment_data/file/139572
/DNSIYC_UK_report_ALL_chapters_DH_V10.0.pdf. 
 
337 
 
 
 
451. Holick, M.F., Resurrection of vitamin D deficiency and rickets. J Clin Invest, 2006. 116(8): 
p. 2062-72. 
 
452. Suda, T., et al., Vitamin D and bone. J Cell Biochem, 2003. 88(2): p. 259-66. 
 
453. Ginty, F., et al., Effects of usual nutrient intake and vitamin D status on markers of bone 
turnover in Swiss adolescents. Eur J Clin Nutr, 2004. 58(9): p. 1257-65. 
 
454. Foo, L.H., et al., Low vitamin D status has an adverse influence on bone mass, bone 
turnover, and muscle strength in Chinese adolescent girls. J Nutr, 2009. 139(5): p. 1002-7. 
 
455. Cashman, K.D., et al., Low vitamin D status adversely affects bone health parameters in 
adolescents. Am J Clin Nutr, 2008. 87(4): p. 1039-44. 
 
456. Hill, K.M., et al., Bone turnover is not influenced by serum 25-hydroxyvitamin D in 
pubertal healthy black and white children. Bone, 2012. 51(4): p. 795-9. 
 
457. Molgaard, C., et al., Does vitamin D supplementation of healthy Danish Caucasian girls 
affect bone turnover and bone mineralization? Bone, 2010. 46(2): p. 432-9. 
 
458. Rauchenzauner, M., et al., Sex- and age-specific reference curves for serum markers of 
bone turnover in healthy children from 2 months to 18 years. J Clin Endocrinol Metab, 
2007. 92(2): p. 443-9. 
 
459. Yang, L. and V. Grey, Pediatric reference intervals for bone markers. Clin Biochem, 2006. 
39(6): p. 561-8. 
 
460. Thalange, N.K., et al., Model of normal prepubertal growth. Arch Dis Child, 1996. 75(5): 
p. 427-31. 
 
461. Dong, Y., et al., A 16-Week Randomized Clinical Trial of 2000 International Units Daily 
Vitamin D-3 Supplementation in Black Youth: 25-Hydroxyvitamin D, Adiposity, and 
Arterial Stiffness. Journal of Clinical Endocrinology & Metabolism, 2010. 95(10): p. 4584-
4591. 
 
462. Trivedi, D.P., R. Doll, and K.T. Khaw, Effect of four monthly oral vitamin D-3 
(cholecalciferol) supplementation on fractures and mortality in men and women living in 
the community: randomised double blind controlled trial. British Medical Journal, 2003. 
326(7387): p. 469-472. 
 
463. Barnes, M.S., et al., Effect of vitamin D supplementation on vitamin D status and bone 
turnover markers in young adults. Eur J Clin Nutr, 2006. 60(6): p. 727-33. 
 
464. Schou, A.J., C. Heuck, and O.D. Wolthers, Vitamin D supplementation to healthy children 
does not affect serum osteocalcin or markers of type I collagen turnover. Acta Paediatr, 
2003. 92(7): p. 797-801. 
 
465. Baroncelli, G.I., et al., Bone turnover in children with vitamin D deficiency rickets before 
and during treatment. Acta Paediatr, 2000. 89(5): p. 513-8. 
 
466. Ambroszkiewicz, J., et al., [Effect of vitamin D supplementation on serum 25-
hydroxyvitamin D and bone turnover markers concentrations in vegetarian children]. Med 
Wieku Rozwoj, 2009. 13(1): p. 34-9. 
 
467. Sochett, E.B., et al., Vitamin D status in hospitalized black children under 2 years of age. S 
Afr Med J, 1985. 67(26): p. 1041-4. 
 
338 
 
 
 
468. Rajakumar, K., et al., Effect of vitamin D supplementation in black and in white children: a 
randomized, placebo-controlled trial. J Clin Endocrinol Metab, 2015: p. jc20151643. 
 
469. Abrams, S.A., K.M. Hawthorne, and Z. Chen, Supplementation with 1000 IU vitamin D/d 
leads to parathyroid hormone suppression, but not increased fractional calcium absorption, 
in 4-8-y-old children: a double-blind randomized controlled trial. Am J Clin Nutr, 2013. 
97(1): p. 217-23. 
 
470. Kumar, G.T., et al., Effect of weekly vitamin D supplements on mortality, morbidity, and 
growth of low birthweight term infants in India up to age 6 months: randomised controlled 
trial. British Medical Journal, 2011. 342. 
 
471. Sai, A.J., et al., Relationship between vitamin D, parathyroid hormone, and bone health. J 
Clin Endocrinol Metab, 2011. 96(3): p. E436-46. 
 
472. Dawson-Hughes, B., S.S. Harris, and G.E. Dallal, Plasma calcidiol, season, and serum 
parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr, 
1997. 65(1): p. 67-71. 
 
473. Pepe, J., et al., Vitamin D status as the major factor determining the circulating levels of 
parathyroid hormone: a study in normal subjects. Osteoporos Int, 2005. 16(7): p. 805-12. 
 
474. Thacher, T.D., P.R. Fischer, and J.M. Pettifor, Vitamin D treatment in calcium-deficiency 
rickets: a randomised controlled trial. Arch Dis Child, 2014. 99(9): p. 807-11. 
 
475. Legius, E., et al., Rickets due to dietary calcium deficiency. Eur J Pediatr, 1989. 148(8): p. 
784-5. 
 
476. Chapuy, M.C., et al., Prevalence of vitamin D insufficiency in an adult normal population. 
Osteoporos Int, 1997. 7(5): p. 439-43. 
 
477. Gordon, C.M., et al., Prevalence of vitamin D deficiency among healthy adolescents. Arch 
Pediatr Adolesc Med, 2004. 158(6): p. 531-7. 
 
478. Harkness, L. and B. Cromer, Low levels of 25-hydroxy vitamin D are associated with 
elevated parathyroid hormone in healthy adolescent females. Osteoporos Int, 2005. 16(1): 
p. 109-13. 
 
479. McCabe, M.P., M.P. Smyth, and D.R. Richardson, Current concept review: vitamin D and 
stress fractures. Foot Ankle Int, 2012. 33(6): p. 526-33. 
 
480. Sadat-Ali, M., A.S. Al-Omran, and H.A. Al-Turki, Parathyroid Glands response to Low 
Vitamin D levels in Healthy Adults: A Cross-Sectional Study. Ulster Med J, 2015. 84(1): 
p. 26-9. 
 
481. Nair, P., et al., Significant perturbation of vitamin D-parathyroid-calcium axis and adverse 
clinical outcomes in critically ill patients. Intensive Care Med, 2013. 39(2): p. 267-74. 
 
482. Jones, G., et al., Vitamin D insufficiency in adolescent males in Southern Tasmania: 
prevalence, determinants, and relationship to bone turnover markers. Osteoporos Int, 2005. 
16(6): p. 636-41. 
 
483. von Hurst, P.R., et al., Vitamin D supplementation suppresses age-induced bone turnover 
in older women who are vitamin D deficient. J Steroid Biochem Mol Biol, 2010. 121(1-2): 
p. 293-6. 
 
484. Brazier, M., et al., Markers of bone remodeling in the elderly subject: effects of vitamin D 
insufficiency and its correction. J Bone Miner Res, 1995. 10(11): p. 1753-61. 
339 
 
 
 
 
485. Miller, S.C., et al., Studies on the role of vitamin D in early skeletal development, 
mineralization, and growth in rats. Calcif Tissue Int, 1983. 35(4-5): p. 455-60. 
 
486. Li, Y.C., et al., Targeted ablation of the vitamin D receptor: an animal model of vitamin D-
dependent rickets type II with alopecia. Proc Natl Acad Sci U S A, 1997. 94(18): p. 9831-
5. 
 
487. Krall, E.A., et al., Effect of vitamin D intake on seasonal variations in parathyroid hormone 
secretion in postmenopausal women. N Engl J Med, 1989. 321(26): p. 1777-83. 
 
488. Lee, M. and N.C. Partridge, Parathyroid hormone signaling in bone and kidney. Curr Opin 
Nephrol Hypertens, 2009. 18(4): p. 298-302. 
 
489. Shah, B.R. and L. Finberg, Single-day therapy for nutritional vitamin D-deficiency rickets: 
a preferred method. J Pediatr, 1994. 125(3): p. 487-90. 
 
490. Pittas, A.G., et al., Review: The role of vitamin D and calcium in type 2 diabetes. A 
systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism, 
2007. 92(6): p. 2017-2029. 
 
491. von Hurst, P.R., W. Stonehouse, and J. Coad, Vitamin D supplementation reduces insulin 
resistance in South Asian women living in New Zealand who are insulin resistant and 
vitamin D deficient - a randomised, placebo-controlled trial. Br J Nutr., 2010. 103(4): p. 
549-555. 
 
492. Chang, E., S.S. Donkin, and D. Teegarden, Parathyroid hormone suppresses insulin 
signaling in adipocytes. Mol Cell Endocrinol, 2009. 307(1-2): p. 77-82. 
 
493. Kumar, S., et al., Impaired glucose tolerance and insulin insensitivity in primary 
hyperparathyroidism. Clin Endocrinol (Oxf), 1994. 40(1): p. 47-53. 
 
494. Rudman, A., et al., Insulin resistance before and after parathyroidectomy in patients with 
primary hyperparathyroidism--a pilot study. Endocr Res, 2010. 35(2): p. 85-93. 
 
495. Chiu, K.C., et al., Insulin sensitivity is inversely correlated with plasma intact parathyroid 
hormone level. Metabolism-Clinical and Experimental, 2000. 49(11): p. 1501-1505. 
 
496. Wallace, T.M., J.C. Levy, and D.R. Matthews, Use and abuse of HOMA modeling. 
Diabetes Care, 2004. 27(6): p. 1487-95. 
 
497. Ghergherechi, R. and A. Tabrizi, Prevalence of impaired glucose tolerance and insulin 
resistance among obese children and adolescents. Ther Clin Risk Manag, 2010. 6: p. 345-9. 
 
498. Pirgon, O., et al., Low 25-hydroxyvitamin D level is associated with insulin sensitivity in 
obese adolescents with non-alcoholic fatty liver disease. Obes Res Clin Pract, 2013. 7(4): 
p. e275-83. 
 
499. Peplies, J., et al., Percentiles of fasting serum insulin, glucose, HbA1c and HOMA-IR in 
pre-pubertal normal weight European children from the IDEFICS cohort. Int J Obes 
(Lond), 2014. 38 Suppl 2: p. S39-47. 
 
500. Viner, R.M., et al., Assessment of childhood obesity in secondary care: OSCA consensus 
statement. Arch Dis Child Educ Pract Ed, 2012. 97(3): p. 98-105. 
 
501. Diamond, T., Y.K. Wong, and T. Golombick, Effect of oral cholecalciferol 2,000 versus 
5,000 IU on serum vitamin D, PTH, bone and muscle strength in patients with vitamin D 
deficiency. Osteoporos Int, 2013. 24(3): p. 1101-5. 
340 
 
 
 
 
502. de las Heras, J., et al., 25-Hydroxyvitamin D in obese youth across the spectrum of glucose 
tolerance from normal to prediabetes to type 2 diabetes. Diabetes Care, 2013. 36(7): p. 
2048-53. 
 
503. Stanley, T., et al., The ratio of parathyroid hormone to vitamin D is a determinant of 
cardiovascular risk and insulin sensitivity in adolescent girls. Metab Syndr Relat Disord, 
2013. 11(1): p. 56-62. 
 
504. Nader, N.S., et al., Effect of vitamin D3 supplementation on serum 25(OH)D, lipids and 
markers of insulin resistance in obese adolescents: a prospective, randomized, placebo-
controlled pilot trial. Horm Res Paediatr, 2014. 82(2): p. 107-12. 
 
505. Birken, C.S., et al., Association between Vitamin D and Circulating Lipids in Early 
Childhood. PLoS One, 2015. 10(7): p. e0131938. 
 
506. Fadda, G.Z., et al., Direct effect of parathyroid hormone on insulin secretion from 
pancreatic islets. Am J Physiol, 1990. 258(6 Pt 1): p. E975-84. 
 
507. Mak, R.H. and R.A. DeFronzo, Glucose and insulin metabolism in uremia. Nephron, 1992. 
61(4): p. 377-82. 
 
508. Akmal, M., et al., Role of parathyroid hormone in the glucose intolerance of chronic renal 
failure. J Clin Invest, 1985. 75(3): p. 1037-44. 
 
509. Prager, R., et al., Peripheral insulin resistance in primary hyperparathyroidism. 
Metabolism, 1983. 32(8): p. 800-5. 
 
510. Lindall, A., et al., Insulin hypersecretion in patients on chronic hemodialysis. Role of 
parathyroids. J Clin Endocrinol Metab, 1971. 32(5): p. 653-8. 
 
511. Dalgard, C., et al., Vitamin D status in relation to glucose metabolism and type 2 diabetes 
in septuagenarians. Diabetes Care, 2011. 34(6): p. 1284-8. 
 
512. Mosmann, T.R., et al., Two types of murine helper T cell clone. I. Definition according to 
profiles of lymphokine activities and secreted proteins. J Immunol, 1986. 136(7): p. 2348-
57. 
 
513. Askenasy, N., A. Kaminitz, and S. Yarkoni, Mechanisms of T regulatory cell function. 
Autoimmun Rev, 2008. 7(5): p. 370-5. 
 
514. Hirota, K., et al., Fate mapping of IL-17-producing T cells in inflammatory responses. Nat 
Immunol, 2011. 12(3): p. 255-63. 
 
515. Taga, K. and G. Tosato, IL-10 inhibits human T cell proliferation and IL-2 production. J 
Immunol, 1992. 148(4): p. 1143-8. 
 
516. Murphy, C.A., et al., Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in 
joint autoimmune inflammation. J Exp Med, 2003. 198(12): p. 1951-7. 
 
517. Athie-Morales, V., et al., Sustained IL-12 signaling is required for Th1 development. J 
Immunol, 2004. 172(1): p. 61-9. 
 
518. Gesser, B., et al., IL-8 induces T cell chemotaxis, suppresses IL-4, and up-regulates IL-8 
production by CD4+ T cells. J Leukoc Biol, 1996. 59(3): p. 407-11. 
 
519. Kim, C.H., et al., Rules of chemokine receptor association with T cell polarization in vivo. 
J Clin Invest, 2001. 108(9): p. 1331-9. 
341 
 
 
 
 
520. Lebre, M.C., et al., Differential expression of inflammatory chemokines by Th1- and Th2-
cell promoting dendritic cells: a role for different mature dendritic cell populations in 
attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol, 
2005. 83(5): p. 525-35. 
 
521. Odum, N., et al., The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential for 
the development of human Th1 cells. Tissue Antigens, 1999. 54(6): p. 572-7. 
 
522. Ponath, P.D., et al., Cloning of the human eosinophil chemoattractant, eotaxin. Expression, 
receptor binding, and functional properties suggest a mechanism for the selective 
recruitment of eosinophils. J Clin Invest, 1996. 97(3): p. 604-12. 
 
523. Kidd, P., Th1/Th2 balance: the hypothesis, its limitations, and implications for health and 
disease. Altern Med Rev, 2003. 8(3): p. 223-46. 
 
524. Agrawal, R., J.A. Wisniewski, and J.A. Woodfolk, The role of regulatory T cells in atopic 
dermatitis. Curr Probl Dermatol, 2011. 41: p. 112-24. 
 
525. Tsoukas, C.D., D.M. Provvedini, and S.C. Manolagas, 1,25-dihydroxyvitamin D3: a novel 
immunoregulatory hormone. Science, 1984. 224(4656): p. 1438-40. 
 
526. Qi, X.P., et al., 1,25-dihydroxyvitamin D(3) regulates LPS-induced cytokine production 
and reduces mortality in rats. World J Gastroenterol, 2008. 14(24): p. 3897-902. 
 
527. Alroy, I., T.L. Towers, and L.P. Freedman, Transcriptional repression of the interleukin-2 
gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear 
hormone receptor. Mol Cell Biol, 1995. 15(10): p. 5789-99. 
 
528. Jeffery, L.E., et al., 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell 
production of inflammatory cytokines and promote development of regulatory T cells 
expressing CTLA-4 and FoxP3. J Immunol, 2009. 183(9): p. 5458-67. 
 
529. Palmer, M.T., et al., Lineage-specific effects of 1,25-dihydroxyvitamin D(3) on the 
development of effector CD4 T cells. J Biol Chem, 2011. 286(2): p. 997-1004. 
 
530. Lee, S.H., et al., Osteoimmunology: cytokines and the skeletal system. BMB Rep, 2008. 
41(7): p. 495-510. 
 
531. Takayanagi, H., Osteoimmunology: shared mechanisms and crosstalk between the immune 
and bone systems. Nat Rev Immunol, 2007. 7(4): p. 292-304. 
 
532. Calvi, L.M., et al., Osteoblastic cells regulate the haematopoietic stem cell niche. Nature, 
2003. 425(6960): p. 841-6. 
 
533. Teitelbaum, S.L., Bone resorption by osteoclasts. Science, 2000. 289(5484): p. 1504-8. 
 
534. Takahashi, S., et al., Elevation of circulating plasma cytokines in cancer patients with high 
plasma parathyroid hormone-related protein levels. Endocr Relat Cancer, 2003. 10(3): p. 
403-7. 
 
535. Tiwari, S., et al., Vitamin D deficiency is associated with inflammatory cytokine 
concentrations in patients with diabetic foot infection. Br J Nutr, 2014. 112(12): p. 1938-
43. 
 
536. Khalifian, S., G. Raimondi, and G. Brandacher, The Use of Luminex Assays to Measure 
Cytokines. J Invest Dermatol, 2015. 135(8): p. 2142. 
 
342 
 
 
 
537. Verschoor, C.P., et al., An Introduction to Automated Flow Cytometry Gating Tools and 
Their Implementation. Front Immunol, 2015. 6: p. 380. 
 
538. Willheim, M., et al., Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on the cytokine 
production of human peripheral blood lymphocytes. J Clin Endocrinol Metab, 1999. 
84(10): p. 3739-44. 
 
539. Hartmann, B., et al., Targeting the vitamin D receptor inhibits the B cell-dependent allergic 
immune response. Allergy, 2011. 66(4): p. 540-8. 
 
540. Geha, R.S., H.H. Jabara, and S.R. Brodeur, The regulation of immunoglobulin E class-
switch recombination. Nat Rev Immunol, 2003. 3(9): p. 721-32. 
 
541. Takatsu, K. and H. Nakajima, IL-5 and eosinophilia. Curr Opin Immunol, 2008. 20(3): p. 
288-94. 
 
542. Georas, S.N., et al., T-helper cell type-2 regulation in allergic disease. Eur Respir J, 2005. 
26(6): p. 1119-37. 
 
543. Malek, T.R., The biology of interleukin-2. Annu Rev Immunol, 2008. 26: p. 453-79. 
 
544. Wang, X. and T. Mosmann, In vivo priming of CD4 T cells that produce interleukin (IL)-2 
but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or 
IFN-gamma-secreting cells. J Exp Med, 2001. 194(8): p. 1069-80. 
 
545. Kimura, A. and T. Kishimoto, IL-6: regulator of Treg/Th17 balance. Eur J Immunol, 2010. 
40(7): p. 1830-5. 
 
546. O'Garra, A. and K. Murphy, Role of cytokines in determining T-lymphocyte function. Curr 
Opin Immunol, 1994. 6(3): p. 458-66. 
 
547. Sloka, S., et al., Predominance of Th2 polarization by vitamin D through a STAT6-
dependent mechanism. J Neuroinflammation, 2011. 8: p. 56. 
 
548. Le Gros, G., et al., Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: 
IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med, 
1990. 172(3): p. 921-9. 
 
549. Seder, R.A., et al., The presence of interleukin 4 during in vitro priming determines the 
lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J 
Exp Med, 1992. 176(4): p. 1091-8. 
 
550. Swain, S.L., et al., IL-4 directs the development of Th2-like helper effectors. J Immunol, 
1990. 145(11): p. 3796-806. 
 
551. Willis, K.S., et al., Vitamin D status and biomarkers of inflammation in runners. Open 
Access J Sports Med, 2012. 3: p. 35-42. 
 
552. Killestein, J., et al., Intracellular cytokine profile in T-cell subsets of multiple sclerosis 
patients: different features in primary progressive disease. Mult Scler, 2001. 7(3): p. 145-
50. 
 
553. Higashi, N., et al., Cytokine expression of skin T-lymphocytes from patients with atopic 
dermatitis. Acta Derm Venereol, 2001. 81(1): p. 3-7. 
 
554. Tang, Q. and J.A. Bluestone, The Foxp3+ regulatory T cell: a jack of all trades, master of 
regulation. Nat Immunol, 2008. 9(3): p. 239-44. 
 
343 
 
 
 
555. La Cava, A., Tregs are regulated by cytokines: implications for autoimmunity. Autoimmun 
Rev, 2008. 8(1): p. 83-7. 
 
556. Gorman, S., et al., Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive 
activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol, 2007. 179(9): p. 
6273-83. 
 
557. Zheng, S.G., et al., IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to 
CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol, 2007. 
178(4): p. 2018-27. 
 
558. Weitzmann, M.N., The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the 
Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica 
(Cairo), 2013. 2013: p. 125705. 
 
559. Zhao, B. and L.B. Ivashkiv, Negative regulation of osteoclastogenesis and bone resorption 
by cytokines and transcriptional repressors. Arthritis Res Ther, 2011. 13(4): p. 234. 
 
560. Takayanagi, H., Mechanistic insight into osteoclast differentiation in osteoimmunology. J 
Mol Med (Berl), 2005. 83(3): p. 170-9. 
 
561. Lee, Y., The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases. 
BMB Rep, 2013. 46(10): p. 479-83. 
 
562. Takayanagi, H., et al., T-cell-mediated regulation of osteoclastogenesis by signalling cross-
talk between RANKL and IFN-gamma. Nature, 2000. 408(6812): p. 600-5. 
 
563. Ji, J.D., et al., Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-
gamma in human osteoclast precursors. J Immunol, 2009. 183(11): p. 7223-33. 
 
564. Nagata, N., et al., Inhibition of RANKL-induced osteoclast formation in mouse bone 
marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell 
population. Bone, 2003. 33(4): p. 721-32. 
 
565. Zhao, W., et al., Bone resorption induced by parathyroid hormone is strikingly diminished 
in collagenase-resistant mutant mice. J Clin Invest, 1999. 103(4): p. 517-24. 
 
566. Cantorna, M.T., Mechanisms underlying the effect of vitamin D on the immune system. 
Proc Nutr Soc, 2010. 69(3): p. 286-9. 
 
567. Axmann, R., et al., Inhibition of interleukin-6 receptor directly blocks osteoclast formation 
in vitro and in vivo. Arthritis Rheum, 2009. 60(9): p. 2747-56. 
 
568. Duplomb, L., et al., Interleukin-6 inhibits receptor activator of nuclear factor kappaB 
ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role 
of Serine727 phosphorylation of signal transducer and activator of transcription 3. 
Endocrinology, 2008. 149(7): p. 3688-97. 
 
569. Liu, D., S. Yao, and G.E. Wise, Effect of interleukin-10 on gene expression of 
osteoclastogenic regulatory molecules in the rat dental follicle. Eur J Oral Sci, 2006. 
114(1): p. 42-9. 
 
570. Dresner-Pollak, R., et al., Interleukin 10-deficient mice develop osteopenia, decreased bone 
formation, and mechanical fragility of long bones. Gastroenterology, 2004. 127(3): p. 792-
801. 
 
571. Edwards, C.J. and E. Williams, The role of interleukin-6 in rheumatoid arthritis-associated 
osteoporosis. Osteoporos Int, 2010. 21(8): p. 1287-93. 
344 
 
 
 
 
572. Roeleveld, D.M. and M.I. Koenders, The role of the Th17 cytokines IL-17 and IL-22 in 
Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. 
Cytokine, 2015. 74(1): p. 101-7. 
 
573. Duque, G., et al., Interferon-gamma plays a role in bone formation in vivo and rescues 
osteoporosis in ovariectomized mice. J Bone Miner Res, 2011. 26(7): p. 1472-83. 
 
574. Jamali, Z., M.K. Arababadi, and G. Asadikaram, Serum levels of IL-6, IL-10, IL-12, IL-17 
and IFN-gamma and their association with markers of bone metabolism in vitamin D-
deficient female students. Inflammation, 2013. 36(1): p. 164-8. 
 
575. Zhang, Y., et al., Vitamin D inhibits monocyte/macrophage proinflammatory cytokine 
production by targeting MAPK phosphatase-1. J Immunol, 2012. 188(5): p. 2127-35. 
 
576. Wong, S.C., et al., Inflammatory cytokines in juvenile idiopathic arthritis: effects on 
physical growth and the insulin-like-growth factor axis. Growth Horm IGF Res, 2008. 
18(5): p. 369-78. 
 
577. Biancotto, A., et al., Baseline levels and temporal stability of 27 multiplexed serum 
cytokine concentrations in healthy subjects. PLoS One, 2013. 8(12): p. e76091. 
 
578. Brown, K., et al., Diet-induced dysbiosis of the intestinal microbiota and the effects on 
immunity and disease. Nutrients, 2012. 4(8): p. 1095-119. 
 
579. Kleiner, G., et al., Cytokine levels in the serum of healthy subjects. Mediators Inflamm, 
2013. 2013: p. 434010. 
 
580. Patel, J.A., et al., Nasopharyngeal acute phase cytokines in viral upper respiratory 
infection: impact on acute otitis media in children. Pediatr Infect Dis J, 2009. 28(11): p. 
1002-7. 
 
581. Basatemur, E. and A. Sutcliffe, Incidence of hypocalcemic seizures due to vitamin D 
deficiency in children in the United Kingdom and Ireland. J Clin Endocrinol Metab, 2015. 
100(1): p. E91-5. 
 
582. Lee, J.Y., T.Y. So, and J. Thackray, A review on vitamin d deficiency treatment in 
pediatric patients. J Pediatr Pharmacol Ther, 2013. 18(4): p. 277-91. 
 
583. Maalmi, H., et al., The impact of vitamin D deficiency on immune T cells in asthmatic 
children: a case-control study. J Asthma Allergy, 2012. 5: p. 11-9. 
 
 
  
345 
 
 
 
Author Bibliography 
1. El-Fakhri N, Williams C, Cox K, McDevitt H, Galloway P, McIntosh N, Ahmed 
SF. An electronic surveillance system for monitoring the hospital presentation of 
nutritional vitamin D deficiency in children in Scotland. Journal of Pediatric 
Endocrinology and Metabolism 2013;26(11-12):1053-8.  
  
346 
 
 
 
2. El-Fakhri N, McDevitt H, Shaikh MG, Halsey C, Ahmed SF. Vitamin D and its 
effects on glucose homeostasis, cardiovascular function and immune function. Hormone 
Research in Paediatrics 2014;81(6):363-78. 
 
 
 
